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  ‘Although neuroscience is my daily routine, I am still in awe every time I hold a human 
brain. After you take into account its substantial weight (an adult brain weighs in at 
three pounds), its strange consistency (like firm jelly), and its wrinkled appearance 
(deep valleys carving a puffy landscape) – what's striking is the brain’s sheer 
physicality: this hunk of unremarkable stuff seems so at odds with the mental processes 
it creates. 
   
  Our thoughts and our dreams, our memories and experiences all arise from this strange 
neural material. Who we are is found within its intricate firing patterns of 
electrochemical pulses. 
   
  When that activity stops, so do you. When that activity changes character due to injury, 
you change character in lockstep. Unlike other parts of your body, if you damage a 
small piece of your brain, who you are is likely to change radically’ 
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Stroke is a devastating condition, affecting over 17 million people worldwide annually. 
Interruption of cerebral arterial blood flow in ischaemic stroke initiates a cascade of 
deleterious events, leading to irreversible cell damage and secondary injury. Specifically, 
the development of cerebral oedema, whereby disruption to the blood–brain barrier (BBB) 
precipitates abnormal fluid accumulation within the brain parenchyma, leads to a consequent 
rise in intracranial pressure (ICP). Persistently elevated ICP results in loss of cerebral 
autoregulation and brain herniation, making it a leading cause of death and disability post-
stroke. Despite this, current treatments fail to prevent the pathophysiological development 
of oedema, rather targeting the symptoms once established. As such, understanding the 
mechanisms underlying cerebral oedema and elevated ICP is essential in order to develop 
more targeted and effective treatments to prevent oedema genesis and improve patient 
outcomes. 
 
Neurogenic inflammation, mediated by substance P (SP), has been linked to profound BBB 
disruption, oedema development and poor functional outcome post-stroke. SP binds to the 
neurokinin 1 tachykinin receptor (NK1-R), with administration of an NK1-R antagonist 
shown to ameliorate BBB dysfunction and cerebral oedema following stroke in rodent 
models. However, more clinically-relevant animal models are required to validate efficacy 
of novel stroke therapeutics to improve clinical translation. Thus, this thesis sought to 
determine the efficacy of NK1-R antagonist treatment in reducing cerebral oedema and ICP 
in a clinically-relevant ovine stroke model. 
 
xii 
Merino sheep (Ovis aries; n=125) were used across the five thesis studies. For Aim 1 
(n=34F), a non-survival permanent middle cerebral artery occlusion (MCAo) model was 
used to determine the efficacy of various NK1-R receptor antagonist regimens or 
decompressive craniectomy in reducing ICP post-stroke. Once an optimum dosage was 
determined, Aims 2 and 3 (n=23F;24M) involved development of a transient MCAo survival 
model and characterisation of the temporal profile of oedema and ICP. Finally, Aim 4 and 5 
(n=9F;9M), sought to determine the ideal time-course of treatment, and investigate the 
efficacy of the NK1-R antagonist following transient stroke via assessment of neurological 
and functional outcomes. ICP was assessed via invasive monitoring, with arterial blood 
pressure, temperature and blood gases also measured. Magnetic resonance imaging (MRI) 
and immunohistochemistry (IHC) was also performed. Motion capture and a modified 
neuroscore was used to assess changes in motor function and demeanour.  
 
This thesis identified that two doses of the NK1-R antagonist were efficacious in reducing 
ICP following permanent MCAo. A transient stroke model was successfully developed and 
characterised, with ICP peaking at 5-6 days post-stroke. NK1-R antagonist treatment, both 
acutely (1-3 days), and in a delayed fashion (5-day), significantly reduced ICP post-stroke. 
Finally, a motion capture tool was successfully established and validated as a quantitative 
method to assess motor function following transient ovine stroke, with animal gait 
significantly impaired post-stroke.  
 
The work presented in this thesis encompasses a comprehensive evaluation of the efficacy 
of NK1-R antagonist treatment in a clinically-relevant ovine model, providing strong pre-
clinical evidence for further investigation. Accordingly, Phase II trials are currently 
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This thesis investigates the mechanisms underlying ischaemic stroke to subsequently 
determine the efficacy of a novel therapeutic agent targeting oedema and elevated 
intracranial pressure. Significant efforts were made throughout the course of candidature to 
publish research findings; therefore, this thesis contains 4 published papers, and 2 papers 
prepared in publication format. The overarching structure of the thesis is as follows; a 
general introduction, two review papers, a synopsis of the relevant background information, 
a methods chapter, four research papers, a general discussion, references, and appendices. 
 
Due to the extensive background information underpinning this doctorate, the first 3 
Chapters detail the ultimate purpose of this thesis. The first chapter is a general introduction 
to stroke, the second introduces the reader to the therapeutic target investigated, and the third 
highlights large animal models of stroke currently available to increase clinical translation. 
Introductory Chapters 2 and 3 comprise previously published works; however, these have 
been revised to avoid excessive repetition and to improve flow of concepts. Introductory 
chapters are then summarised in a brief synopsis including the overarching rationale for this 
thesis, choice of animal model used, and the doctoral aims (Chapter 4), following which 
project methods are discussed in detail (Chapter 5). 
 
The experimental chapters provided include those that have already been published 
(Chapters 6 and 7, presented as accepted for publication) and those prepared in publication 
format (Chapters 8 and 9). The overall thesis is then summarised in a general discussion 
(Chapter 10). Chapters that have been published or prepared in publication format are 
prefaced by a signed statement of authorship. 
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Stroke is the second leading cause of mortality, and the principal cause of adult neurological 
disability, worldwide (Gorelick, 2019, Avan et al., 2019). Initially characterised by the 
World Health Organization (WHO) in 1970, stroke is defined as an acute onset of 
neurological deterioration, lasting more than 24 hours or leading to death, with no apparent 
cause other than that of presumed vascular origin (Muir, 2013, Markus, 2016). Since 
formulation of this definition, significant advances have been made in the fields of public 
health, medicine and basic science, which have dramatically increased our understanding of 
the pathophysiology and clinical manifestations of stroke (Sacco et al., 2013). The 
mechanisms underlying the disease are now recognised as a complex cascade of interrelated 
events leading to cell death and consequent patient deterioration. The purpose of this general 
introduction is to provide an overview of the molecular mechanisms underlying stroke, its 





There are more than 80 million stroke survivors globally, and approximately 17 million 
people experiencing a new or recurrent event each year (Virani et al., 2020, Feigin et al., 
2018, Gorelick, 2019). Despite improvements in stroke prevention and management, 
accumulating risk factors such as atherosclerosis and atrial fibrillation, together with a 
burgeoning elderly population, contribute to an increasing lifetime risk (Virani et al., 2020, 
Feigin et al., 2018), whereby a significant rise in the number of individuals living with stroke 
and its consequences is predicted to occur by the year 2030 (Ovbiagele et al., 2013). In 
Europe, the annual cost of stroke treatment and care is an estimated 27 billion euros, and in 
3 
2012, the cost of stroke in the United States (US) of America reached 71.5 billion US dollars 
(Rajsic et al., 2019). Given the increasing incidence of stroke, the American Heart 
Association has projected that by 2030, the total direct cost for stroke will reach up to 184.1 
billion US dollars per annum (Ovbiagele et al., 2013). This has significant repercussions for 
the global economy and highlights the importance of stroke prevention and improved 
treatment through the development of novel therapies. 
 
1.1.2 Aetiology 
Disturbance of cerebral function in stroke is established to arise secondary to reduced 
perfusion of oxygen-and nutrient-providing arterial blood to neuronal tissue, compromising 
function and ultimately resulting in neuronal cell death. Neurovascular deficits can arise by 
two primary mechanisms: haemorrhage or ischaemia (Virani et al., 2020). Haemorrhagic 
stroke occurs when an arterial blood vessel within the brain bursts, resulting in leakage of 
blood into the surrounding tissue, and the development of either subarachnoid haemorrhage 
(SAH) or intracerebral haemorrhage (ICH). In comparison, ischaemic stroke arises as a 
result of arterial occlusion within the internal carotid or cerebral arteries, caused by 
thrombosis, embolism or systemic hypoperfusion, ultimately resulting in either permanent 
or temporary restriction of blood flow through the affected artery. In both stroke types, the 
symptoms observed post-ictus are largely associated with the anatomical location of the 
vessel affected and the respective distribution of blood flow. Given that the vast majority of 
strokes are ischaemic in nature, accounting for upwards of 87% of all stroke cases (Virani 





1.1.3 Cerebrovascular Anatomy and Clinical Manifestations 
The cerebrovasculature of humans is convoluted and highly complex, spanning a distance 
of approximately 700 kilometres (Greif and Eichmann, 2014). Blood is supplied to the brain 
via the circle of Willis (coW), a complex circulatory anastomosis at the base of the brain, 
which receives blood from the internal carotid arteries (ICAs) and vertebrobasilar system 
(Rosner et al., 2020). The coW, in turn, gives rise to three major paired arteries: the middle 
cerebral arteries (MCAs), anterior cerebral arteries (ACAs) and posterior cerebral arteries 
(PCAs) (Krishnaswamy et al., 2009). In cases of ischaemic stroke, these branches are 
considered end arteries, with occlusion markedly reducing blood supply to the brain territory 
supplied by the artery downstream. Clinically, the MCA is the most common site of 
occlusion, followed by the ACA and PCA, with resultant manifestations allowing for 
identification of the affected vessel (Nogles and Galuska, 2020). 
 
1.1.3.1 Middle Cerebral Artery 
The MCA supplies blood to 85% of the cerebral hemispheres (Figure 1.1). Considered a 
natural continuation of the ICA, it is subdivided into M1 sphenoidal/horizontal, M2 insular, 
M3 opercular and M4 cortical segments (Konan et al., 2020). The M1 segment, which 
horizontally traverses the sphenoidal sylvian fissure, gives rise to lateral lenticulostriate 
branches, which supply the caudate nucleus, internal capsule and basal ganglia (Navarro-
Orozco and Sanchez-Manso, 2020). Upon reaching the junction of the operculo-insular cleft 
of the sylvian fissure, the M1 segment bifurcates into M2 branches, comprising superior and 
inferior trunks. The M2 branches run along the surface and subsequently supply blood to the 
insula, terminating at the central sulcus. Here, the M2 divides into M3 opercular branches, 
which traverse the superficial part of the sylvian fissure, ultimately branching into terminal 
cortical branches (M4). Branches of M4 comprise both superior and inferior divisions, which 
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supply almost the entire lateral surface of the brain including the motor and sensorimotor 
cortices, responsible for modulating motor and sensory functions of the face and upper 
extremities (Hui et al., 2020). 
 
Occlusion of the MCA, clinically referred to as malignant middle cerebral artery infarction 
(MMCAI), often presents as hemiplegia and hemiparesis of the upper limbs, face and mouth, 
contralateral to the lesion, because of decussation of fibres at the level of the medulla 
oblongata (Navarro-Orozco and Sanchez-Manso, 2020). Additional impediments include 
dysarthria, aphasia and hemi-neglect (Acharya and Wroten, 2020). The superior division of 
M4 also gives rise to the artery of the precentral sulcus, which supplies the Broca’s area, 
responsible for speech production. The middle temporal branches of M4 supply the primary 
auditory complex and Wernicke’s area, which is responsible for speech comprehension 
(Acharya and Wroten, 2020). Accordingly, occlusion of the cortical M4 branches can result 
in Broca’s aphasia and loss of verbal fluency, or Wernicke’s aphasia, where the patient 
presents with impaired ability to comprehend spoken language (Acharya and Wroten, 2020, 
Ochfeld et al., 2010). This, however, is dependent on the individual and their respective 




Figure 1.1. Cerebrovascular distribution of the middle cerebral artery and its branches.  (A) Lateral view 
of the brain showing cortical M4 segment of the MCA and its branches. (B) Coronal view of the brain at the 
level of the thalamus showing M1 horizonal, M2 insular, M3 opercular and M4 cortical segments of the MCA, 
including lenticulostriate branches of M1 supplying sub-cortical structures. Figure reprinted from ‘Brain 
(lateral with arteries)’ and ‘Coronal brain with vessels (at caudal thalamus)’, by BioRender.com (2021). 
 
1.1.3.2 Anterior Cerebral Artery 
The ACA lies within the longitudinal fissure and comprises five segments, termed A1 to A5. 
These segments give rise to polar frontal, calossomarginal and pericallosal branches (Figure 
1.2), which extend anteromedially to supply the midline portion of the frontal lobes and 




because of the rich anastomoses between cortical branches (Matos Casano et al., 2020). In 
individuals affected, however, deficits characteristically present as contralateral lower limb 
hemiparesis and hemiplegia. Other motor deficits can include bradykinesia, hypometria, 
akinesia, tremor, dystonia and motor neglect (Toyoda, 2012, Honig et al., 2017). 
 
1.1.3.3 Posterior Cerebral Artery 
The PCA is divided into four segments (Figure 1.2), P1 to P4, comprising anterior temporal, 
posterior temporal, medial occipital, posterior pericallosal, calcarine and parietooccipital 
branches, which largely supply the occipital lobe, in addition to the inferomedial portion of 
the temporal lobe, the midbrain and the upper brain stem (Konan et al., 2020). Interruption 
of blood supply through the PCA and its branches often presents as visual disturbances 
including hemianopia, quadrantanopia and visual agnosia. Patients may also present with 
cognitive and neuropsychological dysfunctions, including aphasia and memory impairment. 
 
 
Figure 1.2. Cerebrovascular distribution of the anterior cerebral artery and posterior cerebral artery 




1.1.4 Cerebral Collateralisation – Infarct Core and Penumbra 
Each major branch of the MCA, ACA and PCA subsequently give rise to multiple small 
anastomoses to provide collateralisation of blood flow. Accordingly, if an artery supplying 
one region of the brain is occluded, neurons receiving direct blood supply will have almost 
complete cessation of cerebral blood flow (CBF), but neurons in the surrounding region will 
continue to receive blood, albeit reduced, from surrounding collateral vessels (Agarwal et 
al., 2013). Neurons receiving direct supply rapidly succumb to ischaemia, necrotising and 
becoming the infarct core. Cells surrounding the core become the penumbra, and although 
they too are receiving reduced blood and are electrically silent, supply via collateral vessels 
is sufficient to sustain survival (Doyle et al., 2008). By definition, regions of the brain 
receiving CBF below 20 mL/100 g/min define the penumbra; this is compared with regions 
of normal blood flow of ±50 mL/100 g/min. When blood flow is <10 mL/100 g/min, the 
tissue forms the infarct core (Hakim, 1998). 
 
Despite receiving blood supply, although reduced, penumbral neurons remain at risk of 
conversion to permanent infarction if supply is not re-established in a timely manner, with 
every minute passing in which the vessel remains obstructed resulting in the death of 1.9 
million neurons, loss of 14 billion synapses and destruction of 12 kilometres of myelinated 
axons (Saver, 2006). Therefore, the duration of ischaemia and overall CBF (as shown in 





Figure 1.3. Evolution of the ischaemic penumbra. Vascular occlusion due to thrombosis or 
thromboembolism results in hypoperfusion to brain tissue within minutes of onset. The area of the brain 
receiving direct blood supply from the vessel rapidly succumbs to ischaemia and becomes the infarct core (dark 
pink). The area surrounding the core continues to receive blood supply, although diminished, from surrounding 
collateral vessels, thus becoming the ischaemic penumbra (light pink). If occlusion persists, the infarct core 
expands because of penumbral cells succumbing to persistent hypoperfusion. Infarct expansion continues to 
develop within the first 24 hours of stroke onset, whereby if blood flow is not re-established, the infarct 
eventually comprises all core and penumbral cells, which ultimately die because of persistent lack of blood 
supply, as seen at 7 days. Figure created with BioRender.com (2021). 
 
1.2 STROKE PATHOPHYSIOLOGY 
 
1.2.1 Mechanisms of Ischaemic Cell Death 
At rest, the brain is responsible for up to 20% of the body’s oxygen consumption (Özugur et 
al., 2020). Unlike other organ systems, neurons are reliant upon a constant supply of glucose 
to perform oxidative phosphorylation for the production of adenosine triphosphate (ATP) as 
the blood–brain barrier (BBB) restricts the movement of other energy sources, such as fatty 
acids, ketones and amino acids, into the brain (Robbins and Swanson, 2014). Consequently, 
immediately following cessation of blood supply, inhibition of mitochondrial aerobic 
respiration occurs. Under anaerobic conditions, mitochondria are forced to generate ATP via 
glycolysis, whereby lactate is produced, accumulating within cells and rapidly decreasing 
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intracellular pH (Kalogeris et al., 2012). Anaerobic respiration is significantly less efficient, 
with only two ATP molecules yielded per cycle compared with 36 under aerobic conditions 
(Sims and Anderson, 2002, Kalogeris et al., 2012). As a consequence, neuronal ATP stores 
are considerably diminished, resulting in impaired neuronal function. 
 
1.2.2 Ionic Imbalances 
The Na+/K+-ATPase pump is found in abundance in neuronal plasma membranes. 
Physiologically, Na+/K+-ATPase pumps consume in excess of 70% of the energy supplied 
to the brain as they are responsible for maintaining the ionic gradients of Na+ and K+ across 
the cell membranes, necessary for propagation of action potentials (Edvinsson et al., 1993). 
Immediately following onset of ischaemia, Na+/K+-ATPase pumps rapidly consume 
remaining ATP stores, such that within ±2 minutes, all remaining reserves are exhausted 
(Doyle et al., 2008). This leads to failure of energy-dependent processes, including the 
activity of the Na+/K+-ATPase pump itself and plasma membrane Ca2+-ATPase (PMCA), a 
transport protein responsible for maintaining a physiologically low intracellular Ca2+ 
concentration (Edvinsson et al., 1993). Consequently, a rapid efflux of K+ and influx of both 
Na+ and Ca2+ ensues. Elevated extracellular K+ and intracellular Na+ and Ca2+ causes 
upregulation of Na+‐K+‐2Cl− co‐transporter 1 (NKCC1), allowing for an influx of Cl− into 
the cell (Martín-Aragón Baudel et al., 2017, Huang et al., 2019). The resultant ionic 
imbalances grossly increase intracellular hyperosmolarity and cause neuronal cell membrane 
depolarisation. 
 
1.2.3 Excitotoxicity and Acidotoxicity 
Neuronal depolarisation in cells that comprise the infarct core precipitates the abnormal and 
excessive release of neurotransmitters from axon terminals, with release of the excitatory 
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neurotransmitter glutamate playing a critical role in ischaemic pathophysiology. Elevated 
extracellular levels of glutamate and K+ initiate peri-infarct depolarisation (PID) within 
minutes of ischaemic onset. Repeated PID leads to excessive accumulation of intracellular 
Ca2+, expansion of compromised cells and resultant penumbral formation (Doyle et al., 2008, 
Hartings et al., 2003). Enhanced synaptic glutamate concentration also increases activation 
of N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors (Doyle et al., 2008). NMDA receptors are permeable to Ca2+, 
allowing for an additional influx upon activation, exacerbating the release of glutamate, 
termed excitotoxicity. Ischaemic injury further enhances the permeability of AMPA 
receptors to Ca2+, leading to a prolonged and pathological intracellular influx. Glutamate 
also acts on G-protein coupled metabotropic glutamate (mGlu) receptors, which further 
contribute to excitotoxicity. Upon glutamate binding, mGlu G-protein subunit disassociation 
leads to increased production of secondary messenger inositol-1,4,5-triphosphate (IP3), 
resulting in increased release of endoplasmic reticulum Ca2+ into the cytosol (Neumar, 
2000). In concert with excitotoxicity, acidotoxicity due to intracellular acidosis initiates 
activation of acid-sensing ion channels (ASICs), with stimulation of glutamate-independent 
ASIC subtype 1a leading to a further influx of Ca2+ into the neuron (Simon, 2006). 
 
Concurrent excitotoxicity and acidotoxicity enormously increase the intracellular Ca2+ 
concentration. Physiologically, intracellular levels of Ca2+ are around 0.1–1 μM but, under 
ischaemic conditions, rise to 50–100 μM (Doyle et al., 2008). Excessive Ca2+ accumulation 
initiates activation of many, if not all, deleterious Ca2+-dependent enzymes, including 
proteases, phospholipases and deoxyribonucleic acid (DNA)-ases (Edvinsson et al., 1993). 
Catabolic enzymatic degradation of vital intracellular structures ensues, including lipolysis, 
proteolysis and endonuclease-mediated DNA destruction (Neumar, 2000). In the absence of 
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abundant ATP, cells are unable to undergo repair and resynthesis of vital structures, resulting 
in significant cellular damage, which grossly affects neuronal function. Such aberrant Ca2+ 
accumulation and excitatory neurotransmitter release can thus rapidly lead to acido- and 
excito- toxic cell death. 
 
1.2.4 Reactive Oxygen Species 
Intracellular overload of Ca2+ causes excessive mitochondrial production of deleterious 
reactive oxygen species (ROS), in particular superoxide anion (O2−), hydroxyl radical (OH•) 
and hydrogen peroxide (H2O2) (Neumar, 2000). As a consequence of excitotoxicity, NMDA 
receptors also recruit Ca2+-dependent nitric oxide synthase (nNOS) via post-synaptic density 
protein 95 (PSD-95), resulting in the production of nitric oxide (NO) (Reis et al., 2017). NO 
subsequently combines with mitochondrial O2− to form the potent free radical, peroxynitrite 
(NO3−) (Reis et al., 2017). Neuronal tissue is particularly susceptible to free radicals because 
of low endogenous levels of antioxidants, including superoxide dismutase (SOD), 
glutathione peroxidase (GPX) and catalase (CAT) (Li and Yang, 2016). Overproduction of 
ROS under ischaemic conditions rapidly consumes remaining antioxidant stores, leading to 
oxidative stress. Here, unchecked abundant free radicals, in particular NO3−, cause 
destruction of cellular structures and key molecules including proteins, lipids and DNA 
(Sugawara and Chan, 2003). 
 
There is evidence to suggest that early damage to DNA is able to undergo a degree of repair 
due to activation of poly(ADP-ribose)polymerase-1 (PARP-1) by NO. However, to perform 
its function, PARP-1 exhausts intracellular nicotinamide adenine dinucleotide (NAD+), 
necessary for producing remaining ATP via glycolysis (Neumar, 2000). This results in 
complete ATP starvation within the cells, energy failure and resultant necrotic cell death. 
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ROS overproduction also leads to activation of resident brain microglia, which subsequently 
secrete ROS and additional cytotoxic factors such as the pro-inflammatory cytokines 
interleukin (IL)-1, IL-6 and tumour necrosis factor alpha (TNF-α) (Jiang et al., 2018). These 
cytokines enhance the expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin 
and E-selectin, causing leukocyte migration, neuroinflammation and exacerbation of cell 
damage in a vicious cycle (Jiang et al., 2018). 
 
1.2.5 Apoptosis 
Ischaemic mitochondrial dysfunction also plays a critical role in mediating programmed cell 
death via apoptosis (Bakthavachalam and Shanmugam, 2017). Ca2+ overload leads to pore 
formation in the outer mitochondrial membrane (the mitochondrial permeability transition 
pore, mtPTP) facilitated by a group of pro-apoptotic proteins of the B-cell lymphoma (BCL-
2) line, including Bax and/or Bak, facilitated by proteins Bad and Bid (Neumar, 2000). Pore 
formation subsequently initiates the intrinsic apoptotic pathway via cytochrome c; activation 
of downstream caspases ensues, with upregulation of caspase 3 causing DNA breakdown 
and initiation of programmed cell death via apoptosis.  
 
The complex interplay of excitotoxicity, acidosis, oxidative stress and apoptosis (as 





Figure 1.4. Mechanisms of ischaemic cell death following stroke.  (1) Immediately following cessation of 
blood supply, inhibition of mitochondrial aerobic respiration occurs, resulting in depletion of ATP and 
accumulation of lactic acid as mitochondria switch to anaerobic respiration. (2) In the absence of sufficient 
ATP, energy-dependent pumps in the plasma membrane become dysfunctional. Notably, failure of Na+/K+-
ATPase and PMCA pumps results in a rapid influx of Na+ and Ca2+ and efflux of K+. Intracellular accumulation 
of Na+ and efflux of K+ drives further influx of Cl− via NKCC1. (3) Net intracellular accumulation of Na+, Cl- 
and Ca2+ results in neuronal depolarisation and significantly increases intracellular hyperosmolarity. (4) As a 
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result of plasma membrane depolarisation, aberrant release of neurotransmitters from axon terminals ensues, 
notably glutamate. Glutamate binds to AMPA and NMDA receptors in the post-synaptic cell membrane, 
leading to rapid influx of intracellular Ca2+ and resulting in a further release of glutamate from the post-synaptic 
cell (excitotoxicity). Intracellular lactic acid accumulation leads to activation of ASICs, which allow a further 
influx of Ca2+. (5) Significant increases in intracellular Ca2+ via NMDA and AMPA receptor activation and 
ASICs lead to activation of Ca2+-dependent enzymes, resulting in lipid peroxidation, protein degradation, 
ribosome disassociation and DNA breakdown. (6) NMDA receptor activation also leads to recruitment of 
nNOS via PSD-95, leading to synthesis of NO. (7) Mitochondrial Ca2+ overload increases synthesis of 
deleterious ROS including O2−, OH• and H2O2, causing damage to cellular structures and activation of 
microglia, with resultant glial ROS synthesis and secretion of cytotoxic factors initiating neuroinflammation. 
(8) NO subsequently binds O2− to form NO3-resulting in further damage to lipids, proteins and, in particular, 
DNA. (9) PARP-1 is synthesised in an attempt to repair damaged DNA; however, this consumes remaining 
NAD+, necessary for producing ATP via glycolysis. This leads to complete energy starvation and necrotic cell 
death. (10) Mitochondrial dysfunction also results in the generation of caspase 3 via cytochrome c, initiating 
programmed cell death via apoptosis. (11) In concert, these processes cause complete ATP starvation, 
irreparable damage to cellular structures and, consequently, cell death. AMPA, a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid; ASIC, acid-sensing ion channel; ATP, adenosine triphosphate; CAS 3, caspase 3; 
DNA, deoxyribonucleic acid; NAD+, nicotinamide adenine dinucleotide; NKCC1, Na+‐K+‐2Cl− co‐transporter 
1; NMDA, N-methyl-D-aspartate; nNOS, nitric oxide synthase; PARP1, poly(ADP-ribose)polymerase-1; 
PMCA, plasma membrane Ca2+-ATPase; PSD-95, post-synaptic density protein 95; ROS, reactive oxygen 
















1.3 CEREBRAL OEDEMA 
 
Irreparable cell damage arising in the minutes post-stroke precipitates numerous secondary 
injury processes, which continue to develop in the days to weeks post-ictus (Muir, 2013). Of 
these injury processes, cerebral oedema is the leading cause of patient deterioration in the 
week following stroke, accounting for significant morbidity and mortality (Hacke et al., 
1996). Cerebral oedema is defined as the excess accumulation of water in the intracellular 
and/or extracellular spaces of the brain (Jha, 2003). Development commences shortly after 
cessation of blood flow and evolves in stages, which are broadly classified as cytotoxic, 
ionic and vasogenic oedema. 
 
1.3.1 Cytotoxic Oedema 
Cytotoxic oedema, characterised by the oncotic swelling of both neuronal and glial cells 
(Figure 1.5), is reported to occur as early as 30 minutes following the onset of ischaemia and 
persists for up to 24 hours (Liebeskind et al., 2019, Steiner et al., 2001b). Here, cellular 
swelling arises because of disrupted ion homeostasis and predominantly affects the cell 
bodies in the parenchymal grey matter (Ayata and Ropper, 2002, Battey et al., 2014). Driving 
this process is the aforementioned dysfunction of Na+/K+-ATPase pumps and amplified 
activation of NMDA receptors, both of which lead to an abnormal and excessive 
accumulation of intracellular Na+ and Cl− (Brogan and Manno, 2015). In addition, non-
selective cation channels, upregulated as a result of ischaemia, provide an additional 
pathway for Na+ influx. ATP depletion triggers calcium-activated, ATP-sensitive non-
selective cation (NCCa-ATP) channel opening, whereby sulfonylurea receptor 1 (SUR-1), 
the pore-forming and regulatory subunit of the receptor, is transcriptionally upregulated 
within 2–3 hours of ischaemia (Simard et al., 2006), permitting the excessive influx of Na+ 
into neurons (Liang et al., 2007). Transient receptor potential (TRP) channels and non-
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selective K+ channels enable a steady efflux of K+; however, there remains a significantly 
greater influx of Na+ to efflux of K+, facilitating neuronal accumulation of Cl− (Simard et 
al., 2007). As a result of these processes, there is a net intracellular accumulation of 
osmotically active molecules, predominantly Na+ and Cl−. This significantly increases 
intracellular osmotic pressure and drives water influx via aquaporin channels (AQP), in 
particular AQP4 (Lo et al., 2005). Although both neuronal and glial cells are affected, 
astrocytic cytotoxic swelling is more prominent than neuronal (Liang et al., 2007). 
Astrocytes are more prone because of their involvement in clearance of K+ and glutamate, 
which ultimately results in cell overload and consequent water inflow. Because of 
extracellular K+ accumulation, NKCC1 is upregulated in astrocytes, but not neurons, and 
AQP4 is shown to be overexpressed in astrocytic end-feet acutely post-stroke, facilitating 
water inflow (Clément et al., 2020). Together, this causes significant cellular swelling and 
ultimately precipitates bleb formation, in which morphological changes to the membrane 
architecture predispose the cell to rupture (Liang et al., 2007). 
 
Given the significant energy crisis and ionic imbalances that ensue immediately following 
ischaemia, cytotoxic oedema is most prominent in the acute stages. Beyond 24 hours, the 
infarct is considered mature, having succumbed to ischaemic injury, and thus cytotoxic 
oedema development declines (Stokum et al., 2016, Michinaga and Koyama, 2015). Despite 
an increase in intracellular fluid and cell size, brain volume remains relatively constant in 
this setting (Simard et al., 2007). Loss of membrane integrity and inflow of water and solutes 
in cytotoxic oedema, however, comes at the expense of the extracellular space, with the 
volume markedly reduced (20% to 4–10%) (Liang et al., 2007). Extracellular depletion of 





Figure 1.5. Development of cerebral oedema following stroke. (A) Physiological conditions: Na+/K+-
ATPase pumps are active and maintain a greater net extracellular concentration of Na+ than within neuroglial 
cells. (B) Cytotoxic oedema: In the minutes post-stroke, Na+/K+-ATPase pump failure permits the excessive 
intracellular accumulation of Na+ and subsequent compartmental shift of water from the interstitial to the 
intracellular space, leading to an increase in intracellular volume and oncotic neuroglial cell swelling. (C) Ionic 
oedema: Depletion of extracellular ions due to cytotoxic oedema leads to the transcapillary formation of ionic 
oedema, in which Na+ from the blood crosses the intact BBB to replenish reserves, leading to additional 
movement of water via osmosis. Here, intracellular volume remains elevated, but extracellular volume remains 
consistent. (D) Vasogenic oedema: Dissolution of barrier integrity permits uncontrolled extravasation of ions 
and large molecules into the parenchyma, leading to excessive accumulation of water, increase in extracellular 
volume and gross increase in total brain volume. Cells have undergone morphological changes to the cell 
membrane, predisposing them to rupture and further contributing to barrier dissolution and vasogenic oedema 
development. Dashed arrows indicate compartmental movement of Na+, whereas continuous arrows indicate 
movement of water. Note the relative time course post-stroke for each of these processes. ICV, intracellular 







1.3.2 Ionic Oedema 
Ionic oedema refers to the initial form of extracellular oedema in which ion depletion within 
the extracellular space creates a driving force for the movement of osmolytes across the 
intact capillary membrane to replenish interstitial concentrations (Stokum et al., 2016). Here, 
increased activity of barrier Na+/H+ exchangers, Na+-K+-Cl− cotransporters or the calcium-
activated potassium channel KCa3.1 enhances transcellular transport of Na+ and Cl− from 
the blood, into the brain, across the intact BBB (O'Donnell et al., 2004, O'Donnell et al., 
2013). Ionic oedema precedes vasogenic oedema by approximately 6 hours and, unlike 
cytotoxic oedema, requires a minimal amount of CBF to deliver water and solutes to the 
endothelium (Liebeskind et al., 2019). Fluid is also hypothesised to be derived from the 
cerebrospinal fluid (CSF), with fluid movement facilitated by endothelial channels and 
transporters (Dobrivojevic et al., 2015). However, this gradient does not immediately 
manifest as mass fluid movement, and ultimately pathological brain swelling, until the 
permeability of the endothelial layer of the BBB is altered (O'Donnell et al., 2004). 
 
1.3.3 Vasogenic Oedema 
Vasogenic oedema occurs in the setting of BBB disruption and unlike cytotoxic and ionic 
oedema, which occur early following central nervous system (CNS) insult, begins to evolve 
as barrier disruption emerges, peaking at approximately 3–5 days post-stroke (Battey et al., 
2014, Hacke et al., 1996). During vasogenic oedema, there is an abnormal movement of 
water from the intravascular compartment to the extracellular space within the brain 




Under physiological circumstances, the BBB maintains a semi-permeable barrier between 
the brain and the circulating blood from the extracellular fluid (Simard et al., 2007). The 
neurovascular unit (NVU) is responsible for the integrity of the BBB and comprises a 
basement membrane, perivascular astrocytes, pericytes, neurons, microglia and endothelial 
cells, with each cellular and structural component playing an essential role in regulating 
movement of molecules across the barrier (Bell et al., 2020). Following stroke, cytotoxic 
oedema, neuroinflammation and ROS accumulation initiates BBB breakdown within 4–6 
hours of stroke onset (Dostovic et al., 2016). If blood flow through the occluded vessel has 
been re-established, as is the goal of reperfusion therapy, flow of blood through damaged 
vessels where integrity has been lost enables the extravasation of large serum proteins such 
as albumin from the intravascular to the extracellular space. This alters osmolarity across the 
barrier and provides a driving force for fluid accumulation predominantly within the white 
matter of the brain (Simard et al., 2007). As these processes continue to develop over the 
days following stroke onset, so too does the abnormal and excessive accumulation of 
parenchymal fluid. 
 
The pathological mechanisms by which BBB breakdown occurs following stroke is thought 
to be via two main routes. First, dissolution of endothelial tight junctions (TJs) following 
stroke enables abnormal paracellular movement of water and molecules between cells. 
Second, upregulated transcellular transport across endothelial cells may provide an 
alternative route for fluid entry. As vasogenic oedema is the focus of this thesis, these 
mechanisms are discussed in greater detail in Chapter 2. Recent evidence also suggests that 
compartmental movement of CSF may contribute to vasogenic oedema formation (Mestre 
et al., 2020). Indeed, disruptions to the glymphatic system (physiologically involved in 
cerebral waste regulation) have also been observed post-stroke, which may provide a route 
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for CSF to enter the infarcted hemisphere along perivascular spaces, thus contributing to 
oedema formation (Jessen et al., 2015). As a consequence of these cumulative processes, 
fluid accumulation in the extracellular space is markedly increased. Progressive vasogenic 
oedema within days of stroke onset leads to an increased parenchymal extracellular water 
content of more than 100% and, consequently, a significant increase in overall brain volume, 
which has implications for intracranial pressure (ICP) (Ayata and Ropper, 2002, Battey et 
al., 2014). 
 
1.4 ELEVATED INTRACRANIAL PRESSURE 
 
An increase in total brain volume within the closed cavity of the skull as a result of vasogenic 
oedema leads to a consequent rise in ICP (Battey et al., 2014, Brogan and Manno, 2015). 
Unfortunately, the development of cerebral oedema and concomitant rise in ICP are the 
leading cause of death in the first week following stroke, with the mortality rate of malignant 
cerebral oedema approaching 80% in the setting of large vessel occlusions, such as the MCA 
(Battey et al., 2014, Hacke et al., 1996, Zhang et al., 2014). 
 
1.4.1 Cerebral Autoregulation 
Normal ICP lies between 0 and 15 mmHg, with elevations in pressure greater than 25 mmHg 
associated with an increased risk of death and disability following stroke (Hewitt and Ellory, 
2012). The skull and underlying inelastic dura mater restrict the expansion of the brain tissue; 
therefore, when the volume of one of the cerebral compartments is increased (brain tissue, 
arterial blood, venous blood or CSF), this must be compensated for by a decrease in one of 
the other compartments, a phenomenon explained by the Monro-Kellie doctrine (Ropper, 
2014). Cerebral autoregulation is a complex, multifactorial process that permits 
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physiological regulation of the cerebral compartments to ensure constant CBF. CBF is 
dependent on cerebral perfusion pressure (CPP), which is defined as the net pressure gradient 
required to supply adequate oxygen and nutrients to neuronal cells (Mount and J, 2021). CPP 
is determined by the difference between ICP and mean arterial blood pressure (MABP), 
where: CPP = MABP – ICP. 
 
In the initial stages of vasogenic oedema development, only small increases in ICP are 
observed as compensatory autoregulation is able to maintain ICP within normal limits. 
However, once compensatory mechanisms are exhausted, the increased volume of the 
cerebral parenchyma results in progressively larger increases in ICP, such that ICP opposes 
MABP. This leads to a marked reduction in CPP, which adversely restricts blood perfusion 
to the brain (Jha, 2003). Compromised cerebral tissue perfusion exacerbates cell injury, 
resulting in further global ischaemia and initiation of a vicious cycle in which progressive 
cytotoxic oedema ensues (Jha, 2003). As vasogenic oedema continues to develop, cerebral 
autoregulation is further impeded and ultimately fails, with ICP rising unabated, resulting in 
devastating neurological consequences, including herniation (Ropper, 2014). 
 
1.4.2 Herniation Syndromes 
The human brain is relatively compartmentalised because of the presence of the fibrous dura 
mater, which forms intracranial folds such as the falx cerebri and tentorium cerebelli (Figure 
1.6). Pressure gradients exist between compartments, with development of hemispheric 
space-occupying oedema resulting in significant compartmental pressure increases 
(Dostovic et al., 2016, Shah and Kimberly, 2016). Persistently elevated ICP can force brain 
tissue to move between compartments in an attempt to relieve pressure, known as brain 
herniation (Shah and Kimberly, 2016). When brain tissue herniates, it can compress adjacent 
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structures, causing tissue deformation and additional constriction of blood vessels, further 
worsening tissue injury and causing neurological deficits and permanent tissue damage (Kim 
et al., 2015). There are several well-recognised anatomical herniation syndromes including 
central (transtentorial), transcalvarial, uncal and subfalcine herniation (Munakomi and J, 
2020). Life-threatening herniation occurs when the cerebellar tonsils herniate downwards 
through the foramen magnum, as occurs in tonsillar herniation, leading to compression of 
vital cardiorespiratory centres within the medulla oblongata (Freeman, 2015). This can lead 
to intermittent or complete cessation of cardiorespiratory functions and subsequent death 
(Kim et al., 2015). 
 
 
Figure 1.6. Evolution of intracranial pressure (ICP) following stroke. The pressure–volume curve for ICP 
has four zones. (1) Baseline intracranial volume under physiological conditions has good compensatory reserve 
and high compliance to minor volume fluctuations. (2) With evolving cerebral oedema and consequent 
increased brain and intracranial volume, gradual depletion of compensatory reserves occurs. (3) With persistent 
developing oedema and increasing brain volume, compensation is further reduced, with minimal compliance, 
leading to increased risk of cerebral ischaemia and herniation. (4) Critically high ICP causes collapse of the 
cerebrovasculature, increasing risk of permanent neurological dysfunction and death. Figure adapted from 
Harary et al., 2018. 
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Elevated ICP is thus commonly associated with devastating outcomes of death or persistent 
disability following ischaemic stroke (Pinto et al., 2020). It is largely accepted this is due to 
the effect of cerebral oedema and accumulation of fluid preceding vital tissue shifts (Steiner 
et al., 2001a). Nevertheless, one study has reported an elevation of ICP in the absence of 
cerebral oedema following ischaemic stroke in a rodent model, where it is proposed that 
increased CSF, as supported by the glymphatic theory, may be driving elevated ICP (Murtha 
et al., 2015). In the case of larger hemispheric strokes, however, such as occlusion of the 
MCA, there is a positive correlation between cerebral oedema and elevated ICP (Engelhorn 
et al., 2002). Effective management of oedema and elevated ICP thus remains crucial to 
reduce death and disability following stroke. 
 
1.5 TREATMENTS FOR STROKE 
 
1.5.1 Reperfusion Therapy 
The main principle of treatment for ischaemic stroke involves timely recanalisation of the 
occluded vessel while improving collateralisation of blood flow (Rabinstein, 2020). The 
basis for early restoration of blood flow is to salvage penumbral cells, minimise permanent 
infarction and reverse neurological deficits. 
 
Currently, recanalisation is achieved via thrombolysis with tissue plasminogen activator 
(tPA) or mechanical thrombectomy (Rabinstein, 2020). Both therapeutic approaches are 
predicated on targeting the penumbra, with more brain tissue and subsequent neurological 
function able to be salvaged if a stroke is detected and treatment is received expeditiously. 
Evidence suggests efficacy of tPA when administered up to 9 hours post-stroke, which has 
markedly extended its previous therapeutic window of 4.5 hours (Ma et al., 2019). Recent 
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advances in mechanical thrombectomy hold significant promise, with evidence of 
efficacious outcomes up to 16 hours post-ictus (Albers et al., 2018, Nogueira et al., 2018, 
Berkhemer et al., 2015, Smith and Yan, 2015, Goyal et al., 2016, Goyal et al., 2015). 
However, this procedure is reliant upon highly trained technicians and necessary imaging 
facilities, thereby limiting accessibility, especially for those located remotely and in low-
income settings. 
 
1.5.2 Complications of Treatment – Reperfusion Injury 
While thrombolysis and reperfusion can prove beneficial, the restoration of blood flow can, 
in some instances, paradoxically worsen injury. Reperfusion at any time post-stroke where 
there is no viable penumbra to salvage can cause additional injury to neuronal tissue and 
associated vasculature, termed ischaemic reperfusion (I/R) injury (Mandalaneni et al., 2020). 
In such instances, restoration of oxygen can lead to aggravated production of ROS, where 
hypoxanthine, which has built up during ischaemia, is rapidly metabolised, leading to 
production of O−, OH and hypochlorous acid. This is further exacerbated by overproduction 
of ROS by mitochondria due to reverse electron transport (RET) when oxygen availability 
is reinstated. In concert with aberrant ROS production, activation of platelets and neutrophils 
lead to exacerbation of neuroinflammation, amplifying BBB dysfunction (Woodruff et al., 
2011). Accordingly, timely access to advanced brain imaging including specialist perfusion 
computed tomography (CT) or magnetic resonance imaging (MRI) is crucial to determine 
the volume of viable penumbra and the likelihood of benefit of reperfusion treatment. 
 
1.5.3 Reperfusion Therapy – Secondary Injury 
Finally, although reperfusion therapies have the potential to salvage the penumbra and 
improve neurological outcomes, unless received in a timely manner (ideally, within 6 hours 
26 
of stroke onset), treatment does not halt the progression of secondary injury processes and 
resultant development of cerebral oedema, and thus neurological dysfunction (Irvine et al., 
2018). Given the heterogeneous nature of stroke, the pathogenesis of secondary injury can 
vary significantly between patients; however, in the setting of MMCAI (being the most 
prevalent), it is estimated that if the initial insult is not fatal, up to 80% of survivors will die 
in the week following stroke because of development of cerebral oedema and the associated 
rise in ICP (Battey et al., 2014, Hacke et al., 1996, Zhang et al., 2014). Such patients often 
exhibit a progressive and slow evolution of brain injury, with surmounting cerebral oedema 
and excessively elevated ICP presenting days following insult due to progressive cellular 
and molecular changes as previously detailed (Battey et al., 2014). Therefore, cerebral 
oedema remains a target for both surgical and pharmacological therapeutic intervention 
(Brogan and Manno, 2015). 
 
1.6 TREATMENTS FOR CEREBRAL OEDEMA 
 
A number of modalities exist for the treatment of cerebral oedema and elevated ICP, 
including general patient management, pharmacotherapies and surgical intervention 
(Freeman, 2015, Wijdicks et al., 2014). Determining the appropriate clinical approach, 
however, demands the need to first identify the evolving pathology. Assessment of oedema 
is indirect and involves imaging via either MRI or CT, in addition to application of clinical 
monitoring devices to measure ICP. Interventions are then typically approached in a 
stepwise manner (Table 1.1), with low-intervention strategies first exhausted before more 




1.6.1 General Management Approaches 
Initial airway assessment is an important step in patient management, allowing for prompt 
intubation in comatose individuals (Jeon et al., 2014). Repositioning is undertaken to 
optimise venous drainage, with head elevation to 30 degrees proved to reduce ICP (Feldman 
et al., 1992, Shah and Kimberly, 2016, Schwarz et al., 2002). Such repositioning can, 
however, be associated with a concomitant decrease in CPP, which can offset any benefits 
to reduction of pressure (Kiening et al., 1997). 
 
Mechanical hyperventilation is also initially considered to bring about a prompt reduction in 
ICP through the reduction of cerebral blood volume (CBV) (Cook et al., 2020, Christensen 
et al., 1973). Carbon dioxide (CO2) is a potent cerebrovasodilator causing vasodilation of 
the cerebral arteries, increasing CBV and thus ICP (Simard et al., 2011). Accordingly, 
increasing respiration rate and decreasing the partial pressure of CO2 (pCO2) rapidly induces 
cerebral vasoconstriction, resulting in a reduction in CBV and ICP (Simard et al., 2011). 
Initially, modest hyperventilation is performed, with more aggressive pCO2 thresholds set if 
ICP continues to rise. However, the immediate efficacy of treatment is often associated with 
unsustained clinical effects and worsening of infarct volume (Stocchetti et al., 2005, Marion 
et al., 2002). Rebound vasodilation following homeostatic regulation of pCO2 and 
consequent return to baseline may also lead to worsening of cerebral oedema and subsequent 
elevation in ICP (Stocchetti et al., 2005, Marion et al., 2002, Simard et al., 2011). Further, 
to date, there is limited quality evidence regarding the efficacy of this approach and its ability 





1.6.2 Pharmacological Intervention 
1.6.2.1 Osmotherapy 
Osmotherapeutic agents used for the management of cerebral oedema and elevated ICP 
include mannitol and hypertonic saline (HTS) (Burgess et al., 2016). Their predominant 
mechanism of action is believed to be via rheological effects, whereby creation of an osmolar 
gradient within the bloodstream draws water from the brain into the intravascular space, 
thereby reducing total brain volume (Brogan and Manno, 2015). An alternate hypothesis is 
that osmotherapies reduce viscosity and cerebrovascular resistance, initiating compensatory 
vasoconstriction and resultant decrease in CBV (Muizelaar et al., 1983). Neuroprotection at 
a cellular level by osmotic agents has also been proposed, largely because of their ability to 
reduce oxidative stress and inflammation via cytokine-mediated pathways; however, limited 
rigorous evidence for this exists (Mojtahedzadeh et al., 2014). 
 
Mannitol has been used to treat acute stroke for more than 30 years (Bereczki et al., 2003). 
Early studies in large hemispheric infarction showed that mannitol administration reduced 
ICP (Schwarz et al., 1998) and increased CPP (Steiner et al., 2001a) when administered 
intravenously, although the effect on stroke outcome remained unclear. Investigations have 
since shown that administration does not have a favourable outcome on function and may 
be associated with heightened mortality independent of stroke severity (Bereczki et al., 2003, 
Papagianni et al., 2018). Further, use of mannitol is contraindicated where there is clear 
evidence of BBB breakdown (Witherspoon and Ashby, 2017) as repeated dosing may lead 
to mannitol accumulation within the brain parenchyma, paradoxically reversing the osmotic 
drive, leading to rebound oedema and resultant neurological deterioration (Brogan and 
Manno, 2015, Cho et al, 2007, Maioriello et al., 2002). Administration has also been shown 
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to cause adverse effects including activation of apoptotic cell death pathways, which can 
aggravate neuronal injury. 
 
HTS is also used to manage elevated ICP in the setting of post-stroke oedema (Cook et al., 
2020). Although its mechanisms of action are comparable to mannitol, it is able to cross the 
BBB less freely and thus may have a stronger osmotic effect (Jeon et al., 2014). Prior studies 
have shown a reversal of transtentorial herniation following HTS administration in a clinical 
setting, indicative of a reduction of cerebral oedema (Koenig et al., 2008). Reductions in ICP 
have also been shown, although such changes appear to be independent of dosing regimen 
(Harutjunyan et al., 2005), with dose frequency and strategy of administration varying 
significantly between studies (Harutjunyan et al., 2005, Schwarz et al., 1998). Despite its 
arguably greater efficacy compared with mannitol, it may still be of limited use if there is 
extensive barrier breakdown. Further, HTS administration is associated with a plethora of 
adverse effects including rebound cerebral oedema; hyperchloremic metabolic acidosis; 
phlebitis; congestive heart failure; transient hypotension; haemolysis; renal failure; osmotic 
demyelination; subdural haemorrhage; seizures; muscle twitching (Georgiadis and Suarez, 
2003); and decreased platelet aggregation, prolonged coagulation and subsequent bleeding, 
in addition to ion imbalances including hypochloraemia and hyperkalaemia (Hauer et al., 
2011, Surani et al., 2015). 
 
Each of the osmolar agents has its own inherent risks and complications. HTS is associated 
with a reduced risk of ICP treatment failure (Burgess et al., 2016) and therefore may be used 
preferentially to mannitol in some patients, for example, those with SAH and vasospasm, 
where insufficient volume depletion and hypotension may further compromise cerebral 
perfusion (Freeman, 2015). Regardless, both osmotherapies require extensive monitoring of 
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electrolytes, osmolarity and volume throughout treatment. Thus, osmotic therapy may be 
used as a temporary measure to buy time and prevent acute brain stem compression until 
other measures such as surgery can be performed (Grande and Romner, 2012). Further, 
ongoing administration of HTS and mannitol for the management of post-stroke cerebral 
oedema and ICP remains controversial, given a lack of high-quality randomised trials 
supporting their efficacy (Wijdicks et al., 2014). This is an important consideration given 
neither treatment targets the mechanisms underlying abnormal fluid movement and 
accumulation within the brain parenchyma, as they simply aim to reverse the osmotic drive 
to reduce brain tissue water content. 
 
1.6.2.2 Barbiturates 
Barbiturates have been used to reduce ICP because of their ability to increase vascular tone, 
reduce cerebral metabolism and inhibit free radical-mediated lipid peroxidation 
(Demopoulos et al., 1980, Kassell et al., 1980). Typically administered agents include 
pentobarbital and thiopental, which are preferentially given to patients with refractory 
intracranial hypertension in titrated doses (Jeon et al., 2014). Initially used as a defence 
against oedema and evolving brain injury in traumatic brain injury (TBI) patients (Eisenberg 
et al., 1988), barbiturate coma is used less frequently for the management of oedema post-
stroke given a lack of randomised control trials to support its efficacy (Wijdicks et al., 2014). 
Further, evidence suggests that barbiturate treatment can be associated with unsustained 
therapeutic properties and severe side effects, such as arterial hypotension and pulmonary 
failure (Bardutzky and Schwab, 2007, Schwab et al., 1997). Accordingly, barbiturate therapy 
is generally only used as a last-line therapy in extreme clinical situations (Mansour et al., 
2013), as the hypotensive effect of therapy is likely to offset any reduction in ICP following 
treatment (Roberts and Sydenham, 2012). 
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1.6.2.3 Corticosteroids 
Corticosteroid treatment for oedema management is predicated upon stabilising the BBB, 
thereby preventing its dissolution and the subsequent development of vasogenic oedema. 
While corticosteroid use has proved beneficial in the setting of intracranial tumours, there 
has been limited efficacy in the setting of ischaemic stroke (Ogun and Odusote, 2001). 
Further, there remains a significant discrepancy between clinical and experimental stroke 
studies, where efficacy of treatment is overwhelming in experimental stroke studies but 
evidence in clinical stroke is lacking (Davis and Donnan, 2004). A Cochrane review 
investigating the efficacy of corticosteroids in stroke deemed only 7 of 22 published trials 
acceptable for further analysis, with many studies reporting small patient cohorts, dosing 
discrepancies, incomparable assessment of outcomes and disparate conclusions (Qizilbash 
et al., 2002). Corticosteroid use for the treatment of cerebral oedema in stroke thus requires 
further assessment, with further inconclusive evidence regarding the benefit of steroid use 
on functional outcome and neurological impairment (Brogan and Manno, 2015, Sandercock 
and Soane, 2011). 
 
1.6.3 Surgical Intervention 
1.6.3.1 Ventriculostomy 
Ventriculostomy is often considered early in the clinical course of management, as invasive 
methods to measure ICP involve insertion of transducers directly into the lateral ventricle 
(Steiner and Andrews, 2006). To bring about a reduction in pressure, this procedure involves 
insertion of an intraventricular catheter and drainage of the CSF, thus reducing the fluid 
compartment (Andrade et al., 2011). Patients submitted to continual CSF drainage present 
with lower ICP levels and favourable outcomes following TBI (Andrade et al., 2011, Chau 
et al., 2020). In the setting of stroke, patients with herniation or cerebellar infarction may 
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present with acute hydrocephalus, whereby placement of a ventriculostomy may be of 
significant benefit. This should, however, be followed by decompressive craniectomy (DC), 
as benefits of CSF drainage are, unfortunately, often short-lived (Wintermark et al., 2013). 
 
1.6.3.2 Decompressive Craniectomy 
DC aims to alleviate elevated ICP through removing part of the skull and opening the 
underlying dura, allowing the oedematous brain to swell freely without the confines of the 
skull, thereby bringing about a rapid, lifesaving reduction in ICP (Yang et al., 2005). The 
exact nature of the DC, including the location and amount of bone removed, is dependent on 
the underlying pathology (Beez et al., 2019). In cases of MMCAI, for example, DC of the 
parietal bone is typically performed, enabling free swelling of the affected parietal lobe 
(Gupta et al., 2004). 
 
The clinical efficacy of DC in the setting of malignant cerebral infarction has been clearly 
established (DECIMAL, HAMLET, DESTINY and DESTINY II trials) (Vahedi et al., 
2007a, Vahedi et al., 2007b, Geurts et al., 2013, Jüttler et al., 2007, Hofmeijer et al., 2009). 
Nevertheless, timing of the procedure is a crucial factor in determining patient outcome as 
evidence suggests that surgery performed later than 24 hours post-ictus is associated with a 
heightened mortality rate (Kurland et al., 2015, Vahedi et al., 2007a). Therefore, early 
identification of evolving cerebral oedema is crucial in maximising treatment efficacy (Chen 
et al., 2007), as when DC is used only as a last resort after conservative physiological 
management and pharmacotherapy have failed to produce meaningful reductions in ICP, 
outcomes are predictably poor (Grindlinger et al., 2016). Further, given that DC surgery is 
highly invasive, there is an increased risk of iatrogenic injury, in addition to a higher 
mortality rate in those older than 60 years and increased likelihood of moderate to severe 
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postoperative disability (Hofmeijer et al., 2009, Vahedi et al., 2007b). Accordingly, the 
correlation between age and functional outcome remains an extremely important pre-
treatment prognostic factor in deciding if patients should undergo DC. Current clinical 
guidelines consequently recommended DC only be performed in patients younger than 60 
in the first 24 hours of symptom onset and prior to any clinical signs of herniation (Chen et 
al., 2007). Finally, although surgical decompression enables the rapid reduction of ICP, it is 
a physical measure and does not influence the evolution of BBB dissolution, or the 
mechanisms underlying the genesis of cerebral oedema. 
 
 






Imaging – confirm presence of space-occupying oedema 
ICP monitoring – determine ICP 




Head elevation and neutral neck position 
Ventriculostomy – CSF drainage 
Mechanical ventilation – light hyperventilation (PaC02 30–35 mmHg) 







Mechanical ventilation – moderate hyperventilation (PaC02 28–30 mmHg) 
If ICP remains >20mmHg, step 3 
  
STEP 3: 
ICP CONTINUES TO 
RISE UNABATED  
Barbiturate coma therapy 
Decompressive craniectomy 
CSF, cerebrospinal fluid; ICP, intracranial pressure; PaCO2, partial pressure carbon dioxide. Table adapted 








The burden of morbidity and mortality associated with cerebral oedema and elevated ICP, 
combined with the limitations of current treatments, emphasises the need for new treatment 
approaches. It is clear that existing treatments do not address the underlying injury 
mechanisms that lead to increased BBB permeability and subsequent development of 
cerebral oedema and elevated ICP. Indeed, there are currently no approved targeted 
treatments that interfere with key injury processes to reduce/reverse the evolution of BBB 
dysfunction and cerebral oedema following stroke. To develop more effective treatments, it 
is thus essential to elucidate the specific molecular mechanisms underlying post-stroke 
oedema genesis. Such an approach has the potential to markedly improve patient survival 
and outcome given it is directly targeting the injury mechanisms, and not simply treating the 
symptoms of cerebral oedema and elevated ICP once established. 
 
To this end, a number of novel therapies targeting cation channels implicated in the 
formation of cytotoxic oedema have been developed in an effort to prevent subsequent 
development of vasogenic oedema, including therapies targeting ASICs, and SUR-1-
regulated NCCa-ATP and TRP channels (Kimberly et al., 2014, Kimberly et al., 2018, Sheth 
et al., 2016a, Sheth et al., 2016b). However, given that cytotoxic oedema develops very early 
following stroke onset, it raises the question as to whether therapies targeting this aspect of 
cerebral oedema would alone be effective and provide clinical benefit beyond the acute 
phase following stroke. 
 
Neurogenic inflammation, specifically the release of neuropeptides such as substance P (SP), 
has been shown to be critically involved in BBB permeability changes and development of 
cerebral oedema following stroke. These processes develop in a delayed fashion and directly 
contribute to the formation of vasogenic oedema. Thus, targeting neurogenic inflammation 
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following stroke may be a strategy to reduce BBB permeability and in turn reduce delayed 




The increasing burden of stroke and concomitant development of cerebral oedema and 
elevated ICP is of significant clinical, and global, concern. This highlights the need for 
continued research and development of novel therapies targeting the mechanisms underlying 
ischaemic injury and oedema genesis. To this end, the following chapter will summarise the 
processes underlying neurogenic inflammation and its potential to be targeted 
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Originally characterised in peripheral tissues as a neurally elicited inflammatory process 
contributing to increased microvascular permeability and tissue swelling (Bayliss, 1901), 
neurogenic inflammation is now understood to occur following acute injury in the CNS. In 
the brain, neurogenic inflammation is characterised by the release of the neuropeptides SP 
and calcitonin gene-related peptide (CGRP). Increased SP expression is observed in 
perivascular tissue following stroke, with the magnitude of SP release being related to both 
the frequency and the degree of the insult. SP release is associated with profound BBB 
disruption and the subsequent development of vasogenic oedema, as well as neuronal injury 
and poor functional outcomes. Inhibition of SP through use of an NK1-R antagonist is highly 
beneficial following ischaemic stroke in preclinical models. In contrast, a beneficial role for 
CGRP has been delineated in stroke, given its potent vasodilatory effects (Omeis et al., 
2008). Therefore, modulating neuropeptides represents a novel therapeutic approach for the 
treatment of cerebral oedema following acute CNS injury. This chapter will provide an 
overview of studies supporting a role for neurogenic inflammation in increased BBB 
permeability, cerebral oedema formation and development of functional deficits following 
stroke. 
 
2.1 THE BLOOD–BRAIN BARRIER 
 
The BBB is a highly specialised, semi-permeable barrier existing between the brain and 
blood, which serves to maintain homeostasis of the cerebral microenvironment by restricting 
the passage of compounds and toxins into the CNS (Ballabh et al., 2004). Structurally, the 
barrier comprises an array of components including endothelial cells with TJs, adherens 
junctions, astrocytes, pericytes and the basement membrane (Ballabh et al., 2004) (Figure 
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2.1). Together, these components provide the structural integrity required to enable the 
barrier to maintain fundamental roles including supplying the brain with essential nutrients 
such as oxygen and glucose, mediating the efflux of waste products, and facilitating the 
movement of nutrients and plasma proteins (Begley and Brightman, 2003). 
 
 
Figure 2.1. Cellular and structural components of the blood–brain barrier. Figure adapted from ‘Brain 
vascular system’, by BioRender.com (2020). 
 
Under normal physiological conditions, nutrients and plasma proteins cross the BBB via two 
main transport mechanisms: paracellular and transcellular transport (Figure 2.2). 
Paracellular transport involves the passage of small solutes (<800 Da) between endothelial 
cells, as facilitated by TJs (Komarova and Malik, 2010). Conversely, transcellular transport 
is used by large plasma proteins, such as albumin, to cross the BBB via endocytosis. Vesicle-
mediated transport of albumin occurs following budding of structures called caveolae into 
vesicles that migrate to the plasma membrane, where they fuse and release their contents 
(Komarova and Malik, 2010). These caveolae are flask-shaped plasma membrane 
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invaginations abundant in endothelial cells of the BBB, where cholesterol and caveolins are 
fundamental structural components (Parton and Simons, 2007). Caveolin-1 is the integral 
protein essential for caveolae formation, as mice with genetic ablation of caveolin-1 lack 
caveolae (Le Lay and Kurzchalia, 2005), and cannot endocytose albumin from the 
vasculature (Schubert et al., 2001). Each of these transport mechanisms are, in turn, central 
to the maintenance and function of the barrier. 
 
2.1.1 Cellular Components of the Blood–Brain Barrier 
The main cellular component of the BBB are mesodermally derived endothelial cells, 
supported by astrocytes and pericytes. Astrocytes are an important component of the BBB 
and have been shown to influence both its structure and its function. Astrocytic end-feet 
envelope the endothelial cells, providing structural support and enhancing the TJs in between 
(Persidsky et al., 2006). Astrocytes are able to rapidly respond to pathological stimuli in their 
surrounding environment and do so through conversion to a hypertrophic state with 
increased expression of intermediate filaments such as glial fibrillary acidic protein (GFAP) 
(Sofroniew, 2000). Pericytes are the other key cellular component, and have diverse 
functions including regulation of capillary haemodynamics (Joo, 1993), permeability of the 
BBB, clearance of toxic metabolites, angiogenesis and neuroinflammation (Yang et al., 
2017). 
 
2.1.2 Tight Junctions 
Tight and adherens junctions form the junctional complexes that make up the BBB and 
comprise a complex network of transmembrane and cytosolic proteins, allowing these 
junctions to seal and mediate the gate function of the BBB (Lo et al., 2001). TJs are domains 
of occluded intercellular clefts, consisting of the integral membrane proteins occludin 
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(Furuse et al., 1993), claudins (Furuse et al., 2002), zonula occludin-1 (ZO-1) (Itoh et al., 
1993) and junctional adhesion molecules (JAMs) (Martin-Padura et al., 1998). 
 
Occludin was the first TJ protein identified and is one of the main junctional components 
(Chen et al., 1997). It consists of nine domains, with the second extracellular domain having 
a pivotal role in occludin assembly and localisation into TJs (Medina et al., 2000). This 
extracellular domain has also been implicated in altering TJ permeability when occludin 
levels decline (Wong and Gumbiner, 1997). It was initially suggested that occludin plays an 
important role in forming TJ-like structures (Furuse et al., 1996); however, TJ strands still 
develop in the absence of occludin (Saitou et al., 2000). Moreover, the morphology of TJs 
and trans-epithelial resistance in occludin-deficient mice do not differ from wild-type mice 
(Saitou et al., 2000), suggesting occludin is dispensable for TJ formation. 
 
Claudins play a major role in both establishing and maintaining properties of the barrier 
(Furuse et al., 2002, Nitta et al., 2003). Upon the discovery of claudin-1 and claudin-2, it 
was revealed that they, not occludin as previously thought, are the major contributors to TJ 
strand formation (Furuse et al., 1998). Indeed, claudin-5-deficient mice demonstrate a size-
selective loosening of the BBB, whereby the movement of small molecules across the barrier 
via paracellular transport is upregulated (Nitta et al., 2003). When Madin-Darby Canine 
Kidney Epithelial (MDCK) cells, a commonly used cell line to model the epithelium, were 
transfected with claudin-1, there was an increase in trans-epithelial resistance and a 
reduction in paracellular transport. This is in contrast to what has been demonstrated in 
occludin-deficient mice, where no changes in trans-epithelial resistance or paracellular 
transport were observed (Saitou et al., 2000). 
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ZO-1 belongs to the family of membrane-associated guanylate kinase (MAGUK) proteins 
(Gonzalez-Mariscal et al., 2000), and binds to the actin cytoskeleton, stabilising the TJs and 
contributing to their function. ZO-1 is also integral in mediating paracellular permeability 
(Fanning et al., 1998), with dissociation of ZO-1 leading to increased BBB permeability 
(Hawkins and Davis, 2005). In vitro studies have established roles for ZO-1 in endothelial 
cell–cell tension and recruitment of TJ proteins (Fanning et al., 1998, Jiao et al., 2011, 
Tornavaca et al., 2015). 
 
JAMs are immunoglobulin G (IgG) type proteins consisting of A-, B- and C- subtypes 
(Stamatovic et al., 2016, Martin-Padura et al., 1998). Comprising a single transmembrane 
domain, the cytoplasmic C-terminus interacts directly with ZO-1 (Bazzoni and Dejana, 
2004). JAMs are identified to play a key role in the formation of tubules and TJ complexes, 
as well as leukocyte adhesion and transmigration (Lamagna et al., 2005, Ebnet et al., 2003). 
Studies have observed reduced JAM expression and migration of JAMs from TJ complexes 
results in a loss of BBB integrity at the microvascular endothelium (Haarmann et al., 2010).  
 
These various components comprising the BBB are tightly regulated to ensure that integrity 
and functionality is maintained. Nevertheless, following acute CNS injury, disruption to the 
structure and function of the barrier results in profound changes in BBB permeability. 
 
2.2 MECHANISMS OF BLOOD–BRAIN BARRIER DISRUPTION POST-
STROKE 
 
Loss of structural integrity and heightened permeability of the BBB is a well-documented 
feature of ischaemic injury (Jiang et al., 2018, Yang and Rosenberg, 2011). The exact 
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mechanisms by which disruption ensues are debatable; however, acute hypertension, 
increased osmolality, classical inflammation, increased para/transcellular transport and 
enhanced activity of matrix metalloproteinases (MMPs) have all been implicated, among 
many others (Sifat et al., 2017). The timing and extent of such BBB permeability changes 
vary according to the severity and duration of the ischaemic insult. Nevertheless, it is 
accepted stroke is associated with both early and late alterations in permeability (Turner and 
Sharp, 2016), with the first alterations occurring within hours of stroke onset, and the second 
some 24–48 hours later (Rosenberg et al., 1998). For example, experimental stroke models 
have revealed that heightened barrier permeability observed at 4–12 hours post-stroke is 
attributable to elevations in caveolin-1 expression, driving changes in the transcellular 
pathway, followed by later disruption at 24–48 hours due to dysregulation of TJ proteins 
occludin, claudin-5 and ZO-1, which initiates changes in the paracellular pathway (Gu et al., 
2012, Nag et al., 2007). Further, increased activity of the MMP system has been implicated 
in post-stroke BBB permeability changes (Turner and Sharp, 2016). Specifically, very early 
BBB permeability alterations have been attributed to the activity of MMP-2, which loosens 
the TJs (Lakhan et al., 2013), whereas delayed permeability changes at 4 hours to 4 days 
post-stroke are linked to profound MMP-9-mediated degradation of the basal lamina (Mun-
Bryce and Rosenberg, 1998) and TJ components (Asahi et al., 2001, Clark et al., 1997). Such 
findings are in keeping with those of clinical stroke, with similar elevations in MMP levels 
observed in patients following ischaemic stroke (Anthony et al., 1997, Montaner et al., 2003, 











Figure 2.2. The blood–brain barrier under physiological conditions and following ischaemic stroke. (A) 
Under physiological conditions, transport across the barrier is regulated by TJs and absorptive mediated 
transcytosis via caveolae. (B) Following stroke, there is a loss of TJ integrity, leading to increased paracellular 
diffusion of water and ions. In addition, there is an upregulation of caveolae-mediated transcytosis, leading to 
an increased movement of albumin into the brain, with water following down its osmotic gradient. Cav-1, 
caveolin 1; ZO-1, zonula occludin 1; JAMs, junctional adhesion molecules; PECAM, platelet endothelial cell 
adhesion molecule; VE-cadherin, vascular endothelial cadherin; Na, sodium; H20, water. Figure created with 
BioRender.com (2020). 
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2.3 NEUROGENIC INFLAMMATION 
 
The concept of neurogenic inflammation was first described in the peripheral nervous system 
(PNS), where activated neurons of the dorsal root ganglia were observed to induce blood 
vessel vasodilation in the lower extremities (Bayliss, 1901). Following these early 
observations, the definition of neurogenic inflammation has evolved to encompass a painful 
local inflammatory response characterised by vasodilation, increased vascular permeability, 
tissue swelling and mast cell degranulation (Severini et al., 2002). In addition, there are 
tissue-specific responses such as smooth muscle contraction in the bladder, 
bronchoconstriction in the airways and ionotropic/chronotropic effects on the heart (Black, 
2002).  
 
Initiation of neurogenic inflammation occurs via activation of unmyelinated sensory c-
fibres. C-fibres respond to a plethora of stimuli including mechanical stimulation, changes 
in the extracellular environment (such as increased osmolarity, pH and temperature 
changes), and a variety of agents including prostanoids, leukotrienes, histamine and 
serotonin (Harrison and Geppetti, 2001, Lewis et al., 2013). Activation initiates release of 
neuropeptides SP, CGRP, neurokinin A (NKA) and neurokinin B (NKB), among others 
(Severini et al., 2002). These neuropeptides act as neuromodulators and neurotransmitters in 
physiological and pathological processes where they are responsible for slow-onset, long-
lasting modulation of synaptic transmission (Kleinman et al., 1985). In particular, SP is the 
most potent initiator of neurogenic inflammation, with CGRP able to further potentiate its 





2.3.1 Substance P 
SP is an 11 amino acid peptide member of the tachykinin peptide family (Figure 2.3), 
produced from alternative splicing of the preprotachykinin A gene (Hokfelt et al., 2000, 
Leeman and Ferguson, 2000, Maggi, 1995). SP is released from primary afferent neurons 
where it acts as a neurotransmitter. Under normal conditions, SP is synthesised and stored 
within both peripheral and central neurons (Hokfelt et al., 2000, Maggi, 1995, Otsuka and 
Yoshioka, 1993), with activation or damage of these neurons resulting in the rapid release 
of SP (Harrison and Geppetti, 2001, Hokfelt et al., 2000). SP may also be released from non-
neuronal cells, including inflammatory and endothelial cells (Hokfelt et al., 2000). 
 
SP is widely distributed throughout both the CNS and the PNS and released in response to 
Ca2+-dependent depolarisation of neurons via various stimuli including changes in pH, 
electrical stimulation and ligand binding (Harrison and Geppetti, 2001). Within the CNS, 
the greatest SP immunoreactivity has been demonstrated in the amygdala, nucleus caudatus, 
putamen, globus pallidus, hypothalamus, substantia nigra, locus coeruleus and dorsal horn 
of the spinal cord (Severini et al., 2002, Sutoo et al., 1999, Ribeiro-da-Silva and Hokfelt, 
2000). Within the PNS, SP is found throughout the enteric nervous system, respiratory tract, 
urinary system, lymphoid organs, blood vessels and cellular components of the blood 
(Severini et al., 2002). Indeed, SP-containing sensory nerves surround virtually all blood 
vessels in the body, with cerebral arteries having a particularly dense supply (Zacest et al., 
2010, Edvinsson et al., 1983). 
 
Following release, SP mediates its effects via high-affinity binding to the NK1-R, but it may 
also bind with varying affinity to the NK2 and NK3 tachykinin receptors depending upon 
receptor density/availability (Regoli et al., 1994). The NK receptors are members of the 
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rhodopsin family of 7-transmembrane G-protein coupled receptors, with the G-proteins 
associated with the intracellular domain of the NK receptor responsible for the transduction 
of the SP signal. Stimulation of intracellular G-proteins results in increased expression of 
cyclic adenosine monophosphate (cAMP) and a cascade of events leading to regulation of 
ion channels, enzyme activity and changes in gene expression (Kavelaars et al., 1994, Regoli 
et al., 1994). 
 
 
Figure 2.3. Two-dimensional molecular structure of substance P. The chemical formula for SP is 
C23H21F7N4O3. The amino acid sequence is H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH. Figure 
created using ADC ChemSketch 10.1 and Inkscape. 
 
The NK1-R is distributed throughout the CNS and is ubiquitously expressed throughout the 
brain (Sutoo et al., 1999, Sutoo et al., 2000). Stimulation of the NK1-R by SP initiates 
various biological processes including vasodilation, smooth muscle contraction and 
relaxation and plasma protein extravasation (Campos and Calixto, 2000). In addition, roles 
for SP have been documented in nociception (Wu et al., 2005), learning and memory 
(Hasenohrl et al., 2000), and anxiety and depression (Rupniak and Kramer, 1999). SP has 
also been implicated in a number of different pathologies including migraine (May and 
Goadsby, 2001a, May and Goadsby, 2001b), anxiety (Ebner et al., 2004, Ebner and 
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Singewald, 2006, Ebner et al., 2008), inflammatory bowel disease (Riegler et al., 1999, 
Goode et al., 2003), asthma (Bertrand and Geppetti, 1996), TBI (Donkin et al., 2011, Donkin 
et al., 2009, Nimmo et al., 2004, Vink et al., 2004) and stroke (Turner et al., 2006, Turner et 
al., 2011, Turner and Vink, 2012). 
 
2.3.2 Calcitonin Gene-Related Peptide 
CGRP is a 37 amino acid neuropeptide, co-expressed with SP in neuronal tissue (Ohtori et 
al., 2002). It has two isoforms, a-CGRP (Figure 2.4) and b-CGRP, with a-CGRP more 
abundant in both the CNS (Lange et al., 2009) and the PNS (Rosenfeld et al., 1983). α-CGRP 
is formed from the alternative splicing of the calcitonin/CGRP gene located on chromosome 
11. CGRP is highly expressed in all vascular tissues, trigeminal ganglia and astrocytes 
(Moreno et al., 1999), and is particularly active in the cerebral circulation (Hanko et al., 




Figure 2.4. Two-dimensional molecular structure of a-calcitonin gene-related peptide. The chemical 




Calcitonin receptor-like receptor (CLR) is the receptor to which CGRP binds, and comprises 
two separate structures that come together, the G-protein coupled receptor CLR, and an 
accessory protein identified as receptor activity modifying protein (RAMP) (McLatchie et 
al., 1998). RAMP1 proteins are responsible for translocating CLRs to the plasma membrane 
so that CGRP molecules can bind to them. In the CNS, the CLR-RAMP1 receptor is 
primarily expressed along endothelial cells. CGRP release activates CLR-RAMP1, causing 
increases in cAMP, and resulting in potent vasodilation and increased blood flow (Bulloch 
et al., 1998, Zhang et al., 2010), with such CGRP-mediated vessel dilation located within 
the smooth muscle layer. CGRP has a particularly strong effect on cerebrovascular 
expansion (Omeis et al., 2008), and given it is co-stored and co-released with SP (Harrison 
and Geppetti, 2001), it is involved in neurogenic inflammation and potentiating the effects 
of SP (Legat et al., 2002). Beyond regulation of vascular tone, CGRP is also involved in 
angiogenesis, pain signalling, and the regulation of various behavioural processes including 
the stress response and fear-related behaviours (Legat et al., 2002, Oku et al., 1987).  
 
2.4 NEUROGENIC INFLAMMATION POST-STROKE 
 
Well documented in peripheral tissues (Severini et al., 2002), the concept of neurogenic 
inflammation as a response to tissue injury has more recently been extended to include the 
CNS (Nimmo et al., 2004, Turner et al., Stumm et al., 2001)(summarised in Figure 2.5). 
Intravenous SP administration induced a significant increase in plasma extravasation in the 
dura mater, an effect abolished by NK1-R antagonist pre-treatment (Cyrino et al., 2002). 
Further, activation of NK1-R on the vascular endothelium was shown to contribute to the 
development of cerebral oedema (Stumm et al., 2001). Similarly, treatment with capsaicin, 
which is known to bind to transient receptor potential vanilloid receptor subtype 1 (TRPV-
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1) receptors initiating release of SP (Tang et al., 2006), elicited a neurogenic inflammatory 
response within the dura mater following administration (Markowitz et al., 1987). Capsaicin-
induced neuropeptide depletion was shown to provide protection from neonatal 
hypoxia/ischaemic injury in rats, resulting in a reduction in infarct volume and apoptosis, 
and improved vascular dynamics, suggesting neuropeptides were mediating such effects 
(Khatibi et al., 2011). Indeed, initial studies in capsaicin pre-treated animals to deplete 
sensory neuropeptides have revealed that neuropeptide depletion prior to acute CNS injury 
is protective, with reductions in BBB permeability, cerebral oedema, and both motor and 
cognitive deficits (Nimmo et al., 2004, Turner and Vink, 2014). These studies clearly 
indicated a role for neuropeptides and neurogenic inflammation in such injury pathways. 
Subsequent studies have now clearly delineated a role for neurogenic inflammation in BBB 
dysfunction and genesis of cerebral oedema observed following acute CNS injury (Turner 
et al., Turner et al., 2011, Turner and Vink, 2012, Nimmo et al., 2004, Vink et al., 2004, 




Figure 2.5. Neurogenic inflammation following ischaemic stroke. Ischaemic insult and initiation of 
downstream injury pathways stimulate development of neurogenic inflammation via co-release of the 
neuropeptide’s SP and CGRP, which leads to vasodilation, increased BBB permeability and vasogenic oedema. 
This leads to a subsequent rise in ICP and decrease in CPP, and resultant global ischaemia, brain herniation, 
neurological dysfunction, disability and death. BBB, blood–brain barrier; CGRP, calcitonin gene-related 
peptide; CLR4, calcitonin receptor-like receptor 4; CPP, cerebral perfusion pressure; ICP, intracranial pressure; 
NK1-R, neurokinin 1 tachykinin receptor; RAMP, receptor activity modifying protein; SP, substance P. Figure 




2.4.1 Substance P in Stroke 
Following observations of SP release from the rabbit carotid body in response to hypoxia 
(Kim et al., 2001), such findings have been replicated in cerebral ischaemia (Turner et al., 
2006, Turner et al., 2011, Turner and Vink, 2012, Turner and Vink, 2014, Yu et al., 1997). 
Overexpression of SP has been observed following stroke, where release is associated with 
an exacerbation of ischaemic tissue damage and poor neurological function (Yu et al., 1997). 
Our group has since further explored the role of neurogenic inflammation in cerebral 
ischaemia (Turner et al., 2006, Turner et al., 2011, Turner and Vink, 2012, Turner and Vink, 
2014). We have shown that at 24 hours following stroke with reperfusion in a rodent model, 
SP immunoreactivity was increased in penumbral tissue, but not within core tissue, of the 
infarcted hemisphere (Turner et al., 2006). Such increases in SP immunoreactivity were 
observed in conjunction with significant disruption of the BBB, as measured by Evan’s Blue 
extravasation, in addition to profound cerebral oedema and persistent functional deficits 
(Turner et al., 2006, Turner et al., 2011, Turner and Vink, 2012, Turner and Vink, 2014). A 
similar SP profile has been observed clinically, with elevated SP levels shown to be present 
in the serum of patients with complete stroke or transient ischaemic attack (TIA) at 12–24 
hours following onset (Bruno et al., 2003). Serum SP levels were on average 4-fold higher 
in stroke/TIA patients compared with healthy controls at 12 hours and began to decline at 
24 hours following injury. Taken together, these findings indicate that neurogenic 
inflammation, and in particular SP release, is a feature in ischaemic stroke that appears to be 
central to changes in BBB permeability and subsequent development of cerebral oedema. 
 
2.4.2 Calcitonin Gene-Related Peptide in Stroke 
Given its role as a potent vasodilator, it is not surprising that CGRP has also been 
investigated in the setting of cerebral ischaemia as a potential neuroprotectant. Indeed, 
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CGRP release is observed to increase under stressful conditions and following ischaemic 
tissue damage (Shao et al., 2015). This is in contrast to reports of reduced local CGRP levels 
following murine stroke with reperfusion, which is not conducive to the repair of damaged 
tissue (Zhang et al., 2011a). However, leptin treatment was shown to enhance CGRP 
expression and in turn reduce infarct volume and both neuronal apoptosis and necrosis, while 
also improving regional CBF. Further, CGRP has been proposed as a modulator of post-
stroke depression (PSD), following observations that both CSF and hippocampal levels of 
CGRP were elevated in a rodent PSD model (Shao et al., 2015). Indeed, 
intracerebroventricular administration of CGRP enhanced PSD symptoms in a dose-
dependent manner, suggesting PSD is mediated, at least in part, by CGRP. A similar pattern 
has been observed in clinical depression, with elevated CGRP levels recorded in the CSF of 
depressed patients (Mathe et al., 1994). Such findings indicate alterations in CGRP levels 
following stroke are more varied than those of SP and are highly dependent on the nature 
and severity of injury. Nevertheless, the increase in CGRP levels observed in some studies 
may represent a protective response to improve CBF and maintain tissue perfusion in the 
setting of cerebral ischaemia. 
 
2.5 NEUROGENIC INFLAMMATION AND THE BLOOD–BRAIN BARRIER 
 
It is well established that neurogenic inflammation increases BBB permeability; however, 
the exact mechanisms by which neurogenic inflammation, and specifically release of SP, 
precipitates such alterations following stroke remain unclear. 
 
Some studies have reported SP/NK1-induced alterations in BBB integrity. Application of 
SP to cerebral capillary endothelial cell cultures has been shown to reduce the expression of 
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TJ components ZO-1 and caludin-5, although immediately following this, TJs were observed 
to be intact (Lu et al., 2008). In fact, it appears that SP may exert its initial effects on 
transcellular rather than paracellular transport across the BBB specifically by increasing 
transcytosis via the activation of caveolae-mediated transport. Indeed, the NK1-R is 
localised in caveolae within endothelial cells, and upon stimulation, can alter its expression 
or location, suggesting that it plays a dynamic role in this environment (Kubale et al., 2007, 
Monastyrskaya et al., 2005). In keeping with these findings, SP-induced stimulation of the 
NK1-R has been shown to stimulate the relocation of protein kinase C-α to caveolae, a 
process integral to the internalisation of caveolae and therefore transcellular transport across 
the barrier (Mineo et al., 1998). 
 
However, the effects of SP on the BBB are not solely limited to alterations in permeability, 
with activation of the NK1-R by SP leading to increased migration of leukocytes, such as 
monocytes and neutrophils, across the barrier into the brain parenchyma via chemotactic 
effects (Cao et al., 2000, Souza et al., 2002, Schratzberger et al., 1997); increased endothelial 
cell expression of adhesion molecules (Annunziata et al., 2002, Toneatto et al., 1999, Li et 
al., 2008, Vishwanath and Mukherjee, 1996); and the exacerbation of local chemokine 
production (Ramnath and Bhatia, 2006). Indeed, SP applied to cultures of cerebral 
endothelial cells led to a dose-dependent increase in intracellular adhesion molecule-1 
(ICAM-1), observed in conjunction with an increase in T cell adherence. Such findings 
suggest that increased SP levels in the setting of neurogenic inflammation have the capacity 
to increase the infiltration of inflammatory cells into the CNS tissue, in turn exacerbating 
the local neuroinflammatory response to acute CNS injury through the production of free 
radicals, pro-inflammatory cytokines and proteases targeting the extracellular matrix, such 
as MMPs (Corrigan et al., 2016a).  
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Taken together, it is evident neurogenic inflammation plays a role in altering BBB 
permeability, along with a capacity to perpetuate classical inflammation by enhancing 
immune cell trafficking into the brain, both of which lead to worsening of injury. Given the 
role of the SP/NK1 system in alterations to BBB permeability and transport following acute 
CNS injury, modulating neurogenic inflammation may represent a novel treatment target to 
interfere with this key injury cascade. 
 
2.6 TARGETING NEUROGENIC INFLAMMATION POST-STROKE 
 
Given the clear evidence that neurogenic inflammation is a feature of stroke associated with 
increased BBB permeability, genesis of cerebral oedema and the development of persistent 
functional deficits, it may represent a novel target for the treatment of cerebral oedema. 
 
2.6.1 Neurokinin 1 Receptor Antagonists in Stroke 
NK1-R antagonists are currently widely used clinically in patients undergoing chemotherapy 
to combat treatment nausea, with administration well tolerated by patients (Huskey et al., 
2003, Inoue et al., 2017). NK1-R antagonists are also proposed to possess anxiolytic and 
antidepressant properties (Ibrahim and Preuss, 2020, Varty et al., 2003). Compounds 
currently approved for clinical use include aprepitant, casopitant, fosaprepitant, maropitant, 
netupitant and rolapitant (Figure 2.6). However, despite existing therapies, the potential 
utility of NK1-R antagonism for the treatment of cerebral oedema following stroke is yet to 




Figure 2.6. Two-dimensional molecular structures of currently in use neurokinin 1 receptor antagonists. 
The formulas for each of these agents are as follows: aprepitant, C23H21F7N4O3; casopitant, C30H35F7N4O2; 
fosaprepitant, C23H22F7N4O6P; maropitant, C32H40N2O; netupitant, C30H32F6N4O and rolapitant, C25H26F6N2O2. 
Chemical structures created using ADC ChemSketch 10.1 and Inkscape. 
 
Yu and colleagues were the first to demonstrate preclinically that the NK1-R antagonist SR-
14033 reduced infarct volume and improved neurological function when measured at 24 
hours following focal cerebral ischaemia (Yu et al., 1997). Despite these initial positive 
results, no further studies were conducted. Our group has since extensively characterised the 
effect of NK1-R antagonist treatment following stroke. We have shown that NK1-R 
antagonist treatment at 4 hours post-stroke in a rodent model was associated with a 
significant reduction in BBB permeability and cerebral oedema, as measured at 24 hours 
(Turner et al., 2011). Further, this was associated with a recovery of behavioural function to 
baseline levels within 4 days of stroke onset. Despite this, no effect on infarct volume was 
observed. Nevertheless, function is a clinically useful measure of outcome and is often the 
endpoint in clinical trials. We have since demonstrated that NK1-R antagonist treatment is 
effective in mild to severe stroke, with a therapeutic window of up to 8 hours post-stroke for 
motor improvements and 12 hours post-stroke for sensory function improvements (Corrigan 
et al., 2016b). Further, we have demonstrated that NK1-R antagonist treatment can safely 
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and effectively be combined with tPA thrombolysis (Turner and Vink, 2012). Further, NK1-
R antagonist treatment also limited the effects of reperfusion injury by reducing tPA-induced 
BBB permeability changes and complications such as haemorrhagic transformation. 
 
2.6.2 Calcitonin Gene-Related Peptide Agonists in Stroke 
Given its potent vasodilatory actions, CGRP has been shown to have neuroprotective actions 
in ischaemia (Bucinskaite et al., 1998, Cai et al., 2010, Kjartansson and Dalsgaard, 1987, 
Liu et al., 2011, Tam and Brain, 2004). Indeed, increased CGRP immunoreactivity showed 
a positive correlation with tissue flap survival following ischaemia (Bucinskaite et al., 1998). 
Despite this, investigations of CGRP treatment following stroke remain limited. Early CGRP 
intervention following brain injury can significantly reduce neuronal apoptosis and tissue 
damage while maintaining nerve regeneration (Macdonald et al., 2007). CGRP induces dose-
dependent increases in vasodilation post-ischaemia, enhancing reperfusion and potentially 
contributing to penumbral rescue (Tam and Brain, 2004). Indeed, CGRP pre-treatment 
reduced infarct volume by 57% and significantly improved CBF in rodent stroke with 
reperfusion (Holland et al., 1994). Further, CGRP administered at the onset of reperfusion 
produced a significant reduction in infarct volume, BBB permeability and cerebral oedema 
following stroke in a rodent model (Liu et al., 2011). Such positive treatment effects were 
observed in concert with a reduction in AQP4 expression, ultrastructural damage to 
endothelial cells and TJ loss, suggesting that CGRP mediated stabilisation of the BBB. 
Indeed, exogenous CGRP significantly increased CBF and protected neurons following 
cerebral ischaemia (Zhang et al., 2010). CGRP has also proved beneficial in haemorrhagic 
stroke, given its ability to counteract vasoconstriction in human SAH (Juul et al., 1994). 
CGRP is also central to the mechanisms underlying remote preconditioning, with 
intracerebroventricular morphine-induced remote preconditioning leading to increased 
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CGRP release in a dose-dependent manner. This suggests CGRP release is part of a 
protective response resulting in reduced lesion volume to protect ischaemic brain tissue from 
ischaemia/reperfusion injury (Zhang et al., 2011b). Such preconditioning effects were 
abolished when a CGRP release inhibitor was administered (Rehni et al., 2008). Further, 
delayed adrenomedullin (a member of the CGRP family) gene transfer 3 days following 
rodent stroke was associated with neuroprotection from the ischaemic insult, as evidenced 
by a reduction in infarct volume and apoptotic cell death combined with enhanced astrocyte 




It is clear that neurogenic inflammation is involved in enhanced permeability of the BBB 
following stroke and the subsequent development of cerebral oedema and poor functional 
outcome. In particular, SP is a key modulator of these processes, with NK1-R antagonist 
administration effective in reducing BBB permeability, cerebral oedema and functional 
deficits in preclinical rodent models of stroke. The role of CGRP following acute CNS injury 
is less clear; however, it has been clarified that CGRP-induced vasodilation improves 
outcomes in addition to stabilising the BBB. CGRP agonists should be further explored for 
their potential utility in improving CBF and stabilising the BBB following acute CNS injury. 
 
Given the inability of current treatments to target the mechanisms of BBB alterations and 
genesis of cerebral oedema and concomitant rise in ICP post-stroke, modulation of 
neurogenic inflammation through the administration of an NK1-R antagonist represents a 
novel therapeutic approach to treat cerebral oedema to both reduce mortality and improve 
outcome. Thus, targeting neurogenic inflammation may provide an alternate treatment 
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strategy that is more specific and efficacious than current pharmacotherapies used, and 
without the risk of invasive surgery. However, this requires evaluation and screening in a 
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While there have been significant advances in understanding the pathophysiology of stroke, 
the translation of novel pharmacotherapies from bench to bedside has unfortunately been 
extremely poor. Over 1000 agents identified to be efficacious in experimental stroke models 
have yielded only one successful clinical therapy to date (O'Collins et al., 2006). This gap 
between theory and practice needs to be urgently addressed to improve patient outcomes and 
survival. Studies in animal models have greatly enhanced our understanding of the molecular 
mechanisms underlying stroke. To date, the majority of preclinical stroke work has been 
conducted in rodent models, which are well established; easy to handle and cost effective; 
comprise large physiological databases; permit extensive behavioural assessment; and 
provide the ease and ability to study transgenic animals. However, there are also a number 
of disadvantages of rodent models, including their small lissencephalic brain, small 
proportion of white matter compared with higher species and flimsy tentorium cerebelli, 
each of which is important when studying the response of the brain to injury. Nevertheless, 
information from rodent studies has greatly advanced our knowledge of the pathophysiology 
of stroke, and these models remain key research tools for initial discovery studies. 
 
A potential strategy to improve clinical translation for stroke is the use of large animal 
models. Indeed, a set of preclinical guidelines has been established to improve the rigour of 
experimental stroke studies and increase their clinical predictive value (Fisher et al., 2009). 
These guidelines strongly recommend that after sufficient evidence of efficacy is obtained 
using rodent models, screening in large animal models should be conducted prior to 
commencement of clinical trials (Fisher et al., 2009). The use of such a large intermediate 
species may enhance successful translation to the clinic given the similarities in 
neuroanatomical structure to the human brain, and closer resemblance to the 
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pathophysiological and clinical manifestations of stroke. In light of these recommendations, 
the acute CNS injury field has moved towards incorporating more studies in large animal 
models as part of the preclinical assessment repertoire. To achieve this, however, the most 
suitable large animal species need to be identified, and both appropriate and reliable injury 
models developed and comprehensively characterised. 
 
Rabbits were among the first larger animal species to be investigated using cerebral 
ischaemia models, and their extensive use was pivotal in preclinical studies determining the 
efficacy of tPA, which to this day remains the only approved pharmacological agent for the 
treatment of ischaemic stroke (Zivin et al., 1985). Many intermediate species have also been 
used to model stroke, including ferrets and gerbils; however, some of these species are 
lissencephalic, such that more researchers are now including larger species in their 
experimental design given their definitive gyrencephalic brain structure. Large animal 
models of stroke are available in a range of species including feline, canine, ovine, porcine 
and non-human primate (NHP) models. The appropriate selection of such experimental 
species for preclinical assessment is absolutely essential (Casals et al., 2011) and needs to 
fit the specific research requirements, as different models may be required to answer 
different stroke pathophysiology questions, and it is unlikely to be a one-size-fits-all 
approach. 
 
This chapter summarises the available large animal models of ischaemic stroke, including 
discussion on the neuroanatomy, recommendations for large animal anaesthesia, surgical 




3.1 CEREBRAL STRUCTURE 
 
A rich diversity of animal species have been used to model stroke to date (Figure 3.1), and 
inter-species differences in cerebral anatomy, brain size and complexity are important 
considerations that may influence experimental outcome. In terms of gross brain size, the 
encephalic weight of all mammalian species generally correlates with overall bodyweight 
(Hofman, 1983, Economos, 1980). Because of their relative brain mass and neuronal 
complexity, large mammals are generally considered more intelligent than their small 
mammal counterparts (Roth and Dicke, 2005). However, absolute brain size does not 
correlate with overall intelligence (Falk and Gibson, 2001, Gibson et al., 2001). NHP species 
possess brains significantly smaller than ungulates, yet express distinct cognitive and 
behavioural superiority, advantageous for neurobehavioural testing (Roth and Dicke, 2005, 
Cook and Tymianski, 2012). Further, humans and NHPs have relatively thick cortices 
compared with rodents, containing numerous high-velocity neurons, leading to enhanced 
processing capacity (Roth and Dicke, 2005). 
 
Although lacking the neuronal complexity of the human brain, the use of small animal 
species, with small brain volumes, offers advantages in fixation procedures and relative 
strain heterogeneity (Fluri et al., 2015). Paradoxically, one of the main criticisms associated 
with past failures of neuroprotective agents and the use of rodent models is the vast 
differences in neuroanatomical structure compared with the human brain. Most notable is 
the lissencephalic (‘smooth brain’) structure of the rodent brain, lacking the cortical sulci 
and gyri of the human. Absence of a convoluted cerebral structure significantly decreases 
the cortical surface area to total brain mass ratio (Cook and Tymianski, 2011). Gyrification 
and enhanced surface area correlates with an increased number of neurons, which has 
implications for cortical functional organisation and development (Dubois et al., 2008). 
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The brains of larger animal species also lend themselves to superior quality MRI studies and 
offer the advantage of using the same instrumentation for physiological monitoring as is 




Figure 3.1. Gross comparative neuroanatomy of various large animal species used to model cerebral 
injury. Note the lissencephalic brain structure of the common marmoset and brown rat compared with the 
larger size and gyrencephalic structure of the dog, pig, sheep and rhesus monkey. Images adapted with 
permission from the University of Wisconsin and Michigan State Comparative Mammalian Brain Collections 
and National Museum of Health and Medicine Collection. Preparation of images and specimens funded by the 
National Science Foundation and the National Institutes of Health. 
 
3.1.1 White Matter 
Gyrencephalic brains have a higher proportion of sub-cortical white matter to grey matter 
compared with lissencephalic brains. White matter distribution correlates with absolute brain 
weight, and as large animal species generally have a greater brain mass they consequently 
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have a higher white to grey matter ratio (Philip et al., 2009). Clinically, the incidence of 
stroke involving regions of white matter is high, and thus using an experimental species that 
has a comparable white to grey matter distribution to that of humans is of particular 
relevance. Further, grey and white matter tissue have different thresholds for injury (Cai and 
Wang, 2016). The white matter, containing the myelinated axons of neurons, is extremely 
vulnerable to the effects of ischaemia and irreversible axonal injury (Petty and Wettstein, 
1999). The neglect of white matter pathology has been exacerbated by ongoing use of 
rodents, which may be in part responsible for the plethora of neuroprotective agents, proven 
in their ability to successfully reduce grey matter damage, failing clinical trials (Dewar, 
1999). In comparison, large animals such as porcine, canine, feline and ovine species have 
a relatively high proportion of white matter. NHPs used for investigation of cerebral injury 
are unique in that they include both lissencephalic and gyrencephalic species. The reduced 
volume of white matter in rodents also has implications in oedema development. This may 
partially account for the considerable inconsistency with respect to ICP increases reported 
in rodents after acute CNS injury (Gabrielian et al., 2011). 
 
3.1.2 Meninges 
In addition to the encephalic structure of large animals, the relative meningeal organisation 
is of importance when considering the progression of injury following stroke. Large animal 
species have well-developed meninges, with a strong and fibrous dura mater comparable to 
that of the human (Wells et al., 2012). This is of particular relevance to studies investigating 
the development of cerebral oedema and resultant rise in ICP as primary outcome measures. 
When pathological and excessive increases in ICP occur clinically, the brain may herniate 
onto adjacent structures or through the foramen magnum onto the brain stem, owing in part 
to the strong tentorium cerebelli that prevents displacement of the brain (Wells et al., 2015). 
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The comparatively flimsy tentorium of the rodent allows movement of the brain downwards 
to accommodate increased volume, leading to inconsistencies in ICP response (Gabrielian 
et al., 2013, Kotwica et al., 1991). Further, the measurable lack of compartmentalisation 
between the cerebrum and cerebellum of the rodent makes herniation unlikely following 
MCAo (Wells et al., 2015). In comparison, the strong fibrous tentorium cerebelli of large 
animals, including that of the sheep and pig, prevents pressure from diffusing downwards to 
accommodate the increased volume of the oedematous brain, leading to accumulation in the 
supra-tentorial compartment. The resultant effect is extensive elevations in ICP, midline 
shift and herniation of the brain, all of which are seen clinically (Wells et al., 2015). The 
ability to successfully measure ICP following transient stroke allows for investigation of 
autoregulation and changes in CPP, which is an important factor influencing reperfusion and 
subsequent evolution of the ischaemic penumbra (Markus, 2004). The choice of an 
appropriate experimental species must therefore take into consideration the ability to achieve 
an injury of clinical relevance. 
 
3.2 CEREBROVASCULAR ANATOMY 
 
Despite the variations in gross neuroanatomical structure, cerebrovascular anatomy is 
largely analogous across all mammalian species, and basic neural and vascular patterns are 
well conserved (Ashwini et al., 2008). In general, large animals have a greater 
cerebrovascular volume and vessel diameter than their small animal counterparts. Blood 
circulation and cerebral metabolism requirements in mammals are directly related to body 
weight, which has significant implications when choosing an appropriate experimental 
model (Dirnagl, 1999). Glucose and oxygen requirements in humans are three-fold greater 
than small animals, and thus the use of larger species with greater blood volume and energy 
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requirements is more clinically applicable, which is especially relevant when modelling 
stroke. 
 
3.2.1 Circle of Willis 
Blood is supplied to cerebral hemispheres by the circulus arteriosus cerebri, or coW. This 
circular anastomosis is located at the base of the skull and is composed of the ACAs, anterior 
communicating artery (ACoA), PCAs, posterior communicating cerebral artery (PCoA) and 
ICAs. The MCA is considered a natural continuation of the ICA, and although it is not part 
of the circle per se, occlusion of the MCA or its anastomoses is associated with the highest 
incidence of ischaemic stroke (Olsen, 1985, Nogles and Galuska, 2020). The basilar artery 
(BA) gives rise to the left and right PCAs and is formed by the vertebral arteries (VAs), 
which supply blood to the brain stem, cerebellum and upper spinal cord. Although the VAs 
and BA do not compose the coW, they are a common route of entry for endovascular 
approaches to stroke induction. 
 
3.2.2 Inter-species Circle of Willis Variations 
The coW is relatively well conserved in all mammalian species (Figure 3.2), and therefore, 
the relative reproducibility of stroke in both rodent and large animals has generally been 
high, enabling the generation of lesions comparable to those seen clinically (Ashwini, 2008). 
Despite similarities, however, there are several key differences between species that may 









Figure 3.2. Comparative cerebrovascular anatomy of the circle of Willis. MCA, middle cerebral artery; 
ICA, internal carotid artery; ACoA, anterior communicating artery; ACA, anterior cerebral artery; PCoA, 
posterior communicating artery; PCA, posterior cerebral artery; BA, basilar artery; VA, vertebral artery. 






In ungulate species, the relative length and calibre of the PCoA is significantly greater than 
that of humans (Kapoor et al., 2003, Ashwini et al., 2008, Deepthi et al., 2016). In both 
porcine and ovine species, the PCA arises directly from the PCoA, rather than the BA, which 
may contraindicate their use in models of PCA stroke. Further, evidence of inter-species 
variation indicates that some animals have a network that comprises the ACoA, while others 
have total absence of the anastomosis (Kapoor et al., 2003). This presence of an ACoA 
network may compromise methods of occlusion involving the ACA because of 
collateralisation, whereas ACoA hypoblastia may lead to worsening of outcome because of 
poor hemispheric blood redistribution. Ruminants have a significantly longer ICA than any 
other species, continuing forward along the ventral aspect of the optic chiasm prior to 
bifurcation into the MCA. This may benefit transcranial approaches to MCAo, as the 
proximal MCA is more easily accessible than other large animal species, allowing for better 
visualisation and vessel access, in turn favouring reproducibility (Kapoor et al., 2003). 
Importantly, both sheep and pigs have a reticulated arterial anastomosis between the 
maxillary and internal carotid known as the rete mirabile (Figure 3.3), responsible for 
thermoregulation (Hoffmann et al., 2014). This complex arterial meshwork is located in the 
cavernous sinus (Deepthi et al., 2016) and is of particular anatomical significance when 
considering endovascular models of cerebral ischaemia, which are rendered virtually 
impossible because of the narrow diameter of arteries that comprise the rete. 
 
 
3.2.2.2 Non-human Primates 
Baboons have a network of arteries that join to form a communication between bilateral 
ACAs, rather than the single vessel found in humans. Some species, however, show a high 
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incidence of complete ACoA hypoplasia, which may, as with ungulates, have repercussions 
for ACA stroke models. Further, in NHP species, 60% of animals contain 
triplication/bifurcation of one or more arteries, and 44% of animals exhibit arterial 
hypoblastia (Langfitt et al., 1966). Such anomalies are seen considerably less in ruminants, 
with reports of variations in approximately 20% of animals and no reported anatomical 
abnormalities in the coW in pigs (Ashwini et al., 2008). Irrespective of species, variations in 
large animals are significantly less than seen in humans, where up to 70% of individuals 
have arterial anomalies in the coW (Ashwini et al., 2008). 
 
3.2.2.3 Canines and Felines 
Dogs and cats report arteria intercarotica caudalis, an intracavernous connection between the 
ICAs, which may have implications for catheter insertion and guidance in endovascular 
methods (Nanda and Getty, 1975). Canines also have extensive leptomeningeal anastomoses 
branching from the PCA, MCA and ACA, potentiating variation in lesion volume due to 
collateralisation (Symon, 1960). Further, as with sheep and pigs, cats have a rete mirabile, 










Figure 3.3. Diagrammatic representation of the extracranial rete mirabile present in porcine and ovine 
species. Note the mesh-like structure of the rete, contraindicating endovascular approaches of vascular 
occlusion in these species. CC, common carotid; ECA, external carotid artery; BA, basilar artery; RM, rete 
mirabile; AP, ascending pharyngeal artery; PCA, posterior cerebral artery; OC, occipital artery; MCA, middle 
cerebral artery; ACA, anterior cerebral artery; IM, internal maxillary artery. 
 
Variations in cerebrovascular anatomy are an important consideration when choosing an 
experimental species as the choice of a particular genus can benefit model reproducibility 
due to anatomical homogeneity, whereas others may favour vascular/endovascular 
approaches. Despite individual variations, the choice of a species must always be made in 
concordance with the clinical condition to enhance translation, with both choice of animal 
and method of occlusion imperative.  
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3.3 SURGICAL CONSIDERATIONS FOR LARGE ANIMAL STROKE 
MODELS 
 
Surgical procedures required for large animal models of stroke are often more technically 
demanding, time consuming and complex than equivalent approaches in small animals such 
as rodents. In addition to extensive aseptic surgical theatre set-up and equipment required, 
often comparable to the clinical theatre environment, there are a number of key 
considerations to be addressed prior to commencing an experiment. Recommended 
anaesthesia, physiological monitoring, antibiotics and analgesia will be discussed in detail 
in the following sections in relation to feline, canine, ovine, porcine and NHP species. 
 
3.3.1 Anaesthesia 
Because of the complexity of surgical procedures required to induce cerebral ischaemia in 
large animal species, anaesthesia is required, often for prolonged periods. Although 
anaesthetic agents are often administered during neurosurgical procedures, it must be 
recognised that human patients are rarely under their influence when suffering a stroke, and 
this should be acknowledged as a potential variable. Nevertheless, principles that apply to 
clinical anaesthesia are recognised as appropriate for large animal models. These conditions 
best preserve normal neurological function throughout and thereby facilitate the accurate 
determination of deficits applicable to the induced injury. 
 
3.3.2 Pre-anaesthetic Considerations and Induction 
It is recommended that all large animals requiring long-duration anaesthesia be fasted prior 
to surgery to reduce the risk of intraoperative regurgitation. Veterinary practice recommends 
food be withheld for a minimum of 12 hours in feline, canine, porcine and NHP species (Hall 
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et al., 2001). There is some speculation regarding optimum fasting duration in ruminant 
species, as abstinence from food has been shown to have little effect on rumen contents 
(Riebold, 2002). Fasting may, however, reduce ruminal tympany, in which gas accumulates 
in the rumen because of the bacterial fermentation process. It is therefore advised that food 
and water be withheld for 6 hours to reduce gaseous accretion.  
 
For the purpose of all large animal surgery, it is highly recommended animals be induced 
with a sedative to ease handling and restraint, reduce distress and in turn decrease the 
required dose rate for maintenance anaesthesia by 30–50% (Flecknell, 2016a). Commonly 
reported induction agents and associated dosing regimens are detailed in Appendix 3.1. 
Anaesthetic induction and sedation also allows for ease of intubation and endotracheal tube 
insertion (Hendrickson and Baird, 2013). Intubation of the animal allows control of 
ventilation by mechanical means, thus facilitating regulation of the respiratory components 
of both pH and pCO2. Although spontaneous breathing is reported, it is often accompanied 
by hypoventilation and consequent increase in lesion volume (Laletin and Bykov, 2015). 
Controlled ventilation in large animals offers significant advantage over rodents and other 
small animals, which can be difficult to intubate because of the small circumference of the 
larynx. Physical intubation in large animals is fairly uniform across species. However, the 
laryngeal anatomy of porcine species is unique because of the situation of the larynx within 
an airway sigmoid curve, which may lead to intubation difficulties (Greene and Benson, 
2002). Consultation with an experienced veterinarian is therefore strongly advised prior to 
endotracheal tube insertion in these species. 
 
It is recommended that mechanically ventilated animals are maintained on a combination of 
air/oxygen or pure oxygen to both preserve blood oxygenation levels and meet metabolic 
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demands. The latter is influenced by variables such as temperature, body weight and 
anaesthetic agent used, and thus oxygen delivery must be adjusted accordingly (Robertson, 
2002). Maintaining animals on pure oxygen for durations of >12 hours is not recommended, 
however, because of the potential development of pulmonary oedema and oxygen toxicity 
(Greene, 2002). Further, the mechanical rate of ventilation for each species must be 
considered in relation to normal respiration rate and body mass to best maintain 
physiological pO2 and pCO2 levels (Pelosi et al., 1998). Species-specific physiological 
variables, including normal respiration rates and recommended ventilation, are summarised 
in Appendix 3.2. 
 
3.3.3 Anaesthetic Maintenance 
Following induction, intraoperative maintenance of anaesthesia can be achieved through the 
use of both intravenous and inhalational agents. The use of intravenous anaesthetic agents 
may be preferential for imaging purposes, where the use of equipment required for 
inhalational anaesthesia may be unfeasible, such as high-field MRI. However, inhalational 
agents are more frequently used, especially for longer-duration procedures. Inhalational 
anaesthetics agents used in rodent and large animal studies tend to be similar, with a 
preference for isoflurane commonly reported in canine, NHP, ovine and porcine models 
(Wells et al., 2015, Platt et al., 2014, Schwartz and Pile-Spellman, 2011, Christoforidis, 
2011). However, respiratory depression and hypotension associated with isoflurane 
administration (Hudetz and Pagel, 2010, Lin et al., 1997) contraindicate prolonged surgical 
use, requiring close monitoring of respiratory and blood pressure parameters, in conjunction 
with depth of anaesthesia. Maintaining animals on a level of isoflurane that maintains the 
minimum alveolar concentration (MAC) below 1.5% is highly recommended as it reduces 
the likelihood of adverse events (Aranake et al., 2013). Intravenous and inhalational 
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anaesthetics may therefore be used in combination to eliminate the likelihood of adverse 
events if an appropriate depth of anaesthesia is not achievable under 1.5% MAC isoflurane 
alone. This can be achieved through continuous intravenous infusion using a pump and 
adjusting dose rates to achieve the desired level of anaesthesia. Intravenous anaesthetic 
agents such as propofol and ketamine have been used in NHP, porcine and ovine studies in 
conjunction with inhalational anaesthetics with reported success (Aranake et al., 2013, 
D'Ambrosio, 2004, Imai et al., 2006, Wells et al., 2015, Lin et al., 1997). Recommended 
MACs of various inhalational anaesthetic agents are detailed in Appendix 3.3. 
 
Given the aforementioned length of anaesthesia required for many large animal models, the 
potential for neuroprotection brought about by anaesthetic regimen may contraindicate use 
of certain agents for extended durations. Valid animal modelling of acute CNS injury 
requires minimal interference from anaesthetic and analgesic agents to best preserve the 
natural course of brain injury, while minimising animal suffering (Rowe et al., 2013). Agents 
such as ketamine exhibit neuroprotective properties via inhibition of the NMDA receptor 
(Hudetz and Pagel, 2010, Orser et al., 1997), which has been shown to attenuate the 
deleterious neurochemical sequelae following brain injury (McIntosh et al., 1990). However, 
ketamine use has also been shown to increase cerebral oxygen metabolic rate (CMRO2), 
which has implications for lesion volume and number of neuronal cells affected (Chang et 
al., 2002). Maintenance of animals on a combination of ketamine and isoflurane may offer 
a beneficial alternative in surgical procedures requiring prolonged duration (>4 hours) 
anaesthesia and has been reported in porcine, ovine and NHP models (Wells et al., 2012, 
Schwartz and Pile-Spellman, 2011, Platt et al., 2014). This anaesthetic combination produces 
a countering effect, eliminating the neuroprotective effect of pure ketamine and the 
respiratory distress associated with pure isoflurane, thus reducing confounding factors of 
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either anaesthetic agent administered alone (Wells et al., 2012, Wells et al., 2015). A 
comprehensive summary of commonly used intravenous, intramuscular and subcutaneous 
anaesthetic agents and recommended dosing regimens is detailed in Appendix 3.4 and 
inhalational agents in Appendix 3.5. These can be used in conjunction with recommended 
regimens from Appendix 3.3. 
 
In addition to potential confounding effects of anaesthesia on outcome parameters, there are 
several species-specific complications that require consideration prior to study 
commencement. Pigs are especially prone to intraoperative development of malignant 
hypotension and hyperthermia, both of which can have fatal consequences (Wedel et al., 
1991, Linkenhoker et al., 2010, Claxton-Gill et al., 1993). Peri-anaesthetic mortality is also 
common in feline and canine species, some 100 times that of humans, and thus animals must 
be carefully monitored for depth of anaesthesia (Carter and Story, 2013). As a result of the 
fermentation process in ruminating species, surgical positioning must be carefully 
considered to avoid excessive pressure on the rumen as up to 25% of anaesthetised animals 
will regurgitate intraoperatively (Riebold, 2002). Irrespective of preoperative fasting to 
reduce ruminal tympany, in some cases, appropriate degassing should be performed to avoid 
excessive pressure on the diaphragm, which can limit ventilation (Carroll and Hartsfield, 
1996). Ruminants salivate excessively, such that for procedures requiring extended duration 
anaesthesia, it is highly recommended that the alkaline saliva is collected and returned to the 
animal via an orogastric tube to prevent the development of acidosis (Riebold, 2002). For 
other species, such as the cat and dog, pre-treatment with an anti-cholinergic agent such as 
atropine can significantly reduce intraoperative salivation.  
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Cumulative evidence calls for rigorous planning of anaesthetic regimens prior to study 
commencement, taking into consideration potential effects on depth and duration of 
anaesthesia, adverse events, and potential confounding effects of anaesthesia on secondary 
injury processes. 
 
3.3.4 Physiological Monitoring 
Physiological monitoring is not consistently reported in the rodent stroke literature as their 
small size makes the installation of monitoring devices technically challenging, and 
complications are often encountered. Large animal models offer significant advantages with 
the ability to assess and control physiological variables more easily given their size, and 
insertion of catheters, probes and other devices is more achievable compared with their 
rodent counterparts. Additionally, clinical monitoring equipment can often be used in these 
species, such as external blood pressure cuffs, pressure probes and electrocardiogram leads, 
increasing access to devices and improving clinical applicability. Physiological parameters 
such as MABP (Chileuitt et al., 1996, Patel et al., 1991), blood gases (Smrcka et al., 1998) 
and pH (Siesjo et al., 1996) have a substantial impact on outcome, and thus tight control is 
essential in surgical procedures inducing stroke to ensure consistency in lesion volume and 
injury severity. 
 
3.3.4.1 Arterial Blood Monitoring 
As a general rule, efforts should be made to ensure oxygen saturation is maintained at greater 
that 90% throughout surgical procedures, irrespective of species. Intraoperative control of 
pH and pCO2 is vital to ensure acidosis or alkalosis is avoided. Control of pH is especially 
important in ruminating species, such as sheep, which are predisposed to developing acidosis 
following preoperative fasting and intraoperative loss of saliva (Riebold, 2002). Acidosis 
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can be corrected with modification of the ventilation parameters, as previously described, or 
intravenous infusion of bicarbonate when buffer levels are low within the blood. If acidosis 
persists, it may become irreversible and lead to premature mortality or necessitate animal 
euthanasia, and thus timely correction of metabolic and respiratory components of pH is 
paramount. 
 
CO2 is a potent cerebral vasodilator, and a relative increase of 1 mmHg pCO2 equates to a 
1.8 mL/100 g increase in CBF (Thomas et al., 2017). In humans, normocapnia is between 
36 and 42 mmHg; therefore, it is recommended large animals are also maintained within 
these limits (Kitano et al., 2007). Hypercapnia in excess of 50 mmHg pCO2 disrupts cerebral 
autoregulation and CBF, which can have significant implications for both ICP and CPP, and 
thus needs to be tightly controlled in studies examining ICP post-injury (Robertson, 2002). 
It is recommended that for procedures requiring craniotomy and micro-clip application, 
moderate hypocapnia is maintained at approximately 28–32 mmHg pCO2 (Young and Stone, 
1994) to promote brain relaxation and permit gentle retraction of the brain during surgery. 
If pCO2 drops below 25 mmHg, however, vasoconstriction may occur to the point of 
inducing moderate hypoxia, leading to infarct expansion, and thus pCO2 must be strictly 
monitored and maintained (Way and Hill, 2011, Wollman and Orkin, 1968). 
 
3.3.4.2 Blood Pressure 
Intraoperative maintenance of blood pressure is essential to ensure adequate tissue perfusion. 
In small animals, MABP lower than 60 mmHg is associated with compromised tissue 
perfusion and increases the risk of global hypoxia and resultant ischaemia (Zhu and Auer, 
1995, Smith, 2002). However, in large animals, tissue perfusion is compromised with MABP 
lower than 70 mmHg (Greene, 2002). In survival models, long-duration hypotension with 
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MABP <70 mmHg can lead to skeletal muscle ischaemia and resultant post-anaesthetic 
myopathy (Smith, 2002). For short procedures, a non-invasive external blood pressure cuff 
applied to one of the limbs can provide periodical blood pressure measurements. However, 
for procedures of long duration (for example, non-survival experiments), intra-arterial 
measurement of blood pressure may be preferred and more accurate given it provides a 
continuous readout of blood pressure. This can be achieved via catheter insertion directly 
into the femoral artery, which can also be used for arterial blood sampling for blood gas 
analysis (Wells et al., 2012). Smaller arteries in the limbs tend to be used for arterial blood 
gas sampling in survival procedures via insertion of a small-gauge catheter, which can be 
removed at the end of the procedure without impeding the animal’s movement or recovery. 
 
3.3.4.3 Intraoperative Fluids 
The large blood volume of large animal species, often comparable to humans, allows for 
ease of venepuncture and repeated collection of samples in a single animal, which is not 
always possible in rodent models, where terminal bleeds and/or anaesthesia may be required 
to yield a sufficient sample volume. Adequate fluid therapy is essential to ensure animal 
wellbeing and can be achieved via multiple routes including intraosseous, intraperitoneal 
and subcutaneous, with intravenous access being the preferred route of administration in 
large species (Mama, 2002). The large diameter of vessels in these species’ benefits insertion 
of intravenous catheters, which would otherwise be challenging in rodents because of small-
calibre vessels. In feline and canine species, the cephalic, and medial and lateral saphenous, 
veins are common sites of catheter insertion, whereas in species such as porcine and ovine, 
the femoral vein or vena cava are commonly used (Mama, 2002). The ability to deliver large 
fluid volumes significantly benefits models of acute CNS injury, allowing for rapid fluid 
replacement. Crystalloid and colloid fluids can be given, depending on whether fluids are 
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being administered for maintenance, replacement or ongoing loss. A minimum rate of 3 
mL/hr is required to maintain venous access, with greater volumes required to replace 
volume lost intraoperatively (Pascoe, 2012). This is especially relevant as long-duration 
surgical procedures are associated with increased loss of saliva and urine, in addition to 
elevated vasopressin secretion and concomitant hypovolemia and hypotension (Pascoe, 
2012). In these circumstances, significantly greater fluid volumes are required to ensure 
MABP is maintained. Fluid therapy must be planned accordingly, taking into account 
anaesthetic regimen, surgical duration and preoperative state. 
 
3.3.5 Antibiotics 
Models of stroke where animals are recovered following surgery necessitate appropriate 
postoperative care. Given the often extensive and highly invasive nature of surgical 
approaches required in large animal models, administration of antibiotics is deemed 
essential. This is especially evident given the facilities for postoperative housing, which are 
rarely an aseptic environment, and most animals inevitably soil wounds with faeces and 
urine. As per veterinary standards, parasitic prophylaxis is also highly recommended for all 
large species prior to commencement of experimentation. Appendix 3.5 details 
recommended antibiotic agents and dosing regimens. 
 
3.3.6 Analgesics 
Sufficient postoperative analgesia is required to ensure pain and distress experienced by the 
animal is minimised. Many methods are used to assess animal pain and guide appropriate 
administration of analgesics. Routine tests interpret particular clinical signs as suggesting 
the presence of pain, including general behaviour, activity, appearance, temperament, 
vocalisations, feeding, and changes in physiological variables such as respiratory and heart 
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rates (Flecknell, 2016b). Treatment is often based on the presence of the aforementioned 
clinical signs, and commonly used analgesics are broadly divided into opioids and non-
steroidal anti-inflammatory (NSAID) medications. For procedures requiring craniotomy by 
either transorbital or pterional means, because of the sensitivity of the meninges it is 
recommended that a combination of analgesics is administered upon induction, such as 
buprenorphine (opioid) and carprofen (NSAID). 
 
It must be acknowledged that in the setting of stroke, some analgesic agents can influence 
ischaemic tissue damage and thus reliability of results. Fentanyl is reported to increase 
ischaemic lesion size in rodent models, while opioids such as butorphanol have been shown 
to enhance ischaemic preconditioning thresholds in canines (Schwartz et al., 1997). 
Therefore, appropriate analgesic regimens should be planned well in advance to ensure 
animal distress is minimised and ischaemic pathophysiologies are not compromised. 
Commonly used analgesics and suggested dose rates are detailed in Appendix 3.6. 
 
3.3.7 Drug Metabolism and Route of Administration 
It is important to acknowledge that variations in digestion, detoxification and metabolism 
between herbivores and carnivores can result in significant differences in half-life, toxicity 
and administration of any given medication. This is especially evident in large animal 
species, as unlike rodents which have high metabolic rates, inter-species and strain variations 
can significantly influence drug interval and dosing regimens. For example, in some species 
which are so-called ‘poor’ biliary excreters (humans), versus ‘high’ biliary (dog) and 
‘intermediate’ biliary (sheep, cats) excreting species, drug elimination may vary 
significantly, thus affecting optimum dosing (Toutain et al., 2010). In veterinary medicine, 
it is also assumed carnivores have a lower clearance of medications versus herbivores, owing 
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in part to extensive oxidative enzyme systems in herbivores providing rapid drug clearance 
via hepatic metabolism (Toutain et al., 2010). 
 
In addition to discrepancies in metabolism, the preferred route of drug administration may 
vary between large animal species because of anatomical and physiological variations. In 
ruminant species, for example, oral application is contraindicated because of ruminal 
digestion. In cats, topical application is undesired because of grooming/licking behaviours 
(Toutain et al., 2010). The majority of large animal models thus require intravenous, 
subcutaneous or intramuscular administration to achieve maximum efficacy. In pigs, 
intramuscular injection must be deep because of the thick nature of the skin and significant 
layers of fat overlying the musculature (Greene and Benson, 2002), an issue not encountered 
in other large animal species. It is highly recommended that prior to commencement of all 
large animal studies, species-specific treatment regimens be devised, taking into account 
dose, metabolism and administration interval, and in consultation with a veterinary 
professional where required. 
 
3.4 EXPERIMENTAL MODELS OF STROKE 
 
Stroke models can be divided into three major subtypes: global ischaemia, focal ischaemia 
and haemorrhagic stroke. Given ischaemic stroke is the most common stroke type and the 
focus of this thesis, only large animal models of ischaemic stroke will be discussed in this 
chapter. 
 
Experimental models of focal ischaemia rely on the permanent or transient disruption of 
blood flow to the desired cerebral area to produce a defined and reproducible lesion. To 
85 
determine the efficacy of novel pharmacotherapies in experimental animals, ensuring lesion 
size is consistent is essential, which can be directly influenced by the method of vessel 
occlusion. Experimental approaches to vessel occlusion in animal species include 
endovascular, transcranial and transorbital approaches. In rodents, the most commonly used 
endovascular method to induce focal ischaemia is via intraluminal thread/suture, in which a 
suture is inserted into the carotid artery and fed through the vasculature to occlude the origin 
of the MCA (Howells et al., 2010). In large animals, comparable endovascular occlusion is 
typically induced via autologous clot, or coil or balloon insertion, because of the large 
vascular diameter (Shaibani et al., 2006, Hill et al., 1955, Rink, 2008, Del Zoppo et al., 1986) 
(Figure 3.4). 
 
Endovascular methods of occlusion allow for reproducibility and can be used to model both 
transient and permanent stroke, offering control of recanalisation timing (Howells et al., 
2010). However, because of the complex vascular anatomy of large species, endovascular 
access to the coW is complicated and all but impossible in animals with a rete mirabile, and 
therefore not feasible in many large animal species (Hoffmann et al., 2014, Sakoh, 2000). 
Thus, access to the coW and anastomoses remains the biggest hurdle in many large animal 
stroke models, and direct access to the cerebrovasculature is often required via transcranial 
and transorbital means (Wells et al., 2012, Watson et al., 1997, Zauner et al., 1995). This 
method allows for permanent occlusion via electrocautery or ligation, or transient occlusion 
by microvascular techniques including aneurysm clip application (Wells et al., 2012, Wells 
et al., 2015) or photothrombosis (Kuluz et al., 2007, Maeda et al., 2005) (Figure 3.3). In 
particular, photothrombotic models have become increasingly used, where a photosensitive 
dye such as Rose Bengal is administered, followed by illumination under light to cause focal 
thrombosis and vessel occlusion. This approach has now been described for rodent (Labat-
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gest and Tomasi, 2013) and large animal models alike (Kuluz et al., 2007, Maeda et al., 
2005). However, the necessary volume of dye required for large animal species must be 
considered a potential variable. 
 
 
Figure 3.4. Schematic representation of different methods of vascular occlusion reported in large animal 
species. (A) Photothrombotic occlusion. (B) External aneurysm/micro-clip occlusion. (C) Autologous 
clot/microsphere occlusion. (D) Endovascular coil occlusion. (E) Endovascular balloon occlusion. (F) Direct 
ligation occlusion. A, B and F methods of occlusion require craniotomy to allow direct access to the 




The following sections will describe the various large animal species currently in use to 
model ischaemic stroke, approaches to vascular occlusion, outcome measures commonly 
assessed and species-specific considerations. 
 
3.5 NON-HUMAN PRIMATE STROKE MODELS 
 
NHP models offer distinct advantages when it comes to investigating cerebral ischaemia, 
providing a representation of key features of human behaviour, pathophysiology and 
neuroanatomy (Cook and Tymianski, 2012). A wide variety of NHP species have been used 
to model cerebral injury to date, including the squirrel monkey, owl monkey, marmoset, 
Senegal bush baby, baboon, rhesus and cynomolgus macaque, and African green and vervet 
monkey (Cook and Tymianski, 2012). 
 
3.5.1 Lissencephalic versus Gyrencephalic Non-human Primate Species 
The clinical applicability of several NHP species has been criticised because of their relative 
neuroanatomical structure, including the marmoset, squirrel monkey, owl monkey and 
Senegal bush baby, all of which are lissencephalic (Boulos et al., 2010). The relative size, 
lack of cortical sulci and gyri, and poor white to grey matter ratio in these species have been 
raised as potential limitations for their use (Cook and Tymianski, 2011). Indeed, a number 
of promising preclinical studies in the common marmoset have failed to produce desired 
outcomes clinically, with critics citing their lissencephalic brain, closer in resemblance to 
the rat than human, as a potential contributor (Philip et al., 2009, Diener et al., 2008). Despite 
noteworthy neuroanatomical variations, the relative reproducibility of stroke in 
lissencephalic NHP species is significantly more consistent than their gyrencephalic 
counterparts, allowing for precise functional mapping (Marshall and Ridley, 2003). It is 
suggested the lack of sulci and gyri favours visual representation of motor and sensory 
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cortices on the cerebral surface compared with gyrencephalic species, where representation 
may lie within the depth of a sulcus (Cook and Tymianski, 2011). 
 
The use of gyrencephalic NHP species may better mimic the heterogeneity of human stroke 
and thus provide greater predictive value. Further, gyrencephalic NHP species exhibit 
additional anatomical features favouring them as models for cerebral ischaemia, including 
large brain mass, complex cortical organisation, dense white matter tracts, comparable 
vascular architecture and a relative grey to white matter ratio that more closely resembles 
the human brain (Cook and Tymianski, 2012). Irrespective of anatomical variations, the 
relatively unknown biological differences between lissencephalic and gyrencephalic NHP 
species add another dimension of uncertainty in choosing an appropriate species. Only one 
study to date has provided a direct comparison of biological differences between an NHP, 
namely the baboon, and the rat, although results of the study were inconclusive (Tagaya, 
1997). Therefore, the relative biological benefit of using a particular NHP species remains 
elusive and requires further investigation, and an NHP per se may not always be the superior 
animal of choice when modelling stroke, with consideration of brain structure and specific 
research questions essential. 
 
3.5.2 Approaches to Experimental Stroke Induction in Non-human Primates 
Historically, the most common gyrencephalic NHP species used to investigate cerebral 
ischaemia is the baboon (Huang et al., 2000, Nehls et al., 1986, Tagaya et al., 1997). 
Transorbital access to the cerebral vasculature in this model requires enucleation (removal 
of the eye) with subsequent occlusion of the MCA and both ACAs required to produce a 
defined cortical lesion in the frontotemporal region, as the rich vascular collateralisation of 
the ACA may produce lesions of varying volumes, thereby complicating reproducibility (Del 
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Zoppo et al., 1986). Early studies in the baboon contributed to the discovery of the ischaemic 
penumbra and were pivotal for the preclinical evaluation of fibrinolytic therapies, including 
tPA (Astrup et al., 1981). Initially characterised as a model of permanent occlusion via either 
vascular suture ligation or aneurysm clip application, adaptations have been made for the 
development of a transient model (D'Ambrosio, 2004, Huang et al., 2000, Nehls, 1986). The 
transient model favours behavioural testing because of the high premature mortality rates 
and prolonged intensive care associated with the permanent occlusion model (Cui et al., 
2013). However, the previously noted discrepancies in cerebrovascular anatomy of the 
baboon require occlusion of the MCA and bilateral A1 segments of the ACA, located 
between the ICA and ACoA, to produce a lesion in the MCA region. In relation to assessing 
functional outcome following stroke, the baboon is not an ideal candidate for 
neurobehavioural assessment because of its inherent aggressive nature and the surgical 
necessity for enucleation to induce cerebral ischaemia may inhibit the ability to perform 
detailed tasks requiring intact binocular vision (Mack et al., 2003). 
 
Several studies have indicated the superiority of the cynomolgus and rhesus macaques as 
experimental NHP species (Hirouchi et al., 2007, Kito et al., 2001, Kuge et al., 2001) as 
there is less pronounced confounding vascular collateralisation in the cynomolgus macaque 
compared with the baboon (de Crespigny et al., 2005). Permanent MCAo (pMCAo) and 
transient MCAo (tMCAo) models have been described in the macaque via transorbital and 
pterional craniotomy approaches (Roitberg et al., 2003, West et al., 2009, Hirouchi et al., 
2007), with both methods of cerebrovascular access producing defined lesions of high 
reproducibility, albeit with the need for extensive surgical skill to induce stroke and avoid 
iatrogenic injury. Further, the need for enucleation in this approach may confound 
assessments requiring binocular vision, and pterional craniotomy requires incision of the 
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temporalis muscle, adversely affecting mastication (Cook and Tymianski, 2011). Extensive 
surgical considerations and postoperative care associated with pterional/transorbital 
approaches to MCAo have prompted the development of a transfemoral endovascular model 
(Maeda et al., 2005). This model circumvents the need for complex surgery and reduces the 
risk of intraoperative trauma and intensive postoperative care. However, additional 
occlusion of the PCA is required to reduced collateral flow, and the endovascular route of 
access is associated with greater variability in lesion volume and higher mortality rate than 
open vessel methods (de Crespigny et al., 2005). Similarly, endovascular autologous clot 
models have been developed in the macaque to more closely approximate the 
thromboembolic stroke scenario (Wu et al., 2016). Although this method of occlusion has 
the advantage of more closely replicating the pathophysiology of human cerebral ischaemia, 
variability in lesion location and volume is a recurring complication (Wu et al., 2016). 
Despite contraindications, the macaque as a species is generally more docile than the 
baboon, offering the ability to perform more complex neurobehavioural tasks to assess 
cognitive, motor and sensory deficits (Cook and Tymianski, 2011). 
 
Photothrombotic methods of vascular occlusion have also been described in NHP species, 
albeit infrequently (Maeda et al., 2005, Furuichi et al., 2007), with this method of occlusion 
benefiting studies investigating combined neuroprotection and thrombolysis treatment 
(Furuichi et al., 2007). However, the light source must be applied for a longer duration 
compared with smaller species to achieve complete vascular occlusion because of vessel 
diameter. Further, photothrombosis in NHPs is associated with variable lesion volume and 
location compared with other occlusion methods, and thus may be of limited clinical 
application (Maeda et al., 2005, Furuichi et al., 2007). 
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3.5.3 Outcome Measures in Non-human Primate Stroke Models 
Irrespective of the specific species used to investigate cerebral ischaemia, the complexity of 
functional and behavioural assessment offered by NHP species is far superior to any other 
experimental model, large animal or otherwise (Mack et al., 2003). This is of particular 
relevance as human prognosis is largely determined by functional outcome, typically as a 
measure of disability or impairment in activities of daily living (Cook and Tymianski, 2011). 
Clinically, ischaemia in the region of the MCA affects sensory, motor and cognitive function 
(Gottesman and Hillis, 2010, Cook and Tymianski, 2011). Conversely, the vast majority of 
preclinical stroke research uses lesion volume as a predictor of poor outcome, yet the precise 
relationship between lesion volume and functional outcome has not been adequately 
assessed in humans because of inherent heterogeneity (Saver et al., 1999). Therefore, the 
ability to test behavioural outcomes in large animal species offers substantial benefit to 
improving clinical translation. There is no predefined disability index for NHPs, although a 
plethora of neurobehavioural approaches have been used to assess motor, sensory, balance, 
reflexive and cognitive behaviours (Mack et al., 2003, Roitberg et al., 2003, Marshall and 
Ridley, 2003). Specific NHP outcome scales have been developed to assess 
neurobehavioural deficits, which replicate clinical scoring systems (Roitberg et al., 2003, 
Mack et al., 2003). Activities such as the ‘hill and valley staircase’ task assess hemi-neglect 
as an indicator of hemiplegia, whereas the Kluver board can be used to test motor control 
(Marshall and Ridley, 2003). Further, the use of NHPs for evaluation of functions such as 
grip offers significant advantage over ungulate quadruped species, such as pigs and sheep, 
where such assessment is not possible. It must be acknowledged that despite the benefits of 
complex testing in primates, the inherent need to train animals to perform a particular 
behaviour, often for extended periods, creates another dimension of discordance in 
evaluating function and behaviour between human and NHP stroke. 
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3.5.4 Considerations in Non-human Primate Stroke Models 
NHP species vary considerably in their relative cerebrovascular anatomy, physiology and 
behavioural characteristics (Cook and Tymianski, 2012). Therefore, the appropriate 
selection of NHP species must be made with due consideration of stroke syndrome 
(general/focal lesion), method of occlusion, route of vascular access and specific outcome 
measures of interest. All NHP models require access to sufficient housing facilities, 
specialised veterinary care, surgical expertise and established neurobehavioural apparatuses 
(Cook and Tymianski, 2011). Further, the ethical challenges inherent in all NHP research 
must be recognised. Primates develop more complex social relationships than many other 
large animal species, and the presence of neurological disease can significantly influence 
animal distress, anxiety and/or depression (Rossi, 2009, Wilkinson, 2009). Little is 
understood regarding how an injury of such severity can affect the social norms and general 
wellbeing for these species. Therefore, considerable effort must be made to eliminate distress 
and pain experienced by the animal, in addition to minimising alterations to environment 
and social structures. Clearly, the extensive limitations and constraints with the use of NHP 
species mean that alternate large animal species may be more appropriate and feasible for 
the modelling of acute CNS injury in many cases, and indeed may be more appropriate when 
considering neuroanatomical structure and neurobiology. 
 
3.6 CANINE STROKE MODELS 
 
The use of canines to model cerebral ischaemia offers advantage because of the relative size 
and gyrencephalic structure of brain, with high white to grey matter ratio, well-established 
white matter tracts and large cerebrovascular diameter (Traystman, 2003). The relative 
cerebrovascular architecture of the dog also offers distinct superiority when compared with 
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other large animal species, as canines lack a cerebrovascular rete mirabile, therefore 
favouring endovascular approaches of vessel occlusion (Gralla et al., 2006, Howells et al., 
2010). Therefore, a plethora of studies have evaluated endovascular MCAo in canine 
models, with varying success reported (Shaibani et al., 2006, Christoforidis, 2011, Rink et 
al., 2008, Hill et al., 1955). 
 
3.6.1 Approaches to Stroke Induction in Canine Models 
The first embolic model of cerebral ischaemia was described in the dog in 1955 using 
autologous blood clots (Hill et al., 1955). Because of the anatomical structure of the coW, 
this model involves the injection of optimally sized emboli into the ICA to induce vascular 
occlusion of the MCA. Autologous clots are prepared using a mixture of the experimental 
animal’s blood and bovine thrombin (Liu et al., 2012). This method of inducing cerebral 
ischaemia mimics the human condition most accurately and is amenable to studies 
investigating the efficacy of novel thrombolytic therapies or thrombectomy devices. 
However, despite clinical applicability, the canine ICA is extremely tortuous, forming a 
petrous loop prior to articulation with the coW, with high variability in convolution between 
animals (Zu et al., 2013). Therefore, the relative size and location of the lesion vary because 
of the distal injection of emboli and variations in vascular architecture. Further, MCAo via 
ICA autologous clot injection produces significantly smaller lesions than those seen 
clinically, given the aforementioned extensive leptomeningeal collateral circulation in 
canines (Zu et al., 2013, Atchaneeyasakul et al., 2016, Symon, 1960). More recently, 
adaptations have been made to the model to address this, including alterations to the route 
of embolus administration, where cells are injected via the BA or VA rather than ICA 
(Qureshi et al., 2004). VA occlusion may, however, be contraindicated because of forceful 
collateral blood flow, preventing embolus anchorage (Atchaneeyasakul et al., 2016). The 
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BA is relatively straight and easy to navigate compared with the ICA, and occlusion 
produces a significant and defined hemispheric lesion. The benefit of this route may, 
however, be outweighed by significant mortality and neurological deficit associated with 
BA occlusion, requiring prolonged intensive care (Atchaneeyasakul et al., 2016, Qureshi et 
al., 2004). The most significant disadvantage associated with the embolic technique of 
cerebral ischaemia is the relative variation in vascular diameter and organisation between 
different dog breeds (Atchaneeyasakul et al., 2016). This is of particular relevance as mixed 
breeds are among the most commonly used canine species, and variation between individual 
experimental animals may significantly limit reproducibility and experimental outcomes. 
 
An alternative method of MCAo in the canine model is the coil occlusion method 
(Christoforidis et al., 2011, Rink et al., 2008). This method involves the use of a soft 
platinum coil, clinically used to treat intracranial aneurysms (Rink et al., 2008). The coil is 
inserted through a micro-catheter and advanced through the vasculature to the target vessel, 
allowing for precise positioning and coil detachment, inducing a permanent occlusion, or 
transient occlusion with vessel recanalisation following coil removal. Coil access to the 
MCA is typically achieved via the VA or PCA, as access via the ICA is complicated because 
of its convoluted structure (Rink et al., 2008, Christoforidis et al., 2011). Comprehensive 
imaging techniques are required for coil guidance and to ensure sufficient vascular occlusion 
(Flecknell, 1996). Several studies have reported endovascular coil MCA access via the 
femoral artery using C-arm fluoroscopy guidance (Flecknell, 1996), which allows for 




The advanced neuroimaging techniques used in the endovascular coil model offer a number 
of benefits to translation. Angiographic guidance in the dog offers significant superiority 
when compared with commonly used rodent models of endovascular MCAo, where the 
relatively small size of the cranial arteries limits procedural evaluation and confirmation of 
occlusion. The use of image guidance in these studies enables specificity in coil placement 
and thus yields a highly specified and reproducible lesion, offering advantages when 
compared with embolic methods. Further, the large size of the canine brain is compatible 
with non-specialised, clinical imaging equipment, representing an appropriate model for 
validation of clinical stroke imaging. Nevertheless, the benefits of neurointerventional 
approaches are not without challenges. The use of advanced imaging techniques requires 
sophisticated skills and complex understanding of the canine cerebrovascular system. PCA 
micro-catheter access may be influenced by breed of dog and thus not achievable in all 
species. Further, MCA cannulation may not always be possible because of variations in 
relative vascular architecture in individual subjects. Despite the clinical relevance of 
vasospasm in the canine model, this can be an issue when advancing the coil and can lead to 
vascular perforation, especially in the BA, which is predisposed to spasm (Rink et al., 2008, 
Christoforidis et al., 2011). Extreme care must be taken in this instance to halt advancement, 
and wait for spasm to resolve, following which coil movement must be limited to purposeful 
advancement as quickly as possible. Despite challenges, the endovascular access to MCAo 
achievable in canine models completely circumvents the need for transorbital access and 
enucleation or craniotomy, and disruption of the temporalis muscle. Therefore, endovascular 
techniques significantly eliminate the occurrence of head trauma and iatrogenic injury 




3.6.2 Outcome Measures in Canine Stroke Models 
The majority of canine studies to date have focused on the use of MRI and other imaging 
techniques to determine lesion volume as an indication of stroke severity (Zu et al., 2013, 
Shaibani et al., 2006). Neurobehavioural assessment has been performed by several groups 
to determine deficits in neurological function following cerebral ischaemia (Christoforidis 
et al., 2011, Boulos et al., 2010). A canine stroke score has been developed to enable clinical 
assessment, which specifically measures canine vocalisation, consciousness, gait, behaviour, 
and sensory and motor function, and has been successfully correlated with infarct volume 
(Boulos et al., 2010). 
 
3.6.3 Considerations in Canine Stroke Models 
Although canine models offer distinct advantages, particularly in relation to the route of 
vascular occlusion, such species are associated with high purchase costs, and access to an 
appropriate institution where advanced imaging techniques are available may not be viable 
(Hasiwa et al., 2011). Further, the use of canines for neuroscientific research is mired with 
ethical complications, especially in Western cultures, where dogs are domestic companion 
animals. Therefore, the use of canine species is often limited, and alternative large species 
may need to be considered. 
 
3.7 FELINE STROKE MODELS 
 
Although less commonly used than canines, several feline models of cerebral ischaemia have 
been described (Watson et al., 1997, Moonen et al., 1991, Combs et al., 1990, Zauner et al., 
1995, Di et al., 1997). Of all the large animals commonly used for investigation of cerebral 
ischaemia, cats are comparatively the smallest species. Despite this, the feline brain has a 
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gyrencephalic structure with high white to grey matter ratio and large vessel diameter (Smith 
et al., 2001), favouring their use over rodents, mice and other small animals in line with the 
desired experimental outcomes. 
 
Early models of focal ischaemia in the cat were produced by occluding the MCA via a 
transorbital approach (Watson et al., 1997, Moonen et al., 1991, Zauner et al., 1995, Combs 
et al., 1990, Di et al., 1997). This method involves supraorbital and periorbital incision and 
subsequent enucleation, enabling periorbital craniotomy and direct access to the MCA. 
Permanent MCAo is subsequently achieved through electrocautery or microvascular clip 
application. Direct vascular access achievable in this model produces a defined and 
reproducible lesion. However, the need for enucleation diminishes the ability to perform 
postoperative functional assessment, similar to that described for NHPs. In early studies, the 
relative accessibility to mixed breed cats, in addition to their gyrencephalic brain, favoured 
them as models to investigate cerebral ischaemia compared with rodents. These early studies 
were instrumental to understanding the effects of insulin on the brain following ischaemia 
and subsequent BBB disruption (Combs et al., 1990). However, similar to other large animal 
species, cats have a rich vascular collateralisation and there is high variability in 
cerebrovascular structure between individual animals. As with dogs, this is extremely 
prevalent between experimental animals because of frequent experimental mixed breed use. 
 
For the past decade, feline models of stroke have not been used, and there has been an 
increased tendency to use larger animals with a greater brain mass and/or genetic similarity 
closer to that of the human for enhanced translation. Although body weight and phylogeny 
do not predict translational success, larger brains allow for easier surgical manipulation, 
which in turn enhances experimental outcome. The decline in feline models may also be a 
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result of the relative ethical considerations associated with the use of cats, which, similar to 
canines, are domestic companion animals. 
 
3.8 PORCINE STROKE MODELS 
 
Porcine models offer distinct advantages because of the presence of cerebral sulci and gyri, 
large intracranial vessel diameter, and relative white to grey matter proportion (Gralla et al., 
2006, Kobayashi et al., 2012). The aforementioned presence of the rete mirabile in pigs, 
however, renders endovascular methods of occlusion unfeasible, and thus direct vascular 
access is often required (Ashwini et al., 2008, Sakoh et al., 2000, Watanabe et al., 2007, 
(STAIR), 1999). 
 
3.8.1 Approaches to Stroke Induction in Porcine Models 
A transorbital vascular approach to MCAo has been described in pigs as a method of 
inducing cortical infarction (Sakoh et al., 2000, Watanabe et al., 2007), allowing for the 
investigation of discrepancies in CBV and flow. Occlusion of the MCA can be achieved by 
either permanent electrocautery or transient micro-clip application (Sakoh et al., 2000, 
Watanabe et al., 2007, (STAIR), 1999). However, this model is associated with variable 
lesion volume and limited reproducibility (Sakoh et al., 2000), with the transorbital approach 
to MCAo described restricting the surgical field of view and thus vessel visualisation. 
Therefore, porcine models require frontotemporal and pterional craniotomy approaches to 
optimise vascular access because of their relatively large size and skull anatomy (Platt et al., 
2014). Transcranial approaches offer a distinct advantage compared with transorbital 
methods, including avoiding the need for enucleation or intraorbital decompression, thus 
preventing loss of vision and the development of postoperative complications such as 
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infection of the dead space following eyeball removal (Imai et al., 2006). Further, 
frontotemporal approaches to MCAo benefit vascular approach and orientation by increasing 
the visual field available, improving surgical access and visibility. 
 
Several studies have described MCAo in the miniature pig using a frontotemporal 
craniotomy approach with a single-entry burr hole drilled in the skull and Kerrison forceps 
used to widen the field to achieve vascular visualisation (Imai et al., 2006). In this model, 
direct electrocautery of the MCA is performed proximal to the origin of the lenticulostriate 
artery and opposing ends of the vessel occluded to ensure complete cessation of blood flow. 
Miniature pig species also have significantly thinner skulls than commonly used large 
domesticated porcine species, potentiating a reduction in surgical duration (Cui et al., 2013). 
It must be recognised, however, that the removal of bone and subsequent dural incision 
required for this approach may have implications for outcome measures, such as ICP, 
because of disruption of intracranial dynamics (Imai et al., 2006). Further, permanent 
vascular cauterisation of the MCA may lead to disruption of the BBB. Although transient 
occlusion may be possible in this model, it has not been adequately addressed and requires 
further investigation. To overcome the need for craniotomy and associated damage to the 
dura, a model has been established in which small-diameter sodium alginate microspheres 
are injected extracranially to induce occlusion of the skull base rete mirabile (Cui et al., 
2013). This method produces a defined cortical lesion and complete unilateral occlusion of 
the rete mirabile, as evident on MRI. Further research on the use of extravascular 




The vascular diameter of pigs favours them for models testing novel thrombectomy devices 
that are otherwise not feasible in small animals (Gralla et al., 2006, Gross, 1997). Several 
porcine models of vascular occlusion have been used to investigate the efficacy of new 
generation thrombectomy devices, with variable success (Chueh et al., 2013, Nogueira et al., 
2012). The testing of devices in these models involves the injection of autologous emboli 
into extracranial vessels, such as the ascending pharyngeal artery (APA). Advanced 
neuroimaging techniques are required for the successful generation of these models in order 
to assess vascular dimensions prior to clot synthesis and administration. It must be reiterated 
that the small diameter of vessels comprising the rete in pigs is not conducive to embolic 
models of MCAo, and thus stroke is only achievable via occlusion of large-diameter 
extracranial vessels (Ringer et al., 2004). Further, the porcine model is contraindicated for 
use in studies evaluating combined tPA treatment, as pigs exhibit a high resistance to 
recombinant tPA (Yakovlev et al., 1995). 
 
Pigs also represent the only large animal species, aside from NHPs, that have been used to 
successfully model photothrombotic stroke (Kuluz et al., 2007). Initially described in piglets, 
this method was developed as an approach to paediatric focal cerebral ischaemia. Because 
of skull thickness, photothrombosis in porcine species requires craniotomy by transorbital 
or transcranial means to enable vascular access and application of the light source. This 
method of occlusion produces a defined lesion with consistent infarction in both grey and 
white matter, platelet activation, and occlusive thrombus formation (Kuluz et al., 2007). 
Photothrombotic occlusion eliminates cerebrovascular trauma that may be associated with 
microvessel clip application and removal required for vascular recanalisation. Although this 
method offers high reproducibility, there is some question regarding the artificial means by 
which occlusion is induced, with atypical lesion features observed that are not seen clinically 
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(Durukan and Tatlisumak, 2007). These findings, however, appear consistent between 
species using photothrombotic models. 
 
3.8.2 Outcome Measures in Porcine Stroke Models 
The majority of porcine studies use lesion volume as a measure of outcome following stroke, 
with neuroimaging commonly used as a means of quantification (Kuluz et al., 2007). MRI 
and positron emission tomography (PET) scanning of the pig brain produces images of high 
resolution, which may benefit morphometric analysis, an advantage because of high clinical 
translatability. Several automatic labelling and processing routines for MRI have been 
developed specifically for pigs, which offer efficient and unbiased analysis of infarct volume 
(Conrad et al., 2014, Saikali et al., 2010). In relation to porcine neurobehavioural assessment, 
pigs have significant cognitive abilities and are capable of learning behavioural tasks in 
relatively short periods of time (Gieling et al., 2011). Neurological assessment in ischaemic 
porcine models has been performed using established canine neurological function scales, 
with minor amendments allowing the evaluation of limb and facial paralysis, consciousness, 
and visual field defects (Cui et al., 2013). A plethora of studies have determined differences 
in gait and locomotor patterns in pigs on various floor surfaces (Thorup et al., 2007, 
Applegate et al., 1988, Wachenfelt et al., 2008); however, few have investigated changes in 
gait characteristics following stroke (Duberstein et al., 2014). The full spectrum of porcine 
neurological deficits following cerebral infarction and discrepancies in normal/abnormal 
behaviour have, however, not yet been adequately assessed, and further investigation is 





3.8.3 Considerations in Porcine Stroke Models 
One disadvantage to using porcine species to model cerebral ischaemia is their relative use 
for the purpose of longitudinal survival studies. Pigs are predisposed to rapid weight gain, 
and thus food intake must be strictly monitored to prevent excessive weight increase, which 
may alter experimental outcomes (Lawrence et al., 2012). Despite this, the use of porcine 
stroke models offers several translational advantages, in addition to the inherent 
neuroanatomical similarities to the human. The relative ethical challenges and high purchase 
costs associated with the use of canines and NHPs are significantly less pronounced in pigs 
(Kobayashi et al., 2012). Further, the use of porcine models may also prove advantageous 
for neurobehavioural and cognitive assessment because of their relatively superior cognition 
and ability to learn tasks rapidly. 
 
3.9 OVINE STROKE MODELS 
 
The large gyrencephalic brain of the sheep, comparable with that of the human, has 
facilitated the development of several ovine models of cerebral ischaemia. As with porcine 
models, the complex cerebrovascular architecture of the rete mirabile in ruminant species 
renders endovascular methods of MCAo unfeasible, and transcranial approaches are 
required. Nevertheless, a comparison between the cerebrovasculature of sheep, humans and 
rodents was recently conducted to determine implications for translation to cerebrovascular 
diseases (Hoffmann et al., 2014). In rodents, vast interarterial anastomoses are present, 
which may prevent cortical infarction upon distal occlusion of the MCA. Cortical 
anastomoses are less frequent in humans and ovine species, providing partial explanation as 
to why occlusion of the MCA has devastating clinical repercussions (Hoffmann et al., 2014), 
thus highlighting the translational value of sheep as an experimental species. 
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3.9.1 Approaches to Stroke Induction in Ovine Models 
The first model of ovine MCAo was developed to address ongoing translational failures and 
limitations in other large animal models (Boltze et al., 2008). This seminal work described 
a model of permanent MCAo via direct electrocautery, with access achieved via pterional 
craniotomy, necessitating incision of the temporalis muscle at its insertion point (Boltze et 
al., 2008). This model offers significant advantages compared with transorbital approaches 
and avoids the need for enucleation, permitting postoperative assessment of binocular vision. 
Further, this approach is associated with significantly enhanced survival, allowing longer 
observation periods compared with many other large animal species, where proximal MCAo 
is associated with premature mortality. However, it must be noted that enhanced survival in 
this model is likely attributable to the fact that the craniotomy site is left open, effectively 
providing surgical decompression at the time of stroke induction, and thus preventing 
elevations in ICP, which is obviously a contraindication for measurement of intracranial 
dynamics in this model. Further, incision of the temporalis is contentious, given the effect 
on limited mastication. 
 
More recently, a new model has been developed by our group, which permits the study of 
transient occlusion while maintaining intracranial dynamics (Wells et al., 2012). This model 
requires removal of the coronoid process of the mandible to allow skull base exposure and 
pterional craniotomy (Wells et al., 2012). MCAo is achieved via direct electrocautery or 
aneurysm clip application, which enables reperfusion. After MCAo, the dura is closed, and 
the bone removed from the area of the craniotomy is reinserted and sealed watertight with 
dental cement to restore intracranial dynamics. This method of access benefits studies 
investigating physiological outcome measures such as ICP, which were not achievable in 
the original model. As previously mentioned, the strong fibrous tentorium cerebelli of the 
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sheep mimics the human meningeal features, benefiting the use of ruminant species for 
investigating the development of ICP following stroke. However, the relative mortality 
(approximately 30%) in this model is high owing to the development of excessive pressures, 
often in excess of 40 mmHg, leading to tonsillar herniation (Wells et al., 2012) and thus 
mimicking the burden of mortality associated with clinical stroke. Further, the complete 
removal of the coronoid process prevents postoperative survival, and animals must be 
maintained under anaesthesia for the entire duration of the experiment. This increases the 
cost and technical expertise required because of the need to keep animals physiologically 
stable and under a surgical level of general anaesthesia throughout the study (Wells et al., 
2012, Wells et al., 2015). Clearly, a modified surgical approach that permits animal survival 
and recovery post-stroke induction would be desirable to study the long-term effects of 
transient occlusion in the ovine model. 
 
Although ovine models have been used successfully to measure cerebral oedema and ICP, 
there is some question regarding the craniotomy approach in relation to disruption of 
intracranial dynamics when compared with non-invasive methods. The relative CSF 
production and resorption rate following dural opening is at present unknown, which has 
implications for experimental outcome. Irrespective of this, ovine permanent MCAo studies 
have shown significant elevations in ICP (>40 mmHg) within 24 hours following craniotomy 
(Wells et al., 2015), suggesting that despite the loss of CSF upon dural excision, the methods 
used to achieve dural and skull closure following vascular access prevent ongoing leakage 
of CSF (thereby allowing CSF to reaccumulate), leading to the pathological development of 
elevated ICP.  
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The transcranial access described in the ovine model favours investigation of behaviour 
compared with transorbital approaches, as binocular vision is left intact. This is particularly 
beneficial in survival models where ICP is a primary outcome, as excessive increases in 
pressure can compress the optic nerve, leading to pupillary dilation and anisocoria, 
commonly used to assess neurological deterioration clinically (Chen et al., 2011). Further, 
the length of the ICA may benefit transcranial approaches to MCAo, as the proximal MCA 
is more easily accessible than in other large animal species, allowing for better visualisation 
and vessel access, thereby favouring reproducibility (Kapoor et al., 2003).  
 
3.9.2 Outcome Measures in Ovine Stroke Models 
Primary assessment of outcome following stroke in the ovine model is similar to that of the 
pig, and imaging techniques remain the preferred method of determining infarct volume as 
an indicator of outcome. Behavioural phenotyping of sheep has been performed, allowing 
for the development of a neurobehavioural score system, which has subsequently been 
correlated with lesion volume (Boltze et al., 2008). This neurologic score point system 
assesses functional deficits that are characteristically seen in large animals following MCAo, 
such as ataxia, state of consciousness, torticollis, fetlock flexion/weakness, hemi-standing 
and hopping reactions. Such assessment is typically carried out by a trained veterinarian to 
subjectively assess the animal’s response. It must be acknowledged, however, that 
assessment of sensory function in ovine models is contraindicated, as sheep rapidly habituate 
to nociceptive stimulation. Further, to date, a comprehensive method to objectively quantify 
kinematics in the sheep does not exist; thus, a method that enables rigorous assessment of 




3.9.3 Considerations in Ovine Stroke Models 
The use of ruminants offers distinct advantages over other large animal models, as sheep 
display similar haematological properties to those seen in humans and NHPs (Boltze et al., 
2011). However, very little is known at present regarding the metabolic and molecular 
pathways following cerebral infarction, which is a major downfall when compared with 
other large animal models, where this is well characterised. Nevertheless, as with pigs, the 
relative ethical challenges associated with the use of canines and NHPs are significantly less 
prevalent in sheep, as is purchase cost and availability. 
 
3.10 ADVANTAGES AND LIMITATIONS OF LARGE ANIMAL MODELS 
 
As highlighted throughout this chapter, large animal models provide significant benefits in 
improving clinical translation, including the utilisation of sophisticated imaging 
technologies, similarities in neuroanatomical structure, and wide spectrum of clinically 
relevant data recording and analysis options. Key advantages and limitations of large animal 
models are summarised in Table 3.1. 
 
However, while this chapter has highlighted the many advantages of large animal species 
and their ability to better mimic human ischaemic stroke, there are also a number of 
disadvantages that affect the ability to pursue large animal studies. Foremost is the 
significant expense of not only the large animals themselves, but also the technical support 
and infrastructure required to appropriately house and care for the animals, as well as 
performing the experiments themselves. 
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Table 3.1 Summary of advantages and limitations of large animal models of stroke 
Advantages Disadvantages 
Brain more closely resembles the human 
Higher proportion white matter 
Gyrencephalic structure 
Strong tentorium cerebelli 
Relative cortical organisation 
Ability to use clinically relevant outcome 
         measures, such as MRI, PET/CT 
Ability to use clinically relevant equipment for  
         anaesthesia, physiological monitoring,  
         surgical procedures 
Ability to undertake chronic/co-morbidity studies 
Increased clinical translation 
Difficult to handle 
Higher purchase and maintenance cost of animals 
Higher costs of facilities required to perform  
        procedures and house animals 
Longer gestation time and life span 
Transgenic selection and production of transgenic        
        strains limited 
Poor availability of physiological databases 
Ethical considerations higher 
Behavioural assessment more cumbersome 
Increased anatomical variability 
Limited access to species appropriate antibodies 
 
 
Procedures often require access to specialised facilities with operating theatres, housing and 
imaging equipment capable of accommodating large animals, often comparable to clinical 
spaces. In addition, specialised surgical instruments, along with clinical anaesthetic and 
monitoring equipment, are required. Extensive surgical skill and technical expertise is 
necessary for the vast majority of large animal injury models to produce lesions of consistent 
size, while also obviating iatrogenic brain injury. Large animal model studies may be further 
hampered as access to specific species may be difficult in some countries. For example, the 
use of ovine species in Australia and New Zealand is common because of high availability; 
however, the use of some porcine species is limited by stringent quarantine laws. Therefore, 
appropriate experimental species must be selected carefully, taking into consideration not 
only the injury type and surgical procedure required, but also species availability and access 
to an appropriate surgical facility. 
 
Further, longer life spans of large species mean that chronic studies take considerably longer 
than smaller animals (Agoston, 2017). However, this may also offer the opportunity to study 
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stroke in concert with co-morbidities. Biochemical and molecular data are less readily 
available for larger animal species, as are functional outcome tests to characterise effects of 
therapeutic intervention on neurological outcome. Further, acquiring antibodies for routine 
immunohistochemistry or western blotting is more challenging than for rodent counterparts. 
Indeed, the vast majority of biological assays are optimised in rats and mice, which has 
implications for the validity and reliability of data when protocols are adjusted for 
application in larger animals. Nevertheless, such assays are possible using large animal 
tissues although may require extensive optimisation and different retrieval/extraction 
protocols compared with rodent tissue. Finally, the rete mirabile, present in some species, 
may influence CBF after acute brain injury, although this has not yet been characterised. 
 
While rodents will always have a valuable place in studies of acute brain injury, especially 
in initial characterisation and screening of potential therapeutic interventions, the use of 
large animal models is becoming increasingly important to improve the chances of 
successful translation. Indeed, one could argue that the emphasis on rodent models of acute 
brain injury over recent decades has hampered our ability to identify the critical injury 
factors associated with stroke and its complications, and our ability to develop a therapeutic 




Large animal models are a key step in the stroke translational framework. Following initial 
discovery studies in rodents to identify novel therapeutic agents or pathophysiological 
mechanism/pathways of outstanding promise, these should then be assessed in an 
























Following ischaemic stroke, aberrant release of neuropeptide SP initiates the development 
of neurogenic inflammation (Turner et al., 2006, Turner et al., 2011, Turner and Vink, 2012, 
Turner and Vink, 2014, Yu et al., 1997). This is associated with increased BBB permeability, 
development of cerebral oedema and persistent neurological deficits. It has been extensively 
demonstrated in rodent stroke studies that blocking the action of SP with an NK1-R 
antagonist reduces BBB permeability and cerebral oedema and improves functional deficits 
(Turner and Vink, 2014, Turner and Vink, 2013, Turner and Vink, 2012). Therefore, NK1-
R antagonist treatment may represent a novel approach to treating cerebral oedema and 
elevated ICP post-stroke. However, given the poor translation from rodent studies to the 
clinic, evaluation of the NK1-R antagonist in an intermediate, large animal stroke model is 
required prior to clinical trial in order to improve the likelihood of clinical efficacy. 
 
4.1 STAIR GUIDELINES: SUITABILITY OF A LARGE ANIMAL MODEL 
 
To address the limitations of past studies and advocate for more rigorous preclinical 
screening, the Stroke Therapy Academic Industry Roundtable (STAIR) guidelines were 
formulated to improve the quality of preclinical stroke studies, with the goal of increasing 
successful clinical translation. However, a systematic review conducted in 2003 found that 
out of over 1000 novel therapies for stroke, only one was successful in translation (tPA, 
O'Collins et al., 2006). Further, only five of 550 trials evaluated met the interpretation of the 
STAIR guidelines. This highlights the need for adherence to STAIR recommendations to 
improve direct linkage between animal models and the clinical situation. The studies in this 
thesis were therefore designed to address the STAIR guidelines and increase the likelihood 
of successful translation of the NK1-R antagonist through use of a clinically relevant large 
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animal model. Specifically, because of the primary outcome measures of interest (ICP and 
cerebral oedema) and availability of large animal species in Australia, an ovine model was 
chosen. A brief discussion of STAIR criterion the proposed ovine model aims to address, 
with particular reference to the relevant thesis chapters, is provided below. 
 
4.1.1 Replication in a Second Species 
It is strongly recommended that the efficacy of putative therapies be established in two 
species prior to clinical assessment. More specifically, once initial efficacy has been 
demonstrated in rodent models, promising therapeutic agents should ideally be screened in 
larger animal species whose brains bear closer similarity to that of humans. The efficacy of 
NK1-R antagonist treatment in rodent stroke models has been clearly establish, therefore 
this thesis seeks to address whether such treatment is also efficacious in an ovine stroke 
model (Chapters 6 and 8). 
 
Following from seminal work conducted by Boltze et al. (2008), in 2012 our group first 
proposed the use of sheep to investigate the evolution of ischaemic injury, in particular 
elevated ICP, following permanent stroke (Wells et al., 2012).  Neuroanatomically, the large 
gyrencephalic structure, with high ratio of white to grey matter, cortical organisation and 
strong tentorium cerebelli, make sheep an ideal species to model stroke and investigate the 
development of cerebral oedema and ICP. This is of particular relevance given that 
vasogenic oedema develops predominantly in the white matter of the brain, which has direct 
implications when determining the efficacy of the NK1-R antagonist in targeting oedema 
genesis. Our group has previously demonstrated that sheep exhibit extensive cerebral 
oedema and elevations in ICP following permanent MCAo (Wells et al., 2015), further 
highlighting their value as a translational species to model ischaemic stroke.  
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4.1.2 Dose of Drug and Pharmacokinetics 
Unfortunately, preclinical pharmacokinetic studies are often not pursued because of 
extensive cost. This limits the ability to successfully translate pre-clinical dosing regimens 
to clinical studies, as although a drug may prove effective in rodent stroke models, it may 
not be feasible, or safe, to simply extrapolate dosing to humans (Bracken, 2009, Perel et al., 
2007). Efficacious treatment outcomes obtained in large animal species may, however, be 
more predictive of clinical efficacy given their more comparable size. Irrespective of this, 
pharmacokinetics and pharmacodynamics vary considerably between species due to 
differences in metabolism. Generation of dose–response curves is thus critical in both small 
and large animal studies for effective clinical translation. Pharmacokinetic data for the NK1-
R antagonist obtained following administration in the sheep is therefore presented in Chapter 
8 of the thesis. 
 
4.1.3 Testing in Permanent and Transient Stroke Models 
When modelling stroke, the STAIR guidelines strongly recommend duration of ischaemia 
be taken into consideration. In the past, the vast majority of studies have adopted permanent 
stroke models; however, the development of cerebral oedema is more prominent following 
transient stroke. Further, the majority of clinical ischaemic stroke cases involve an element 
of reperfusion whereby recanalisation may occur, either spontaneously or purposefully 
through intervention. In addition, as cerebral oedema peaks between 3- and 5-days post-ictus  
(Battey et al., 2014, Hacke et al., 1996), this necessitates study of the evolution of injury 
beyond the acute phase. This is often not possible in permanent stroke models because of 
the severity of injury, with high mortality rates and ethical limitations precluding permanent 
survival models. Prior to this doctorate, a survival model of transient stroke in the sheep was 
lacking, limiting the evaluation of injury evolution. This highlights the need for well-
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characterised ovine permanent, and transient, stroke models to further enhance their 
translational value as an experimental species and enable the reliable screening of novel 
therapies targeting oedema genesis. Therefore, this thesis developed an ovine model of 
transient stroke with reperfusion, with studies outlined in this thesis encompassing both 
permanent (Chapter 6) and transient (Chapters 7–9) stroke. 
 
4.1.4 Consideration of Sex and Age Differences 
The established model of ovine stroke characterised by Wells et al. in 2012 involved 
permanent occlusion of the MCA (Wells et al., 2012). Because of the severity of the resultant 
infarct and ethical requirements, animals were kept under general anaesthesia for the 
duration of the experiment (±24 hours), prior to euthanasia (Chapter 6). This, unfortunately, 
has inherent limitations, including the use of only female animals because of the inability to 
catheterise the convoluted urethra of male sheep. STAIR guidelines, however, dictate gender 
as an important consideration given sex differences in stroke mechanisms and therapeutic 
response. To address this, studies in this thesis (Chapters 7–9) have sought to characterise 
response to injury and treatment in both male and female sheep. 
 
Further, given the population in which stroke is most prevalent is adults over the age of 65, 
the age of animals used in preclinical studies is of relevance. The average life span of sheep 
is 10–12 years, with domesticated sheep primarily raised for wool, meat and occasionally 
dairy production. However, because of reduced fertility, tooth wear and disease 
susceptibility, the mean age of animal culling is 5 years (Munoz et al., 2019, Hoffman and 
Valencak, 2020). Further, the average age of animals used for research purposes is 
approximately 3 years, where animals are generally only aged at the researchers’ request and 
are often culled earlier because of the aforementioned wellbeing considerations. 
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Accordingly, sheep aged 18–36 months were used in this study. Animals in this age bracket 
are reaching skeletal maturity, and can be considered comparable to young adults (Cake et 
al., 2006). However, given limited research into the equivalence of human to ovine age, this 
is largely anecdotal, and further research is required to draw meaningful comparisons, 
especially in regard to neurological maturity equivalencies (Hoffman and Valencak, 2020). 
 
4.1.5 Consideration of a Clinically Useful Therapeutic Window 
The STAIR guidelines indicate the necessity of a clinically useful therapeutic window, that 
is, the duration after stroke in which a treatment is efficacious. The therapeutic window for 
thrombolysis (Ma et al., 2019) and mechanical thrombectomy (Albers et al., 2018, Nogueira 
et al., 2018, Berkhemer et al., 2015, Smith and Yan, 2015, Goyal et al., 2016, Goyal et al., 
2015) has increased significantly in recent years. However, following vessel recanalisation, 
it is essential that treatments targeting secondary complications are effective when 
administered beyond the acute phase post-stroke. The ability to study longer time-points 
following stroke is essential not only to elucidate the temporal profile of key injury factors 
such as cerebral oedema and elevated ICP, but also to meaningfully determine the 
therapeutic window of any novel treatment. We have specifically addressed this criterion by 
assessing administration of the NK1-R antagonist both early and late after stroke (Chapter 
8) in the ovine transient stroke model. 
 
4.1.6 Physiological Monitoring and Neuroimaging 
It is strongly recommended that physiological variables be recorded to limit variability in 
infarct volume. The large size of the sheep allows for application of clinical equipment for 
the accurate assessment of physiological parameters including blood pressure, blood gases, 
blood electrolytes and CBF. Further, invasive neuromonitoring can be carried out, including 
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the application of clinical devices to measure brain tissue oxygenation (PbtO2) and ICP, in 
addition to high resolution CT and MRI. This enables more accurate quantification of infarct 
volume, comparable to clinical assessment. Accordingly, studies within this thesis include 
physiological monitoring, encompassing blood pressure and arterial blood gas/electrolyte 
analysis (Chapters 6–9), invasive neuromonitoring and neuroimaging (Chapters 6–8). 
 
4.1.7 Functional Outcome 
Finally, in determining the efficacy of therapies clinically, it is vital to determine how 
treatment influences long-term function. Indeed, functional outcome is often the major 
endpoint in clinical trials. As per the STAIR guidelines, the ultimate goal of preclinical 
assessment is to show that, in concert with tissue endpoints, functional neurological 
outcomes are also improved in treated populations. Specifically, it is recommended that the 
effect of treatment on functional outcome is assessed for a minimum of 28 days following 
stroke onset. Functional assessment typically aims to assess behavioural outcomes, 
including both motor and sensory domains. Obtaining measures of functional motor outcome 
is particularly paramount given the standard for functional assessment via clinical scoring, 
where clinical evaluation via the modified Rankin Scale (mRS) and National Institutes of 
Health Stroke Scale (NIHSS) remain the most routinely used methods for assessing stroke 
severity worldwide (Chalos et al., 2020). The amenable nature of sheep enables ease of 
handling, neurological assessment and advanced quantitative biomechanical assessment. 
However, comprehensive assessment of ovine functional kinematics following stroke has 
previously been lacking. To address the lack of functional assessment, a novel approach to 




4.2 HYPOTHESES AND AIMS 
 
The overarching goal of this thesis was to examine the effect of NK1-R antagonist treatment 
on cerebral oedema and elevated ICP following stroke in a clinically relevant ovine model. 
The specific aims and respective hypotheses were as follows: 
 
AIM 1. To determine the effect of NK1-R antagonist treatment or decompressive 
craniectomy surgery on ICP following permanent stroke in an ovine model. This aim 
sought to evaluate three different treatment regimens of the NK1-R antagonist (EU-C-001, 
PresSuraNeuro) and compare pharmacotherapy with surgical intervention via 
decompressive craniectomy (DC). This study was performed to determine whether the NK1-
R antagonist could be as effective in reducing ICP as surgical intervention with DC. In 
addition, this study sought to determine the most effective NK1-R antagonist treatment 
regimen to reduce ICP following permanent stroke in the ovine model. 
 
AIM 2. To develop a survival model of transient MCAo in the sheep. Prior to the thesis, 
methods to induce transient stroke in the ovine model were incompatible with survival 
because of the surgical approach used. Therefore, the purpose of this study was to modify 
the surgical approach to transient MCAo so that sheep were able to be recovered for long-
term assessment (28 days) following stroke onset. 
 
AIM 3. To determine the temporal profile of cerebral oedema and ICP following 
transient stroke in an ovine model. To evaluate the efficacy of the NK1-R antagonist, it 
was first essential to characterise the course of cerebral oedema and elevated ICP 
development for 7 days following stroke with reperfusion in the ovine model. In addition, 
both males and females were utilised in this aim, given that urinary catheterisation was not 
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required, allowing investigation of sex differences in the temporal profile following stroke. 
 
AIM 4. To determine the efficacy of NK1-R antagonist treatment, administered either 
early or late following stroke, in reducing cerebral oedema and elevated ICP following 
transient stroke in an ovine model. For this aim we sought to determine the efficacy of 
NK1-R antagonist treatment in a clinically relevant therapeutic window following transient 
ovine MCAo. Specifically, we sought to determine if the NK1-R antagonist could produce 
a clinically meaningful reduction in ICP when administered either early (before elevated ICP 
was established) or late (when ICP was already elevated) post-stroke. Further, we also 
sought to assess whether any differences in response to treatment between genders were 
apparent. 
 
AIM 5. To develop a novel method to assess motor outcome following stroke in an ovine 
model. For this aim, we sought to develop a method to quantitatively assess functional 
outcome and recovery following ovine stroke. To achieve this in a robust and clinically 
relevant manner, we sought to carry out motion capture to assess the gait and kinematics of 
experimental animals. Given limited research in this area, this necessitated the development 
of a novel method of assessment, and significant troubleshooting and ongoing optimisation. 
 
Hypothesis 1. NK1-R antagonist treatment will reduce cerebral oedema and ICP, comparable 
to decompressive craniectomy, at 24 hours following permanent stroke in the ovine model. 
 
Hypothesis 2. The development of cerebral oedema and elevated ICP in the ovine transient 
stroke model will be comparable to that seen clinically, peaking within 3–5 days of stroke 
onset. 
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Hypothesis 3. NK1-R antagonist treatment will reduce cerebral oedema and elevated ICP, 
measured at 6 days following transient stroke, with reperfusion in the ovine model. 
 
Hypothesis 4. Kinematic evaluation of animals pre- and post-transient stroke in the ovine 
model will provide a quantitative and reliable method in which motor function following 



































Although specific procedures are discussed within each experimental chapter, a 
comprehensive overview of methods undertaken, especially those beyond the scope and 
detail of publication, are provided below. 
 
5.1 STUDY DESIGN 
 
A total of 125 (40 M, 78 F) merino sheep (Ovis aries) were used in this thesis. Animals were 
sourced from a single farm in Gum Greek, South Australia and were aged 18 – 36 months, 
with a weight range of 60.38±6.67 kgs. Castrated wethers and ewes with either very small 
or no horns were used preferentially as they were easier to position and operate upon given 
the temporal/parietal surgical approach. All animals were transported from the farm in 
groups of 6-12 on days not exceeding 35 °C to the South Australian Health and Medical 
Research Institute (SAHMRI) Preclinical, Imaging and Research Laboratories (PIRL). On 
arrival, animals were examined by a veterinarian for general wellbeing and absence of 
neurofunctional deficit (Boltze et al., 2008). Sheep were treated prophylactically with 
antiparasitic ivermectin administered intramuscularly (0.25 mg/kg, Ivomec 0.8 g/L) and 
cydectin administered by oral drench (0.1% Moxidectin), and examined for presence of nasal 
bot fly larvae and itchmite. Thereafter, animals were housed in groups of 20-30 in outdoor 
paddocks with free access to water and grazing pastures. All animals were acclimatised to 
pasture for a minimum of 7 days, following which they were transported to smaller yard 
housing to undergo acclimatisation to bucket feeding and human contact for an additional 7 
days prior to commencing experimental procedures. 
 
A minimum of 6 animals were randomised into relevant treatment groups for each of the 
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thesis aims. ICP (Chapters 6-8), MRI (cerebral oedema and infarct volume; Chapters 6-8) 
and functional assessment (Chapter 9) were the primary outcome measures for this thesis, 
with secondary outcome measures including the measurement of physiological parameters 
and immunohistochemistry (IHC). Historical sham data (for example, ICP) was used to 
determine baseline parameters across aims in order to minimise animal numbers required 
for ethical purposes (in accordance with the 3R’s for the use of animals for scientific research 
- Replace, Reduce, Refine - guidelines) and reduce experimental costs (Wells et al., 2015, 
Wells et al., 2012). The breakdown of animal numbers for each experimental group is shown 
in Table 5.1. 
 
5.2 ETHICS APPROVAL 
 
All studies were approved by The University of Adelaide (M-2014-015; M-2015-018) and 
SAHMRI (SAM 104, SAM 3, SAM 141) animal ethics committees. Experimentation was 
conducted in accordance with the Australian National Health and Medical Research Council 
code of care and use of animals for scientific purposes (8th Edition, 2013), and adhere with 
the Animal Research Reporting of In Vivo Experiments (ARRIVE) guidelines (Percie Du 





Table 5.1 Animal allocations across experimental chapters and aims 














Outcome Measures Assessed 
























Vehicle 6F Fixed Y Y N 
DC 6F Fixed Y Y N 
1xNK1 6F Fixed Y Y N 
2xNK1 6F Fixed Y Y N 
3xNK1 
 
6F Fixed Y Y N 






2hr MCAo 1 day Vehicle 4M; 5F Fixed Y Y N 
2 days Vehicle 5M; 3F Fixed Y Y N 
3 days Vehicle 3M; 3F Fixed Y Y N 
4 days Vehicle 3M; 3F Fixed Y Y N 
5 days Vehicle 3M; 3F Fixed Y Y N 
6 days Vehicle 3M; 3F Fixed Y Y N 
7 days Vehicle 3M; 3F Fixed Y Y N 





2hr MCAo 6 days Vehicle 3M; 3F Fixed Y Y N 
Early NK1 3M; 3F Fixed Y Y N 
Late NK1 
 





2hr MCAo 28 days Vehicle 7M; 6F Fresh 
Fixed 
N Y Y 
Late NK1 6M; 7F Fresh 
Fixed 
N Y Y 
          
123 
5.3 SURGICAL APPROACH TO MCAo 
 
5.3.1 Animal Preparation  
Twenty-four hours prior to surgery, all animals were moved to indoor pens where they were 
individually housed and fasted for a minimum of 12 hours pre-operatively to reduce the risk 
of intraoperative regurgitation. This also reduced the rate of fermentation and thus 
development of ruminal tympany due to anaesthetic suppression of eructation, as described 
in Chapter 3. 
 
5.3.2 Anaesthesia Induction and Maintenance 
Animals were transported to a procedure room and induction commenced. For animals in 
Chapter 6, anaesthesia was induced with intramuscular thiopentone (1000 mg in 20 mL, 
Jurox Pty Ltd, Australia); whereas those in Chapters 7, 8 and 9, a combination of ketamine 
(0.05 mL/kg, 100 mg/mL Injection, CEVA, Australia) and diazepam (0.08 mL/kg, 5mg/mL 
Injection, Pamlin, CEVA, Australia), administered intramuscularly, was used. Change in 
induction protocol for Chapter 7 onwards was made following observations of poor recovery 
from anaesthesia with thiopentone in survival animals.  
Following induction, animals were positioned supine on a trolley and an endotracheal tube 
placed via direct laryngoscopy. Wool was shorn from the surgical site and sites of 
intravenous/arterial access and skin cleaned with 4% chlorhexidine (Beckton-Dickinson E-
Z Scrub™, Australia). Protective gel ointment (Poly Visc, Alcon, Australia) was deposited 
in the eyes to prevent corneal drying due to loss of the blink response under anaesthesia. 
Animals were then transported to a surgical theatre and mechanical ventilation commenced. 
The ventilation rate was set to 15 breaths/minute and tidal volume to 10 mL/kg, adjusted 
124 
thereafter to normalise oxygen and carbon dioxide tensions. Anaesthesia was maintained via 
a combination of inhalational isoflurane delivered at 1.5-2 % minimum alveolar 
concentration (MAC) via vaporiser (Henry Shein, Australia) and intravenous ketamine at 4 
mg/kg/hr. To prevent intraoperative hypothermia, a heated breathing circuit (Darvall 
Anaesthesia, Australia) was used which warmed inspired gas to 38.5 ˚C - 40 ˚C. This was 
paired with an oesophageal temperature probe to provide closed-loop temperature control. 
 
5.3.3 Cannulation and Fluid Management 
An arterial catheter (22 g, Terumo SURFLO®) was inserted in the left hind leg for arterial 
blood sampling for blood gas and electrolyte analysis. To ensure patency and minimise risk 
of thrombotic complications, the catheter was regularly flushed (2 mL) via a 500 mL bag of 
sodium chloride (Baxter Health, Australia) attached to a pressurised bag pump (maintained 
at 300 mmHg). The pressure bag was used in combination with a standard flow-regulating 
device allowing fluid to be continually administered at a rate of approximately 3 mL/hr. A 
cannula (20 g, Terumo SURFLO®) was inserted into the external jugular vein for fluid and 
ketamine administration. Crystalloid fluids were administered intravenously throughout 
surgery via continuous infusion with compound sodium lactate at a rate 60 mL/hr 










Figure 5.1. Surgical theatre set up, with surgery in progress. All procedures were carried out aseptically, 
with animals draped and surgeon scrubbed as shown, and overhead theatre lights positioned to illuminate the 
operating area.  
 
5.3.2 Induction of Stroke  
All surgical procedures were carried out aseptically (Figure 5.1). Two different approaches 
to accessing the MCA were used in this thesis. The studies outlined in Chapter 6 used a non-
survival surgical approach (Wells et al., 2012), whereas the studies outlined in Chapters 7-9 
used a modified surgical approach that was compatible with survival (Sorby-Adams et al., 
2019a). 
 
5.3.2.1 Non-survival Surgical Approach - Permanent MCAo  
To achieve stroke in the non-survival model, animals were placed prone in the sphinx 
position with their head tilted 90 degrees for a right MCA approach. A 5 cm vertical incision 
was made running equidistant between the right eye and ear, terminating just below the 
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zygomatic arch. Underlying branches of the superficial temporal artery were identified and 
cauterised, and the large fat pad that sits behind the orbit removed to improve visualisation. 
The temporalis and other muscles of mastication were then stripped from the coronoid 
process of the mandible and the coronoid subsequently fractured at its base, adjacent to the 
zygomatic arch (Figure 5.2). Remaining muscles of mastication were stripped to expose the 
pterion, which comprises the junction of the parietal, sphenoid and frontal bones of the skull. 
Visualisation of the pterion was necessary to perform a craniotomy with adequate access to 
the proximal MCA. With the assistance of loupe magnification and a head mounted light 
source (Surgical Acuity, Wisconsin), a small craniotomy was performed over the junction 
of the parietal and squamous temporal bones using a high-speed pneumatic drill (Midas 
Rex® Legend Electric System (ICP), Medtronic, USA) with a 5 mm fluted ball drill bit 
(Midas Rex® Legend, Medtronic, USA), taking care not to breach the underlying dura. Bone 
was also removed anteroinferiorly from the greater wing of sphenoid to adequately expose 
the MCA. The craniotomy was then extended extradurally with a Kerrison rongeur (2 mm, 
upward facing) anteriorly and inferiorly to provide access to the anterior temporal lobe 
























Figure 5.2. Surgical approach to ovine stroke. (A and C) demonstrate the non-survival approach, where the 
coronoid process is removed and the corresponding craniotomy is unobscured, allowing access to the 
underlying temporal lobe. (B and D) demonstrate the survival approach, where preservation of the coronoid 
process impedes access to the underlying skull bones making appropriate craniotomy more challenging. Three-
dimensional (3D) reconstruction of the skull was performed using images acquired on a Philips CT and 
prepared using 3D slicer and MeshMixer. Brain surface image obtained from the McGill Brain Imaging Centre 
(Brain Surfaces STL; Nitzsche et al., 2015) 
 
5.3.2.2 Survival Surgical Approach - Temporary MCAo with Reperfusion 
To maintain the animals’ ability to masticate post-operatively, the surgical method to 
achieve transient stroke necessitated a less invasive approach (developed according to Aim 
2). Here, animals were placed on their left side, and head tilted to enable a posterior 
frontotemporal surgical approach. A 5 cm incision was then made horizontally between the 
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ear and the orbital rim along the superior temporal fossa. The coronoid process was left intact 
(Figure 5.2) and displaced laterally using Cloward retractors inserted inferiorly. Underlying 
muscles of mastication were then stripped from the floor of the cranium as far rostral as the 
fibrous ring attaching the posterior orbit to the border of the parietal bone, enabling 
visualisation of the pterion. A craniotomy was performed using the same landmarks and 
procedures as the non-survival approach (section 5.3.2.1). The anterior component of the 
craniotomy was frequently the most difficult part of the exposure, and the most critical in 
order to achieve satisfactory proximal MCA access. This was particularly challenging in the 











Figure 5.3. Neuroanatomical structure of the lateral surface of the ovine brain. The approximate location 
of the craniotomy is indicated by the dashed line. The middle cerebral artery can be seen faintly on the cortical 
surface.  During surgery visualisation is optimised with gentle retraction of the temporal lobe. 
 
5.3.2.3 Craniotomy, Durotomy and MCA Occlusion 
Once sufficient bony exposure and craniotomy was achieved in both non-survival and 
survival approaches, a horseshoe-shaped durotomy was performed with an inferiorly based 
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flap. Ideally, the cortical branches of MCA were seen running subpially on the surface of 
the brain (Figure 5.3). Branches were then followed proximally, neurosurgical textile pads 
(patties) inserted over the exposed brain to prevent contusion (Neuray® Surgical Patties, 
Medtronic, USA), and gentle upwards retraction of the anterior temporal lobe performed to 
follow each branch to its bifurcation point. Further gentle retraction and careful CSF 
aspiration from the pre-chiasmatic cistern allowed identification of the proximal MCA 
where it looped around the optic tract, medial to where the free tentorial edge meets the roof 
of the cavernous sinus. To include the perforating branches when performing an occlusive 
MCA stroke, proximal exposure of the artery at its origin was deemed important (see 
cerebrovasculature in Figure 5.4). At this point of the surgical procedure, the animal was 
randomised into one of the following experimental groups, according to study aim: 1) Sham: 
the proximal MCA was dissected but not occluded; 2) Permanent occlusion: the proximal 
MCA was cauterised with Malis bipolar diathermy forceps (Valleylab Inc., Colorado); or 3) 
Temporary occlusion with reperfusion: the proximal MCA was occluded for 2 hours with a 
temporary mini aneurysm clip (Aesculap YASARGIL® Aneurysm Clip, Germany) before 




Figure 5.4. The ovine cerebrovasculature. This resin cast shows in intricate detail the complex anatomy of 
the ovine cerebrovascular system. (A) The lateral aspect of the brain shows the course of the middle cerebral 
artery (MCA) with branches running along the cortical surface, as indicated by the arrowhead. (B) The inferior 
aspect of the brain shows in more detail the MCA at its site of bifurcation from the internal carotid artery 
(ICA). The arrowhead indicates the ideal site of M1 MCA occlusion prior to its division into M2 cortical 
branches. Also of note is the intricate structure of the rete mirabile, which can be see prior to continuation of 
the ICA into the circle of Willis (see Figure 3.2, Chapter 3, for diagrammatic representation).  
 
5.3.2.4 Restoring Intracranial Dynamics and Wound Closure 
After sham surgery, permanent MCA occlusion, or aneurysm clip release, synthetic dural 
regeneration matrix (Durepair®, Medtronic, USA) was used to cover the brain and 
watertight dural closure achieved with ethyl cyanoacrylate (Bostik, Australia). The bone flap 
from the craniotomy was reinserted and cranioplasty performed with dental acrylic cement 
(Sledgehammer, Keystone, Germany), which was applied and manipulated into the edges of 
the craniotomy, restoring the integrity of the cranial cavity and thus homeostasis of ICP 
dynamics. The surgical site was then treated with 1.0 mL 0.5% local anaesthetic Marcain 
(Bupivacaine hydrochloride 5 mg/mL, AstraZeneca, Australia) and muscle layers opposed 
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using 0.1 braided polyglactin suture with tapercutting needle (Vicryl®, ETHICON, 
Australia) using a horizontal mattress suture technique of wound closure to prevent infection 
(Kudur, 2009). 
 
5.3.3 Physiological Monitoring  
Arterial blood samples (2.0 mL) were collected every 3-4 hours via the indwelling arterial 
catheter and analysed (Machine AVL Scientific Corporation USA, Manufactured by 
Hersteller, OPTI Critical Care Analyzer–Model OPTI3, Serial No. OP3-2759) to determine 
pO2, pCO2, bicarbonate, base excess, haematocrit, haemoglobin, pH, Na+ and K+ levels. 
Rectal and oesophageal temperature and end tidal CO2 (ETCO2) were also measured at this 
time. A pulse oximeter attached to the side of the mouth enabled continuous measurement 
of oxygen saturation and pulse rate. Intraoperative pO2 was maintained at >100 mmHg to 
ensure adequate oxygenation of the brain to prevent hypoxia and exacerbation of ischaemia. 
Mean arterial blood pressure (MABP) was maintained at approximately 70-90 mmHg to 
ensure adequate arterial pressure during reperfusion to ensure sufficient blood return to the 
area of ischaemia. Physiological pCO2 was considered 36-44 mmHg; as CO2 is a potent 
cerebral vasodilator, it was essential to induce mild hypocapnia (>40 mmHg) to promote 
moderate brain relaxation and facilitate adequate MCA exposure during surgery, and also to 
reduce the effects of elevated pCO2 on ICP. Finally, target pH was ±7.42 to prevent 
metabolic acidosis (pH <7.41) as metabolic disturbances predispose to respiratory acidosis, 
resulting in elevations in CO2. A summary of physiological variables recorded, and normal 




5.3.4 Blood Pressure Monitoring 
Given the relationship between MABP, ICP, CPP, and cerebral ischaemia, efforts were made 
to obtain regular measurements of MABP intraoperatively. Arterial blood pressure (ABP) 
was monitored continuously via insertion of an indwelling arterial catheter (Chapter 6), or 
at 5-minute intervals via application of a paediatric blood pressure cuff (Easy Care Cuff, 
Phillips) on the upper left front limb (Chapters 7-8). Although application of the blood 
pressure cuff to the limb provided an estimate of blood pressure at regular intervals, 
measurement via direct catheterisation of the artery enabled recording of accurate 
physiological measurements in real time, and subsequent correlations to the ICP response. 
In Chapter 6, where non-survival animals were used, femoral artery catheterisation was 
achieved via invasive means. This approach, however, was not achievable in survival 
animals due to permanent occlusion of the femoral artery. 
Table 5.2 Physiological variables recorded intraoperatively 
Abbreviation Description Physiological value 
pH pH 7.42 - 7.46 
pO2 Partial pressure of oxygen >100 mmHg 
pCO2 Partial pressure of carbon dioxide 36 - 42 mmHg 
ETCO2 End tidal/alveolar carbon dioxide 30 - 48 mmHg 
BE Base excess -2 - +2 
SpO2 Oxygen saturation >90 
HCO3- Bicarbonate 22 - 33 
Hb Haemoglobin 7.3 - 10 
Hct Haematocrit 23.5 - 33 
Na+ Sodium 130-145 
K+ Potassium 3.9 - 4.1 
PR Pulse rate 60 - 85 beats per minute 
rTemp Rectal temperature 37.5 - 39.5 ºC 
Values based on Byrom et al., 2010. 
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5.3.4.1 Invasive Arterial Blood Pressure Monitoring in Non-survival Animals 
Animals were positioned supine on the operating table and hindlimbs extended to expose 
the ventromedial aspect of the left hindlimb. Using a sterile technique, the femoral artery 
was palpated, and an incision made using a size 22 scalpel blade along the ventromedial 
aspect of the hindlimb running laterally. Upon incision, the underlying muscle was dissected 
using a blunt technique, allowing the femoral artery to be isolated from the adjacent nerve 
and vein. A 3 cm segment of the artery was located, fascia cleared, and the distal end tied 
off. A haemostatic clamp (straight mosquito) was subsequently applied to proximal segment 
of the vessel, a small incision made in the exposed section, and 12 g, 42 cm sterile spinal 
manometer tube (Baldwin Medical, Australia) inserted into the vessel. A female-taper Luer 
lock (Becton-Dickinson, Australia) was subsequently attached to the distal end of the 
catheter, and Codman® Microsensor transducer (Codman & Shurtleff Inc., Massachusetts) 
attached to the male-taper of the Luer lock. This set-up allowed for simultaneous continuous 
ABP monitoring (LabChart Reader, ADInstruments, Australia), and sampling of arterial 
blood for blood gas analysis. The catheter remained in situ for the duration of the experiment 
thereafter. 
 
5.4 INTRACRANIAL PRESSURE MONITORING 
 
 
The method in which ICP was monitored varied depending on the experimental aim, with 
differences in the duration of ICP monitoring between survival and non-survival 
experiments. Those animals in Chapter 6 underwent continuous ICP monitoring throughout 
the entire 24-hour period following stroke. For animals in Chapters 7 and 8, prior to the pre-
determined survival time-point, animals were re-anaesthetised and ICP measured for 3-4 
hours only (as discussed in detail in Chapters 7 and 8). 
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Regardless of ICP monitoring duration, procedures were performed in the same fashion. 
Burr holes with a diameter of 5 mm were drilled bilaterally into the skull using a handheld, 
Codman® Cranial Hand Drill (Codman & Shurtleff Inc., Massachusetts), approximately 1 
cm lateral to the sagittal suture and 1 cm posterior to the horn buds. Once the skull was 
breached, the underlying dura was incised, and plastic bolts from a Codman Microsensor™ 
Skull Bolt Kit for Intraparenchymal Procedures (Codman & Shurtleff Inc., Massachusetts) 
secured into the burr holes. A Millar strain gauge Codman® Microsensor transducer 
(Codman & Shurtleff Inc., Massachusetts) was used to measure ICP (the same fabrication 
as used to monitor ABP) with a range of –50 mmHg to +250 mmHg. The Codman® 
Microsensor comprises a pressure sensing microchip transducer mounted in a titanium case, 
with a 1.2 mm diameter tip attached to a 0.7 mm diameter nylon lead measuring 40 cm in 
length. The nylon lead of the Microsensor was attached to a bridge amplifier and PowerLab 
data acquisition device (ADInstruments, Australia). LabChart software (ADInstruments, 
Australia) installed on a computer (Dell, UK) to which the PowerLab and bridge amplifier 
were connected allowed for the analogue signal from the Codman microsensor to be 
continually recorded at frequencies of approximately 1 KHz.  
 
Once attached to the bridge amplifier and PowerLab, the Codman Microsensor™ was laid 
flat, with the tip of the sensor immersed in sterile saline. The device was subsequently 
zeroed, and two-point pressure checks (0 mmHg, 100 mmHg) performed to ensure 
transducer accuracy. Following zeroing and checking, the prepared probes were attached to 
skull bolts and transducers advanced 15 mm into the brain parenchyma to allow continuous 
recording of ICP for the aforementioned durations. At the conclusion of recording, probes 
were removed, and two-point checks re-performed to determine extent of drift, if any, 
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throughout the duration of the experiment. ICP readings from the ipsilateral hemisphere 
were preferentially used for data analysis. 
 
5.5 POSTOPERATIVE RECOVERY  
 
On completion of intraoperative procedures, animals were removed from anaesthesia and 
extubated. Thereafter, their post-operative fate was dependent upon the specific 
experimental aim. Animals in Chapters 7, 8 and 9, once lucid, were transported to post-
operative recovery pens. Here they were placed under a forced air warming blanket (Darvall, 
Australia) and treated with subcutaneous antibiotic Rilexene (Chapter 6 and 7; 1 mL/10 kg 
every 12 hours, 15 g/100 mL Cephalexin, VIBRAC, Australia) or Depocillin (Chapter 8 and 
9; 1 mL/25 kg every 12 hours Procaine benzylpenicillin, Intervet, Australia), non-steroidal 
anti-inflammatory Carprevine (0.7 mg/kg every 12 hours, 50 mg/mL Carprofen, Norbrook, 
Australia) and opioid Temgesic (1.0 mL, 300 μg/mL Buprenorphine hydrochloride, Reckin 
Benckiser, Australia) for pain relief. Note the differences in the antibiotic agent use across 
studies was due to a change in the preferred antibiotic agent used by SAHMRI PIRL and not 
researcher preference. Antibiotic and NSAID treatment was continued for 3 days following 
surgery, with additional opioid and NSAID administered as required thereafter upon 
veterinary advice.  
 
All animals remained in indoor single pens 7 days post-operatively to allow for close 
continuous monitoring. Here, they were fed once daily with a combination of feedlot, nuts, 
grain and lucerne hay (Laucke Mills, South Australia), with free access to water. Clinical 
evaluation of was performed bis in die in accordance with ethical guidelines, more frequently 
as clinical scoring and animal condition dictated. Specifically, animal wellbeing was 
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monitored through recording of food consumption and water intake, urine and faeces output, 
ability to walk and stand unassisted, signs of pain such as the presence of teeth grinding, 
droopy ears and signs of wound infection such as swelling of the surgical site (see Appendix 
5.1 for ovine stroke clinical record sheet, which also details humane endpoint). Animals 
were weighed weekly or more frequently as required. In addition, continuous animal 
monitoring was performed via closed-circuit television (CCTV), with researchers able to 
check on animals remotely via CCTV monitoring software available on personal mobile 
devices.  
 
5.6 MAGNETIC RESONANCE IMAGING 
 
All animals underwent MRI under general anaesthesia (1.5% isoflurane, Henry Shein, 
Australia) with time of acquisition varying according to the experimental aims. Images were 
acquired on a 1.5 Tesla (T) Siemens Syngo2004A Sonata (Siemens AG, Munich, Germany) 
with a 12-channel head coil. The specific scanning sequences included T1 magnetisation-
prepared rapid acquisition with gradient echo (MPRAGE), T1 turbo spin echo (TSE), T2 TSE, 
T2 fluid attenuated inversion recovery (FLAIR), T2 star, diffusion-weighted imaging (DWI, 
with B1000 and B0 values acquired), DWI apparent diffusion coefficient (ADC), magnetic 
resonance angiography (MRA) time-of-flight (TOF) and T1 MPRAGE following contrast 
administration (details in section 5.6.2). Sequence parameters are summarised in Table 5.3. 
The level of vital MRI coronal slices in the territory of MCA are shown in Figure 5.6, and 
corresponding neuroanatomical landmarks in Figure 5.7. 
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Table 5.3 MRI imaging sequences 
Sequence Orientation Slice 
Thickness 
(mm) 
Pixel size TR (ms) TE (ms) FA NA IT Purpose 
T1 MPRAGE Isometric 1 0.58/0.58 1900 3.93 15 1 1100 Morphology 
          
T1 TSE Coronal 5 0.58/0.58 490 9.3 90 2 
 
Morphology 
          
T1 TSE Axial 5 0.58/0.58 450 9.3 90 2 
 
Morphology 
          




          




          
T2 FLAIR Coronal 5 0.46/0.46 8700 162 150 2 2500 Oedema 
          
T2 star Coronal 5 0.46/0.46 1050 26 20 1 
 
Haemorrhage 
          
DWI ADC Coronal 5 1.56/1.56 3600 95 90 10 
 
Infarction 
          
DWI ADC Axial 5 1.56/1.56 3000 84 90 10 
 
Infarction 
          
DWI TRACE Coronal 5 1.56/1.56 3600 95 90 10 
 
Infarction 
          
DWI TRACE Axial 5 1.56/1.56 3000 84 90 10 
 
Infarction 
          
MRA TOF Isometric 5 0.39/0.39 40 5.16 25 2 
 
Cerebrovascular anatomy 
          
T1 MPRAGE fs 
GAD 
Isometric 5 0.58/0.58 1900 3.93 15 1 1100 Morphology 
          
 




































Figure 5.5. Location of vital MRI slices in the coronal plane. Slices in the territory of the middle cerebral 
artery most commonly affected by stroke are indicated by the vertical white lines. From anterior to posterior 
slices; A, B, C and D, corresponding neuroanatomical landmarks shown in Figure 5.7. A – anterior, P – 
posterior, S – superior, I – inferior, L – left, R – right. Figure created from T1 SPC MRI atlas (Ella and Keller, 
2015, Ella et al., 2017, Ella et al., 2019). Scale bar 1 cm. 
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Figure 5.6. Neuroanatomical landmarks of critical coronal sections in the territory of the middle cerebral 
artery (MCA). The left panel shows an atlas of key neuroanatomical areas, and the right panel shows 





Table 5.4 Neuroanatomical landmarks of the cortex (C) and inner cortex (IC) 
Annotations for cortical structures (C) Annotations for inner brain structures (IC) 
1 Anterior sygmoideus gyrus 1 Lateral ventricle 
2 Cerebellum 2 Fourth ventricle, aqueduct 
3 Cingulate gyrus 3 Accumbens 
4 Insular cortex 4 Amygdala 
5 Ectolateral gyrus 5 Anterior commissure 
6 Entolateral gyrus 6 Bed nucleus 
7 Gyrus rectus 7 Caudate nucleus 
8 Lateral gyrus 8 Claustrum 
9 Medulla oblongata 9 Corpus callosum 
10 Midbrain 10 Fornix 
11 Occipital lobe 11 Globus pallidus 
12 Olfactory bulb 12 Globus Pallidus additional structure 
13 Olfactory tract 13 Hippocampus 
14 Orbital gyrus 14 Hypothalamus 
15 Orbitofrontal gyrus 15 Internal capsule 
16 Parahippocampal gyrus 16 Lateral septal nucleus 
17 Pituitary gland 17  Mamillothalamic tract 
18 Pons 18 Medial septal nucleus 
19 Postcruciate gyrus 19 Medullary lamina 
20 Posterior sygmoideus gyrus 22  Optic tract 
21 Posterior sylvian gyrus 23 Periaqueductal grey matter 
22 Precruciate gyrus 24 Pineal gland 
23 Suprasylvius gyrus 25 Preoptic hypothalamic area 
24 Sylvian gyrus 26 Putamen 
25 Temporal lobe 28 Thalamus 
 
Atlas regions from Ella et al., 2019. 
 
 
5.6.3 MRI Analysis of Infarct Volume 
Diffusion weighted imaging sequences were used to assess infarct volume (Figure 5.8, A). 
DWI is able to detect changes in ischaemic brain tissue in as little as 2.5 minutes post-ictus 
in experimental animals, and is highly sensitive in the hyperacute examination of clinical 
stroke (Linfante et al., 2001). These sequences enable assessment of the apparent diffusion 
coefficient (ADC) of water, with a decreased ADC signal corresponding with energy failure, 
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such as that of ATP dependent pumps during acute stroke and accumulating cytotoxic 
oedema. When cytotoxic oedema plateaus after the first 24 hours of stroke onset, the ADC 
evolves to appear bright. 
Ergo, these sequences are particularly robust and allow for identification of the evolving 
infarct. In order to undergo volumetric quantification of the infarct, segmentation tools in 
ITK-SNAP were used to perform semi-automated segmentation of diffusion-weighted 
lesions (Figure 9). This consisted of a combination of three-dimensional (3D) active contour 
segmentation and subsequent manual post-processing of the segmentation while adjusting 
image thresholds. This semi-automated method was chosen to maximise reproducibility 
whilst excluding artefacts. The 3D active contour segmentation consisted of multiple steps: 
First, in the pre-segmentation phase, independent component analysis automatically 
segmented parts of the DWI image which were subsequently manually identified as 
foreground or background. To obtain the optimal distinction between foreground and 
background, thresholds of the image windows were adjusted. After thresholding, a “speed 
image” with a separate foreground and background was created (Figure 5.9, B). Next, in the 
active contour phase, seed regions were manually placed within the region of interest (ROI) 
(Figure 5.9, B, white circle). These seeds were then automatically grown within the ROIs to 
form the temporary segmentation (Figure 5.9, C). On completion of active contour 
expansion, the 3D volume segmentation was assessed, and areas not automatically included 
in the active contour manually included in a follow-up manual segmentation. For a full 





































Figure 5.7. Infarct segmentation on ITK-SNAP. (A) The DWI sequence of interest is loaded into ITK-SNAP 
and automatic thresholding applied to better identify the infarct. (B) after thresholding, a ‘speed image’ is 
created as shown, and threshold further adjusted to optimise demarcation between the infarct and surrounding 
tissue. Seeds were then placed in the seed image and grown (circle), allowing the infarct to be segmented from 
unaffected tissue, as shown by the white overlay in (C). (D) The segmentation can be seen in 3D and volumes 






5.6.1 MRI Analysis of Cerebral Oedema 
T2 FLAIR images were used to quantify cerebral oedema. Here, the inversion pulse applied 
to suppress high signals emanating from normal fluid-filled spaces such as ventricles and 
sulci enables determination of the extent of cerebral oedema by visualisation of areas in the 
brain of increased parenchymal water content, which appear bright (Figure 5.8, A) (Hudak 
et al., 2014, Battey et al., 2014). 
 
Quantification of cerebral oedema was thereby achieved via direct measurement of white 
matter hypersensitivities. The specific approach to analysis, however, changed throughout 
the course of this thesis. In the initial studies (Chapters 6 and 7), manual segmentation was 
performed on coronal FLAIR images by an assessor blinded to the treatment group (HOROS 
v.3.3.6). As an understanding of analysis procedures were developed throughout the course 
of this doctorate, more comprehensive measures were performed, with updated approach 
applied in Chapter 8. This involves quantification of the hypersensitive FLAIR region using 
semi-automated methods described in section 5.6.3. Here, co-registration of oedema FLAIR 
and infarct DWI segmentations were performed, following which the infarct was subtracted 
from the oedema volume, thereby providing a quantitative measure of peri-infarct fluid. 
In Chapter 8, quantification of the relaxation signal on T2 scans was also performed to 
determine parenchymal water content. Here, 8 ROI’s measuring 10 mm2 were drawn in the 
ipsi- and contra- lateral hemispheres on axial scans at the level of the foramen of Monro. 
The mean signal intensity for each ROI was recorded, and the average intensity of all ROI’s 
summed for each hemisphere. Signal intensity ratios were then calculated by normalising 
the signal intensity within the ipsilateral hemisphere to the signal intensity of the 
contralateral hemisphere. The normalised values in the stroke affected hemisphere were then 
exported for final interpretation. 
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5.6.2 MRI Analysis of BBB Permeability 
To assess the permeability of the BBB, pre- and post-contrast T1 MPRAGE series (Figure 
5.8, D) were obtained following intravenous administration of 0.1 mL/kg Gadolinium-
diethylene-triamine-pentaacetic acid (Gadovist, Gd-DTPA or GAD) (Magnevist, Bayer 
HealthCare, Germany). Gd-DTP is a large molecule that cannot enter the brain tissue when 
the BBB is intact (Aksoy et al., 2013). Leakage of GAD into brain tissue thus reflects 
breakdown and disruption of the barrier, permitting the abnormal movement of water into 
the brain (Aksoy et al., 2013) Dynamic sequences were unfortunately not obtained in this 
thesis; therefore, quantification of the influx constant (Ktrans) was unable to be performed 
(Varatharaj et al., 2019). Instead, single time point series were used to perform qualitative 



























Figure 5.8. MRI sequences used for quantitative analysis 3 days post stroke. (A) Diffusion weighted 
imaging (DWI) showing the infarct core with cytotoxic oedema (hypertensive) used for quantification of infarct 
volume. (B) Apparent diffusion coefficient (ADC) maps showing infarct core (hypotensive) and surrounding 
vasogenic oedema (hypertensive rim). (C) T2 fluid attenuated inversion recovery (FLAIR) showing infarct and 
oedema (hypertensive) with evident midline shift used for quantification of oedema. (D) TI MP-RAGE 
following administration of 0.1 mg/kg Gadovist showing evidence of BBB breakdown identified as the 




5.6.4 MRI Analysis of Mass Effect 
To determine the mass effect of cerebral oedema, T2 WI were used to determine pathological 
abnormality in which the degree of midline shift (MLS) was measured. Clinically, elevated 
ICP is associated with significant MLS and compression or obliteration of the 
perimesencephalic cisterns, with the degree of MLS being a predictor of poor prognosis and 
mortality.  MLS is therefore regarded as an imaging feature supporting the Munro-Kellie 
doctrine (Liao et al., 2018). In this thesis, extent of shift from the midline was measured in 
mm from the septum pellucidum at the level of the foramen of Monro by blinded assesment 
(HOROS v3.1.1). 
 
5.7 COLLECTION OF BIOLOGICAL FLUIDS 
 
5.7.1 Collection of Cerebrospinal Fluid 
CSF was collected via lumbosacral tap prior to induction of stroke and on days 1, 3, 6 
thereafter in the cohort from Chapter 9. Note that as collection was performed in animals 
that did not undergo ICP monitoring there were no concerns regarding multiple CSF draws 
and the associated effects on ICP measurement accuracy. To obtain samples, animals were 
induced with a combination diazepam and ketamine as previously described (section 5.3.1). 
Animals were then placed in the prone position on a surgical table and the sagittal plane of 
the animal’s vertebrae manipulated so that it was perpendicular to the horizontal plane of the 
table. Palpation of the hips was performed to determine the correct sagittal plane orientation 
of the spine and the optimal site for CSF collection was identified by the midline depression 
between the last lumbar and first sacral vertebrae. The area was shorn and cleaned using a 
4% chlorhexidine preoperative surgical scrub brush (Beckton-Dickinson E-Z Scrub™, 
Australia), povidone-iodine applied and site surgically prepared. A 19 g medium bevel point 
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spinal needle with stylet (BMDi TUTA Healthcare, Australia) was inserted perpendicular to 
the skin and the needle advanced slowly through the subcutaneous tissue and interarcuate 
ligament until a sudden drop in resistance was felt indicating the advancement through the 
dural membrane and entry into the subarachnoid space. The stylet was then removed, and 2 
mL of CSF aspirated via a syringe and deposited into a 3 mL tube, the sample placed 
immediately on ice for 20 minutes, centrifuged (15 mins at 4 °C 3000 relative centrifugal 
force (RCF)), extracted into 3 x 500 μL aliquots and stored at -80 °C until use.  
 
5.7.2 Collection of Serum 
For the animals in Chapter 9, 8.5 mL of whole blood was collected in Serum Separator tubes 
containing Silica/clot activator (Vacutainer® SST™ II Advance Tube, Beckon-Dickinson, 
Australia), either by direct venepuncture or via indwelling venous jugular catheter. Once 
filled, the tube was gently inverted 180° and back 5-6 times to ensure mixing of silica 
activator with the blood. Blood samples were subsequently left to clot at room temperature 
(not exceeding 25 °C) for 30 minutes. Samples were then centrifuged at 2000 RCF for 15 
minutes at 18-25 °C to separate cellular blood components from serum, following which 
serum was carefully aliquoted in 500 μL samples into pre-labelled Eppendorf tubes and 
transferred to a -80 °C freezer for storage. Any evidence of haemolysis was carefully 
documented for future analyses. 
 
5.7.4 Collection of Blood for Pharmacokinetics 
To complete pharmacokinetic assessment following NK1-R administration, a subset of 
animals underwent additional blood collection (n=6, 3M, 3F) as detailed in Chapter 8. By 
direct venepuncture or via indwelling venous catheter, whole blood was collected in 
K2EDTA tubes (Vacutainer® K2EDTA tubes, Beckon-Dickinson, Australia). Twelve mL 
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of blood was taken per animal at the following time points; immediately prior to 
administration and at 4, 8, 12 16, 24, 28 and 48 hours thereafter. Tubes were gently inverted 
180° and back 6-8 times to ensure mixing of anticoagulant to avoid microclotting. 
Immediately following inversion, samples were placed in an ice bath for 20 minutes, after 
which samples were centrifuged at 1500 RCF for 10 min at 18-25 °C. Immediately following 
centrifuge, blood was aliquoted into pre labelled 2 mL iobind polypropylene t tubes (PCR 
clean, Eppendorf™, Australia). Samples were then flash frozen by immersion in liquid 
nitrogen for approximately 1 minute, following which cryovials were transferred to a -80 °C 
freezer for storage. 
The NK1-R antagonist was subsequently extracted from plasma samples via protein 
precipitation extraction. Analytes were separated using high-performance liquid 
chromatography on an ACE C18-AR column, and the eluates monitored by an API4000™ 
liquid chromatography mass spectroscopy (SCIEX) in positive multiple reaction monitoring 
mode. The extracts were then assayed against a calibration cure, data analysed via Analyst® 
software (SCIEX) and processed in Watson LIMS™ (Thermo Scientific).  
 
5.8 NK1-R TREATMENT ADMINISTRATION 
 
For the NK1-R treatment studies (Chapters 6-8), animals were randomised to receive either 
the NK1 tachykinin receptor antagonist or equal volume of saline vehicle. The NK1-R 
compound used, EU-C-001, was supplied by PresSuraNeuro (Hoffmann et al., 2005, 
Australian Patent AU2002328837B2 (under embargo), May 5, 2005). The dose of NK1-R 




The NK1-R dosing regimen differed across the studies, as detailed in Table 5.5. Treatment 
was delivered via intravenous jugular catheter (18 g, Terumo SURFLO®) at a volume of 1 
mL/kg of 1 mg/mL solution (i.e., 65 kg animal was administered 65 mL of prepared EU-C-
001). The EU-C-001 is formulated as a powder and prior to administration was dissolved in 
warmed (37 °C) sterile saline (e.g., 60 mg EU-C-001 dissolved into 60 mL saline) for 
administration as a slow bolus over approximately 10 minutes via intravenous line.  
 
Table 5.5 NK1-R antagonist administration regimens 
Chapter NK1-R treatment regimens 
6 3 NK1-R treatment groups 
 1 × NK1 - bolus at 4 h post-stroke onset 
 2 × NK1 - bolus at 4 h and 9 h post-stroke 
 
3 × NK1 - bolus at 4 h, 9 h and 14 h post-stroke 
 
8 Early NK1-R - treatment commenced at 28 h post-stroke 
 
Animals treated on days 1, 2 and 3 post-stroke - bolus of NK1-R antagonist administered, 
followed by up bolus 5 h later 
 
 Late NK1-R - treatment commenced at 124 h post-stroke 
 
Animals treated on 5 days post-stroke – bolus of NK1-R antagonist, followed up by bolus 
5 h later 
 
 
5.9 PERFUSION  
 
All animals were humanely killed via exsanguination under general anaesthesia (isoflurane 
3%) and were perfused with tris-saline (Tris(hydroxymethyl) aminomethane and sodium 
chloride solution (Sigma-Aldrich, Australia). Animals were laid in a prone position on a 
post-mortem table, the neck dissected to expose the carotid arteries, and infusion lines 
inserted bilaterally and secured into place.  Heparin (25000 IU heparin in 5 mL saline, Pfizer, 
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USA), followed by a 10 mL saline flush was administered via jugular catheter to prevent 
coagulation following exsanguination. A perfusion pump was attached, and at a pressure of 
140 mmHg, sheep were perfused with 4 L of chilled tris-saline via the carotid artery lines, 
after which the jugular veins were incised, ensuring a clean circuit for tris saline to flow 
through the brain, clearing out blood from the cerebrovasculature.  
Following perfusion and confirmation of death, animals were removed from anaesthesia, 
endotracheal tube cuff-deflated, and extubated. Animals were then rapidly decapitated, and 
a hexagon marked at boundaries rostral to the highest point of the orbital ridge, lateral to the 
head of the coronoid, and caudal at the occipital crests using an oscillating saw. The bone 
was cut along the boundaries of the hexagon at a depth of approximately 1 cm rostrally, and 
0.5 cm caudally and laterally.  Using an osteotome, the bone was levered, and the skull cap 
removed, allowing the brain to be separated from the encasing cranium without damage. The 
tentorium and cranial nerves were incised, and the brain gently removed from the skull. The 
brain was then placed in a custom brain matrix and sections cut into 0.5-1 cm coronal slices 
perpendicular to the dorsal surface, starting at the anterior pole and extending to the 
cerebellum. Sections were placed with the anterior face down in Pre-Load II embedding 
cassettes (Leica Biosystems, Australia) and labelled accordingly. Tissue was then immersed 
in 10% neutral-buffered formalin for a minimum of 14 days to allow for fixation and 
processing for immunohistochemistry (IHC) thereafter.  
Critical coronal sections in the region of the MCA are shown in Figure 5.9, with 



















Figure 5.9. Critical coronal brain sections in the territory of the middle cerebral artery (MCA). Locations 
of sections are indicated by the vertical black line, from anterior to posterior A, B, C and D. Corresponding 
neuroanatomical landmarks of these sections can be seen in figure 5.9. A – anterior, P – posterior, S- superior, 






Figure 5.10. Neuroanatomical landmarks of critical coronal sections in the territory of the middle 
cerebral artery (MCA). The left panel shows the regions on immunohistochemical specimens stained with 
Weil’s myelin stain to better demarcate white matter tracts. The right panel shows regions in fresh brain 
specimens. Refer to Table 5.4 for corresponding numerical atlas regions. Weil images converted to binary 
obtained from the University of Wisconsin and Michigan State Comparative Mammalian Brain Collections 
and National Museum of Health and Medicine Collection. Preparation of images and specimens funded by the 




5.10 TTC STAINING 
 
In Chapter 6, 2,3,5-Triphenyltetrazolium chloride (TTC) staining was used to differentiate 
between metabolically active and inactive brain tissue, in which viable brain tissue stained 
pink whilst the area of infarct appeared white. A 3% TTC (Sigma-Aldrich, Australia) 
solution prepared in 10 mL tris-saline was used in which brain slices were immersed. Slices 
were then placed in a 37 °C water bath and incubated in dark room conditions for a total of 
10 minutes on the anterior face and 10 minutes on the posterior face. Anterior and posterior 
sides of all brain slices were photographed on a flatbed scanner (Canon CanoScan 
LiDE700F, Canon Inc., Japan) and immersion fixed in 10% neutral-buffered formalin 
immediately thereafter, as detailed above. Lesion volume was calculated using ImageJ 
software (Version 1.49v), in which the area of infarct on both the anterior and posterior faces 
for each slice was calculated and the total area of infarct determined. For the purpose of data 
analysis, total brain volume was calculated in pixels and area of infarct calculated as a 
percentage of the whole brain. Due to the infarct being indistinguishable by TTC beyond 3 
days following stroke (Mcbride et al., 2015), staining was not repeated for Chapters 7 and 
8. 
 
5.11 HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY 
 
Fixed brain tissue slices were processed, embedded in paraffin wax and 5-micon coronal 
sections mounted on silane coated glass slides for histological examination. Haematoxylin 
and eosin (H&E) staining was used to demarcate the infarct and examine gross pathological 
abnormalities. Immunohistochemistry (IHC) was used to probe neurogenic inflammation, 
vasogenic oedema and BBB permeability, with staining details outlined in Table 5.6. Whole 
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slides were scanned (NanoZoomer 2.0-RS, Hamamatsu Photonics, Japan) and visualised on 
NDP view software (NDP.view v2.0, Hamamatsu Photonics, Japan) for future assessment. 
 
Table 5.6 Antibody details for immunohistochemistry 
Antibody  Dilution  Retrieval  Brand Catalogue no. 
Albumin 1:2000 No retrieval  Dako  A0001 
SP 1:5000 Citrate Abcam  ab14184 
Caveolin-1 1:500 EDTA Cell Signalling Technologies  3238 





5.12 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
In Chapter 7, serum and CSF samples were analysed using enzyme-linked immunosorbent 
assay (ELISA) to determine levels of SP, with plates run according to the manufacturer’s 
instructions (Abcam; KIT-ab133029). All samples were diluted 1:4 in assay buffer for 
appropriate compliance with each individual plate standard curve. Standards were run along 
with the serum and CSF samples and the plate immediately analysed following addition of 
the stop solution using a spectrophotometric microplate reader (Synergy HTX, multi-mode 
reader). At optical density of 405 nm light absorbance was calculated to give an inverse 
reading of SP proportional to its captured measure on the plate. 
 
5.13   FUNCTIONAL ASSESSMENT 
 
The assessment of motor function completed in this thesis required a significant period of 
troubleshooting to determine the most robust method. Firstly, we sought to identify common 
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deficits observed following ovine stroke in the existing literature, and in our prior studies. 
Most noticeable was significant deficit of the contralateral fetlock joint, as shown in Figure 
5.11.  This loss of motor control was seen to affect the distal phalanges, resulting in constant 
flexion of the joint and impaired gait during forward motion. Postural deficits were also seen, 
including lowering of the head and shoulders, and behavioral disturbances including 













Figure 5.11. Observable post-stroke motor deficit. Following right middle cerebral artery occlusion, the left 
forelimb fetlock joint can be seen in partial flexion (foreground of B) compared with the contralateral 
unaffected limb (foreground of A). 
 
5.13.1 Gait analysis – Hoof Impression Assessment 
To assess function of the lower limb and the influence of hemiparesis on gait, we initially 
sought to emulate commonly used, highly cost-effective rodent gait models, in which 
animals’ paws are painted and animals are encouraged to walk over paper, creating prints 
A B 
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which are used to measure stride length and width. A comparable experiment was designed 
in which sheep were required to traverse a shallow pit (1 m × 3 m) of semi-soft clay. This 
necessitated determining the optimum mix of clay and soil to ensure a consistency in which 
an impression of the hoof could be taken (Figure 5.12A), with the ability to hold its structure 
when the animal initiated forward movement, whilst simultaneously ensuring it did not dry 
out.  Here, the intention was for hoof impressions to be made in the clay (Figure 5.12B) and 
measured to provide an estimate of stride length and width, in addition to any differences in 
weight baring (as indicated by the depth of the impression) pre- and post-stroke. Initial trials 
of this method, however, proved futile as sheep were completely unwilling to step on the 













Figure 5.12. Soil and clay combinations for hoof impressions. (A) Determining optimum soil and clay 
mixtures for hoof impressions using sand, sand and clay, and sand and soil. (B) Once the optimum mixture of 





5.13.2 Gait Analysis – High Speed Cameras  
Following failure of hoof impression attempts, quantitative and less tactile means of 
assessing gait kinematics were considered. Two-dimensional (2D) video analysis of gait, 
such as use of video cameras, can serve as a means to analyse motion, with systems being 
adapted using a single camera (Zult et al., 2019). Accordingly, we sought to use a single 
video camera to measure trajectories of black and white quadrant markers placed at various 
anatomical locations on the animal to allow us to measure kinematics of the gait cycle.  
 
As sheep are inherently flock animals who spend significant durations engaged in 
ambulatory grazing (McBride et al., 2016), we sought to design a functional run in which 
animals could execute forward ambulatory movement during which 2D kinematics could be 
assessed via video capture. It was imperative the design of the functional testing space was 
both ethologically suitable for sheep and ensured high quality video data was obtained. It 
was also important the design was easy to set up, and did not compromise the well-being of 
the animal, nor the safety of the equipment or personnel working with the animals. Although 
a functional run was successfully built, unfortunately the camera system trialed did not 
operate at a sufficient frame rate to accurately capture marker trajectories. 
 
5.13.3 Gait Analysis – Motion Capture 
The preferred approach for the kinematic assessment of gait is the use of a three-dimensional 
(3D) motion analysis system. These systems typically incorporate multiple cameras and 
active (light-emitting diodes), or passive (retro reflective) markers. The 3D analysis of gait 
is highly accurate and reliable and is commonly reported in the clinical literature. 
Assessment of motion using such a system following stroke in the ovine model could provide 
quantitative and discreet measures relating to stride length, stance duration, swing duration 
158 
and joint angle. Accordingly, we sought to use a Vicon Vero motion capture system (Vicon 
Motion Capture Systems, Oxford, UK) to overcome the challenges associated with 2D video 
assessment, in conjunction with a standard composite scoring system to allow for assessment 
of function beyond the scope of kinematic assessment. Detailed methodologies are reported 
in Chapter 9.  
 
5.14 EXCLUSION CRITERIA 
 
Animals excluded across the studies are summarised in Table 5.5. For Chapter 7, 8 and 9, 
animals were excluded early in the experimental course, and therefore, replacement animals 
were produced retrospectively. For Chapter 6, data was unfortunately lost after completion 




















Reason(s) No. animals 
included in 
analysis 
Chapter 6 34 8 Significant data loss due to system failure of PACS 
system where original MRI data was stored. MRI data 
for a total of 8 animals was lost. There was no 
premature mortality seen in this study. 
 
26 
Chapter 7 47 5 1 animal was excluded due to insufficient reperfusion 
following MCAo, as seen on MRA, resulting in a 
permanent rather than a transient occlusion. 
4 animals were excluded due to significant anaesthetic 
difficulties which confounded the experimental course, 
with animals unstable throughout the induction of 
stroke surgery, necessitating repeat boluses of 
ketamine and diazepam and a prolonged increase in the 
percentage of isoflurane required to maintain surgical 
levels of anaesthesia, which resulted in significantly 
lowered MABP, decreased cerebral perfusion pressure 
and ultimately profound infarct expansion. 
 
42 
Chapter 8 18 0 No animals excluded, surgery and post-operative 
recovery was carried out without complication. 
 
18 
Chapter 9 30 2 1 animal was excluded due to permanent MCAo, as 
identified on MRA, resulting in significant loss of 
function necessitating euthanasia 24 hours post stroke 
1 animal was excluded due to kidney failure, most 
likely as a result of excessive GAD accumulation. The 
animal deteriorated over time, and by day 10 post-








5.15 STATISTICAL ANALYSES 
 
Data analyses were performed using GraphPad Prism (Chapters 6, 7, 8 and 9) and Stata Corp 
(Chapter 9). One-way analysis of variance (ANOVA) and Tukey’s post-hoc analyses were 
performed for ICP, cerebral oedema, midline shift and infarct volume. Two-way ANOVAs 
with Sidak’s post-hoc tests were used to determine gender differences where appropriate. 
Pearson’s correlations were also be run to determine the relationship between outcomes 
measures of interest in each individual chapter. Intraclass Correlation Coefficients (ICC) and 
mixed effects linear regression models were fitted to assess gait kinematics, and two-way 
ANOVAs with Friedman post-hoc tests to determine differences in composite scoring in 
Chapter 9. Data are presented as SEM, SD or 95% CI. A p value <0.05 and an R value >0.04 
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Background and Purpose: The morbidity and early mortality associated with stroke is largely 
attributable to cerebral oedema and elevated intracranial pressure (ICP). Existing 
pharmacotherapies do not target the underlying pathophysiology and are often ineffective in 
sustainably lowering ICP, whilst decompressive craniectomy (DC) surgery is lifesaving yet 
with surgical/peri-operative risk and increased morbidity in the elderly. Accordingly, there 
is an urgent need for therapies that directly target the mechanisms of oedema genesis. 
Neurogenic inflammation, mediated by substance P (SP) binding to the tachykinin NK1 
receptor (NK1-R), is associated with blood-brain barrier (BBB) disruption, cerebral oedema 
and poor outcome post-stroke. NK1-R antagonist treatment ameliorates BBB dysfunction 
and cerebral oedema in rodent stroke models. However, treatment has not been investigated 
in a large animal model, an important step towards clinical translation. Consequently, the 
current study compared the efficacy of NK1-R antagonist treatment to DC surgery in 
reducing ICP post-stroke in a clinically relevant ovine model.  
 
Methods: Anaesthetised female Merino sheep (65±6 kg, 18-36 months) underwent sham 
surgery (n=4) or permanent middle cerebral artery occlusion (n=22). Stroke animals were 
randomised into one of 5 treatments: 1 × NK1-R bolus (4h), 2 × NK1-R bolus (4h; 9h), 3 × 
NK1-R bolus (4h; 9h; 14h), DC surgery (performed at 4h) or saline vehicle. ICP, blood 
pressure and blood gases were monitored for 24h post-stroke. At 24h post-stroke 
anaesthetised animals underwent MRI, followed by perfusion, removal and processing of 
brains for histological assessment.  
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Results:  Two × NK1-R, 3 × NK1-R administration or DC surgery significantly (p<0.05) 
reduced ICP compared to vehicle. 1× NK1-R was ineffective in sustainably lowering ICP. 
On MRI, midline shift and cerebral oedema were more marked in vehicles compared to 
NK1-R treatment groups.  
 
Conclusion: Two or 3 boluses of NK1-R antagonist treatment reduced ICP comparable to 
DC surgery, suggesting it may provide a novel alternative to invasive surgery for 



















6.1 INTRODUCTION  
 
Elevated intracranial pressure (ICP) arising as a result of malignant cerebral oedema is the 
leading cause of death in the first week following stroke (Hacke et al., 1996). Despite the 
devastating impact of elevated ICP on patient outcome, clinical management remains sub-
optimal. Pharmacological options for ICP management are limited, and while osmotic 
therapies (including mannitol and hypertonic saline) are used in some centres (Zhang et al., 
2018), there is no evidence that these therapies are independently effective in improving 
outcome. Furthermore, the efficacy of other pharmacological interventions including 
corticosteroids and barbiturates remain ambiguous for the treatment of post-stroke cerebral 
oedema (Brogan and Manno, 2015). In selected patients with malignant middle cerebral 
artery (MCA) territory infarction, surgical intervention with decompressive craniectomy 
(DC) may be required. This procedure rapidly alleviates pressure by removing a large 
portion of the skull and opening the dura overlying the swollen brain, thereby providing 
space for the oedematous brain to swell freely until cerebral oedema resolves, typically 
beyond the first week following stroke (Xiao-Feng et al., 2005). However, although this 
procedure reduces compression on cerebral structures and the risk of life-threatening 
tonsillar herniation, it is also associated with increased morbidity in those aged greater than 
60 years, the patient population in which stroke is most prevalent (Jüttler et al., 2007, Das et 
al., 2019). It is clear that current pharmacological and surgical interventions are inadequate 
as they target the symptoms, rather than the underlying cause of cerebral oedema and 
concomitant rise in ICP (Bardutzky and Schwab, 2007, Simard et al., 2007). An enhanced 
understanding of the mechanisms that underlie the genesis of cerebral oedema and raised 
ICP is thus critical for the development of more targeted and effective treatments.   
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Although factors associated with the pathogenesis of cerebral oedema are not completely 
understood, neurogenic inflammation has been identified as a potential therapeutic target 
(Corrigan et al., 2016a, Stumm et al., 2001, Turner et al., 2006). Neurogenic inflammation 
is a neurally-mediated process involving the release of neuropeptides, including substance 
P (SP) and calcitonin gene-related peptide, which initiate vasodilation, increased 
microvascular permeability and oedema (Hokfelt et al., 2000). Although well established as 
a precipitant of oedema development within peripheral tissues such as the skin and lungs 
(Alves et al., 1999), neurogenic inflammation remained largely unexplored as a potential 
mechanism of cerebral oedema development (Lewis et al., 2013, Sorby-Adams et al., 2017). 
This was until studies depleting neuropeptides or blocking the action of neuropeptide SP at 
the tachykinin NK1 receptor (NK1-R), to which SP binds preferentially, showed a 
ubiquitous role for this process in the genesis of cerebral oedema following stroke and 
traumatic brain injury (TBI) (Nimmo et al., 2004, Donkin et al., 2009, Turner et al., 2011b, 
Turner and Vink, 2014, Turner et al., 2006, Turner and Vink, 2012, Vink et al., 2003, 
Corrigan et al., 2016a). Specifically, increased SP immunoreactivity within the penumbral 
perivascular tissue is associated with profound BBB disruption and cerebral oedema at 24 
hours post-stroke and poor functional outcomes up to 7 days following middle cerebral 
artery occlusion (MCAo) in rats, with NK1-R blockade ameliorating these effects (Turner 
et al., 2011b, Turner and Vink, 2012, Turner and Vink, 2014, Corrigan et al., 2016a). 
Increased plasma SP levels have also been reported clinically following severe acute 
ischaemic stroke, elevated levels of which were associated with increased mortality (Lorente 
et al., 2016). Comparable alterations in SP levels have also been observed in clinical TBI 
correlating with injury severity and mortality (Lorente et al., 2015).  
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The cumulative evidence from these studies suggests an important role for SP in the 
development of cerebral oedema and poor outcome following acute CNS injury. However, 
pre-clinical evaluation of the NK1-R antagonist has been limited to small animal stroke 
models, with the most extensive screening to date performed in small and large animal 
models of TBI. Whilst rodent species are essential for establishing basic biological 
processes, it is often difficult to obtain clinically relevant outcome measures, thereby 
limiting clinical translation. Given the extremely poor translation of stroke neuroprotectants 
from the laboratory to the clinic (Xu and Pan, 2013), evaluation of promising therapies in a 
large, intermediate species is essential. Species such as sheep are an ideal candidate for such 
studies due to the ability to utilise clinically relevant outcome measures in addition to 
similarities in neuroanatomical structure, including gyrencephalic cerebral organisation and 
significant portion of white matter (Sorby-Adams et al., 2018). Of particular relevance when 
investigating elevated ICP; however, is the strong tentorium cerebelli of the sheep, 
separating supra- and infra- tentorial compartments, bearing structural similarity to that of 
the human (Dostovic et al., 2016). In the setting of clinical malignant cerebral oedema, this 
leads to compartmentalisation of pressure within the supratentorial space, tonsillar 
herniation, and ultimately often fatal compression of the brain stem as the brain attempts to 
alleviate dangerously elevated ICP. Indeed, ovine stroke models replicate key clinical 
hallmarks following stroke including elevated ICP, cerebral oedema, midline shift and 
tonsillar herniation (Wells et al., 2012, Wells et al., 2015, Sorby-Adams et al., 2018). As 
such, the aim of the present study was to determine the effect of inhibition of SP with an 
NK1-R antagonist, compared to DC surgery, on ICP following permanent ischaemic stroke 




6.2 MATERIALS AND METHODS  
 
6.2.1 Experimental Procedure 
All experimental procedures were approved by the Animal Ethics Committees of the 
University of Adelaide (M-2011-240) and South Australian Health and Medical Research 
Institute (SAHMRI; SAM104) and conducted according to guidelines established for the use 
of animals in experimental research as outlined by the Australian National Health and 
Medical Research Council code of practice for the care and use of animals for scientific 
purposes (8th edition, 2013).  
 
6.2.2 Animals and Experimental Design 
Female merino sheep (n=26) aged 18–24 months old (65±6 kg) were allocated to the study. 
Animals were randomised into either sham surgery or permanent MCA occlusion (MCAo). 
Following induction of stroke, animals were then further randomised into one of the 
following groups: 1) saline vehicle treatment at 4 hours post-stroke (n=6); 2) 1 × bolus NK1-
R antagonist at 4 hours post-stroke (n =3); 3) 2 × boluses of NK1-R antagonist at 4 hours 
and 9 hours post-stroke (n =3); 4) 3 × boluses of NK1-R antagonist at 4-, 9- and 14-hours 
post-stroke (n=6); or 5) decompressive craniectomy (n=5) at 4 hours post-stroke. Note that 
the dose for the NK1-R antagonist treatment was the same across all the NK1-R treatment 
groups, the only difference was the number of boluses that each group received, either one 
(1 × NK1-R), two (2 × NK1-R) or three (3 × NK1-R) boluses. The NK1-R antagonist used 
in the study was a test compound supplied by PresSuraNeuro (Hoffmann et al., 2005, 
Australian Patent AU2002328837B2, May 5, 2005), prepared at a concentration of 1 mg/mL 
in warmed saline (37 °C) and administered at a dose of 1 mL/kg via an indwelling jugular 
venous catheter, as per previous studies in our laboratory (Vink et al., 2017).  
170 
6.2.3 Anaesthesia and Physiological Monitoring 
Anaesthesia was induced with intravenous thiopentone (1000 mg in 20 mL, Jurox Pty Ltd, 
Australia) and maintained with 1.5% inhalational isoflurane (Veterinary Companies of 
Australia Pty Ltd, Australia) in a mixture of oxygen and room air (500:5000 mL/min), plus 
intravenous ketamine (Parnell Australia Pty Ltd, Australia) infusion at 4 mg/kg/hr via a 
femoral venous line. These two anaesthetic agents were used in combination to avoid the 
intrinsic neuroprotective properties of either above certain doses, and to maintain a twilight 
general anaesthesia (Schifilliti et al., 2010, Hudetz and Pagel, 2010). With the animal supine, 
an arterial catheter was placed in the right femoral artery for continuous blood pressure 
monitoring and periodic arterial blood gas sampling, and a venous catheter inserted for 
anaesthetic and fluid administration. The animal was then placed prone in the sphinx 
position, a burr hole drilled in the right parietal bone posterior to the coronal suture and 
approximately 20 mm from the sagittal suture, dura perforated, and skull bolts secured. A 
Codman microsensor ICP probe (Codman & Shurtleff Inc., Massachusetts) was introduced 
into the bolt, calibrated, and inserted intraparenchymally to measure ICP within the 
supratentorial compartment. Using LabChart Reader (v 8.1.1), mean arterial blood pressure 
(MABP) and ICP were continuously recorded throughout the 24-hour monitoring period. 
Arterial blood gas sampling was conducted prior to MCAo or sham surgery and at hourly 
intervals throughout the monitoring period until the completion of the experiment to 
maintain physiological pO2, pCO2 and pH.  
 
6.2.4 Surgical Approach to MCAo 
We have previously described the surgical approach to proximal MCAo in detail (Wells et 
al., 2015, Wells et al., 2012). Briefly, a 5 cm vertical incision was made posterior to the right 
eye, terminating at the zygomatic arch. The underlying muscle was retracted, coronoid 
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process removed, and the skull revealed. A small craniotomy was performed at the junction 
of the parietal and squamous temporal bones with a high-speed pneumatic drill using a 5 
mm cutting burr (Midas Rex® Legend, Medtronic, USA). All intra-dural work was carried 
out with loupe magnification and a head mounted light source (Surgical Acuity, Wisconsin). 
A horse-shoe shaped durotomy was performed with an inferiorly based flap allowing for 
gentle upward retraction of the anterior temporal lobe to achieve visualisation of the 
proximal MCA. Animals then either underwent sham surgery in which the proximal MCA 
was dissected but not occluded, or permanent MCA in which the proximal MCA was 
occluded via Malis bipolar diathermy forceps (Valleylab Inc., Colorado). The exposed brain 
was irrigated with saline during surgery to prevent dehydration of the cerebral cortex. After 
completion of sham or MCAo surgery the dura was approximated, and synthetic dura 
(Durepair®, Medtronic, USA) interleaved under the existing dura (in the case of dural 
retraction following incision) and closed watertight with ethyl cyanoacrylate (Bostik, 
Australia). Once dural closure was confirmed and no leakage of CSF observed, the 
craniotomy site was reinforced with dental acrylic cement (Lang Dental, IL) that was 
manipulated into the edge of the craniotomy and the wound closed in layers, maintaining the 
shape of the cranial cavity and importantly, the homeostasis of ICP dynamics. For animals 
allocated to the DC group, at 4h following stroke the wound was opened, dental acrylic 
removed, and the craniotomy site widened (3 cm x 6 cm) to allow for decompression. A 
dural pouch was created using Durepair to expand the intracranial cavity, after which the 
bone was left off and the overlying skin sutured closed, simulating clinical DC and expansile 
duraplasty. For all groups, the head was then returned to a neutral position for monitoring 




6.2.5 Magnetic Resonance Imaging 
At 24 hours following stroke or sham surgery onset animals were placed under general 
anaesthesia (3% isoflurane) in a 1.5 Tesla Siemens Sonata (Siemens AG, Munich, Germany) 
magnetic resonance imaging (MRI) scanner. The scanning sequence included time-of-flight 
magnetic resonance angiography (TOF MRA; TR 26.0 ms, TE 3.69 ms, slice thickness 0.50 
mm, slices per slab 48), diffusion weighted imaging (DWI; TR 5600.0 ms, TE 80 ms, slice 
thickness 3.0 mm, slices per slab 25), fluid attenuated inversion recovery (FLAIR; TR 
5000.0 ms, TE 386 ms, slice thickness 0.9 mm, slices per slab 96), T1 (TR 2300.0 ms, TE 
2.58ms, slice thickness 0.9 mm, slices per slab 96) and T2 (TR 3200 ms, TE 410 ms, slice 
thickness 0.9 mm, slices per slab 96) weighted images.   
 
The degree of midline shift on MRI was used as a marker of the amount of expansion of the 
infarcted hemisphere, indicative of cerebral oedema. Extent of shift from the midline was 
assessed using axial T2 weighted scans and measured in mm from the septum pellucidum at 
the level of the foramen of Monro (HOROS DICOM image viewer v3.1.1). To calculate 
cerebral oedema, coronal FLAIR images were analysed using HOROS (v3.1.1). After 
optimal adjustment of brightness and contrast, oedema volume was determined from 
sequences using computer-aided manual tracing of the hyperintense lesion by a blinded 
assessor. The areas were then summed and multiplied by the slice thickness to give a total 
volume in cm3.  
 
To calculate infarct volume, segmentation tools in ITK-SNAP (v 3.7) were used to perform 
semi-automated segmentation of the MRI diffusion lesions using diffusion-weighted images 
(Yushkevich et al., 2006). A combination of “three-dimensional active contour 
segmentation” and subsequent manual post-processing of the segmentation while adjusting 
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image thresholds was performed to maximise reproducibility whilst excluding artefacts. The 
“three-dimensional active contour segmentation” consisted of multiple steps: First, in the 
pre-segmentation phase, independent component analysis automatically segmented parts of 
the DWI image and these were manually identified as foreground or background. To obtain 
an optimal distinction between foreground and background, thresholds of the image 
windows were adjusted. After thresholding, a “speed image” with a separate foreground and 
background was created. Next, in the active contour phase, seed regions were manually 
placed within the region of interest (ROI). These seeds were then automatically grown within 
the ROIs to form the temporary segmentation. Subsequently, areas that were not 
automatically included in the “active contour segmentation”, were manually included in the 
follow-up infarct segmentation.  The total volume of the segmentation was exported and 
reported in cm3 for analysis. 
 
6.2.6 Histological Examination 
Following MRI, intravenous heparin (5000 I.U./5mL; Pfizer, New York) was administered 
and animals euthanised via common carotid perfusion fixation with cold TRIS-buffered 
saline under isoflurane anaesthesia. The brains were subsequently removed and sliced into 
10 mm coronal slices using a custom-made matrix. Sections were then immersion fixed in 
10% neutral-buffered formalin for a minimum of 14 days prior to being processed, 
embedded in paraffin wax and sectioned coronally at 5-micron intervals for histological 
examination by haematoxylin and eosin (H&E), albumin (1:2000, Dako Pty Ltd; A0001), 
SP (1:5000 citrate retrieval, Abcam Pty Ltd; ab14184), NK1-R (1:1000 citrate retrieval, 
Advanced Targeting Systems Pty Ltd; AB-N-33AP) and caveolin-1 (cav-1; 1:1000 EDTA 
retrieval, Cell Signalling Technologies Pty Ltd; 3238) immunohistochemistry.  
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6.2.7 Statistical Analysis 
All data are expressed as mean ± SD. Physiological data (arterial blood pressure, pH, pO2, 
pCO2) were analysed using one-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc tests (Prism v.8.0.1, GraphPad, California). Values were averaged for each 
treatment group across all time points and reported as a single value. Raw ICP and MABP 
data underwent a logarithmic exponential transformation as previously described and were 
expressed as geometric mean ± SD (Wells et al., 2015, Matthews et al., 1990).  ICP was 
analysed by two-way ANOVA and lesion volume, cerebral oedema and midline shift data 
were analysed by one-way ANOVA, all followed by Tukey’s post-hoc tests. A p-value of 
<0.05 was considered significant. Correlations were performed between cerebral oedema 
and midline shift; ICP and cerebral oedema; to determine the relationship between these 




6.3.1 Surgery, Mortality and Physiological Parameters 
All experimental procedures were carried out without complication and there was no 
premature mortality or unexpected events in any of the groups. Basic physiological 
parameters are expressed in Table 6.1. For all groups, there was no statistically significant 
difference in pO2, pCO2, or pH at any of the time-points following stroke. However, there 
was a statistically significant difference in MABP between sham, 1 × NK1-R (p=0.02) DC 




6.3.2 Intracranial Pressure 
ICP remained physiologically stable across all time points in sham animals (9±3 mmHg). At 
both 4- and 9-hours post-stroke, there was no significant difference in ICP between sham or 
any of the stroke groups. By 14 hours following injury, ICP in vehicle animals was 
significantly elevated (24±11 mmHg) compared with shams (10±3 mmHg) (p=0.019). 
However, no difference in ICP was seen between vehicle or any of the treatment groups at 
this time-point (Figure 6.1).  
 
ICP in vehicle animals continued to rise and by 19 hours post-stroke measured 32±11 
mmHg, which was significantly elevated (p=0.0002) compared with shams recording an ICP 
of 13±6 mmHg. Following intervention, by 19 hours there was a significant reduction in ICP 
seen in 2 × NK1-R (18±4 mmHg; p=0.013), 3 × NK1-R (17±7 mmHg; p=0.015) and DC 
(19±11 mmHg; p=0.042) treated animals compared with vehicle. Conversely, there was no 
reduction (p>0.05) in ICP seen following 1 × NK1-R treatment (31±9 mmHg) compared 
with vehicle, with ICP remaining significantly elevated compared with sham (p=0.002). 
 
By the 24-hour post-stroke time-point, ICP in vehicle animals had continued to rise (39±7 
mmHg) and remained significantly elevated compared with shams (12±8 mmHg; p<0.001), 
DC (23±12 mmHg; p=0.013), 2 × NK1-R (20±6 mmHg; p<0.001) and 3 × NK1-R (19±7 
mmHg; p<0.005) treated animals. ICP continued to rise in the 1 × NK1-R treatment group 
Table 6.1 Basic physiological parameters 
Group pCO2 (mmHg) ± SD pO2 (mmHg) ± SD 
MABP (mmHg) ± 
SD 
pH (-log [H+]) ± 
SD 
Sham 43±8.41 113±14.09 79±8.78 7.48±0.039 
Vehicle 40±6.09 127±31.28 104±10.17 7.46±0.062 
1× NK1-R 36±2.55 138±25.06 112±10.18 7.51±0.033 
2 × NK1-R 43±6.56 149±33.99 98±5.81 7.45±0.031 
3 × NK1-R 37±2.34 135±20.53 111±15.66 7.52±0.018 
DC 42±3.78 150±17.22 108±10.65 7.45±0.082 
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(35±9 mmHg) and remained significantly elevated compared with both shams (p<0.001) and 
2 × NK1-R (p=0.029) treatment animals. ICP in 2 × NK1-R and 3 × NK1-R treatment groups 
was comparable (p>0.05) with DC across all time points following stroke. No rebound 






Figure 6.1. 24-hour ICP following middle cerebral artery occlusion. There was no significant difference in 
sham ICP across any of the time points. At 14 h post-stoke ICP was elevated in vehicle animals compared with 
shams (p<0.05) and by 19 h post-stroke, ICP was significantly elevated in vehicle (p<0.001) and 1× NK1-R 
(p<0.01) treated animals when compared with 2 × NK1-R (p<0.05), 3 × NK1-R (p<0.05) and DC treatment 
groups (p<0.05). By 24 h, ICP remained significantly elevated in vehicle animals compared with sham 
(p<0.0001), 2 × NK1-R (p<0.01), 3 × NK1-R (p<0.01) and DC (p<0.05) treatment groups. ICP also remained 
elevated at 24 h post-stroke in 1 × NK1-R treatment groups compared with sham (p<0.001) and 2 × NK1-R 





MRI was unremarkable in sham animals (n=4) with no evidence of cerebral oedema, midline 
shift or infarction (Figure 6.2 A). At 24 hours, all stroke animals showed evidence of 
hyperintensity on T2 weighted and FLAIR images in the territory of the MCA, indicative of 
the infarct core and surrounding vasogenic oedema (Figure 6.2).  In addition, DC treated 
animals showed evidence of transcalvarial herniation through the craniectomy site (Figure 
6.2 D). No animals showed evidence of tonsillar herniation or brain stem compression on 




























Figure 6.2. MRI findings 24h post middle cerebral artery occlusion. There was no evidence of 
hyperintensity, or tissue deformation, seen in sham animals (A). Midline shift was evident in all stroke animals 
as seen on axial T2 weighted images (B-D). Cerebral oedema as shown in coronal FLAIR MRI images was 
greater in vehicle (B), DC (F) and 1 × NK1-R (C) groups compared with 2 × NK1-R (D) and 3 × NK1-R (E) 
groups. This was associated with a smaller lesion volume as shown in DWI MRI images in the coronal plane. 
Note the transcalvarial herniation through the craniotomy site in DC treated animals (F).  
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Cerebral oedema calculated on FLAIR MRI (Figure 6.3, Table 6.2) was reduced in DC 
(p=0.012) and 1 × NK1-R treatment groups (p=0.042) when compared with vehicle 
(Fig.3A). However, treatment with 2 × NK1-R (p=0.001) and 3 × NK1-R (p=0.001) was 
associated with a more significant reduction in cerebral oedema volume compared with 
vehicle (Figure 6.3 A).  Midline shift was evident in all stroke animals (Table 6.2) with no 
statistical significance seen between groups (p=0.2; Figure 6.3 B). Nevertheless, there was 
a moderate positive relationship between the volume of cerebral oedema and the amount of 
midline shift (r=0.46; Figure 6.3 C). No significant differences (p=0.17) were observed in 
infarct volume across any of the treatment groups following stroke, as measured on DWI 

















Table 6.2 MRI characteristics post middle cerebral artery occlusion 
 
Treatment Oedema FLAIR MRI (cm3) Midline Shift T2 (mm) Infarct DWI MRI 
(cm3) 
Vehicle 
   
86 19.48 1.8 33.9 
87 36.45 3.5 24.5 
60 20.96 3 25.9 
66 31.14 2 34.4 
57 27.61 3.5 20.1 
59 23.32 3.4 56.5 
Mean±SD 25.56±6.10 2.87±0.71 32.55±11.85 
 
1 × NK1 
      
69 10.84 1.8 22.1 
75 21.51 3.2 23 
88 11.44 2.2 12.7 
Mean±SD 14.60±6.0 2.40±0.72 19.27±5.70 
 
2 × NK1 
      
70 4.230 0.8 8.3 
72 3.520 0.5 17.2 
91 11.789 2.6 34.7 
Mean±SD 6.51±4.58 1.30±1.14 20.07±13.43 
 
3 × NK1 
      
71 5.49 1.8 11.6 
73 13.50 2.7 20.7 
74 7.56 0.7 10.6 
76 8.33 1.1 20.8 
89 18.23 4.1 32.1 
90 16.27 1.7 23.7 
Mean±SD 11.56±5.17 2.02±1.23 19.92±8.0 
 
DC 
      
101 19.38 2.6 26.8 
102 15.46 2.9 23.7 
105 15.74 1 16.6 
106 12.80 1.4 15.6 
107 8.36 1.8 24 




Figure 6.3. Cerebral oedema and infarct volume findings at 24 hours post middle cerebral artery 
occlusion.   (A) Cerebral oedema volume, as measured on FLAIR MRI, was decreased in 1 × NK1-R (p<0.05), 
2 × NK1-R (p<0.001), 3 × NK1-R (p<0.01) and DC (p<0.05) treatment groups when compared with vehicle. 
(B) There was no difference in midline shift in any of the vehicle or treatment groups post-stroke. (C) Despite 
this, there was a relative moderate positive correlation between cerebral oedema and midline shift. (D) There 
was also a moderate positive correlation between cerebral oedema and ICP measured at 24 h post-stroke. (E) 
There was no significant difference in infarct volume as measured on DWI MRI between any treatment groups. 
*p<0.05, **p<0.01, ***p<0.001 compared with vehicle.  
 
6.3.4  Histological Analysis 
6.3.4.1 H&E 
There was no evidence of tissue injury or infarction in sham tissue (Figure 6.4 A). Following 
stroke (Figure 6.4 B) there was marked tissue pallor and loss of grey-white matter 
differentiation, indicative of infarction within the MCA territory of the right hemisphere. 1 
× NK1-R (Figure 6.4 C) treatment tissue was comparable with vehicles, however there was 
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an increased preservation of tissue, in particular the sub-cortical white matter, in the 2 × 
NK1-R (Figure 6.4 D), 3 × NK1-R (Figure 6.4 E) and DC (Figure 6.4 F) treated groups.  
 
6.3.4.2 Albumin  
There was minimal evidence of albumin extravasation in sham tissue (Figure 6.4 A). 
Following stroke, marked albumin extravasation, indicative of BBB breakdown and 
subsequent vasogenic cerebral oedema formation, was observed both macroscopically 
within the infarcted territory and microscopically in the perivascular tissue of the infarct in 
vehicles (Figure 6.4 B), 1 × NK1-R (Figure 6.4 C) and DC (Figure 6.4 F), when compared 













Figure 6.4. Haematoxylin and Eosin staining and albumin immunoreactivity in (A) sham, (B) vehicle, 
(C) 1 × NK1-R, (D) 2 × NK1-R, (E) 3 × NK1-R and (F) DC animals.  H&E staining shows evidence of 
pallor and reduction of grey-white matter differentiation, which is especially prominent in vehicle and 1 × 
NK1-R treated animals. Enhanced albumin extravasation was seen macroscopically in vehicle, 1 × NK1-R and 
DC treated animals compared with sham, 2 × NK1-R and 3 × NK1-R treatment groups. This pattern of albumin 





6.3.4.3 Substance P 
There was low to no observable immunoreactivity of SP in sham tissue (Figure 6.5 A). 
Furthermore, similarly low levels of SP immunoreactivity were observed in the infarcted 
hemisphere of vehicle and each of the treatment groups following stroke.  
 
6.3.4.4 NK1-R 
Low levels of perivascular NK1-R immunoreactivity were observed in sham tissue (Figure 
6.5 B). Following stroke, an increase in perivascular NK1-R immunoreactivity was observed 
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Little to no perivascular cav-1 immunoreactivity was observed in sham tissue (Figure 6.5 
C). Following stroke, a marked increase in perivascular cav-1 immunoreactivity was 
observed in vehicles, 1 × NK1-R and DC tissue when compared with sham, 2 × NK1-R and 








Figure 6.5. Substance P (SP), NK1 receptor (NK1-R) and caveolin-1 (cav-1) immunoreactivity. There 
was no identifiable increase in SP, NK1-R or cav-1 immunoreactivity in sham animals. (A) Low levels of SP 
immunoreactivity were seen perivascularly in vehicle, 1 × NK1-R, 2 × NK1-R, 3 × NK1-R and DC groups. 
(B) This was concordant with an increase in NK1-R immunoreactivity, which was most prominent in vehicle, 
1 × NK1-R and DC animals. (C) Cav-1 immunoreactivity was significantly enhanced in 1 × NK1-R, 2 × NK1-







6.4 DISCUSSION  
 
In this study we have demonstrated that administration of 2 or 3 boluses of an NK1-R 
antagonist is effective in reducing ICP following stroke in a clinically relevant ovine model. 
This reduction in ICP following treatment was associated with improved BBB integrity, as 
shown by albumin immunohistochemistry, and a trend towards reduction in the volume of 
cerebral oedema in the infarcted hemisphere. These findings corroborate previous 
experimental (Turner et al., 2011, Turner and Vink, 2014, Turner and Vink, 2012, Turner et 
al., 2006, Nimmo et al., 2004, Donkin et al., 2009, Vink et al., 2003, Corrigan et al., 2012, 
Corrigan et al., 2016b) and clinical (Lorente et al., 2016, Lorente et al., 2015) studies to 
further support the role of SP in the pathogenesis of elevated ICP, cerebral oedema and 
increased permeability of the BBB following acute CNS injury. Indeed, the reduction in ICP 
following treatment observed in this study is consistent with findings in an ovine model of 
TBI (Vink et al., 2017). Taken together, we have now successfully demonstrated the efficacy 
of NK1-R antagonist treatment for the reduction of cerebral oedema and its consequences in 
both rodent and sheep models of stroke (Turner and Vink, 2012, Turner and Vink, 2014, 
Turner et al., 2011, Turner et al., 2006) and TBI (Donkin et al., 2009, Vink et al., 2017, 
Corrigan et al., 2012, Corrigan et al., 2016b). Taken together these findings clearly 
demonstrate that SP release is a ubiquitous feature of acute CNS injury and that blockade of 
this pathway is able to preserve BBB integrity and halt the development of cerebral oedema 
and subsequent rise in ICP. 
 
Despite the clear treatment effect of blocking the NK1-R to reduce ICP in this study, we did 
not observe a significant increase in perivascular SP immunoreactivity within the infarcted 
territory in any of the treatment groups following stroke. This is in keeping with previous 
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findings in a rodent model of MCAo (Turner, 2007), where minimal SP immunoreactivity 
was observed following permanent MCAo, yet profound perivascular staining was identified 
following transient stroke with reperfusion. These observations are most likely due to the 
fact that in the setting of permanent MCAo, the release and peak in SP occurs acutely due to 
the severity of the ischaemic insult. As such, SP has likely been degraded by the time of 
tissue harvest at 24 hours post-stroke. In comparison, in previous rodent transient MCAo 
studies, perivascular SP immunoreactivity was observed primarily in the penumbral tissue. 
The relative proportion of penumbra to ischaemic core is likely to be much less following 
permanent compared with transient MCAo due to the extensive collateral failure associated 
with longer durations of ischaemia. Not surprisingly, this suggests the magnitude and timing 
of SP release in the neurogenic inflammatory response is dependent upon the duration and 
severity of the ischaemic insult (Corrigan et al., 2016b). Indeed, following vascular 
occlusion, temporary changes in transient receptor potential channels of c-fibres as a result 
of alterations in temperature, pH and ligand binding instigates release of SP (Hokfelt et al., 
1975). When there is no reperfusion, compromised cells undergo ischaemic necrosis quickly 
with associated acute changes in cellular function, leading to a rapid return of receptor 
channel potential and decrease in SP release. Comparatively, in the setting of transient 
MCAo, compromised cells in the penumbra experience long durations of electrical silence 
and alterations in neuronal function, leading to sustained activation of c- fibres and persistent 
SP release (Astrup et al., 1981, Hofmeijer and Van Putten, 2012, Turner, 2007). Taken 
together, these findings may provide an explanation as to why SP was not observed on IHC 
in this study. 
 
We did not observe any effect on infarct volume following NK1-R antagonist treatment, 
irrespective of the number of boluses administered. This is not surprising considering that 
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we used a permanent stroke model and given that the NK1-R antagonist is targeting BBB 
disruption rather than other pathways in the ischaemic injury cascade. A transient stroke 
model with reperfusion followed by delivery of an NK1-R antagonist may, however, yield 
different results on infarct volume. Nevertheless, we also did not observe an effect on infarct 
volume at 24 hrs following 2-hour MCAo thread occlusion in our rodent studies (Turner et 
al, 2011). In these previous rat studies, however, we did demonstrate that increased 
perivascular SP immunoreactivity was associated with increased BBB permeability, 
profound cerebral oedema and persistent functional deficits (Turner et al., 2011, Turner et 
al., 2006, Turner and Vink, 2012, Turner and Vink, 2014).  
 
In the present study we have identified that increased BBB permeability was sustained to 24 
hours post-stroke in vehicle-treated animals, as identified by increased albumin 
extravasation. Furthermore, the corresponding increase in perivascular caveolin-1 
immunoreactivity in the vehicle group may provide an explanation for persistent changes in 
barrier permeability seen. Caveolae are invaginations of the plasma membrane present in 
endothelial cells, including those that comprise the BBB, with a key role in regulating 
transcytosis of large molecules, including albumin, across the barrier (Abbott et al., 2006). 
Cav-1 is an integral protein for caveolae formation, with upregulation associated with 
enhanced albumin extravasation and the development of vasogenic cerebral oedema (Nag et 
al., 2007).  Furthermore, cav-1 is upregulated following rodent cortical cold injury and feline 
TBI, despite maintenance of TJ integrity (Nag et al., 2007, Povlishock et al., 1978), 
suggesting that physical breakdown of the barrier through loss of TJ is not necessary for the 
development of cerebral oedema. The NK1-R is located within caveolae, suggesting that its 
activation may play a role in regulating transcytosis (Kubale et al., 2007, Monastyrskaya et 
al., 2005). Indeed, this is consistent with the observation of reduced barrier permeability 
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following NK1-R antagonist administration in previous studies (Turner and Vink, 2012, 
Turner and Vink, 2014, Turner et al., 2011, Vink et al., 2017, Corrigan et al., 2016a, Donkin 
et al., 2007). It is proposed that SP release following acute CNS injury leads to NK1-R 
activation, including those receptors located within the caveolae of endothelial cells, which 
facilitates enhanced transcytosis of albumin across the barrier, altering the osmotic gradient 
and leading to the development of vasogenic oedema. Inhibition of transcytosis-mediated 
albumin extravasation through administration of the NK1-R antagonist diminishes 
alterations in the osmotic gradient across the barrier, thus preventing the abnormal 
accumulation of water in the parenchyma and subsequent development of oedema and rise 
in ICP. 
 
As previously mentioned, in this study we were able to reliably measure changes in ICP 
throughout the 24-hour monitoring period. Clinical studies investigating fluctuations in ICP 
following malignant MCA stroke have recorded pressures as high as 43 mmHg in patients 
who ultimately died, compared with 28 mmHg in survivors (Hacke et al., 1996). In the 
present study pressures as high as 50 mmHg were recorded in vehicle animals, however, 2 
or 3 boluses of the NK1-R antagonist were sufficient to diminish ICP to less than 30 mmHg. 
Furthermore, 2 × NK1-R animals recorded pressures of less than 20 mmHg throughout the 
24-hour monitoring period, with the exception of one animal, and 3 boluses of the antagonist 
was sufficient to maintain pressures below 25 mmHg, again with the exception of one animal 
who recorded a maximum pressure of 28 mmHg. One dose of the NK1-R antagonist, 
however, was insufficient to produce a treatment effect with pressures averaging 35 mmHg. 
These findings suggest that multiple boluses of the NK1-R antagonist is a potentially viable 
therapeutic strategy to reduce elevated ICP following stroke, with the ability to bring about 
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a clinically-meaningful and sustainable reduction in pressure comparable to that observed in 
surviving patients (Hacke et al., 1996). 
 
Furthermore, the reduction in ICP we observed with repeated NK1-R boluses was 
comparable to surgical decompression, which is encouraging given the limitations of current 
available pharmacotherapies used for ICP management, often necessitating early DC. DC 
performed prior to onset of clinical signs and herniation has been shown to yield improved 
functional outcomes; however, if surgery is performed when there is evidence of clinical 
deterioration, it may be too late to yield beneficial outcomes (Shah et al., 2019). Furthermore, 
although DC is the most powerful tool currently available to combat elevated ICP, the 
procedure is highly invasive, thus benefits remain controversial, and the long-term 
implications of this procedure on ICP dynamics are not well understood (Lilja-Cyron et al., 
2019, Shah et al., 2019, Funchal et al., 2018). A pooled analysis of the randomised control 
trials DECIMAL, HAMLET, and DESTINY compared early DC with conventional medical 
management of patients with evidence of MCA territory infarction and NIHSS >15/20 
(Vahedi et al., 2007a, Vahedi et al., 2007b, Geurts et al., 2013, Jüttler et al., 2007, Hofmeijer 
et al., 2009). These studies found that DC significantly reduced fatality rates and improved 
functional outcome compared with conventional pharmacotherapy alone. However, whilst 
some studies report reduced mortality and improved survival, it was at the cost of a higher 
number of individuals moderately to severely disabled (Kurland et al., 2015, Vahedi et al., 
2007a). This becomes an issue of increasing concern given that DC is associated with higher 
mortality rates in those aged greater than 60 years of age, the most prevalent stroke patient 
population (Hofmeijer et al., 2009, Benjamin et al., 2018). The correlation between age and 
functional outcome remains an extremely important pre-treatment prognostic factor in 
deciding if patients should undergo DC (Chen et al., 2007), highlighting the need for 
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development of new therapies that can be administered to a wider patient population in a 
safe and timely manner, eliminating the need for surgical decompression and associated 
morbidity. In this study we have demonstrated that repeated dosing of NK1-R antagonist 
treatment was able to reduce ICP comparable to DC surgery, thus providing an alternate 
treatment strategy, circumventing the need for invasive surgery. 
 
6.4.1 Limitations 
Although we have established that the NK1-R antagonist is an effective strategy to lower 
ICP and have previously determined that the ovine model is viable candidate for the 
screening of promising novel therapeutics, we must acknowledge the limitations of the 
study. Due to the invasive nature of the surgery and significant deficits that ensued following 
permanent MCAo, animals were required to be maintained under anaesthesia for the 
duration of the experiment. We recognise that human patients are rarely under the influence 
of anaesthesia at onset of stroke, and that the use of anaesthetic agents may affect outcome 
measures. Despite this, the agents used for induction and maintenance were chosen to reduce 
any potential neuroprotective or damaging effects, as previously described in detail (Wells 
et al., 2015). Indeed, as ketamine is known for its neuroprotective properties, and inhalation 
isoflurane for its sub-neuroprotection and association with reduced blood pressure, the 
combination was used to bring about a countering effect. The synergistic use of these agents 
permitted adequate anaesthesia with controlled MABP whilst preventing inadvertent 
neuroprotection as a confounding factor, an important consideration when modelling acute 
ischaemic stroke. It must be acknowledged, however, that we did observe significant 
differences in MABP across several of the groups. Nevertheless, these alterations in blood 
pressure did not follow the same pattern as the alterations in ICP so it is therefore unlikely 
that they significantly contributed to the observed treatment effects. The differences in 
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MABP observed between groups most likely reflects both the within group and between 
group heterogeneity in the amount of isoflurane required to maintain twilight anaesthesia 
during surgery whilst balancing ketamine dosing to maintain adequate blood pressure. 
Furthermore, only female animals were used in the present study due to the inherent need 
for catheterisation of animals during long-duration anaesthesia. Females were selected 
preferentially over males upon veterinary advice given the difficulty in catheterising the 
highly convoluted male urethra, and thus we were unable to determine gender discrepancies.  
 
Though we were able to establish a significant increase in ICP following ovine stroke, MRI 
findings were not strongly associated with ICP. We acknowledge that the small sample sizes 
in this study may have led to a low statistical power. Furthermore, it must be noted that this 
is frequently seen in clinical stroke cases, where MRI and CT findings are not always a good 
predictor of ICP. MRI was not possible in the entire cohort, leading to uneven group sizes. 
Despite a larger cohort available for ICP in both treatment and vehicle groups, only animals 
with matching ICP/MRI data were included, leading to variations in group sizes. 
Furthermore, the reliable measurement of cerebral oedema on MRI at a single time-point is 
somewhat contentious, as the hyperintensity of vasogenic oedema is difficult to distinguish 
from the ischaemic lesion itself. The measurement of the entire FLAIR lesion volume 
therefore includes areas of infarction as well as oedema and is thus an indirect measure of 
oedema volume. A more robust approach to measuring oedema volume would be to perform 
sequential MRI’s and evaluate the change in diffusion lesion volume across times points 
following reperfusion, which was not feasible in this study due to cost.  It should also be 
acknowledged that whilst MRI findings did not correlate with ICP, we were able to observe 
MRI features similar to that seen clinically, including transcalvarial herniation in DC treated 
animals and reduced midline shift. Finally, testing of multiple NK1-R antagonists was not 
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feasible in this study given the time and cost involved in conducting sheep experiments. 
However, in our rodent studies of TBI we have previously tested 2 different NK1-R 
antagonists and recorded comparable results (Donkin, 2006) which provided the basis for 
the use of the agent in the present study. 
 
For future studies we will work alongside the animal ethics committee of the South 
Australian Health and Medical Research Institute to develop a survival model of transient 
MCAo which obviates the need for long duration anaesthesia, allowing for the study of 





Use of multiple boluses of an NK1-R antagonist is effective in lowering ICP following ovine 
stroke, producing a reduction in pressure that is comparable to decompressive surgery.  We 
propose that the mechanism by which the NK1-R antagonist is exerting its action to reduce 
pressure is largely via caveolae mediated albumin transcytosis. Administration of the NK1-
R is thus preventing abnormal albumin extravasation from the vasculature to the brain 
parenchyma and ameliorating the subsequent development of vasogenic oedema and 
concomitant rise in ICP. These findings suggest that NK1-R antagonist treatment may 
represent a novel intervention for the management of elevated ICP following stroke.  
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Background and Purpose: Cerebral oedema and elevated intracranial pressure (ICP) are the 
leading cause of death in the first week following stroke. Despite this, current treatments are 
limited and fail to address the underlying mechanisms of swelling, highlighting the need for 
targeted treatments. When screening promising novel agents, it is essential to use clinically 
relevant large animal models to increase the likelihood of successful clinical translation.  As 
such, we sought to develop a survival model of transient middle cerebral artery occlusion 
(tMCAo) in the sheep and subsequently characterise the temporal profile of cerebral oedema 
and elevated ICP following stroke in this novel, clinically relevant model.  
 
Methods: Merino sheep (27M; 31F) were anaesthetised and subject to 2 hours tMCAo with 
reperfusion or sham surgery. Following surgery, animals were allowed to recover and 
returned to their home pens. At preselected time points ranging from 1 to 7 days post-stroke, 
animals were re-anaesthetised, ICP measured for 4 hours, followed by imaging with MRI to 
determine cerebral oedema, midline shift and infarct volume (FLAIR, T2, DWI). Animals 
were subsequently euthanised, and their brain removed for immunohistochemical analysis. 
Serum and cerebrospinal fluid samples were also collected and analysed for substance P (SP) 
using ELISA. 
 
Results: ICP and MRI scans were normal in sham animals. Following stroke, ICP rose 
gradually over time and by 5 days was significantly (p<0.0001) elevated above sham levels. 
Profound cerebral oedema was observed as early as 2 days post-stroke and continued to 
evolve out to 6 days, resulting in significant midline shift which was most prominent at 5 
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days post-stroke (p<0.01), in keeping with increasing ICP. Serum SP levels were 
significantly elevated (p<0.01) by 7 days post tMCAo. 
 
Conclusion: We have successfully developed a survival model of ovine tMCAo and 
characterised the temporal profile of ICP. Peak ICP elevation, cerebral oedema and midline 
shift occurred at day 5-6 following stroke, accompanied by an elevation in serum SP. Our 
findings suggest that novel therapeutic agents screened in this model targeting cerebral 
oedema and elevated ICP would most likely be effective when administered prior to 5 days, 




















Worldwide, over 17 million people suffer a stroke each year, of which one third will die and 
one third will remain permanently disabled as a result (Feigin et al., 2017). Cerebral 
ischaemia initiates a cascade of interrelated events precipitating brain tissue injury and cell 
death (Ayata and Ropper, 2002). Of these secondary injury processes, increased 
microvascular permeability and loss of structural integrity of the blood-brain barrier (BBB) 
are key to the development of cerebral oedema, a pathological state in which fluid 
abnormally accumulates in the extracellular space of the cerebral parenchyma, resulting in 
an overall increase in brain volume. This leads to a subsequent rise in intracranial pressure 
(ICP), which has devastating consequences including infarct expansion, displacement of 
brain tissue, tonsillar herniation and death (Steiner et al., 2001c, Raslan and Bhardwaj, 2007, 
Kim et al., 2015, Battey et al., 2014). 
 
Stroke patients often exhibit a progressive and slow evolution of brain injury, with cerebral 
oedema and elevated ICP presenting some days following initial insult to tissue, most 
commonly around 3-5 days following onset (Hewitt and Ellory, 2012). Despite the 
devastating impact of cerebral oedema and elevated ICP, however, existing treatments fail 
to address the underlying pathophysiology, thereby limiting their efficacy (Battey et al., 
2014). Novel therapies that target the underlying cause of swelling and prevent the evolution 
of cerebral oedema are urgently required to improve post-stroke outcomes. To this end, our 
laboratory has identified that the tachykinin neuropeptide substance P (SP) is a key mediator 
of BBB dysfunction and development of cerebral oedema following stroke (Turner et al., 
2006, Turner et al., 2011, Turner and Vink, 2012) and traumatic brain injury (TBI) (Vink et 
al., 2003, Nimmo et al., 2004, Donkin et al., 2009, Corrigan et al., 2012). Specifically, SP 
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release leads to neurogenic inflammation, manifesting following acute central nervous 
system (CNS) injury as increased BBB permeability and the development of cerebral 
oedema. Furthermore, we have established that blockade of the receptor for SP, the 
tachykinin NK1 receptor (NK1-R), reduces both BBB permeability and cerebral oedema in 
rodent models of stroke (Turner and Vink, 2012, Turner et al., 2011, Turner and Vink, 2014) 
and TBI (Donkin et al., 2009, Corrigan et al., 2016a, Corrigan et al., 2012), suggesting that 
this is a common feature of acute brain injury.  
 
An enhanced understanding of the underlying pathophysiology of cerebral oedema and 
elevated ICP following stroke is essential in guiding the development of more effective 
therapies, and pre-clinical stroke studies are an essential step in this process. However, the 
poor clinical translation of stroke therapies from the laboratory to the clinic to date has 
emphasised the importance of appropriate species and model selection (Casals et al., 2011). 
The use of large intermediate species for these studies is an essential step in the pre-clinical 
phase to improve translation to the clinic due to similarities in neuroanatomical structure, 
such as a large gyrencephalic brain that is closer in similarity to that of the human compared 
with many widely adopted small animal models. In light of this, a number of large animal 
species are used as pre-clinical stroke models, including sheep (Wells et al., 2015, Wells et 
al., 2012, Boltze et al., 2008), dogs (Christoforidis et al., 2011, Qureshi et al., 2004, Boulos 
et al., 2011, Cameron et al., 2008), pigs (Platt et al., 2014, Sakoh et al., 2000, Watanabe et 
al., 2007) and non-human primates (D'Ambrosio et al., 2004, Nehls et al., 1986, Tagaya et 
al., 1997, Furuichi et al., 2007, Yuji et al., 2001), each with their own inherent advantages 
and disadvantages (Sorby-Adams et al., 2018). Although gyrencephalic non-human primates 
are of significant value in modelling the human condition, the extensive cost, housing 
requirements and ethical considerations may preclude their use in large scale studies. Pigs 
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are a widely used experimental species in models of cardiovascular (Kamoi et al., 2014, 
Suzuki et al., 2011) and traumatic brain injury (TBI) studies worldwide (Pfenninger et al., 
1989, Duhaime et al., 2000, Lighthall, 1988, Manley et al., 2006, Ross et al., 1994), however, 
the Yucatan mini-pig is not available in Australia, and the rapidly increasing bodyweight of 
other strains can make long-term studies difficult. Sheep are an accessible experimental 
species and have been used extensively to model a number of neurological conditions, 
including non-accidental head injury (Anderson et al., 2014, Sandoz et al., 2012), TBI (Vink 
et al., 2008, Vink et al., 2017) and Huntington’s Disease (Reid et al., 2013, Morton et al., 
2014). Although sheep have earned a reputation as unintelligent animals, the evidence is 
quite to the contrary, as sheep demonstrate excellent facial recognition, executive decision 
making and emotional processing, often comparable to humans on equivalent tasks (Morton 
and Avanzo, 2011, Keith et al., 2007, Tate et al., 2006). Specifically, the high proportion of 
white to grey matter in the sheep brain is of particular benefit when studying the 
pathophysiology of oedema and ICP, given that oedematous fluid predominantly 
accumulates in the white matter following ischaemic stroke (Jha, 2003, Mahajan and Bhagat, 
2016). The strong fibrous tentorium cerebelli of the sheep, comparable with that of the 
human, also prevents the brain from moving downwards to accommodate increased volume 
of the oedematous brain, resulting in persistent elevations in ICP, midline shift and 
herniation of the brain, all of which are seen clinically. Additional advantages of large animal 
models, including sheep, are the ability to obtain multiple serum and cerebrospinal fluid 
(CSF) samples from an individual animal over time which is not possible in rodents, as well 
as using clinical physiological monitoring equipment and MRI. As such, large animal stroke 
models, such as the sheep, are an excellent additional screening tool following evaluation in 
rodents and prior to progression to clinical trials.  
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There are two models of ovine middle cerebral artery occlusion (MCAo) currently in use 
(Boltze et al., 2008, Wells et al., 2012) both of which involve permanent occlusion of the 
MCA. In the Boltze model (Boltze et al, 2008) the craniotomy is left open so that animals 
are effectively given decompression at the time of stroke, allowing for the investigation of 
long-term time-points without premature mortality, although intracranial pressure dynamics 
cannot be investigated. Conversely, in the Wells model (Wells et al., 2015, Wells et al., 
2012) the craniotomy is closed following MCAo so that the evolution of ICP can be 
accurately studied. However, survival time-points beyond 24hrs are not possible in this 
model due to the resulting malignant MCA infarction and ethical requirement to maintain 
animals under anaesthesia for the duration of the experiment. As such, there is a clear 
requirement for an ovine MCAo stroke model where the MCA is temporarily occluded to 
study the effects of reperfusion injury and longer time-points following stroke onset. 
Furthermore, there is an increasing incidence of patients who successfully recanalise 
following stroke onset. This is largely due to the increased use of endovascular clot retrieval 
for reperfusion of large strokes, such as occlusion of the internal carotid artery (ICA) or M1 
segment of the MCA (Goyal et al., 2016). The mechanical recanalisation of the MCA 
produced in a transient MCAo model closely aligns with the vascular reperfusion achieved 
with endovascular thrombectomy, and thus may be more representative of the evolving 
human condition. 
 
Accordingly, the aims of the present study were to: 1) develop a survival model of ovine 
MCAo stroke with reperfusion; and 2) characterise the temporal profile of intracranial 
pressure changes following stroke; and 3) determine the contribution of SP to BBB 
permeability and cerebral oedema that develops in this model. By determining the clinical 
204 
course of ICP following ovine MCAo, an optimal time window for administration of 
therapeutic agents targeting elevated ICP due to cerebral oedema can be established.   
 
7.2 MATERIALS AND METHODS  
 
7.2.1 Ethics Statement 
All experimental procedures were approved by the Animal Ethics Committees of The 
University of Adelaide (M-2014-015) and South Australian Health and Medical Research 
Institute (SAHMRI; SAM 3; SAM 141). Experiments were conducted in accordance with 
the Australian National Health and Medical Research Council (NHMRC) code of practice 
for the care and use of animals for scientific purposes (8th edition, 2013).  
 
7.2.2 Experimental Design 
A total of 58 (n=27M;31F) merino sheep (weight range 65±7kg; age 18-36 months) were 
used in this study. Animals (3M and 3F/time point) were pre-operatively randomised to daily 
post-stroke survival time points ranging from day 1 to day 7. Animals allocated to the stroke 
groups underwent two surgeries: tMCAo surgery with recovery, and ICP monitoring on the 
designated day post-stroke. An additional group of animals underwent the surgical procedure 
without MCAo and acted as sham controls (n=4F). These animals had ICP continuously 
recorded for 4 hours immediately following the sham surgical procedure. Finally, an 
additional follow-up cohort of 12 animals (n=6F;6M) underwent stroke surgery and were 
included to obtain serum and CSF samples over the 7-day post-stroke time-course. This was 
not possible in the main stroke cohort due to the risk that repeat CSF sampling might 
potentiate changes in intracranial dynamics leading to inaccurate measurements of ICP. All 
animals were group housed in conventional sheep paddocks for a minimum of 2 weeks prior 
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to surgery to allow for acclimatisation.  Animals were then moved to individual indoor pens 
48 hours prior to surgery and fasted overnight for a minimum of 12 hours prior to the 
procedure.  
 
7.2.3 Experimental Procedure 
7.2.3.1 Animal Preparation and Anaesthesia 
Anaesthesia was induced with a combination of intravenous ketamine (0.05 mL/kg, 100 
mg/kg Injection, CEVA, Australia) and diazepam (0.08 mL/kg, 5 mg/mL injection, Pamlin, 
CEVA, Australia). Following induction, animals were intubated via endotracheal tube 
insertion to ensure airway patency for ventilation. Animals were then positioned on an 
operating table on their left side, with hind limbs exposed for arterial access. An arterial 
catheter was inserted in the left hind leg for blood gas sampling and a cannula inserted into 
the external jugular vein for fluid and drug administration. Intraoperative anaesthesia was 
maintained via a combination of inhalational isoflurane (Henry Shein, Australia; 1.5-2.0%) 
in 100% oxygen and intravenous (jugular) ketamine at an infusion rate of 4 mg/kg/hr. 
Crystalloid fluids were administered throughout surgery via continuous intravenous infusion 
with compound sodium lactate (Baxter Health, Australia) to assist hydration and ionic 
balance. In addition, intraarterial sodium chloride (Baxter Health, Australia) was infused at 
a rate sufficient to ensure arterial catheter patency. Following surgery, animals were 
recovered and treated with subcutaneous antibiotic Rilexine (1 mL/10kg every 12 hours, 15 
g/100 mL Cephalexin, VIBRAC, Australia), NSAID Carprieve (0.7 mg/kg, 50 mg/mL every 
12 hours, Carprofen, Norbrook, Australia) and opioid Temgesic (1.0 mL, 324 µg/mL 
Buprenorphine hydrochloride, one dose post-operatively, Reckin Benckiser, Australia) for 
pain relief. Antibiotic and NSAID treatment were continued for a minimum of 3 days 
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following surgery, with additional opioid and/or NSAID administered as required thereafter 
for pain management.  
 
7.2.3.2 Surgical Approach  
A model of ovine stroke was modified from previously published works (Wells et al., 2015, 
Wells et al., 2012) in order to achieve tMCAo with reperfusion (Figure 7.1). This 
modification enabled the recovery of animals from surgery and the study of longer time-
points (beyond 24 hours) following stroke. In this particular approach, it was necessary to 
keep the coronoid process of the mandible intact and preserve the surrounding temporalis 
muscle to ensure animals were able to masticate following surgery. To achieve this, a 5 cm 
horizontal incision was made posterior to the orbital rim of the right eye and terminating 
anterior to the ear. Upon incision, the temporalis muscle was retracted, and the coronoid 
process elevated to expose the underlying skull. Cloward retractors (Codman & Shurtleff 
Inc., Massachusetts) were inserted, and blades adjusted to provide space for a small 
craniotomy to be drilled at the junction of the parietal and squamous temporal bones with a 
high-speed pneumatic drill using a 5 mm cutting burr (Midas Rex, Medtronic, MN). 
Following craniotomy, a horseshoe durotomy was performed, the brain exposed, and the 
anterior temporal lobe gently retracted to expose the right proximal MCA. A small amount 
of CSF was aspirated to ensure sufficient visualisation of the proximal MCA; however, this 
was kept to a minimum to reduce the impact on intracranial volume. Gentle dissection of the 
MCA from the arachnoid mater was performed to allow for a temporary aneurysm clip 
(Aesculap, Germany) to be applied proximal to the MCA bifurcation using a clip applicator 
(YASARGIL® Aneurysm clip system, Germany). Successful clipping of the MCA resulted 
in an immediate decrease in vessel calibre, confirming reduced blood flow. The dura was 
then gently re-opposed onto the brain and the craniotomy site filled with sterile saline to 
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prevent dehydration of the underlying cortical tissue, and the surgical site draped. The clip 
was left in situ for 2 hours and subsequently removed with clip applicators to achieve 
reperfusion. Visual confirmation of reperfusion was noted when the calibre of the vessel 
increased, and blood returned to the distal MCA. Successful reperfusion also was confirmed 
on magnetic resonance angiography (MRA) performed at the pre-selected timepoints.  
 
Following reperfusion, the dura was approximated and interleaved with synthetic dura 
(Durepair®, Medtronic, USA) to cover the exposed brain. Dural closure was then achieved 
with ethyl cyanoacrylate (Bostik, Australia), and the bone previously removed reinserted 
into the craniotomy site and reinforced with dental acrylic cement (Sledgehammer, 
Keystone, Germany) to create a watertight seal, thus restoring intracranial dynamics.  The 
surgical site was then treated with 1.0 mL 0.5% local anaesthetic Marcain (bupivacaine 
hydrochloride 5 mg/mL, AstraZeneca, Australia) and closed using a 0.1 Vicryl braided 
polyglactin Suture (ETHICON, Australia) using the horizontal mattress suture technique of 
wound closure to minimise risk of infection. The animal was removed from anaesthesia, 
extubated, transferred to a post-operative recovery pen and pain relief administered. Mean 
arterial blood pressure (MABP) was monitored at 5-minute intervals throughout surgery via 
application of a paediatric blood pressure cuff (Easy Care Cuff, Phillips) on the upper left 
front limb. Blood samples (Machine AVL Scientific Corporation USA, Manufactured by 
Hersteller, OPTI Critical Care Analyzer–Model OPTI3, Serial No. OP3-2759) were acquired 
hourly via arterial catheter sampling to determine pO2, pCO2, haematocrit, haemoglobin, 
pH, Na+ and K+ levels. End tidal CO2 was also recorded at regular intervals. Animals were 
maintained on a heating pad throughout all surgical procedures and rectal temperature 





Figure 7.1. Surgical approach to ovine transient middle cerebral artery occlusion.   (A) Surgical approach 
showing site of incision (1; black dotted line) posterior to the orbital rim (2) and superior to the coronoid 
process (3). This approach enabled the skull base to be accessed without disrupting the coronoid process or 
zygomatic arch (5), allowing for craniotomy (4) and direct access to the MCA, whilst ensuring post-operative 
recovery of the animal and the ability to masticate following the procedure. (B) Superior view of craniotomy 
site showing the aneurysm clip applied to the proximal MCA. 
  
7.2.2.3 ICP Measurement  
At 4 hours prior to the pre-determined post-stroke time-point, or immediately following 
surgery in shams, anaesthetised (using aforesaid isoflurane and ketamine maintenance 
protocols) animals were placed prone in the sphinx position on the operating table. Bilateral 
burr holes were drilled into the left and right parietal bone, posterior to the coronal suture 
and approximately 10 mm from the sagittal suture. The dura was perforated, and skull bolts 
secured, following which Codman microsensor ICP probes (Codman & Shurtleff Inc., 
Massachusetts) were inserted to an approximate depth of 15 mm into the brain parenchyma 
and ICP recorded continuously for a period of 4 hours post time of MCAo or sham surgery 
(LabChart Reader, ADInstruments, v. 8.1.1). Two-point checks (0mmHg, 100mmHg) were 
performed prior to insertion of probes and at the end of the recording period to confirm 
measurement accuracy.  ICP readings that were selected for final analysis (left or right) were 
based on calibration data, with readings preferentially selected from the right hemisphere 
probe. Raw ICP data underwent a logarithmic exponential transformation as previously 
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described and was expressed as geometric mean ± SEM (Wells et al., 2015a, Matthews et 
al., 1990).   
 
7.2.2.4 Magnetic Resonance Imaging 
Following the 4-hour ICP monitoring period, animals were moved to a 1.5 Tesla Siemens 
Syngo2004A (Siemens AG, Munich, Germany) MRI scanner, during which they were 
maintained under general anaesthesia (3% isoflurane). Sequences were acquired including 
time-of-flight magnetic resonance angiography (TOF MRA; TR 26 ms, TE 3.69 ms, slice 
thickness 0.50 mm), diffusion weighted imaging (DWI; TR 5600 ms, TE 80 ms, slice 
thickness 3.0 mm), fluid attenuated inversion recovery (FLAIR; TR 5000 ms, TE 386 ms, 
slice thickness 0.9 mm), T1 weighted imaging (TR 2300 ms, TE 2.58ms, slice thickness 0.9 
mm) and T2 weighted imaging (TR 3200 ms, TE 410 ms, slice thickness 0.9 mm). T1 
weighted post-contrast images were also acquired following intravenous administration of 
0.1 mL/kg gadolinium-diethylene-triamine-pentaacetic acid (GAD) (Magnevist, Bayer 
HealthCare, Germany) to determine the extent of BBB breakdown on MRI.  
 
The degree of midline shift was used as a surrogate marker for the anatomical sequelae of 
cerebral oedema. Shift from the midline was assessed using axial T2 weighted scans and 
measured in mm from the septum pellucidum at the level of the foramen of Monro (HOROS 
DICOM image viewer v3.1.1). To calculate cerebral oedema, coronal FLAIR images were 
analysed using HOROS DICOM image viewer (v3.1.1). After optimal adjustment of 
brightness and contrast, oedema volume was determined from sequences using computer-
aided manual tracing of the hyperintense lesion by a blinded assessor. The areas were then 
summed and multiplied by the slice thickness to give a total volume in cm3.  
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To calculate infarct volume, segmentation tools in ITK-SNAP (v 3.7) were used to perform 
semi-automated segmentation of the MRI diffusion lesions, in which a separate foreground 
and background was created using diffusion-weighted images (Yushkevich et al., 2006).  A 
combination of “three-dimensional active contour segmentation” and subsequent manual 
post-processing of the segmentation while adjusting image thresholds was performed to 
maximize reproducibility whilst excluding artefacts. The “three-dimensional active contour 
segmentation” consisted of multiple steps: First, in the pre-segmentation phase, independent 
component analysis automatically segmented parts of the DWI image and these were 
manually identified as foreground or background. To obtain an optimal distinction between 
foreground and background, thresholds of the image windows were adjusted. After 
thresholding, a “speed image” with a separate foreground and background was created. Next, 
in the active contour phase, seed regions were manually placed within the region of interest 
(ROI). These seeds were then automatically grown within the ROIs to form the temporary 
segmentation. Subsequently, areas that were not automatically included in the “active 
contour segmentation” were manually included in the follow-up infarct segmentation.  The 
total volume of the segmentation was exported and reported in cm3 for analysis. 
 
7.2.2.5 Perfusion and Histological Examination 
Following MRI, intravenous heparin (5000 I.U./5mL; Pfizer, NY) was administered and 
animals humanely euthanised via common carotid perfusion fixation with cold TRIS-
buffered saline under isoflurane anaesthesia. The brains were subsequently removed and 
sliced into 10 mm coronal slices using a custom-made sheep brain matrix. Sections were 
then immersion fixed in 10% neutral-buffered formalin for a minimum of 14 days prior to 
being processed, embedded in paraffin wax and sectioned coronally at 5-micron intervals 
for immunohistochemistry for albumin, SP, and caveolin-1 (Table 1).  
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Table 7.1 Immunohistochemistry protocols 
Antibody  Dilution  Retrieval  Brand Catalogue no. 
Albumin 1:2000 No retrieval  Dako  A0001 
SP 1:5000 Citrate Abcam  ab14184 




7.2.2.6 Serum and CSF Collection 
Blood samples were collected (Vacutainer® SST™ II Advance Tube, Beckton-Dickinson, 
Australia) from animals (n=12, 6M;6F) pre-injury and at 4, 8, 12 and 16 hours post stroke 
and on days 1, 3, 5, and 7 via jugular venepuncture. Following collection, samples were 
centrifuged (15 mins at 2000 RCF) and serum extracted into 10 x 500 µl aliquots and stored 
at -80 °C. CSF was collected via lumbosacral tap prior to induction of stroke and on days 1, 
3 and 6 thereafter. Note that this was performed in the follow up cohort, and these animals 
did not undergo ICP monitoring so there were no concerns regarding multiple CSF draws 
and the associated effects on ICP measurement accuracy. Prior to collection, animals were 
induced with combination diazepam and ketamine as previously described. The animals 
were then placed in the prone position on a surgical table and the sagittal plane of the 
animal’s vertebrae was manipulated so that it was perpendicular to the horizontal plane of 
the bench. The animal was shaved to allow for clear access to the lumbosacral joint and 
appropriate visualisation of landmarks. Palpation of the hips was performed to determine the 
correct sagittal plane orientation of the spine and the optimal site for CSF collection was 
determined via identification of the midline depression between the last lumbar and first 
sacral vertebrae. The area was cleaned using a 4% chlorhexidine preoperative surgical scrub 
brush (Becton-Disckinson E-Z Scrub™, Australia), povidone-iodine applied and site 
surgically prepared. A spinal needle with stylet (BMDi TUTA Healthcare, Australia) was 
inserted perpendicular to the skin and the needle advanced slowly through the subcutaneous 
tissue and interarcuate ligament until a sudden drop in resistance was felt indicating the 
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advancement through the dural membrane and entry into the subarachnoid space. The stylet 
was then removed, and 2 mL of CSF aspirated via a syringe and deposited into a 3 mL 
container; sample placed immediately on ice for 20 minutes, centrifuged (15 mins at 3000 
RCF), extracted into 3 x 500 µL aliquots and stored at -80 °C.  
 
7.2.2.7 Analysis of Serum and CSF  
Serum and CSF samples were used to quantify expression of SP using enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s instructions (Abcam; KIT-
ab133029).  All samples were diluted 1:4 in assay buffer for appropriate compliance with 
each individual plate standard curve. Standards, serum and CSF test samples were run, and 
the plate immediately analysed following addition of stop solution using a 
spectrophotometric microplate reader (Synergy HTX, multi-mode reader). At optical density 
of 405 nm light absorbance was calculated to give an inverse reading of SP proportional to 
its captured measure on the plate. 
 
7.2.3 Statistical Analysis 
All data are expressed as mean ± SEM. Physiological data (MABP, pH, pO2, pCO2) were 
analysed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc tests 
(Prism v.8.0.1, GraphPad, California). ICP, infarct volume, cerebral oedema and midline 
shift data were analysed by one-way ANOVA with multiple comparisons followed by 
Tukey’s post-hoc tests. ELISA evaluation was performed for each plate using individually 
generated standard curves and an R value of 0.9709 was accepted to improve the efficacy of 
inter-plate accuracy. ELISA values were then analysed via one-way ANOVA with Tukey’s 
post-hoc. Pearson’s correlations were run between midline shift and cerebral oedema, 
cerebral oedema and ICP and midline shift and ICP to determine the relationship between 
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variables. A two-way ANOVA with Sidak’s multiple comparison test was run to determine 
gender differences in physiological variables during both surgery and ICP monitoring. 
Gender discrepancies were also established for infarct volume, cerebral oedema, midline 
shift and ICP in addition to CSF and serum SP via two-way ANOVA with Sidak’s post-hoc. 




7.3.1 Surgery, Mortality and Post-operative Course 
There was no premature mortality of animals seen in the present study. One animal was 
excluded due to insufficient reperfusion following MCAo as seen on MRA, resulting in a 
permanent rather than a transient occlusion (Figure 7.2). In all other animals, temporary 
occlusion of the MCA with reperfusion was successfully performed. A further 4 animals 
were excluded due to significant anaesthetic difficulties which confounded the experimental 
course (n=2 in 2 days group; n=2 in 3 days group). Specifically, the excluded animals were 
unstable throughout the induction of stroke surgery, necessitating repeat boluses of ketamine 
and diazepam and an increased rate of isoflurane to maintain surgical levels of anaesthesia, 
which resulted in significantly lowered MABP, decreased cerebral perfusion pressure and 






Figure 7.2. Middle cerebral artery (MCA) reperfusion following transient MCA occlusion (MCAo) (A) 
compared with permanent MCAo (B) on time-of-flight magnetic resonance angiography. Evidence of 
vessel patency, indicated by the white arrow, following clip removal in transient MCAo animals compared 
with permanent MCAo animals, where the vessel cannot be visualised MRA (data not reported). MCA-middle 
cerebral artery; ACA-anterior cerebral artery; ICA-internal carotid artery; BA-basilar artery; RM-rete mirabile. 
 
All animals were able to use their jaw and masticate following surgery. A comprehensive 
behavioural analysis was beyond the scope of this study; however, all animals in the ICP 
cohort were observed for jaw alignment and eating behaviour, the presence/absence of 
fetlock weakness and demeanour throughout the post-stroke period. Nine of 42 animals 
demonstrated evidence of jaw misalignment following stroke surgery, which persisted to the 
end of the experiment in 3/9 animals. Although 25/42 animals showed reduced food intake 
post-stroke, as compared to their pre-stroke daily intake, body weight remained within 
acceptable limits (15%). Fourteen of 42 animals showed weakness of the fetlock joint 
following stroke, manifesting as knuckling, which was most commonly observed on day 1 
and typically resolved by day 4 post-stroke. An alteration in demeanour, as demonstrated by 
a lowered head position and droopy ears, was observed in 26/42 animals and was most 
prevalent at days 5-7 post-stroke, coinciding with elevated ICP. 
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7.3.2 Physiological Parameters 
Physiological variables for pCO2, MABP and pH were within normal limits for all groups 
throughout the duration of the experiment (Table 7.2). As animals were maintained on 100% 
oxygen (6.0 L/min) through the course of surgery and ICP monitoring this resulted in pO2 
values that were significantly above the normal range of 90-100 mmHg. These observations, 
however, were observed across all experimental groups. No significant differences (p>0.05; 
Table 7.2) between pO2, pCO2 and pH were observed between groups during stroke surgery 
or the 4-hour period of ICP monitoring. There was, however, a statistically significant 
decrease in MABP during the ICP monitoring period seen at 1-day post-stroke compared 














Table 7.2 Surgical and intracranial pressure monitoring physiological parameters 
 
 
 PCO2 (mmHg) ± SEM                                                                                               
 Surgery Day ICP Monitoring 
Group Male Female All animals Male Female All animals 
Sham  43.19±3.43     
1 Day 41.19±3.39 39.83±2.07 40.51±1.80 36.08±1.61 37.42±2.32 36.75±1.30 
2 Day 43.83±2.05 45.25±2.84 44.54±1.60 38.33±1.02 41.42±2.14 39.88±1.27 
3 Day 46.58±1.72 46.25±1.50 46.42±1.02 47.28±2.98 40.25±1.75 44.47±2.43 
4 Day 46.81±3.13 43.0±3.47 44.90±2.26 42.89±0.45 38.17±4.19 40.53±2.16 
5 Day 50.08±3.17 44.33±2.51 47.21±2.22 41.58±0.79 39.58±2.19 40.58±1.13 
6 Day 45.42±2.38 41.33±1.62 43.38±1.58 47.75±1.75 42.83±1.96 45.29±1.61 




MABP (mmHg) ± SEM 
 Surgery Day ICP Monitoring 
Group Male Female All animals Male Female All animals 
Sham  79.35±6.27     
1 Day 84.61±12.54 86.17±8.80 85.39±6.86 97.25±8.76 77.64±8.54 87.44±7.01 
2 Day 74.17±0.87 92.92±4.01 106.98±25.30 88.50±11.35 107.39±17.88 96.44±10.66 
3 Day 75.42±5.47 91.42±4.03 83.42±4.69 93.75±14.42 99.88±12.63 96.20±8.97 
4 Day 92.75±3.82 84.17±3.99 88.46±3.13 116.33±10.19 127.50±6.91 121.92±6.05* 
5 Day 96.75±1.32 80.97±13.45 88.86±7.00 117.92±7.58 104.75±1.98 111.33±4.58 
6 Day 78.67±9.04 91.17±2.98 119.56±6.87 122.67±2.85 108.42±5.21 115.54±4.15 
7 Day 114.17±11.28 84.25±10.31 99.21±9.56 137.42±17.12 116.75±10.33 127.08±10.07* 
       
       
      (continued) 
       
       
       
       






       
 PO2 (mmHg) ± SEM 
 Surgery Day   ICP Monitoring   
Group Male Female All animals Male Female All animals 
Sham  112.77±5.75     
1 Day 213.94±50.81 213.08±66.77 213.51±37.52 294.36±64.89 191.64±38.27 243±40.78 
2 Day 200.17±37.13 83.67±10.83 141.92±31.27 166.67±14.21 250.92±62.62 208.79±34.34 
3 Day 289.50±96.27 187.0±38.56 238.25±51.73 241.81±126.13 237.38±72.13 240.03±72.76 
4 Day 193.00±73.93 113.50±8.75 153.25±37.74 304.67±47.92 163.0±17.10 233.83±39.00 
5 Day 193.83±30.12 188.47±57.77 191.15±29.16 228.17±70.65 251.33±29.37 239.75±34.61 
6 Day 342.33±101.85 217.58±76.33 279.96±63.39 319.56±122.91 422.67±57.68 371.11±64.95 




pH ± SEM 
 Surgery Day   ICP Monitoring   
Group Male Female All animals Male Female All animals 
Sham  7.46±0.02     
1 Day 7.43±0.03 7.44±0.01 7.43±0.01 7.42±0.01 7.42±0.03 7.42±0.01 
2 Day 7.43±0.02 7.45±0.04 7.44±0.02 7.43±0.03 7.48±0.03 7.45±0.02 
3 Day 7.41±0.04 7.41±0.01 7.41±0.02 7.39±0.04 7.41±0.03 7.40±0.02 
4 Day 7.41±0.02 7.44±0.02 7.42±0.02 7.35±0.05 7.48±0.02 7.41±0.04 
5 Day 7.38±0.02 7.43±0.07 7.40±0.02 7.47±0.02 7.43±0.07 7.45±0.03 
6 Day 7.39±0.03 7.45±0.01 7.42±0.02 7.40±0.02 7.44±0.03 7.42±0.02 
7 Day 7.40±0.02 7.42±0.02 7.41±0.01 7.48±0.02 7.44±0.03 7.46±0.02 
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7.3.4 Intracranial Pressure 
ICP remained within normal limits for the duration of the 4-hour monitoring period in sham 
animals (8±2 mmHg). From 1 to 4 days following tMCAo, ICP levels were comparable with 
sham (p>0.05; Figure 7.3). However, by 5 days post-stroke, ICP was significantly elevated 
(28±10 mmHg; p<0.0001) from sham levels and post-stroke days 1-4 (p<0.0001). ICP 
remained significantly elevated out to 6 days post-stroke when compared with shams (25±5 
mmHg; p=0.0001) and 1 (p=0.0001), 2 (p=0.0003), 3 (p=0.03) and 4 day (p=0.0007) post-
stroke time points. By 7 days, ICP began to decline (18±2 mmHg; p=0.02 when compared 
with 5 days) but remained significantly elevated compared with sham (p=0.04), although 




Figure 7.3. Temporal profile of ICP following transient middle cerebral artery occlusion.  ICP was 
significantly elevated at 5 days (p<0.001) and 6 days (p<0.05) post-stroke when compared with shams. By 7 
days, ICP began to normalise, though remained elevated compared with sham (p<0.05). ****p<0.0001; 
***p<0.001 compared with sham. n=6/time-point, n=4 sham. 
 



















MRI was normal in sham animals, with no evidence of infarction, cerebral oedema or 
midline shift observed (data not shown). At each time-point following stroke, there was 
evidence of MCA recanalisation following clip removal as seen on MRA, with the exception 
of one animal that was excluded due to persistent MCAo (Figure 7.2). All stroke animals 
showed evidence of hyperintensity on T2 weighted and FLAIR images in the MCA territory, 
indicative of the infarct core and surrounding extracellular oedema (Figure 7.4). There was 
no significant difference in infarct volume at any of the time points post-stroke as measured 




Figure 7.4. MRI findings post transient middle cerebral artery occlusion. Cerebral oedema, as shown in 
coronal FLAIR MRI images, evolved from 1-6 days following stroke, beginning to resolve by 7 days. This 
evolution in cerebral oedema was associated with enhanced extravasation of Gadolinium (GAD) across the 
BBB as seen on T1 weighted post-contrast series when compared with pre-contrast T1 series. Lesion volume, 
as shown in DWI MRI images, was comparable across time-points following stroke.  
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Cerebral oedema evolved over time from 1 to 6 days post tMCAo, with the largest volume 
of cerebral oedema seen at 5 (8.86±2.03 cm3) and 6 days (7.01±0.9 cm3). This increase in 
the volume of oedema was accompanied by increased extravasation of GAD across the 
barrier, as seen in T1 post-contrast sequences, indicative of BBB breakdown (Figure 7.4). 
However, although a qualitative evolution of cerebral oedema post-stroke was apparent 
(Figure 7.4), accompanied by increased GAD contrast, there was no statistically significant 
difference between time-points (Figure 7.5 B; p>0.05). Midline shift was evident in all 
stroke animals. The degree of midline shift evolved over time following stroke (Figure 7.5 
C) and was most prominent at 5 days post-stroke (3.92±0.59 mm) when compared with 1 
(p=0.002) and 7 days (p=0.04), in keeping with ICP findings. No animals showed evidence 




Figure 7.5. Quantification of infarct volume, cerebral oedema and midline shift on MRI.  There was no 
significant difference (p>0.05) in infarct volume at any of the time-points following stroke. The evolution of 
cerebral oedema showed a similar pattern to intracranial pressure; however, changes were not significant 
(p>0.05). Midline shift was significantly greater at 5 days when compared with 1 (<0.01) and 7 (p<0.05) days 
post-stroke.  Data shown as mean ± SEM. * p<0.05 compared with 7 days, ** p<0.01 compared with 1 day. 
 
Despite the fact that cerebral oedema findings were not significantly different between time 
points, there was a moderate positive correlation seen between midline shift and cerebral 
oedema calculations (r=0.49; Figure 7.6 A). However, there was no positive correlation seen 
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between ICP and cerebral oedema (r=0.23; Figure 7.6 B) or ICP and midline shift (r=0.20; 
Figure 7.6 C). n=6/time-point. 
 
 
Figure 7.6. Relationship between ICP, cerebral oedema, midline shift and infarct volume. There was a 
moderate positive correlation seen between cerebral oedema and midline shift (r=0.49). Despite this, there was 
no correlation seen between ICP and cerebral oedema (r=0.23), or ICP and midline shift (r=0.20). Note data 
from all time points was used for comparison between variables.  
 
 
7.3.6 Substance P ELISA 
A reduction in serum SP was observed between 4 and 16 hours following transient MCAo, 
however, changes were not significant (p>0.05; Figure 7.7). At 7 days post-stroke, SP levels 
were significantly elevated compared with 4 (p=0.04), 8 (p=0.008), 12 (p=0.003) and 16 
hours (p=0.002) and 1 day (p=0.04) following occlusion. Despite a qualitative increase, the 
concentration of serum SP at day 7 was not significantly elevated (p>0.05) when compared 
with pre-stroke measurements.  Despite a relative increase in SP seen in the serum post-
stroke, no significant changes (p>0.05) in SP levels in the CSF (Figure 7.7) were observed 







Figure 7.7. Temporal profile of serum and cerebrospinal fluid Substance P (SP) levels following stroke. 
At 7 days post-stroke, SP in the serum was significantly elevated compared with levels seen at 4 hours 
(p<0.05), 8, 12, 16 hours (p<0.01) and 1 day (p<0.05) following stroke.  Furthermore, despite a qualitative 
increase, SP concentration pre-stroke was comparable with day 7. In the CSF, there was no significant 
difference seen in SP levels at days 1, 3 and 6 post-stroke (p>0.05). Data shown as mean ± SEM. * p<0.05 
compared with 4 hours and 1 day; **p<0.01 compared to 8 hours, 12 hours and 16 hours. n=12/time-point 
serum; n=8/time-point CSF. 
 
 
7.3.7 Gender comparisons 
No differences in pCO2, pO2, MABP or pH were seen between sexes during either stroke 
surgery or ICP monitoring (p>0.05; Table 7.2). There was no significant difference in ICP 
between male and female animals at any of the post-stroke time-points (p=0.93; Figure 7.8 
A). Furthermore, there was no significant difference in infarct volume (p=0.79; Figure 7.8 
B), cerebral oedema (p=0.41; Figure 7.8 C) or midline shift (p=0.39; Figure 7.8 D) seen 
between sexes following stroke. SP levels in the serum were not significantly different 
between males and females (p=0.41; Figure 8D). However, there was a significant increase 
in SP seen in the CSF of females when compared with males, pre-stroke (p=0.002), and at 
1 (p<0.0001), 3 (p<0.0001) and 6 (p=0.002) day post-stroke time-points, although there 
were no significant within group differences observed in the females at any time-point pre-




Figure 7.8. Sex differences post middle cerebral artery occlusion. There was no significant difference in 
ICP seen between sexes at any of the post-stroke time points (p>0.05). Furthermore, there was no significant 
difference seen between males and females in infarct volume, cerebral oedema or midline shift (p>0.05). SP 
levels in the serum were not significantly different between sexes (p>0.05) but were significantly elevated in 
the CSF of female animals compared with males at both pre- and post-stroke time points (p<0.01). Data shown 
as mean ±SEM. ***p<0.01, ****p<0.0001 females compared with males. n=3/time-point ICP infarct volume, 








7.3.8.1 Albumin  
There was minimal evidence of albumin extravasation in sham tissue (Figure 7.9 S). 
Following stroke, marked albumin extravasation, indicative of BBB breakdown and 
subsequent vasogenic cerebral oedema formation, was observed both macroscopically 
within the infarcted territory and microscopically in the perivascular tissue of the infarct, 
which was most prominent at 4-, 5- and 6-days post-stroke.  
 
7.3.8.2 Substance P 
Little to no perivascular SP immunoreactivity was observed in sham tissue (Figure 7.10, 
Substance P, S). Following stroke, a marked increase in perivascular SP immunoreactivity 




Low levels of caveolin-1 immunoreactivity were observed in sham tissue (Figure 7.10, 
Caveolin-1, S). Following stroke, an increase in perivascular caveolin-1 immunoreactivity 




Figure 7.9. Albumin immunoreactivity in sham (S) and post-stroke animals at 1 (1), 2 (2), 3 (3), 4 (4), 5 
(5), 6 (6) and 7 days (7) post-stoke.  Enhanced albumin extravasation evolved over time following stroke and 
was most prominent at 4-6 days post transient MCAo. This pattern of albumin staining is consistent with 







Figure 7.10. Substance P (SP) and caveolin-1 immunoreactivity. There was no identifiable 
immunoreactivity of SP or caveolin-1 in sham animals (S). Low levels of SP immunoreactivity were seen 
perivascularly at 1-4 days post stroke. At 5 and 6 days following transient MCAo, there was an increase in SP 
seen in the perivascular tissue of the ischaemic penumbra in the affected hemisphere. This increase in SP was 
concordant with an increase in caveolin-1 immunoreactivity perivascularly, which was most evident at 5-6 
days.  Arrows indicate increased immunoreactivity of SP and cav-1 seen surrounding vessels. Scale bar 100 











7.4 DISCUSSION  
 
This study is the first to describe a surgical approach to ovine tMCAo with reperfusion. 
Through this study we have successfully developed a model that conserves tissue and 
permits post-operative recuperation, allowing for investigation of the pathophysiology of 
ischaemic stroke, in particular post-stroke complications such as BBB disruption, 
development of cerebral edema and elevated ICP. This method of transient stroke induction 
provides a clinically relevant model in which promising novel treatments targeting stroke 
and its complications can be screened. Using this model, we have successfully characterised 
the temporal profile of ICP out to 7 days post-stroke. 
 
Although a number of studies have reported raised ICP following transient stroke in small 
animal models (Beard et al., 2015, Murtha et al., 2015) and large animal species at early 
time-points (Wells et al., 2015) this study is the first in which ICP was recorded out to 7 
days post-stoke in a large gyrencephalic species. We have established that ICP peaks at 5-6 
days following ovine transient MCAo. These findings are comparable with human patients, 
where ICP is shown to peak 3-5 days post-stroke, indicating that our model reliably 
replicates the clinical situation (Battey et al., 2014).  The modest difference in the time 
course between the ovine model and humans may reflect the additional time taken to restore 
intracranial dynamics following surgery due to CSF aspiration required for optimal 
visualisation of the proximal MCA. Indeed, a closed skull approach to MCAo where ICP 
dynamics are maintained through the induction of stroke may yield a timeline of ICP 
changes that directly align with clinical pathogenesis; however, this was not possible due to 
the complex ovine extracranial anastomosis, the rete mirabile, which precludes endovascular 
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access via the ICA for insertion of a balloon catheter, autologous clot or other occlusive 
agent.  
 
Regardless, at 5-6 days post-stroke this study consistently observed elevated ICP readings 
above 20 mmHg. Clinically, ICP readings of ³20 mmHg warrant investigation for possible 
treatment and intervention (Battey et al., 2014, Lavinio and Menon, 2011), as persistently 
elevated ICP is associated with poor outcome following ischaemic stroke, widely accepted 
as being attributable to the development of oedema in the cerebral parenchyma (Ayata and 
Ropper, 2002). Despite this, conflicting studies have reported an elevation of ICP in the 
absence of cerebral oedema following small ischaemic stroke in rats (Beard et al., 2015, 
Murtha et al., 2015). However, the underlying pathophysiology of increased ICP was not 
reported and requires further investigation. Furthermore, in the case of larger hemispheric 
strokes seen clinically, such as that of proximal MCA or ICA occlusion, there is a positive 
correlation between cerebral oedema and elevated ICP (Engelhorn et al., 2002). We did not, 
however, observe such a relationship, which may reflect within group variability and the 
different cohorts that were required to populate the time course. Further, when measuring 
elevated ICP following stroke, the influence of autoregulation must also be taken into 
consideration. The ability to maintain cerebral homeostasis plays an important role in 
moderating the pathogenesis of elevated ICP. A loss of autoregulation has been shown to 
enhance the progression of ischaemia and development of cerebral oedema, and thus plays 
an important role during MCA reperfusion (Dohmen et al., 2007). It is proposed that 
autoregulation may be enhanced early following stroke, and become dampened at 6 days 
post-stroke (Reinhard et al., 2012), in keeping with our observations of significantly elevated 
ICP at 6 days post-stroke. Elevated ICP is associated with a decreased ability to autoregulate 
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following head injury, indicating a strong positive correlation between the two (Reinhard et 
al., 2012). 
 
We observed an evolution of cerebral oedema over time following stroke, although changes 
were not significant between time-points. Nevertheless, as previously stated it is widely 
accepted that the increased volume of the brain as a result of cerebral oedema positively 
correlates with subsequent elevations in ICP (Battey et al., 2014, Brogan and Manno, 2015, 
Beard et al., 2015). The development of vasogenic cerebral oedema in particular occurs 
following loss of integrity of the BBB, permitting the abnormal extravasation of proteins 
across the damaged barrier. This creates an osmotic drive pulling water from the vasculature 
into the extracellular cerebral parenchyma, leading to an overall increase in brain volume 
and concomitant rise in ICP (Battey et al., 2014). Our study was able to confirm that there 
was disruption to BBB via visualisation of GAD within the brain parenchyma, suggesting 
that the cerebral oedema seen was vasogenic in nature. This finding was substantiated by 
the increased extravasation of albumin following tMCAo, which was most prominent at 5-
6 days post-stroke. Albumin is unable to cross the intact barrier under physiological 
conditions due to its large size and structure (Quinlan et al., 2005). Previous studies have 
established that albumin crosses the barrier via the transcellular pathway, facilitated by 
caveolae (Abbott et al., 2006), of which caveolin-1 (cav-1) is an integral component (Nag 
et al., 2007). Indeed, increased barrier permeability in association with caveolin-1 
upregulation has been observed in the absence of tight junction breakdown, confirming the 
integral role of caveolae in maintenance of barrier integrity (Povlishock et al., 1978, Nag et 
al., 2007). Our immunohistochemistry findings of increased cav-1 immunoreactivity at 5-6 
days post-stroke corroborate this, providing a potential mechanism that may be driving 
sustained barrier permeability and evolution of cerebral oedema. Furthermore, the 
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volumetric enlargement of the brain as a result of vasogenic oedema leads to displacement 
of cerebral tissue and subsequent shift of the midline, a critical state in which compression 
of adjacent brain structures precedes potentially fatal tonsillar herniation (Huttner and 
Schwab, 2009). We observed significant midline shift at 5 days following stroke in keeping 
with elevated ICP. Taken together, our findings of enhanced GAD, albumin and cav-1 
immunoreactivity at 5-6 days post-stroke suggest a loss of barrier integrity at this time-point, 
precipitating the development of vasogenic cerebral oedema, extensive midline shift and the 
subsequent rise in ICP. 
 
We also demonstrated that serum SP levels were increased at 7 days following stroke when 
compared with pre-stroke values. This followed a non-significant decline in serum SP at 4 
hours which continued to decline up to 16 hours following injury. This suggests a peak 
increase in the levels of serum SP may occur ahead of the 4 hour-post-stroke sampling time-
point. Indeed, rodent TBI studies reported an early peak in plasma SP levels at 30 minutes 
post-injury but a decline by 5 hours post-injury (Donkin and Vink, 2010) Similarly, SP 
levels were increased in serum samples obtained within 12 hours following the onset of both 
clinical stroke (Bruno et al., 2003, Lorente et al., 2016) and TBI (Lorente et al., 2015), with 
higher levels associated with early mortality. Although some discrepancy between 
experimental and clinical time-points exists, it is important to acknowledge that it is difficult 
to draw firm comparisons given the complications in obtaining clinical samples at acute 
time-points. We also examined SP levels in the CSF following stroke, though observed no 
differences at 1-, 3- or 6-day time-points. Although females consistently had higher CSF SP 
levels compared with males at all post-stroke time-points, there was no significant change 
in these levels post-stroke. This suggests that females have higher baseline levels of SP. 
Indeed, gender differences in the SP response have previously been observed (Pittenger et 
232 
al., 2016, Simões et al., 2018). A comprehensive sampling regimen, including sampling at 
4- and 6-days post-stroke for serum and 4- and 5-days post-stroke for CSF, would be 
required to provide a detailed time-course of changes in SP in the serum and CSF in the 
setting of ischaemic stroke, and may reveal changes beyond those observed in the current 
cohort. Nevertheless, the increase in serum SP levels observed, in conjunction with the 
increased barrier permeability and vasogenic oedema seen with albumin IHC and MRI, 
support a potential role for SP in the genesis of cerebral oedema and development of elevated 
ICP in this model. Indeed, our rodent stroke studies support this (Turner and Vink, 2012, 
Turner and Vink, 2014, Turner et al., 2011, Turner et al., 2006, Corrigan et al., 2016a, 
Corrigan et al., 2012) and corroborates our recent work demonstrating the efficacy of NK1-
R antagonist treatment in reducing ICP in an ovine model of permanent MCAo (Sorby-
Adams et al, 2019b). Taken together, these findings suggest that neurogenic inflammation 
occurs following ischaemic stroke and may contribute to the increased BBB permeability 
and elevated ICP observed, suggesting that blocking the action of SP with a tachykinin NK1-
R antagonist may be an effective strategy to mitigate these post-stroke complications and 
improve outcome. 
 
7.4.1 Limitations and future directions 
Although the findings of this study demonstrate successful model development and clearly 
show the evolution of ICP following stroke, several limitations must be acknowledged. It 
must firstly be recognised that human patients are rarely under anaesthesia when suffering 
a stroke. This is of particular importance due to the implied effects of anaesthesia, both 
protective and deleterious. Ketamine has been shown to have neuroprotective effects 
(Hudetz and Pagel, 2010), whilst isoflurane is associated with respiratory depression, 
decreased MABP and thus diminished oxygen supply to neuronal cells (Murr et al., 1993), 
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exacerbating cerebral ischaemia. These limitations have been discussed in detail in our 
previous studies (Wells et al., 2015, Wells et al., 2012), however due to the nature of the 
surgical procedure, anaesthesia is unavoidable (Lin et al., 1997). The decision to maintain 
animals on a combination of ketamine and isoflurane was made on the basis of prolonged 
duration (4-5 hours) of surgical procedures. The anaesthetic combination produces a 
countering effect, eliminating the neuroprotective effect of pure ketamine and the respiratory 
distress associated with pure isoflurane, thus reducing confounding factors of either 
anaesthetic agent administered alone (Schifilliti et al., 2010).   
 
There was a large within group variability, particularly for the MRI parameters, observed at 
each of the time-points following stroke. This may reflect differences in collateral flow or 
autoregulation capacity within the individual animals. Indeed, there is a considerable degree 
of variation in the severity and timing of cerebral oedema in human patients following 
stroke. Variability may also be attributable to the severity of stroke in addition to the relative 
age of the sheep compared with the greater stroke population. In this study we used sheep 
aged 18-36 months, which are the equivalent to mid-adulthood in humans, whereas clinical 
stroke most commonly occurs in those over 60 years of age. Furthermore, the exclusion of 
experimental animals due to anaesthetic complications or lack of reperfusion decreased the 
total sample size. This could be addressed by increasing the overall sample size for each 
group to increase statistical power. It must also be acknowledged that we used different 
cohorts of animals to generate the stroke ICP data, sham ICP data and serum/CSF for the 
ELISAs. This led to an inability to run true correlations between groups, for example 
between the SP and ICP datasets, limiting the conclusions we can draw regarding the 
potential relationship between serum/CSF SP and ICP. Furthermore, there was some 
discrepancy seen between elevated ICP and oedema at 5-6 days in the first cohort, and 
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elevated serum SP seen at 7 days in the second cohort. Our findings suggest that SP is 
involved in the evolution of oedema, however, given that different cohorts were used in this 
study it was difficult to establish a definitive relationship between the two. As such, the 
differences in the time course of SP elevations and increased ICP are most likely attributable 
to the different cohorts used for each of these outcome measures. 
 
In order to reduce the number of animals required we utilised a historical cohort of sham 
animals that underwent sham surgery immediately followed by ICP monitoring. We 
acknowledge that we would have preferentially used the same regimen as the stroke cohort, 
but it was not possible to generate an additional sham control cohort for this study alone. 
When measuring ICP, values would ideally be obtained from the same animal from 1-7 days 
post stroke to look at the evolution of pressure intrinsic to that animal. This could be 
addressed through the use of a telemetric system to remotely and non-invasively measure 
ICP. As sheep are quadrupeds, however, some questions remain regarding the impact of 
head position, in particular when feeding, on ICP measurements obtained using this method. 
Furthermore, the use of individual cohorts of animals allowed us to harvest the brain at 
specific time-points following stroke and perform IHC accordingly, an important aspect to 
understanding the evolution of the injury.  
 
The reliable measurement of cerebral oedema on MRI at a single time-point is somewhat 
contentious, as the hyperintensity of vasogenic oedema is difficult to distinguish from the 
lesion itself. The measurement of the entire FLAIR lesion volume therefore includes areas 
of infarction as well as oedema and is therefore an indirect measure of oedema volume. A 
more robust approach to measuring oedema would be to undergo sequential MRI’s and 
evaluate the change in diffusion lesion volume between 2 time points following reperfusion, 
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which was not feasible in this study due to cost. Furthermore, although GAD was utilised, 
T1 weighted MRI images were only taken at a single time-point following administration. 
As such, it is difficult to obtain a quantitative measure of GAD extravasation across the 
barrier. A more robust approach to this would be to obtain dynamic contrast enhanced (DCE) 
and dynamic susceptibility contrast (DSC) sequences to obtain quantitative, clinically 
relevant measurements of barrier permeability. Finally, although gender differences were 
examined in this study the hormonal status of the female animals at the time of stroke and 




In this study, we have successfully developed a surgical approach to tMCAo with 
reperfusion in the sheep that permits recovery and the examination of long-term time-points 
following stroke. In this novel model we have determined the temporal profile of ICP, 
showing that ICP peaks at 5-6 days following stroke, in conjunction with midline shift, an 
evolution of cerebral oedema, increased serum SP levels, enhanced SP immunoreactivity 
and increased albumin extravasation.  These results suggest a putative role for SP in BBB 
disruption and the subsequent genesis of cerebral oedema and associated rise in ICP 
following stroke. As such, agents targeting elevated ICP and cerebral oedema would be most 
effective when administered prior to 6 days post-stroke, or as early as possible following 
stroke-onset. We conclude that this ovine model provides a promising platform to screen 
novel treatments targeting post-stroke complications and verify treatment efficacy prior to 





This study was supported by funding from the NHMRC (Project Grant 1082556) and the 
NeuroSurgical Research foundation (Australia). The authors would like to thank Sunthara 
Rajan Perumal for the acquisition of the MRI. We would also like to acknowledge the 
facilities and technical assistance of the National Imaging Facility, a National Collaborative 
Research Infrastructure Strategy (NCRIS) capability, at LARIF, South Australian Health 




































Elevated Intracranial Pressure Following 
Transient Stroke: The NK1 Tachykinin 




Prepared in publication format by SORBY-ADAMS, A. J., MARIAN, O.C., BILECKI., 

















Background and Purpose: Following stroke, substance P (SP)-mediated neurogenic 
inflammation has been linked to profound blood-brain barrier (BBB) disruption, cerebral 
oedema, elevated intracranial pressure (ICP) and poor functional outcome. SP elicits its 
effects by binding the NK1 tachykinin receptor (NK1-R), with administration of an NK1-R 
antagonist ameliorating barrier dysfunction and cerebral oedema following stroke in rodent 
models. Due to a plethora of neuroprotectants developed in rodents failing clinical trials, 
stroke academic and industry guidelines now suggest screening promising novel agents in 
large animal species to improve the likelihood of successful translation. Accordingly, this 
study examined the efficacy of NK1-R antagonist treatment in reducing cerebral oedema 
and ICP in a clinically relevant ovine model of transient middle cerebral artery occlusion 
(MCAo). 
 
Methods: Merino-sheep (12M; 12F; 61±6 kg; 18-36 months) were anaesthetised-and-
subject to 2 hours MCAo with reperfusion. Animals were randomly allocated into one of 
the following regimens, in which 2 boluses of the NK1-R antagonist (1 mg/kg) were given 
5 hours apart: early treatment at 1-3 days post stroke (n=6), delayed treatment at 5 days post 
stroke (n=6) or saline vehicle (n=6). At 6 days post stroke, when elevated ICP is known to 
be established in this model, animals were re-anaesthetised and ICP measured for 3 hrs, 
followed by MRI to evaluate infarct volume (DWI), cerebral oedema (FLAIR) and 
parenchymal water content (T2), and also to confirm vascular reperfusion (MRA). Following 
MRI, anaesthetised animals were euthanased, and brains removed for immunohistochemical 
analysis of albumin, caveolin-1 and claudin-5. An additional cohort of animals (n=6) 
underwent MCAo and late treatment administration only, following which whole blood 
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samples were obtained at four-hourly intervals for the assessment of NK1-R antagonist 
pharmacokinetics. 
 
Results: ICP was significantly decreased following both early and delayed administration of 
the NK1-R antagonist compared with vehicles (p<0.05). Profound cerebral oedema was 
observed in vehicle treated animals at 6 days, in keeping with the elevated ICP. Cerebral 
oedema and midline shift were significantly reduced following both NK1-R treatment 
regimens (p<0.05). Marked perivascular caveolin-1 and albumin reactivity was observed in 
vehicle animals, with a decrease in reactivity seen following both early and late treatment. 
Pharmacodynamic assessment of the NK1-R was variable for Cmax and 50% Cmax. The Tmax, 
however, was comparable for all animals, with a maximum peak at 8 hours, and a t1/2 of 11 
hours post-administration.  
 
Conclusion: This study demonstrates that NK1-R antagonist treatment is an efficacious 
novel therapy for cerebral oedema and elevated ICP following stroke in an ovine model. 
Specifically, treatment is able to both prevent increases in ICP when administered early (1-
3d) post-stroke, and also reduce established ICP when administered in a delayed (5d) 
fashion. This provides compelling evidence for future clinical evaluation of NK1-R 










Cerebral oedema and concomitant rise in intracranial pressure (ICP) account for a mortality 
rate of up to 80% in the first week following middle cerebral artery (MCA) stroke (Hacke 
et al., 1996). Surmounting oedema typically peaks within 3 to 5 days post-ictus, with the 
deleterious effect of space-occupying swelling leading to secondary neurological 
deterioration and irreversible brain tissue damage (Thorén et al., 2017, Jüttler et al., 2007). 
Conservative pharmacological management, such as osmotherapeutics, aim to reduce 
oedema via rheological mechanisms (Brogan and Manno, 2015). In the setting of blood-
brain barrier (BBB) breakdown, however, therapy is largely ineffective and may be 
associated with rebound oedema, necessitating surgical intervention via decompressive 
hemicraniectomy (DC) (Jüttler et al., 2007, Mori et al., 2001). Whilst early DC (within 48 
hours of stroke onset) improves survival, it is associated with increased risk of transcalvarial 
herniation, haematoma, and morbidity in the elderly (Gopalakrishnan et al., 2018). Ergo, 
determining an optimal treatment solution for post-stroke cerebral oedema represents an 
urgent unmet need in the field of neurointensive medicine.  
 
Identification of molecular pathways underlying the pathogenesis of cerebral oedema is 
essential in developing novel therapeutics which halt or prevent oedema progression. 
Attenuating neurogenic inflammation has been identified as one such strategy to combat 
cerebral oedema and elevated ICP post-stroke (Turner et al., 2011b, Turner and Vink, 2012, 
Sorby-Adams et al., 2017, Sorby-Adams et al., 2019b, Turner and Vink, 2007). In the setting 
of cerebral ischaemia, neurogenic inflammation occurs via noxious stimulation of sensory 
c-fibers present in high densities around cerebral blood vessels, leading to the aberrant 
release of neuropeptide substance P (SP) (Harrison and Geppetti, 2001, Hokfelt et al., 2000). 
Pre-clinical studies have shown that elevated perivascular SP is associated with increased 
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BBB breakdown, cerebral oedema, elevated ICP, and poor functional outcome following 
stroke in experimental models (Sorby-Adams et al., 2019a, Turner et al., 2006, Turner et al., 
2011a). SP preferentially binds the neurokinin 1 tachykinin receptor (NK1-R), a G-protein 
coupled receptor expressed along endothelial cells of the BBB (Johnson et al., 2017). NK1 
receptors are particularly abundant within endothelial caveolae, which facilitate paracellular 
transport across the barrier. Following stroke, it is proposed that binding of SP to the NK1-
R compromises BBB integrity by increasing transport of osmotically active molecules such 
as albumin across the barrier (Vink and van den Heuvel, 2010). This drives an abnormal 
accumulation of water in the cerebral parenchyma and consequent rise in ICP. 
Administration of a NK1-R antagonist has subsequently been shown to reduce BBB 
permeability, cerebral oedema and functional deficits following stroke in rodent models 
(Turner et al., 2011a, Turner and Vink, 2014, Turner and Vink, 2012, Corrigan et al., 2016), 
further supporting the role of neurogenic inflammation in the pathogenesis of secondary 
injury post-stroke. 
 
Unfortunately, however, numerous novel stroke therapeutic agents developed in rodents 
have failed to demonstrate efficacy in clinical trials, calling for more rigorous pre-clinical 
screening in accordance with the Stroke Therapy Academic and Industry Roundtable 
(STAIR) guidelines (O'Collins et al., 2006, (STAIR), 1999). For promising therapeutics 
such as the NK1-R antagonist, it is suggested that, prior to clinical evaluation, screening in 
a large animal species is performed to increase the likelihood of successful clinical 
translation (Fisher et al., 2009). Furthermore, advances in the acute management of stroke 
have highlighted the need for more ‘reperfusion-centric’ pre-clinical stroke research (Kuan 
and Sun, 2015). This is particularly relevant given the extended window for vascular 
recanalisation interventions (Broderick and Hill, 2021). Indeed, the tissue plasminogen 
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activator (tPA) thrombolysis window has expanded in selected patients well beyond 4.5h, 
and endovascular clot retrieval has shown efficacious outcomes up to 24h post-stroke in 
patients selected by multimodal imaging, for example perfusion-core mismatch detected on 
either CT perfusion or MRI (Nogueira et al., 2018, Ma et al., 2019, Albers et al., 2017, 
Thomalla et al., 2020). This has been game-changing for stroke management, with more 
patients than ever receiving reperfusion intervention. Restoration of blood flow and re-
oxygenation of ischaemic tissue can, however, exacerbate tissue injury and trigger 
deleterious complications including exacerbation of haemorrhagic transformation, flow-no 
reflow phenomena and post-stroke cerebral oedema (Eltzschig and Eckle, 2011, Kloner et 
al., 2018). Re-initiation of blood flow can also cause ischaemia/reperfusion (I/R) injury and 
consequent accumulation of reactive oxygen species (ROS), inflammation, apoptosis, and 
increased permeability of the BBB, thereby exacerbating development of oedema. Clinically 
relevant, large animal models encompassing both permanent and transient occlusion are thus 
required to appropriately replicate the clinical scenario, establish the development of 
oedema, and provide a window for therapeutic intervention with anti-oedema agents.  
 
We have previously determined the course of cerebral oedema and elevated ICP following 
both permanent (Wells et al., 2015) and transient stroke in a clinically-relevant ovine model 
(Sorby-Adams et al., 2019a). Specifically, following permanent MCA occlusion, significant 
cerebral oedema and elevated ICP was observed within 24 hours of stroke onset, whereas 
following 2-hour MCAo occlusion with reperfusion, ICP was shown to be significantly 
elevated at 5- and 6-days post-ictus, accompanied by profound midline shift. To determine 
the efficacy of NK1-R antagonism we subsequently assessed NK1-R treatment following 
permanent MCAo, showing that treatment administration produced reductions in ICP 
comparable to DC (Sorby-Adams et al., 2019b). However, whether NK1-R antagonist 
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treatment is also effective in stroke with a component of reperfusion has not yet been 
assessed. As such, this study sought to evaluate the efficacy of NK1-R antagonism following 
transient MCA occlusion in an ovine stroke model. Given the delayed nature of cerebral 
oedema and ICP development, two different treatment regimens were assessed to determine 
if the NK1-R antagonist could produce a clinically meaningful reduction in cerebral oedema 
and ICP when administered either early (before elevated ICP was established) or late (when 
ICP was already elevated), post-stroke. Furthermore, we also sought to assess the 
pharmacokinetics of the NK1-R following late administration, and to assess whether any 
differences in response to treatment between genders were apparent. 
 
8.2 MATERIALS AND METHODS 
 
8.2.1 Ethics Statement 
This study was approved by the South Australian Health and Medical Research Institute 
(SAHMRI) Animal Ethics Committee (SAM 141, SAM 3). All experiments were conducted 
in accordance with the Australian National Health and Medical Research Council code of 
care and use of animals for scientific purposes (8th Edition, 2013). 
 
8.2.2 Experimental Design 
Twenty-four merino sheep (Ovis aries) were used in this study (12M;12F; 61±6 kg; 18-36 
months old).  Animals were sourced from a single farm in Gum Greek, South Australia, and 
transported to the SAHMRI Preclinical Imaging Research Laboratories (PIRL), where they 
were acclimated for 2 weeks in conventional outdoor paddocks prior to experimental 
procedures. Animals were pre-operatively randomised to one of the following treatment 
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regimens: early NK1-R treatment at 1-3 days post stroke (n=6), delayed NK1-R treatment 
at 5 days post stroke (n=6), or saline vehicle (n=6). The experimental timeline was as 
follows: induction of stroke on day 0; early (1-3 days) or late (5 days) NK1-R treatment; 
ICP monitoring (6 days). An additional cohort of animals (n=3M;3F, 18-36 months) 
underwent delayed treatment following which repeat collection of whole blood was 
performed at 4 hourly intervals for pharmacokinetic assessment of the NK1-R antagonist 
compound. 
 
8.2.3 Surgical Approach 
8.2.3.1 Preoperative Preparation 
Animals were fasted for 12 hours preoperatively to reduce intraoperative regurgitation. 
Anaesthesia was induced via intramuscular administration of ketamine (0.05 mL/kg, 100 
mg/kg Injection, CEVA, Australia) and diazepam (0.08 mL/kg, 5 mg/mL Injection, Pamlin, 
CEVA, Australia). Animals were intubated, and a jugular catheter (18 g, Terumo 
SURFLO®) inserted for delivery of intraoperative (1000 mL Hartmann’s solution, Baxter 
Health, Australia) and post-operative (as required) crystalloid fluids. Animals were moved 
to a surgical theatre and placed on their left side on an operating table. Anaesthesia was 
maintained throughout surgery with inhalational isoflurane (1.5-2.0 % minimum alveolar 
concentration (MAC); mixed in 3 L of air and 500 mL of oxygen; Henry Schein, Australia) 
and continuous ketamine infusion via jugular line (4 mg/kg/hr). An arterial catheter (20 g, 
Terumo SURFLO®) was placed in the distal hindlimb to yield arterial blood gas samples. 
The catheter was regularly flushed (2 mL) via a 500 mL bag of sodium chloride (Baxter 
Health, Australia) attached to a pressurised bag pump (maintained at 300 mmHg). A 
paediatric blood pressure cuff (Easy Care Cuff, Phillips) was placed on the proximal 
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forelimb for a non-invasive measure of ABP which was manually recorded at 5-minute 
intervals.  
 
8.2.3.2 Intraoperative Procedures 
MCA occlusion with reperfusion surgery was performed as previously described in detail 
(Sorby-Adams et al., 2019a). Briefly, a pterional craniotomy was performed, dura incised, 
MCA visualised, and an aneurysm clip (Aesculap YASARGIL® Aneurysm Clip, Germany) 
applied to the proximal MCA and left in situ for 2 hours, after which it was removed to 
allow reperfusion. The dura was subsequently closed watertight with a synthetic dural 
regeneration matrix (Durepair®, Medtronic, USA) and superglue (Bostik, Australia), and a 
cranioplasty performed using autologous bone and dental cement (Sledgehammer, 
Keystone, Germany) to restore intracranial dynamics. The muscle was reopposed using a 
horizontal mattress suture technique, and the incision site treated with 1.0 mL 0.5% 
subcutaneous local anaesthetic Marcain (Bupivacaine hydrochloride 5 mg/mL, 
AstraZeneca, Australia). Hourly arterial blood samples were obtained and analysed 
(Machine AVL Scientific Corporation USA, Manufactured by Hersteller, OPTI Critical 
Care Analyzer–Model OPTI3, Serial No. OP3-2759) to ensure sodium, potassium, 
haematocrit, haemoglobin, bicarbonate, carbon dioxide and oxygen levels were maintained 
within normal physiological limits.  
 
8.2.3.3 Postoperative Recovery 
Animals were removed from anaesthesia, extubated and transported to a post-operative 
recovery pen. Once lucid, subcutaneous non-steroidal anti-inflammatory (NSAID; 0.7 
mg/kg, 50 mg/mL every 12 hours, Carprofen, Norbrook, Australia) and intramuscular 
Buprenorphine (Temgesic, 1.0 mL, 300 ug/ml Buprenorphine hydrochloride, Reckin 
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Benckiser, Australia) were administered for pain relief, and intramuscular Depocillin for 
antibiotic cover (1 mL/25 kg every 12 hrs Procaine benzylpenicillin, Intervet, Australia). 
NSAID and antibiotic treatment was continued for 3 days post-operatively, and as required 
thereafter. All animals were assessed twice daily for clinical signs of stroke, in addition to 
general wellbeing, including urine and faecal output, food and water intake, and signs of 
apathy. Animals remained in indoor housing for the duration of the experiment and 
monitored remotely via closed-circuit television for 24-hour assessment. 
 
8.2.4 NK1-R Administration 
The dose of NK1-R antagonist was chosen based on previous studies following ovine 
permanent MCAo, where NK1-R antagonist treatment was initiated at 4 hours following 
stroke, with a subsequent bolus administered 5 hours later (Sorby-Adams et al., 2019). 
Animals herein were treated with 2 boluses, 5 hours apart, of 1 mg/kg NK1-R-antagonist as 
follows: early treatment on days 1, 2 and 3 post-stroke (n=6), delayed treatment at 5 days 
post-stroke (n=6) or saline vehicle (n=6). The NK1-R antagonist, supplied by 
PresSuraNeuro (EU-C-001, Hoffmann et al., 2005, Australian Patent AU2002328837B2 
(under embargo), May 5, 2005), was warmed to ±37 °C and administered as slow bolus via 
jugular catheter (18 g, Terumo SURFLO®). Vehicle animals received an equal volume (1 
mL/kg) of saline (Baxter Health, Australia), also via jugular catheter.  
 
8.2.5 Intracranial Pressure Monitoring 
All animals underwent ICP monitoring at 6 days following stroke. Animals were re-
anaesthetised with ketamine (0.05 mL/kg, 100 mg/kg Injection, CEVA, Australia) and 
diazepam (0.08 mL/kg, 5mg/ml Injection, Pamlin, CEVA, Australia), and maintained with 
isoflurane (1.5-1.75% MAC, Henry Shein, Australia). Animals were placed in the sphinx 
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position on the operating table, and bilateral burr holes (5 mm) drilled using a Codman® 
Cranial Hand Drill (Codman & Shurtleff Inc., Massachusetts), approximately 1 cm lateral 
to the sagittal suture and 1 cm posterior to the horn buds. The underlying dura was incised, 
and plastic bolts from a Codman Microsensor™ Skull Bolt Kit for Intraparenchymal 
Procedures (Codman & Shurtleff Inc., Massachusetts) secured into the burr holes. Codman 
Microsensor™ transducers attached to a bridge amplifier and PowerLab data acquisition 
device (ADInstruments, Australia) were used to measure ICP. Transducers underwent two-
point calibration checks to ensure accuracy (0 mmHg and 100 mmHg), following which 
they were advanced through skull bolts approximately 15 mm into the cerebral parenchyma. 
ICP was recorded for a duration of 3 hrs. Transducers were subsequently removed, and two-
point checks re-performed to determine drift, if any. Physiological variables were recorded 
hourly throughout the monitoring period as previously described (section 8.2.3.2). Given 
that CO2 is a potent cerebral vasodilator, efforts were made to maintain pCO2 within 
physiological limits (36-44 mmHg), and also to prevent metabolic acidosis (pH <7.41) to 
reduce any predisposition to respiratory acidosis and thus potential elevation of CO2. 
 
8.2.6 Magnetic Resonance Imaging 
8.2.6.1 Image Acquisition 
Following ICP recording, animals were transported to a 1.5 T Siemens Syngo2004A 
(Siemens AG, Munich, Germany) MRI scanner for neuroimaging. Anaesthesia was 
maintained  via inhalational isoflurane (3% MAC) and the following sequences acquired: 
time-of-flight magnetic resonance angiography (TOF MRA; TR 26 ms, TE 3.69 ms, slice 
thickness 0.50 mm), diffusion weighted imaging (DWI; TR 5600 ms, TE 80 ms, slice 
thickness 3.0 mm), fluid attenuated inversion recovery (FLAIR; TR 5000 ms, TE 386 ms, 
slice thickness 0.9 mm), T1 weighted imaging (TR 2300 ms, TE 2.58ms, slice thickness 0.9 
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mm) and T2 weighted imaging (TR 3200 ms, TE 410 ms, slice thickness 0.9 mm). T1 
weighted post-contrast images were also acquired following intravenous administration of 
1 mL/kg gadolinium-diethylene-triamine-pentaacetic acid (Gadolinium) (Magnevist, Bayer 
HealthCare, Germany) to determine the extent of BBB breakdown on MRI.  
 
8.2.6.2 Image Analysis  
Infarct volume and cerebral oedema were calculated using segmentation tools in ITK-SNAP 
(v 3.7), as previously described (Sorby-Adams et al., 2019a, Yushkevich et al., 2006). DWI 
sequences were used to perform semi-automated three-dimensional (3D) quantification of 
the lesion. To determine cerebral oedema, 3D quantification of hyperintensities were 
calculated using FLAIR sequences. As MRI was only acquired at a single time point, DWI 
volumes were subtracted from FLAIR to provide a measure of peri-infarct oedema. Midline 
shift was used as a surrogate marker of cerebral oedema and was assessed using axial T2 
weighted scans and measured as the distance in mm from the septum pellucidum at the level 
of the foramen of Monro (HOROS DICOM image viewer v3.1.1).  
 
To determine parenchymal water content, quantification of the relaxation signal was 
performed on axial T2 scans at the level of the foramen of Monro. Here, eight regions of 
interest (ROI’s) measuring 10 mm2 were drawn in the ipsilateral and contralateral 
hemispheres. The mean signal intensity for each ROI was summed, and the average intensity 
for all ROI’s reported for each hemisphere. Signal intensity ratios were then calculated by 
normalising the signal intensity within the stroke hemisphere to the signal intensity of the 
contralateral hemisphere. The normalised values in the stroke affected hemisphere were then 
exported for final interpretation. 
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8.2.7 Immunohistochemistry  
Following MRI, animals were humanely euthanased via common carotid artery perfusion 
fixation with cold TRIS-buffered saline and bilateral jugular exsanguination under 
isoflurane anaesthesia (3%) following administration of intravenous heparin (5000 
I.U./5mL; Pfizer, New York). The brains were removed and sliced into 10 mm coronal 
sections, following which they were immersion fixed in 10% neutral-buffered formalin for 
a minimum of 14 days prior to being processed, embedded in paraffin wax and sectioned 
coronally at 5-micron intervals. Histological examination was performed via albumin 
(1:2000, Dako Pty Ltd; A0001), caveolin-1 (cav-1; 1:1000 EDTA retrieval, Cell Signalling 
Technologies Pty Ltd; 3238) and claudin-5 (1:500 EDTA retrieval, Invitrogen Pty Ltd; 35-
2500) immunohistochemistry (IHC) to examine vasogenic oedema, transcellular BBB 
permeability and paracellular BBB permeability respectively.  
 
8.2.8 Pharmacokinetics 
A separate cohort of animals underwent blood collection for pharmacokinetic (PK) 
measurement of the NK1-R antagonist EU-C-001 (n=6, 3M, 3F). All animals underwent 
stroke surgery as described (section 8.2.3.2) and were administered 2 × doses of the NK1-R 
antagonist at the late time point, 5 days following stroke onset. Blood samples were collected 
5 minutes prior to treatment administration, and at 4, 8, 12, 16, 24 and 28 hours thereafter. 
Whole blood was collected in K2EDTA tubes (BD Vacutainer® K2EDTA tubes), with 12 
mL of blood collected per animal, per time point (total 84 mL collected over the 28-hour 
sampling period). Tubes were gently inverted 180° to ensure mixing of anticoagulant to 
avoid microclotting. Samples were then placed in an ice bath for 20 minutes and centrifuged 
at 1500 RCF for 10 min at 18-25 °C. Plasma was aliquoted into 2 mL LoBind polypropylene 
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tubes (PCR clean, Eppendorf™, Australia) and samples flash frozen by liquid nitrogen 
immersion and transferred to a -80 °C freezer. 
 
EU-C-001 and its desmethyl metabolite were subsequently extracted from plasma samples 
via protein precipitation extraction. Analytes were separated using high-performance liquid 
chromatography on an ACE C18-AR column, and the eluates monitored by an API4000™ 
liquid chromatography mass spectroscopy (SCIEX) in positive multiple reaction monitoring 
mode. The extracts were then assayed against a calibration cure, data analysed via Analyst® 
software (SCIEX) and processed in Watson LIMS™ (Thermo Scientific). The lowest limit 
of quantification (LLOQ) of the EU-C-001 compound was calculated as 0.200 ng/mL. 
 
8.2.9 Statistical Analysis 
Data are expressed as mean ± SD. Data was tested for normality using the Shapiro-Wilk 
normality test, or by assessing Q-Q plots of residuals. Physiological data (arterial blood 
pressure, pH, pO2, pCO2) were analysed using one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc tests (Prism v.8.0.1, GraphPad, CA). Values were averaged 
for each treatment group during surgery and ICP monitoring and reported as a single value. 
ICP measurements underwent logarithmic exponential transformation as previously 
described (Wells et al., 2015, Matthews et al., 1990). Values were reported at hourly 
intervals for 3 hours and expressed as geometric mean ± SD and analysed by two-way 
ANOVA. Cerebral perfusion pressure (CPP) was calculated by subtracting hourly ICP 
measurements from mean arterial blood pressure (MABP). MRI parameters (lesion volume, 
cerebral oedema, midline shift and T2 prolongation) were analysed by one-way ANOVA, all 
followed by Tukey’s post-hoc tests. To determine the effect of gender on all outcome 
measures, two-way ANOVA’s with Sidak’s post-hoc tests were performed. Correlations 
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were also run between cerebral oedema and infarct volume; cerebral oedema and midline 
shift; oedema and T2  prolongation; ICP and cerebral oedema; to determine if a relationship 




8.3.1 Surgery, Mortality and Postoperative Course 
There was no premature mortality observed throughout the experimental course, with all 
animals surviving to terminal experimental endpoints. Reperfusion was achieved in all 
animals, as confirmed by MRA (data not shown). Animals were observed for behavioural 
and neurological deficits following stroke surgery. Evidence of subdued demeanour was 
reported, although this was observed irrespective of treatment group (data not shown). The 
most common deficit observed was reduced food and water intake (n=6), which was most 
apparent at 5 (n=6) and 6 days (n=6) post-stroke. Other deficits included lowering of the 
head and drooping of the ears (n=2) and teeth grinding (n=3) on day 1 post-stroke. A subset 
of animals also displayed motor deficit, identified as a weakness in the contralateral fetlock 
joint following stroke, which was most prevalent at 1-3 days following stroke (n=3).  
 
8.3.2 Physiological Parameters 
Physiological parameters for pCO2 (F 2, 15 =2.745, p=0.096), pO2 (F 2, 15 =3.053, p=0.077), 
pH (F 2, 15 =1.612, p=0.232) and MABP (F 2, 15 =1.926, p=0.180) were comparable between 
all groups throughout transient MCAo surgery (p>0.05), irrespective of gender (p>0.05). 
During ICP monitoring, pH (F 2, 15 =1.985, p=0.172) and pO2 (F 2, 15 =0.1043, p=0.902) 
levels were normal between groups and comparable between genders (p>0.05). However, 
blood pressure in vehicle animals was significantly higher compared with the late treatment 
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group (F 2, 15 =10.36, p=0.002), although no differences were observed between male and 
female animals (p>0.05). PCO2 was also higher in vehicle animals compared with early (F 
2, 15 =18.86, p=0.0016) and late (F 2, 15 =18.86, p<0.0001) treatment groups, but no effects 
of gender were observed (p>0.05). A summary of all physiological variables obtained during 
surgery and ICP monitoring is provided in Table 8.1. 
  
Table 8.1 Physiological variables (Data expressed as mean +/- SD) 
  pCO2 (mmHg)  
  Surgery Day ICP Monitoring 
  Males Females All animals Males Females All animals 
Vehicle 45±4 41±3 43±4 44±3 42±3 43±3 
Early NK1 39±5 41±1 40±3 38±1 38±1 38±1 




MABP (mmHg)  
  Surgery Day ICP Monitoring 
  Males Females All animals Males Females All animals 
Vehicle 79±16 91±5 85±12 123±5 108±9 116±10 
Early NK1 87±17 82±8 84±12 107±7 96±12 101±11 
Late NK1 75±10 73±5 74±7 92±3 93±6 93±4 
  
  
pO2 (mmHg)  
 Surgery Day ICP Monitoring 
 Males Females All animals Males Females All animals 
Vehicle 333±188 218±132 275±158 320±213 423±100 371±159 
Early NK1 288±148 255±73 241±105 250±97 440±66 345±128 




 Surgery Day ICP Monitoring 
 Males Females All animals Males Females All animals 
Vehicle 7.39±0.05 7.45±0.02 7.42±0.05 7.40±0.03 7.44±0.06 7.42±0.05 
Early NK1 7.47±0.05 7.44±0.04 7.46±0.04 7.48±0.01 7.44±0.12 7.46±0.08 
Late NK1 7.45±0.01 7.44±0.03 7.45±0.02 7.47±0.06 7.52±0.05 7.49±0.05 
 
8.3.3 Intracranial Pressure 
At 6 days post-stroke, a sustained elevation in ICP was seen in vehicle animals (Figure 
8.1A). During the first hour of monitoring, ICP was 17.73 ± 6.70 mmHg, levels significantly 
higher than those recorded in sham animals (9 ± 3 mmHg) in our previous studies (Sorby-
Adams et al 2019). Elevated ICP in vehicle animals was sustained throughout the second 
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(20.06 ± 5.41 mmHg) and final hour (24.51 ± 5.45 mmHg) of ICP recording. In comparison, 
early NK1-R antagonist treatment (1-3 days post-stroke) brought about a significant 
reduction in ICP compared with vehicles (F 2, 44 =28.06). This was evident during the second 
(ICP 11.50 ± 3.93 mmHg, p=0.022), and third (ICP 13.06 ± 3.34, p=0.0002) hour of ICP 
monitoring. Late NK1-R antagonist treatment also reduced ICP, sustaining a reduction 
throughout the first (9.21 ± 4.09 mmHg, p=0.006), second (9.63 ± 4.11 mmHg, p=0.0005), 
and final hour (11.43 ± 1.97 mmHg, p<0.0001) of ICP recording. There were no differences 
(p>0.05) in treatment efficacy between the early and late NK1-R treatment regimens. 
Despite differences in ICP response between vehicle and treatment animals, no differences 
in CPP were seen across any of the treatment groups (F 2, 44=0.930, p>0.05, CPP 84.76 
±16.41 mmHg, Figure 8.1B). Furthermore, the observed differences in ICP and CPP were 
seen irrespective of gender, with comparable CPP and ICP recordings seen in both male and 
female animals, and across all treatment groups (p>0.05, data not shown). 
 
Figure 8.1. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP).  (A) At 6 days post-stoke, 
ICP was elevated in vehicle animals. Early NK1 treatment administered from 1-3 days following stroke 
brought about a reduction in ICP compared with vehicle, which was evident in the second (p<0.05) and third 
(p<0.001) hour of ICP recording. Delayed treatment at 5 days also brought about a significant reduction in 
ICP, which was evident throughout the first (p<0.01), second (p<0.001) and third (p<0.0001) monitoring hour. 
(B) No difference in CPP was observed between treatment groups at any time-point (p>0.05). Data presented 
as mean ± SD. *=p<0.05, **=p <0.01, *** =p<0.001 and ****=p<0.0001 compared to vehicle. 
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8.3.4 MRI 
Infarct volume, calculated on DWI MRI, was comparable in both vehicle and NK1-treated 
animals (F 2, 15 =3.207, p>0.05; Figure 8.2A). Cerebral oedema, assessed on FLAIR, was 
reduced following both early (F 2, 15 =3.207, p=0.040) and late (F 2, 15 =3.207, p=0.049) NK1-
R antagonist administration when compared with vehicles (Figure 8.2B). This was 
accompanied by a significant reduction in T2 midline shift in both early (F 2, 15 =12.99, 
p=0.001, 1.03 ± 0.49 mm) and late (F 2, 15 =12.99, p=0.001, 1.12 ± 0.64 mm) treatment 
animals compared with vehicles (3.07 ± 1.08 mm; Figure 8.2C). Despite a reduction in 
oedema and midline shift, the amount of water in the ipsilateral hemisphere, as measured by 
T2 prolongation, was only reduced following late (F 2, 15 =3.68, p=0.043), but not early NK1-
R antagonist F 2, 15 =3.68, p=0.228) treatment (Figure 8.2D). Nevertheless, there was a 
qualitative increase in gadolinium extravasation across the BBB seen in vehicle animals 
compared with both the early and late NK1-R treatment groups (Figure 8.5). No gender 
differences were observed with respect to infarct volume, oedema or T2 prolongation 
(p>0.05). However, there was a significant difference in midline shift within the vehicle 
group, with male animals having a greater shift from the midline compared with females 
(p=0.039, data not shown). Gender differences in midline shift were not observed in either 




Figure 8.2. Infarct volume, cerebral oedema, midline shift and T2 prolongation on MRI. (A) No 
differences (p>0.05) in infarct volume between vehicle and NK1-R antagonist groups were observed. (B) 
Cerebral oedema was reduced following both early (p<0.05) and late (p<0.05) NK1-R antagonist treatment, 
(C) accompanied by a reduction in midline shift seen in early (p<0.01) and late (p<0.01) treatment groups 
respectively. (D) Despite a reduction in oedema volume, water content in the stroke effected hemisphere was 
only reduced in late treatment animals (p<0.05) compared with vehicle. Data presented as mean ± SD. 
*=p<0.05, **=p <0.01, compared to vehicle. 
 
In determining the relationship between outcome measures assessed, there was a poor 
correlation seen between infarct volume and oedema (r=0.046; Figure 8.3A). The 
relationship between oedema and midline shift, however, was strong (r=0.658; Figure 8.3B), 
and there was a moderate relationship between oedema and T2 prolongation (r=0.548; Figure 
8.3C). Despite observed relationships between MRI parameters, there was a poor 
relationship seen between ICP and oedema volume (r=0.310; Figure 8.3D). 
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Figure 8.3. Correlations between outcome measures. (A) There was no relationship observed between 
infarct volume and oedema. (B) A positive relationship was seen between oedema and midline shift, and (C) 






Figure 8.4. MRI findings following stroke. (A, D, G) Coronal DWI images indicate the lesion area which 
was comparable across all groups. (B, E, H) FLAIR images show a visible and significant reduction in cerebral 
oedema following both early (E) and late (H) NK1-R antagonist administration compared with vehicles (B). 











Figure 8.5. Pre and post gadolinium T1 images. (A, C, E) T1 images were comparable between treatment 
groups prior to gadolinium administration. (B, D, F) Following gadolinium administration, a bright rim was 
evident along the stroke affected hemisphere in territory of the MCA.  Gadolinium extravasation into the 
parenchymal tissue was evident in vehicle treated animals (B), however there was less leakage evident in both 





In sham animals, minimal albumin reactivity was observed, with weak staining localised to 
the vascular lumen (Figure 8.6, Albumin, Sham). Following stroke in vehicle animals, 
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marked albumin reactivity was observed. This was seen in the parenchyma, although it was 
significantly enhanced in the perivascular space. In both early and late NK1-R antagonist 




Caveolin-1 immunoreactivity was not detected in sham tissue (Figure 8.6, Caveolin-1, 
Sham). Following stroke, an increase in perivascular caveolin-1 immunoreactivity was 
observed in vehicle animals. In both early and late NK1 treatment animals, however, there 
was decreased reactivity within the perivascular tissue. Furthermore, there appeared to be 




Endothelial tight junction protein claudin-5 was identified in sham animals, circumscribing 
vessels within the brain parenchyma (Figure 8.6, Claudin-5, Sham). Following stroke, a loss 
of claudin-5 immunoreactivity was observed, which was consistent across vehicle and NK1-








Figure 8.6. Immunohistochemical findings of caveolin-1, claudin-5 and albumin.  Vehicle animals showed 
marked caveolin 1 and albumin reactivity. Following both early and late NK1-R treatment regimens, reactivity 
of caveolin-1 and albumin was reduced, comparable to sham. Claudin-5 reactivity was observed in sham 




The level of EU-C-001 in the plasma was below the limit of quantification (BLQ) prior to 
treatment administration (Figure 8.5, A). The maximum concentration (Cmax; Figure 8.5C) 
and 50% Cmax (Figure 8.5D) calculated across time points was highly variable between 
animals; however, the timing of the maximum (Tmax; Figure 8.5E) was consistent, with 
highest peak seen at 8 hours following administration. The half-life (t1/2) was less variable 
with an approximate average of 11 hours (Figure 8.5F). Furthermore, a constant decrease in 
plasma concentration was observed following the Tmax at 8 hours, with a relative return to 
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baseline between 20 and 28 hours (Figure 8.5A). Male and female animals had comparable 



















Figure 8.7. Plasma concentration of EU-C-001 following late treatment administration.  (A) plasma 
concentration over time, (B) difference in male and female plasma concentration, (C) maximum concentration, 
(D) 50% of the maximum concentration, (E) half-life and (F) time to maximum concentration for each of the 






This study demonstrates the efficacy of NK1-R antagonist administration to reduce cerebral 
oedema and ICP following stroke with reperfusion in a clinically relevant large animal 
model. A significant and sustained reduction in ICP at 6 days post-stroke was observed 
following treatment, accompanied by a decrease in cerebral oedema and midline shift. More 
specifically, NK1-R antagonist administered either early (1-3d) post-stroke, before the onset 
cerebral oedema and elevated ICP, or in a delayed fashion (5d) post-ictus, when significant 
cerebral oedema and elevated ICP are established, were both shown to be effective in 
substantially reducing pressure. 
 
In the neurointensive care unit, ICP in excess of 20 mmHg is classified as ‘high’ and is 
considered the threshold for intervention (Robba and Citerio, 2019). In vehicle animals, this 
study observed intracranial hypertension in excess of 24 mmHg. As per clinical guidelines, 
the current stepwise approach to treatment first seeks to minimise pressure conservatively, 
with therapy intensity modulated in accordance with the ICP response (Robba and Citerio, 
2019). Conservative strategies to reduce ICP, however, almost consistently fail (Jüttler et 
al., 2007). This is largely due to their predominant mechanism of action, with intervention 
aimed at alleviating symptoms, rather than targeting the underlying cause of oedema 
genesis. When BBB integrity is compromised, as is established in this model and frequently 
reported in the clinical literature, pharmacological management with osmotherapeutic 
agents can paradoxically worsen injury, aggravating pressure differentials and causing 
devastating shifts of brain tissue (Schwarz et al., 1998, Chen et al., 2019, Jüttler et al., 2007, 
Manno et al., 1999). Decompressive surgery is thus often necessitated, albeit with numerous 
contraindications, inherent risk of post-operative complications, and maximal efficacy only 
achieved within 48 hours of stroke onset. Clinical management of ICP must also not be at 
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the expense of CPP. If pressure autoregulation is preserved, higher CPP (70 mmHg) is 
tolerated and may reduce ICP whilst maintaining cerebral blood flow to ischaemic tissue. If 
pressure autoregulation is not preserved, however, elevated CPP increases cerebral blood 
volume, resulting in an adverse rise in ICP (Robba and Citerio, 2019). 
 
The reduction in ICP observed in this study thus addresses several limitations to current 
approaches to ICP management. Firstly, NK1-R antagonist administration produced a 
significant and sustained reduction in ICP following early treatment administration at 1-3 
days. Although treatment ceased at 3 days, reduction in ICP and oedema remained at 6 days, 
suggesting that treatment is efficacious in maintaining barrier permeability, whilst not 
associated with rebound oedema commonly reported for existing pharmacological agents. 
Secondly, we established that treatment was effective when administered both early and in 
a delayed fashion, increasing benefits to patients presenting with cerebral oedema and 
elevated ICP in the days following stroke onset. Thirdly, as treatment is administered 
intravenously, this circumvents the need for invasive surgery, minimising risks of 
transcalvarial herniation and morbidity in the elderly associated with DC. Finally, NK1-R 
administration maintained CPP at approximately 80 mmHg in both treatment regimens, 
meaning that the reduction in ICP we observed was not at the expense of CPP, thereby 
avoiding further tissue compromise due to ischaemia.  
 
The reduction in ICP observed following NK1-R antagonist treatment in this study supports 
findings from our previous work in which treatment was administered following permanent 
ovine stroke (Sorby-Adams et al., 2019). Taken together, these results suggest NK1-R 
antagonist treatment is effective in reducing ICP in the setting of both complete and partial 
MCA territory occlusion. Nevertheless, the inability to perform repeat, daily measurements 
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to determine the clinical course of ICP in real time must be acknowledged as a limitation of 
this study. The ICP system we used, although clinically applied, is not telemetric, meaning 
that animals were anaesthetised for the duration of ICP recording. Furthermore, anaesthesia 
and adequate animal positioning were necessary given the position of the head can 
significantly influence ICP dynamics (Ng et al., 2004). Given the need to open the skull and 
underlying dura to install the intraparenchymal probes, there was also a small amount (<1 
mL) of CSF leakage. Previous studies investigating CSF dynamics in sheep report a 
formation rate of approximately 7.8±0.7 mL/h at an average resting pressure of 11.9±1.4 
cmH2O, with CSF formation constant over a wide range of CSF pressures (Mollanji et al., 
2001). Although we have not observed CSF leakage in any of our experiments, in 
performing ICP recording on a single day, when ICP is known to be elevated, we sought to 
reduce the influence of repeat dural opening and thereby increase the validity of our findings. 
Finally, throughout the ICP monitoring period, pCO2 was significantly higher in vehicles 
compared with treatment animals. Given the inverse relationship between pCO2, CBF and 
pCO2, this may have influenced ICP recordings. Nevertheless, no differences in CPP were 
seen between any of the experimental groups. 
 
The results of this study suggest that the reduction in ICP observed was a result of attenuated 
cerebral oedema. Although we did not observe a strong correlation between cerebral oedema 
and ICP, reduced cerebral oedema and associated midline shift was observed in both early 
and late NK1-R antagonist treatment groups. However, a significant reduction in 
parenchymal water content was only observed in the late treatment group. The ability to 
accurately assess intracerebral water content is a significant benefit of large animal species. 
This is especially evident given the propensity for vasogenic oedema to develop in the white 
matter (Simard et al., 2007). Neglect of white matter pathology has been amplified by the 
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continued use of rodent experimental models, where relative white to grey matter ratio is 
considerably less than that of humans and large, gyrencephalic species (Dewar, 1999). 
Furthermore, the brains of larger animal species lend themselves to superior quality MRI 
studies (Sorby-Adams et al., 2018, West and Kaiser, 2020). Neuroimaging remains central 
to the assessment of clinical stroke, with perfusion and diffusion sequences particularly 
important. Indeed, a paradigm shift from ‘time is brain’ to ‘imaging is brain’ has been 
proposed, with imaging increasingly used to guide stroke intervention (Puig et al., 2020). 
Evidence of perfusion-diffusion ‘mismatch’, where a hypointense lesion is identifiable on 
DWI apparent diffusion coefficient images, but not FLAIR, indicates patient eligibility for 
intervention, whereas visualisation on both FLAIR and DWI denotes in-eligibility, as the 
infarct is beyond the window for effective thrombolysis (Mcgarry et al., 2020). In this study, 
we utilised clinically comparable scanning sequences (FLAIR, DWI, T2) to quantify infarct 
and oedema volume and quantify changes in parenchymal water dynamics. However, one 
limitation of our imaging protocol was a lack of sequential scanning across post-stroke time-
points. In clinical studies, scans obtained within 24 hours of stroke onset are deemed 
necessary to determine the evolution of ischaemic injury on subsequent scans. As MRI was 
only obtained at 6 days in the present study, it was difficult to reliably and accurately 
delineate the infarct from the surrounding oedema and thus examine evolution of the injury. 
Given infarct volume is a major predictor of the extent and clinical severity of cerebral 
oedema (Thorén et al., 2020), sequential imaging is highly advised for future studies to better 
evaluate accumulating oedema and thus the effect of treatment.  
 
In line with our previous work, the attenuation of cerebral oedema with NK1-R antagonist 
treatment observed in this study is most likely due to inhibition of transcytosis-mediated 
albumin extravasation via caveolae (Sorby-Adams et al., 2019a, Corrigan et al., 2016). This 
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is supported by our histological findings, where NK1-R antagonist administration was 
shown to decrease albumin and caveolin-1 immunoreactivity. NK1-R are expressed within 
endothelial caveolae, whereby upon SP biding, caveolae undergo internalisation (Bowden 
et al., 1994, Kubale et al., 2007). Aberrant SP release, as seen following ischaemic stroke, 
leads to upregulation of NK1-R expression and increased caveolae formation. The main 
structural component of caveolae, caveolin-1, is directly involved in shuttling albumin from 
the abluminal to basolateral cell surface, resulting in an increase in parenchymal 
concentration. As albumin accounts for up to 80% of colloid osmotic pressure, its 
accumulation in the brain abnormally draws water into the parenchyma, resulting in an 
increase in total brain volume and subsequent rise in pressure (Gounden et al., 2021). Our 
findings of comparable claudin-5 immunoreactivity between vehicle and treatment animals 
further suggests a putative role of caveolae, suggesting the NK1-R is targeting paracellular, 
rather than transcellular transport across the BBB. Thus, unlike current pharmacotherapies 
used in the clinical management of cerebral oedema and elevated ICP, the NK1-R antagonist 
is directly targeting the mechanisms underlying the development of oedema. It is, however, 
important to note we did not perform quantification of histological findings. This may 
provide more insight into discreet differences between groups and represents an avenue for 
future analysis. 
 
In addition to its role in facilitating albumin transport, SP has been shown to increases 
neutrophil adhesion to vascular endothelial cells, leading to increased leukocyte recruitment 
(Bost and Pascual, 1992, Ho et al., 1997, Johnson et al., 2017, Lai et al., 1998). In vehicle 
animals, we observed significant white blood cell infiltration in the infarct core, as identified 
by haematoxylin counter-staining. Although white blood cells were observed in the 
parenchyma of all stroke animals, these appeared to be more prevalent in vehicle animals. 
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Increased expression of NK1-R by leukocytes is proposed to occur via upregulation of pro-
inflammatory cytokines following stroke onset, sensitising cells to the effects of SP (Rasley 
et al., 2002, Marriott and Bost, 2000). Consequent leukocyte extravasation via adhesion 
molecules ensues, promoting cell migration and surmounting neuroinflammation. SP has 
also been shown to increase the inflammatory responses of resident glial cells, such as 
microglia (Burmeister et al., 2017, Martinez and Philipp, 2016, Lim et al., 2017). Although 
not performed in this study, investigation of microglial activation may provide insight into 
the interaction of SP with other neuronal cell lines (Johnson et al., 2017). Further analysis 
should also be directed at exploring the effects of treatment on integrity of other BBB 
constituents (immunoglobulin G, Zona-occludens-1, matrix metalloproteinases), and 
neuroinflammation (microglia, astrocytes, pro-inflammatory cytokines) in order to further 
elucidate the mechanisms of NK1-R antagonist treatment following transient ischaemic 
stroke.  
 
Although the efficacy of NK1-R antagonism has been demonstrated in prior models of 
permanent stroke in both rodents and sheep, this was the first to perform pharmacodynamic 
assessment of the EU-C-001 compound. Analysis in a large animal species is beneficial 
given their significant blood volume comparable to humans (sheep:  ±4 L; humans: ±5 L), 
allowing for multiple blood draws, mimicking studies performed clinically. Ruminants have 
an intermediary metabolic clearance, and despite anatomical variation of their 
gastrointestinal system, metabolism is largely analogous between poly- and mono-gastric 
species (Toutain et al., 2010). Our findings demonstrated a peak concentration of EU-C-001 
in the plasma 8 hours following administration, with levels still present at 12 and 16 hours, 
decreasing at 20 hours. Although the oestrous cycle was not determined in this particular 
cohort of animals, no significant differences were observed between male and female 
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animals in pharmacokinetic response. This provides critical evidence regarding the normal 
clearance from the plasma, with no evidence of a secondary adsorption or distribution peak 
seen up to 48 hours following administration. Given PK analyses were performed in animals 
receiving the late treatment regimen, this may provide explanation as to why outcomes were 
most improved in late, compared with early treatment regimens. In animals receiving 
treatment at 1-3 days post-stroke, although repeat dosing was performed, washout could 
have occurred by 6 days when ICP recording and MRI was performed. Nevertheless, if 
treatment attenuated secondary injury mechanisms and the development of neurogenic 
inflammation in the first 1-3 days following stroke, efficacious outcomes are still plausible 
when assessed at 6 days, as shown by the response to ICP and oedema reported herein. 
Whilst investigation of PK within both regimens is desirable, it was beyond the scope of the 
current study. Furthermore, although pharmacodynamic findings provided key evidence 
regarding the bioavailability of the NK1-R antagonist, it is possible that peak concentrations 
were missed due to the 4-hourly time-points for blood collection (for example, the maximum 
peak could have been at 2 hours). Future compartmental analysis of pharmacokinetics could 
be warranted to determine availability of EU-C-001 in the brain versus the plasma, in 




This study demonstrated that NK1-R antagonist treatment was effective in reducing ICP 
when given either before or after the establishment of elevated pressure, accompanied by 
significant reductions in cerebral oedema and midline shift. Taken together, the findings 
from this study provide compelling evidence for NK1-R antagonist treatment as a novel 
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therapy for the treatment of cerebral oedema and elevated ICP following transient stroke 
which warrants clinical investigation.  
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9.0 ABSTRACT  
 
Background and Purpose: Motor impairment is a common feature of ischaemic stroke. When 
determining the therapeutic value of novel interventions, assessment of function is thus 
imperative. The poor clinical translation of treatments developed in rodent models of stroke 
has led to the increased use of large animals. The ability to accurately assess function in 
these species, however, remains a significant hurdle. This study aimed to develop a method 
to assess motor function using motion capture in addition to developing a neurological 
outcome assessment scale in a clinically relevant ovine stroke model.  
 
Methods: Merino-sheep (Ovis aries, 13M;13F, 18-36 months) were anaesthetised-and-
subjected to 2 hours middle-cerebral-artery-occlusion (MCAo) with reperfusion. Animals 
underwent baseline assessment 8, 5 and 3 days pre-operatively, and at 3 days post-stroke. 
Neurological assessment was carried out to determine changes in animal demeanour and 
neurological status pre- and post- stroke. To assess gait, 10 infrared cameras (Vicon Motion 
Systems Ltd. Oxford, UK) operating at a frame rate of 200 Hz measured the trajectories of 
42 retro-reflective markers placed at defined anatomical locations. Kinematic parameters 
including stride, stance and swing duration, and limb joint angles were then calculated using 
MATLAB® (MathWorks Inc., Natick, MA). Intraclass Correlation Coefficients (ICC’s) 
were used to assess the repeatability of each outcome of interest across baseline trials. The 
average of all baselines compared to 3-day post-stroke parameters were used to assess 
changes in kinematics following MCAo using linear mixed models. 
 
Results: Motion capture assessment of baseline trials was reliable for the majority of 
assessed variables (ICC >0.50). Following stroke, kinematics measures were significantly 
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reduced (p<0.05); these included forward velocity, position of the head relative to the torso, 
and stance and stride duration of the forelimbs. Neurological assessment was able to indicate 
changes in animal impairment following injury, such as differences in gait, posture, appetite, 
postural reactions, and circling behaviours. 
 
Conclusion: This study has developed a reproducible method of functional assessment 
following stroke in an ovine model. Using both motion capture and composite scoring 
allowed for the comprehensive evaluation of post-stroke deficits. This method has the 
potential to be applied to other large animal models of acute central nervous system injury 



















Stroke is a leading cause of death and the principal cause of adult neurological disability 
worldwide (Gorelick, 2019, Johnson et al., 2019). New approaches to reperfusion have 
extended the previously narrow window for intervention (Ma et al., 2019, Albers et al., 
2018), resulting in reduced mortality, yet a higher incidence of patients facing persistent 
neurological impairment (Ballester et al., 2019). To improve functional outcomes in the 
increasing number of patients who survive stroke, new therapies targeting secondary injury 
and neurological recovery mechanisms are urgently required (Chollet et al., 2014). 
 
Animal models are an essential step in the development of novel stroke therapeutic agents, 
with restoration of function a key indicator of a treatment’s efficacy. However, the 
translation of pre-clinical findings to clinically efficacious stroke therapies has to date been 
largely ineffective (Kringe et al., 2020). This may, in part, be a consequence of pre-clinical 
experimental design, with the vast majority of failed trials being conducted in rodents, with 
many studies lacking comprehensive functional assessment (O'Collins et al., 2006). Due to 
their potential for enhanced clinical translation, large animal species are becoming 
increasingly used as a screening tool once initial therapeutic efficacy has been demonstrated 
in small animals (Hainsworth et al., 2017, Sorby-Adams et al., 2018a, Herrmann et al., 2019, 
Eaton and Wishart, 2017). Species such as dogs, pigs, sheep, and non-human primates 
(NHP’s) have been used to model stroke, each with their own inherent benefits and 
disadvantages (see Sorby-Adams et al., 2018 for review). Porcine species commonly used 
in America, such as the Yucatan mini pig, are not readily available in other countries such 
as Australia. The routine use of NHP’s remains expensive and ethically challenging, with 
strict housing requirements restricting their use to a few specialised laboratories (Sorby-
278 
Adams et al., 2018). In comparison, the relative availability, amenable nature, and 
comparable neuroanatomy of sheep make them a promising species in which to model stroke 
(Wells et al., 2015, Wells et al., 2012, Boltze et al., 2008, Sorby-Adams et al., 2019a, Sorby-
Adams et al., 2019b). Motor deficits have been documented following ovine middle cerebral 
artery (MCA) occlusion, including noticeable hemiplegia of the contralateral limbs and 
general apathetic behaviour (Sorby-Adams et al., 2019a, Boltze et al., 2008). These deficits 
are comparable to those seen clinically, where malignant MCA occlusion often presents as 
unilateral hemiplegia and hemiparesis, and resultant compensatory reliance on unaffected 
ipsilateral limbs (Nogles and Galuska, 2020, Jones, 2017). Post-stroke clinical assessment 
of upper limb function is often carried out using exams such as the National Institute of 
Health Stroke Scale (NIHSS), the Fugl-Meyer assessment and the Wolf motor function test 
(Quinn et al., 2009, Vliet et al., 2020). Lower limb differences in gait kinematics can also 
serve as a quantitative means of determining asymmetry and extent of neurological deficit, 
with studies demonstrating a significant increase in swing duration, and decrease in gait 
speed and stride length following stroke onset (Alexander et al., 2009, Rozanski et al., 2019). 
 
Assessment of functional deficits in animal stroke models is essential in determining their 
relevance to clinical disability and enabling the evaluation of novel therapeutics. In rodents, 
this encompasses composite scores such as the Bederson scale and Modified Neurological 
Severity Score (mNSS), motor function tests such as rotarod, cylinder test, ledged beam, 
grid walking, reaching chamber and staircase test, and systems to assess gait such as the 
Catwalk and DigiGait (Schaar et al., 2010). Equivalent functional assessment in large 
animals presents a new set of challenges. Firstly, unlike their small animal counterparts, 
neurological exams are not well described for ungulate species. Although neurological 
exams for quadrupeds do exist, standard clinical tasks such as grip and grasp reflexes cannot 
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be assessed (Boltze et al., 2008, Cui et al., 2013). Secondly, tests developed for rodents are 
often difficult to translate to large animals due to the need for significant upscaling, whilst 
others are completely inappropriate for large species (e.g., rotarod). Thirdly, the relative size 
and strength of large animals requires the construction of robust systems that are both 
adaptable for use in farming environments and able to withstand a higher level of physical 
demand. It is also essential that such systems enable safe handling of the animal throughout 
assessment to ensure both animal and handler wellbeing. The development of a method to 
mitigate these challenges could lend itself to detection of both acute and long-term 
functional changes post-stroke.  
 
In sheep, assessment of kinematics using motion capture serves as a quantitative means to 
assess gait, with systems being adapted for use in ovine musculoskeletal, orthopaedic and 
spinal cord-injury (SCI) models (Safayi et al., 2014, Safayi et al., 2015, Safayi et al., 2016, 
Wilson et al., 2017). In these studies, retro-reflective markers are placed on distinct 
anatomical locations allowing for the assessment of joint angles, stride length, and duration 
of stance, stride and swing. In large animal stroke models, gait assessment using motion 
capture has the potential to enhance functional assessment, and could be used alone, or in 
conjunction with conventional scoring systems. Accordingly, the objectives of this study 
were to develop a method to assess gait kinematics using motion capture in an ovine model 
of stroke, in addition to use of a composite scoring system. Specifically, the aims were to: 
1) assess the repeatability of gait kinematics obtained using motion capture across baseline 
trials; 2) determine if a change in gait kinematics was detected 3-days post stroke; and, 3) 




9.2 MATERIALS AND METHODS 
9.2.1 Ethics 
This study was approved by the South Australian Health and Medical Research Institute 
(SAHMRI) Animal Ethics Committee (SAM 3). A total of 26 adult Merino sheep (Ovis 
aries) (57±4 kgs, 18-36 months,) were used (n=13F; 13M). All animals were obtained from 
a single farm in Gum Creek, South Australia. Six months prior to commencing the study, 
animals were moved from the farm to the research facility (SAHMRI Preclinical Imaging 
and Research Facility (PIRL)), where on arrival they were examined by a veterinarian and 
judged to be healthy prior to inclusion in the study based on complete physical and 
orthopaedic examinations. They were fed once daily by facility staff to gradually acclimatise 
animals to human proximity, until they underwent staged habituation and surgical 
procedures, as described below (section 9.2.4). 
 
9.2.2 Experimental Design 
To determine the repeatability of both motion capture and composite scoring, pre-stroke, 
baseline assessment was carried out on three occasions; 8-, 5- and 3- day prior to stroke 
induction. To compare pre- and post-stroke parameters, assessment was also carried out 3 
days following stroke onset.  
 
9.2.3 Motion Capture Assessment 
9.2.3.1 System Design Ethological Considerations 
The system designed for motion capture sought to take advantage of the inherent flight zone 
of ungulates, defined as the distance in which a person can approach an animal before it 
moves away (Grandin, 1999, Grandin, 1987, Grandin, 1997). The positioning of the eyes in 
the lateral aspect of the skull results in a wide visual field allowing sheep to move in a flock 
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and assess the surrounding environment for threats, yet results in a blind spot directly behind 
and directly in front of them. Studies have shown working along the edge of an animal’s 
flight zone at approximately 90 degrees allows for ease of movement (Kilgour, 1971, 
Kilgour, 1972). Consideration of the flight zone was thus incorporated in the system design 
to improve animal handling and welfare. 
 
9.2.3.2 System Fabrication 
A functional run measuring 10 m × 5 m × 1.5 m was fabricated using standard building and 
farming equipment (Figure 9.1A). One length of the run was defined as the capture volume 
(the space in which cameras can detect movement of the subject), with the other perimeters 
allowing for the continuous movement of the animal. The capture area comprised a 10 cm 
high wooden platform over which the animal walked, covered by matte rubber matting (2 
ply Natural Insertion Rubber, Clark Rubber, Australia). Ramps (1 m) on either end allowed 
smooth transition to/from the platform. The capture area was enclosed with matte, 
galvanised steel fencing (Cyclone Ringlock™, Australia) comprising six horizontal wires 
of graduated spacing with a wire diameter of 2.5 mm and 0.9 m total fence height (Figure 
9.1B). For the remaining periphery of the run, robust, galvanised steel interlocking 1.1 m 
high fencing was used. The run was enclosed in a large building, with limited external light 



















Figure 9.1. Orthographic and perspective views of the functional run. (A) Orthographic view of the run 
demonstrates the peripheries of the run allowing for continuous movement and the capture area. (B) 
Perspective view of the capture area shows elevated platform, ramping, and fencing used to contain animals 
as they execute forward movement. 
 
 
Animals were encouraged to walk forwards through the run, with a researcher with whom 
the sheep was familiar walking behind them at a consistent pace. As the sheep turned the 
corners of the run, the researcher appeared in their visual field along the edge of their flight 
zone, encouraging continuous forward movement. Animals executed movement at their own 
pace, thus this design did not artificially alter gait asymmetry. This design also allowed for 
the synchronised capture of force through an integrated force plate which was built into the 








Ten motion capture cameras (Vicon Vero, Vicon Motion System Ltd., Oxford, UK) were 
placed equidistant around the periphery of the capture area, five on either side, 
approximately 1 m back from a fence line (Figure 9.2). Vicon Nexus software (v2.10) was 
used to capture marker data at a frame rate of 200 Hz. An additional video camera (Vicon 
Vue, Vicon, Oxford, UK) operating at a frame rate of 60 Hz captured video data to be 











Figure 9.2. The camera positions and 3D capture volume shown on the Vicon Nexus interface. Grey 
rectangles represent position of each infrared camera (1 – 10) and video camera (DV1). The rectangle with 
number 1 indicates the position of the force plate. The final three-dimensional (3D) capture volume was 5 m 
in length x 5 m in width x 2 m in height. 
 
9.2.4 Acclimation and Habituation 
To familiarise animals to their surroundings, animals underwent staged acclimatisation prior 
to baseline assessment. On arrival to the facility, animals were initially group housed in 
outdoor paddocks, then moved to undercover pens, where they were housed in groups of 
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six. Four weeks prior to surgery, they were then separated into pairs, following which they 
underwent a three-stage habituation protocol.  
 
In the first stage of habituation, pairs of animals (housed together) were allowed to roam the 
functional area without a handler for 30 minutes on five consecutive days. In the second 
phase, individual animals traversed the run in a clockwise direction (30 minutes for five 
consecutive days), with a handler walking behind them to encourage forward movement. In 
the third phase, the animals were additionally trained to step into, and out of, a modified 
transport crate; grain (Laucke Mills, South Australia) was used to encourage animals to step 
into the crate without handler intervention. Both acclimatisation and testing were carried out 
by four trained handlers familiar to the sheep.  
 
9.2.5 Anatomical Landmarks 
Spherical retro-reflective markers (9 mm and 15 mm diameter; B&L Engineering, 
California, USA) were non-invasively attached to 42 anatomical landmarks (Figure 9.3) 
using hooked Velcro® (Velcro USA Inc, Manchester, NH, US). The opposing loop surface 
of the Velcro® was adhered to the animal using superglue (Bostik, Australia). To ensure 
consistent marker placing, 6 days prior to baseline testing, animals were intubated and 
anaesthetised (isoflurane, 1.5% minimum alveolar concentration (MAC), Henry Schein, 
Australia), anatomical locations palpated, and landmarks tattooed using a handheld tattoo 
gun and India ink (Windsor and Newton, Australia). Animals were shorn at 2-week intervals 
to facilitate marker removal and reattachment to the skin to reduce obstruction by long wool. 












Figure 9.3. Anatomical locations for assessment. Retro-reflective markers attached to each location were 15 
mm in diameter, with the exception of markers on the PHAL, PHAL and DPHAL, which were 9 mm. Figure 
adapted from a sheep skeleton on display at the Museum of Veterinary Anatomy, Faculty of Veterinary 
Medicine and Animal Science, University of São Paulo, Brazil. 
 
Table 9.1 Sites of marker attachment 
Position Acronym Anatomical location of attachment 
   
Global HEAD On the head between the eyes 
 T1 Spinous process of T1 
 T13 Spinous process of T13 
 L7 Spinous process of L7 
   
Forelimb GTUB Greater tubercle of the humerus 
 LEPIRAD Lateral epicondyle of the radius 
 ULNA Distal tubercule of the ulna 
 METAR Proximal tubercule of the metatarsal 
 PPHAL Forelimb proximal phalange 
 PHAL Forelimb phalange 
 DPHAL Forelimb distal phalange 
   
Hindlimb ILIUM Iliac crest 
 ISCHTUB Ischial tuberosity 
 GTROC Greater trochanter of the femur 
 LEPI Lateral epicondyle of the femur 
 LTIB Lateral condyle of the tibia 
 TIB Tibia 
 LMAL Lateral malleolus 
 FTAR Fused tarsal of the metacarpus 
 PPHAL Hindlimb proximal phalange 
 PHAL Hindlimb phalange 
 DPHAL Hindlimb distal phalange 
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9.2.5 Surgical Approach 
9.2.5.1 Preoperative Preparation 
Animals were moved indoors pre-operatively and fasted for 12 hours. Anaesthesia was 
induced with intramuscular ketamine and diazepam as per previous studies (Sorby-Adams 
et al., 2019a). A jugular catheter (18 g, Terumo SURFLO®) was inserted for delivery of 
intraoperative crystalloid fluids (Hartmann’s, Baxter Health, Australia). Anaesthesia was 
maintained with inhalational isoflurane (1.5-2.0 % MAC in in 3 L of air and 500 mL of 
oxygen, Henry Schein, Australia) and continuous ketamine infusion (4 mg/kg/hr) via jugular 
line. An arterial catheter (20 g, Terumo SURFLO®) was placed in the distal hindlimb to 
yield arterial blood gas samples. A paediatric blood pressure cuff (Easy Care Cuff, Phillips) 
was placed on the proximal forelimb for a non-invasive measure of arterial blood pressure 
(ABP), which was manually recorded at 5-minute intervals.  
 
9.2.5.2 Intraoperative Procedures 
Stroke surgery was performed as previously described (Sorby-Adams et al., 2019a). Briefly, 
an incision was made between the right ear and orbital rim, coronoid process of the mandible 
lateralised, and skull based exposed to perform a small craniotomy using a pneumatic drill 
(Midas Rex® Legend Electric System (ICP), Medtronic USA). A 2 cm skull flap was 
removed, underlying dura breached, proximal MCA located, and an aneurysm clip 
(Aesculap YASARGIL® Aneurysm Clip, Germany) placed over the diameter of the vessel 
which remained in situ for 2 hours. The clip was subsequently removed to achieve 
reperfusion, dura closed watertight with synthetic matrix (Durepair®, Medtronic, USA) and 
superglue (Bostik, Australia), cranioplasty performed using dental cement (Sledgehammer, 
Keystone, Germany), and surgical site closed in layers using polyglactin suture (Vicryl®, 
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ETHICON). Arterial blood samples were obtained at hourly intervals intra-operatively to 
maintain the animal within normal physiological limits.  
 
9.2.5.3 Postoperative Recovery 
Animals were removed from anaesthesia and placed in a metabolism crate to limit excessive 
lateral movement of the head. Once lucid, subcutaneous non-steroidal anti-inflammatory 
(NSAID, 0.7 mg/kg, 50 mg/mL every 12 hours, Carprofen, Norbrook, Australia) and 
intramuscular Buprenorphine (Temgesic, 1.0 mL, 300 µg/ml Buprenorphine hydrochloride, 
Reckin Benckiser, Australia) was administered for pain relief, and intramuscular Depocillin 
for antibiosis (1 mL/25 kg every 12 hours Procaine benzylpenicillin, Intervet, Australia). 
NSAID and antibiotic treatment was continued for 3 days post-operatively, and as required 
thereafter. Assessment was carried out bis in die to determine animal wellbeing, including 
urine and faecal output, food and water intake, and signs of apathy. Animals remained in 
indoor housing for 3 days post-operatively, where they were also monitored remotely via 
closed-circuit television. 
 
9.2.6 Motion Capture Data Collection 
On testing days, the Vicon system was calibrated, and the global coordinate system (GCS) 
set to the upper right corner of the force plate using a light emitting diode wand (Vicon 
Active Wand, Vicon Motion System Ltd., Oxford, UK). Animals were placed into the 
modified transport crate in their home pen, reflective markers attached to anatomical 
locations, and animals moved to the functional testing space where they completed a 
minimum of 20 traverses of the functional run. Once motion capture was complete, animals 
were placed in the transport crate, reflective markers removed, and returned to their home 
pen with free access to food and water.  
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9.2.7 Motion Capture Data Post-processing 
Post-processing of motion capture data was performed using Vicon Nexus software (version 
2.10, Vicon Motion System Ltd., Oxford, UK). Five trials in which the animal maintained a 
consistent walking pace without running or trotting were reconstructed, and markers 
labelled. Spline and cyclic algorithms were used to fill all visible gaps (Vicon Motion 
System Ltd., Oxford, UK). A fourth order, zero lag, low pass Butterworth filter was applied 
with a cut off frequency of 10 Hz. Data were exported to C3D format and further processed 
with custom MATLAB® code (Mathworks, Natick, MA, USA, Appendix 9.1).  
 
Parameters of interest were classified into global and limb-specific. Global parameters 
correspond to the outcome measures pertaining the entire trial, e.g. forward velocity. These 
outcomes were reported as average values across trials ± SD (Table 9.2). For the notation, 
the z axis corresponds to the vertical direction with the positive axis pointing up, the y axis 
corresponds to the direction of the progression, and the x-axis corresponds to the lateral      





Table 9.2 Global outcome measures 
Outcome Direction Measure Purpose 
Mean Absolute Velocity 
T1 
Forward Velocity of T1 
Determine velocity of 
forward movement 
Mean Head to T1 Left/right 
Position of the head in relation 
to T1 
Determine preference for 
side of the run (left or 
right) 
Mean Head to T1 Vertical 
Position of the head in relation 
to T1 
Determine lowering of the 
head 
Mean T1 to T13 Vertical 
Position of T1 in relation to 
T13 
Determine lowering of the 
neck 
Mean T1 to L7 Vertical Position T13 in relation to L7 
Determine lowering of the 
back 
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Limb-specific parameters were computed from the observation of the kinematic data of each 
limb within its corresponding gait cycle. For each trial, the gait cycles were identified 
following the method from (Ghoussayni et al., 2004). Changes in the velocity of each limb’s 
hoof marker (DPHAL) were detected in the vertical and progression directions, determining 
when the marker stopped moving (entering stance phase) or started moving (entering swing 
phase). One gait cycle per limb was extracted from each trial to calculate kinematic measures 
of interest using two-dimensional (2D) planar analysis in the Cartesian coordinate system 
of the sagittal plane (Figure 9.5). Joint angles were defined between two vectors. The 
METAR/FTAR, PPHAL, and PHAL were used to determine the fetlock angle of the fore 
and hind limbs. The LEPIRAD, ULNA, METAR, and PPHAL and the TIB, LMAL, FTAR 
and PPHAL, were used to determine the angle of the carpus and tarsus, respectively. The 
GTUB, LEPIRAD, and ULNA and the GTROC, LEPI, LTIB, and LMAL were used to 
determine the angle of the elbow and stifle, respectively. The primary outcomes assessed, 



















Figure 9.4. Ovine movement in the Cartesian coordinate system. The z axis corresponds to the vertical 
direction (up and down), the y axis corresponds to the direction of the progression (forward), and the x-axis 







Table 9.3 Limb-specific outcome measures 
Outcome Direction Marker(s) used Variables Measured Purpose 
Stance Duration (s) Vertical DPHAL (each limb) 
Duration from end of swing to beginning 
of a new swing cycle  
Determine stance duration 
Swing Duration (s) Vertical DPHAL (each limb) 
Duration from beginning of swing to 
beginning of stance   
Determine swing duration 
Stride Duration (s) Vertical DPHAL (each limb) 
Duration from entering swing to ending 
stance   
Determine stride duration 
Hoof Lateral Deviation (cm) Left/right DPHAL (each limb) Lateral (outward) deviation of distal limb  
 
Hoof Forward Swing Velocity (m/s) Forward DPHAL (each limb) 
The speed at which the animal is moving 
the limb forwards during swing  
The speed (m/s) the animal is 
lifting or dragging the limb 
during swing 
Hoof Vertical Swing Velocity (m/s) Vertical DPHAL (each limb) 
The speed at which the animal is lifting 
the hoof upwards during swing  
The speed (m/s) the animal is 
lifting or dragging the limb 
during swing 
Range Hoof Height in Swing (cm) Vertical DPHAL (each limb) 
Range of upwards movement of the hoof 
during swing 
The amount (cm) the animal is 
lifting or dragging the limb 
during swing 
Stride Length (cm) Vertical DPHAL (each limb) 
The length of the stride from stance to 
swing 
Determine length of stride 
Distance Matching Limb during stance 
(cm) 
Left/right 
Forelimb DPHAL and Hindlimb 
DPHAL 
Distance between limbs 
Determine splay of limbs pre- 
and post-stroke 
Forelimb Fetlock Angle Stance (º) Vertical 
Forelimb PHAL, PPHAL and 
METAR 
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral lower 
limb deficit 
Forelimb Fetlock Angle in Swing (º) Vertical 
Forelimb PHAL, PPHAL and 
METAR 
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral lower 
limb deficit 
Carpal Angle in Stance (º) Vertical 
METAR, PPHAL, LEPIRAD and 
ULNA 
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral mid limb 
deficit 
    (continued) 
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Carpal Angle in Swing (º) Vertical 
METAR, PPHAL, LEPIRAD and 
ULNA 
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral mid limb 
deficit 
Elbow Angle in Stance (º) Vertical LEPIRAD, ULNA and GTUB   
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral upper 
limb deficit 
Elbow Angle in Swing (º) Vertical LEPIRAD, ULNA and GTUB  
Maximum, minimum and range of joint 
during stance  
Determine forelimb ipsi- 
versus contra-lateral upper 
limb deficit 
Hindlimb Fetlock Angle in Stance (º) Vertical Hindlimb PHAL, PPHAL and FTAR 
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral lower 
limb deficit 
Hindlimb Fetlock Angle in Swing (º) Vertical Hindlimb PHAL, PPHAL and FTAR 
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral lower 
limb deficit 
Tarsal Angle in Stance (º) Vertical FTAR, PPHAL, TIB and LMAL  
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral mid limb 
deficit 
Tarsal Angle in Swing (º) Vertical FTAR, PPHAL, TIB and LMAL  
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral mid limb 
deficit 
Stifle Angle in Stance (º) Vertical LTIB, LMAL, GTROC and LEPI  
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral upper 
limb deficit 
Stifle Angle in Swing (º) Vertical LTIB, LMAL, GTROC and LEPI  
Maximum, minimum and range of joint 
during stance  
Determine hindlimb ipsi- 
versus contra-lateral upper 
limb deficit 
Ratio Stance to Stride (%) Vertical DPHAL (each limb) Ratio of time in stance compared with stride   
 
Ratio Swing to Stride (%) Vertical DPHAL (each limb) Ratio of time in swing compared with stride   




9.2.8 Neurological Scoring Assessment 
A 12 criteria neurological assessment score was adapted from previous work (Boltze et al., 
2008). Assessment was based on the common system for neurologic dysfunctions in large 
animals (Lorenz et al., 2010). This study, however, specifically focused on the functional 
deficits observed in animals following MCAO, including changes in state of activity, 
behaviour, and motor dysfunction (Table 9.4). A score of 0 was considered normal, with a 
possible total score of 25 indicating severe deficit. 
 
Scoring took place approximately 2 hours prior to commencing motion capture procedures. 
Each examination was scored at time of assessment and simultaneously recorded on three 
cameras (GoPro HERO6) positioned anteriorly, posteriorly and laterally to the assessment 
space. Observations of level of consciousness and position of the head gave a score for 
animal demeanour (Table 9.4, criteria 1). Animals who were in a state of stupor or were 
comatose warranted euthanasia, and no further investigations were performed. 
Abnormalities in animal behaviour were assessed by accumulating scores for presence of 
torticollis, food debris in the mouth indicating inability to properly masticate, general ataxia 
or dysmetria in limb movements, evidence of abnormal flexion at the fetlock and/or carpus 
joints, and circling (Table 9.4, criteria’s 2, 3, 4 and 5, respectively). Circling behaviours 
(Table 9.4, criteria 6) were monitored prior to animal handling on assessment days by 









Table 9.4 Neurological scoring system  
Criteria Assessment  Score 
1 State of Activity/Consciousness 0 – 3 
        Normal 0 
        Apathetic 1 
        Stupor 2 
        Comatose 1 
   
2 Presence of Food Debris in the Mouth 0 – 1 
        No food 0 
        Food present 1 
   
3 Presence of Torticollis 0 – 1 
        Absent 0 
        Present 1 
   
4 Partial Flexion of Fetlock and/or Carpus 0 – 1  
       Absent 0 
       Present 1 
   
5 Ataxia/Dysmetria 0 – 3 
        Normal 0 
        Dysmetric limb movement 1 
        Staggering 2 
        Animal falls down 3 
   
6 Circling Movements 0 – 2 
        None 0 
        Occasional 1 
        Continuous 2 
   
7 Hemi-standing 0 – 4 
        Immediate adjustment of both limbs 0 
        Delayed adjustment of hindlimb 1 
        Delayed adjustment of forelimb 2 
        Delayed adjustment of both limbs 3 
        No adjustment of both limbs 4 
        Knuckling limb on hoof release + 0.25/limb 
   
8 Forelimb Lateral and Medial Hopping         0 – 2 
        Normal response/immediate adjustment 0 
        Delayed adjustment 1 
        No adjustment 2 
        Knuckling limb on hoof release + 0.25/limb 
   
9 Limb Medial Adjustment “Lateral Dragging” 0 – 2 
        Normal response/immediate adjustment 0 
        Delayed adjustment 1 
        No adjustment 2 
        Partial correction + 0.25/limb 
   
10 Forced Forelimb Movement “Wheelbarrowing” 0 – 2 
         Normal response/immediate adjustment 0 
         Drifting to side 1 





Three postural reaction tests (Table 9.4; Criteria 7-9) were conducted by forcefully shifting 
the animal’s weight over their centre of gravity on individual limbs and assessing their ability 
to correct the movement. Criteria 7 refers to “hemi-standing”, which evaluated the animal’s 
ability to correct and co-ordinate fore- and hind- limbs during a lateral movement on the left 
and right side of the body. Criteria 8 encompassed “lateral dragging”, which involved the 
forced lateral movement of each individual limb and assessment of the animal’s ability to 
return the limb back to the medial starting position. Quarter scores were also given where 
animals dragged a limb on return or if correction back to original position was only partial. 
Criteria 9 refers the “hopping reaction” which assessed forelimbs individually to determine 
the animal’s ability to correct the limb during lateral movement. Forced forward movement 
of the animal on both forelimbs (“wheelbarrowing”, criteria 10) assessed for any sideways 
deviation, indicative of hemineglect and potential hemiparesis. Additional quarter scores 
were allocated in criteria 7 and 8 if the animal exhibited abnormal reactions beyond observed 
delays, including the inability of the animal to fully extend a held limb upon release, causing 
‘knuckling’ on ground.  Criteria 10 was reported independently, and scores for hemi-
standing, hopping, and lateral drag were incorporated into measures for the contralateral and 
ipsilateral side of the body. 
 
9.2.9 Statistics 
9.2.9.1 Motion Capture 
Statistical analysis for motion capture was performed with Stata (version 15.1, StataCorp, 
College Station, TX). Descriptive statistics are presented for each outcome as mean and 
standard deviations (SD). Analysis of variance (ANOVA) models were used to determine if 
there was a difference between the three baseline measures (8-, 3- and 1-day pre stroke) for 




repeatability of each outcome of interest. For stride-related measures, two ICC values were 
derived; one un-adjusted and one adjusted for the potential confounding effect of walking 
speed (measured as mean absolute velocity at T1).  Interpretation of ICC values was <0.50 
poor; 0.50-0.75 fair; 0.75-0.90 good; >0.90 excellent (Koo and Li, 2016). 
 
Mixed effects linear regression models were fitted to determine the change in gait-related 
measures from baseline to 3 days post-stroke. For ease of interpretation in the models, a 
single baseline measure was used comprised of the mean of the three baseline measures. A 
random effect of sheep was used to account for the correlation between repeated or multiple 
measures on the same animal. Fixed effects were time (pre-, post-stroke), limb (left, right), 
and a time-by-limb interaction term. The interaction term was necessary as the right sided 
stroke was expected to cause left-sided deficits (with potential right-sided compensation) 
thus producing a side-dependent effect of time. For models in which the interaction term 
was not significant, the baseline to post-stroke comparisons within limb are interpreted with 
caution. Two models were fitted for each stride measurement; the first un-adjusted and the 
second adjusted for velocity. For the velocity outcome measure, only an unadjusted model 
was fitted. Estimates of the difference between baseline and post-stroke were derived for 
each limb. Results are presented as p-value, mean difference and 95% confidence intervals 
(CI). p<0.05 was considered statistically significant. 
 
9.2.9.2 Neurological Scoring 
Neurological examination scores were analysed using Prism (version 9.0, GraphPad, CA).  
Friedman, non-parametric, one-way ANOVAs were performed with repeated measures and 
Dunn’s post hoc test for multiple comparisons. All score values are expressed as mean and 






Two animals were euthanised before the experimental endpoint and excluded from the study. 
Specifically, one animal had an unsuccessful reperfusion of the MCA resulting in a 
permanent stroke, and the other had kidney failure leading to seizures. As such, twenty-four 
animals reached the experimental endpoint and were included in the final analysis.  
 
9.3.1 Motion Capture 
9.3.1.1 Baseline Repeatability Analysis of Global Parameters 
No statistically significant differences were detected for any of the global measures across 
the three baseline sessions (all p ≥ 0.05) (Table 9.5). The repeatability of forward velocity 
was poor (ICC <0.50), with animals walking at variable speeds between sessions. The mean 
walking speed across all baseline trials was 1.28 m/s, however, despite poor repeatability, 
the SD was low for all animals (+/- 0.20 m/s). Repeatability of measures in the vertical plane 
were good (all ICC > 0.70), with the position of the head in relation to T1, T1 to T13, and 
T13 to L7, consistent across baseline testing sessions. The position of the head to T1 in the 
left/right axis was also repeatable (ICC >0.50), with animals consistently holding their head 
slightly to the right of the run (approximately 3 cm). Repeatable variables are denoted with 










Table 9.5 Baseline global parameters (mean +/- SD) 



















(0.21) 0.656 1.28 (0.20) 
0.41 (0.20, 
0.66) 
Mean Head to 






(5.79) 0.707 3.39 (6.04) 
0.58 (0.36, 
0.76) * 
Mean Head to 






(4.31) 0.751 9.89 (4.10) 
0.70 (0.51, 
0.84) * 







(1.07) 0.919 -0.51 (1.09) 
0.74 (0.56, 
0.86) * 







(1.50) 0.875 -3.13 (1.46) 
0.80 (0.66, 
0.90) * 
*  = ICC >0.50        
 
9.3.1.1 Baseline Repeatability Analysis of Limb Parameters 
There was no significant difference between baseline trials for all limb-related variables 
(p>0.11). Repeatability was good for some, but not all, of the recorded measures (highlighted 
by an asterix (*) in Table 9.6). To allow for comparison between post-stroke trials, the 
outcome measures for each individual limb are described herein. 
 
For the forelimbs, the majority of outcome measures were reproducible. Specifically for the 
left forelimb, the variables that reported fair to good repeatability included swing duration, 
hoof vertical swing, range hoof height and stride length. Joint angles were also repeatable, 
with the exception of the minimum fetlock angle in swing. When adjusted for velocity, the 
ICC increased for all variables, and stride duration which was previously considered un-
repeatable across trials was subsequently considered fair. For the right forelimb, all joint 
angles were repeatable, with ICC values increasing when adjusted for velocity. Swing and 
stride duration, hoof lateral deviation, vertical swing and height range were also repeatable, 





The repeatability of hindlimb parameters was similar to that of the forelimbs (Table 9.7). In 
the left hindlimb, repeatable variables un-adjusted for velocity included swing duration, hoof 
vertical swing, hoof height range, and stride length. All hindlimb angles were repeatable. 
When adjusted for velocity, the ICC increased for all variables, and hoof forward swing and 
stride duration became repeatable measures. For the right hindlimb, variables repeatable in 
the un-adjusted model included swing duration, hoof vertical swing, hoof height range, and 
stride length. Joint angles were all repeatable, with the exception of the minimum fetlock 
angle during swing. When adjusted for velocity, the ICC for all variables increased, and both 
stride duration and hoof forward swing were repeatable. The distance between the matching 
limbs during stance were also considered repeatable for the fore- and hind- limbs when both 






























and 95% CI 
Adjusted ICC and 
95% CI 
Stance Duration (s) 0.40 (0.07) 0.42 (0.09) 0.41 (0.09) 0.41 (0.01) 0.580 0.41 (0.20, 0.66) 0.45 (0.24, 0.69) 
Swing Duration (s) 0.35 (0.02) 0.36 (0.03) 0.36 (0.02) 0.36 (0.00) 0.433 0.60 (0.39, 0.78) * 0.67 (0.47, 0.82) * 
Stride Duration (s) 0.75 (0.08) 0.78 (0.11) 0.77 (0.11) 0.77 (0.01) 0.553 0.45 (0.24, 0.69) 0.59 (0.38, 0.77) * 
Ratio Stance To Stride (%) 0.52 (0.04) 0.53 (0.05) 0.52 (0.05) 0.52 (0.01) 0.644 0.36 (0.16, 0.63)  0.28 (0.09, 0.60) 
Ratio Swing To Stride (%) 0.48 (0.04) 0.47 (0.05) 0.48 (0.05) 0.48 (0.01) 0.644 0.36 (0.16, 0.63) 0.28 (0.09, 0.60) 
Ratio Stance To Swing (%) 1.11 (0.18) 1.16 (0.19) 1.12 (0.21) 1.13 (0.02) 0.642 0.34 (0.14, 0.62) 0.28 (0.10, 0.60) 
Hoof Lateral Deviation (cm) 7.29 (1.98) 7.47 (2.31) 7.45 (2.59) 7.40 (0.08) 0.959 0.40 (0.19, 0.65) 0.41 (0.20, 0.66) 
Hoof Forward Swing Velocity (m/s) 2.77 (0.15) 2.68 (0.25) 2.71 (0.21) 2.72 (0.03) 0.378 0.44 (0.22, 0.68) 0.42 (0.20, 0.67) 
Hoof Vertical Swing Velocity (m/s) 0.39 (0.08) 0.35 (0.08) 0.36 (0.10) 0.37 (0.02) 0.275 0.64 (0.44, 0.80) * 0.70 (0.51, 0.84) * 
Range Hoof Height in Swing (cm) 7.16 (1.54) 6.39 (1.59) 6.63 (2.08) 6.73 (0.33) 0.305 0.74 (0.56, 0.86) * 0.78 (0.62, 0.88) * 
Stride Length (cm) 98.44 (5.15) 96.51 (6.17) 98.64 (6.31) 97.88 (0.96) 0.399 0.73 (0.56, 0.86) * 0.82 (0.68, 0.91) * 
Minimum Forelimb Fetlock Angle Stance (º) 4.10 (10.78) 5.82 (8.63) 5.47 (8.43) 5.12 (0.75) 0.799 0.56 (0.35, 0.76) * 0.54 (0.31, 0.75) * 
Maximum Forelimb Fetlock Angle Stance (º) 19.51 (10.98) 21.01 (8.81) 20.93 (8.56) 20.47 (0.70) 0.83 0.53 (0.31, 0.74) * 0.50 (0.27, 0.72) * 
Range Forelimb Fetlock Angle in Stance (º) 15.41 (4.18) 15.18 (3.21) 15.46 (3.20) 15.35 (0.12) 0.962 0.63 (0.43, 0.80) * 0.63 (0.43, 0.80) * 
Minimum Forelimb Fetlock Angle in Swing (º) -29.70 (10.51) -26.87 (7.91) -27.49 (8.31) -28.04 (1.22) 0.527 0.43 (0.21, 0.68) 0.43 (0.21, 0.69) 
Maximum Forelimb Fetlock Angle in Swing (º) 12.00 (11.16) 13.48 (9.42) 13.08 (8.78) 12.84 (0.63) 0.867 0.56 (0.35, 0.75) * 0.52 (0.29, 0.74) * 
Range Forelimb Fetlock Angle in Swing (º) 41.70 (6.60) 40.35 (5.80) 40.57 (5.63) 40.88 (0.59) 0.713 0.68 (0.49, 0.83) * 0.69 (0.49, 0.83) * 
Minimum Carpal Angle in Stance (º) -13.90 (4.43) -14.74 (4.57) -14.78 (5.10) -14.47 (0.41) 0.766 0.71 (0.53, 0.84) * 0.72 (0.54, 0.85) * 
Maximum Carpal Angle in Stance (º) -1.74 (4.94) -2.29 (5.10) -2.42 (4.90) -2.15 (0.30) 0.883 0.78 (0.63, 0.89) * 0.79 (0.63, 0.89) * 
Range Carpal Angle in Stance (º) 12.15 (3.49) 12.45 (3.84) 12.36 (3.45) 12.32 (0.12) 0.959 0.68 (0.49, 0.83) * 0.72 (0.54, 0.85) * 
Minimum Carpal Angle in Swing (º) -77.34 (8.01) -74.86 (8.16) -77.88 (10.11) -76.72 (1.32) 0.463 0.75 (0.59, 0.87) * 0.81 (0.66, 0.90) * 
Maximum Carpal Angle in Swing (º) -3.19 (4.75) -3.96 (5.26) -4.18 (4.74) -3.77 (0.43) 0.766 0.81 (0.66, 0.90) * 0.81 (0.66, 0.90) * 
Range Carpal Angle in Swing (º) 74.15 (6.85) 70.90 (7.44) 73.71 (8.37) 72.95 (1.44) 0.289 0.73 (0.55, 0.86) * 0.82 (0.68, 0.90) * 
Minimum Elbow Angle in Stance (º) 51.94 (5.22) 51.97 (4.71) 51.92 (5.99) 51.94 (0.02) 1.000 0.80 (0.65, 0.89) * 0.85 (0.73, 0.92) * 
Maximum Elbow Angle in Stance (º) 76.21 (5.88) 76.88 (5.93) 77.23 (5.99) 76.78 (0.43) 0.833 0.89 (0.80, 0.94) * 0.89 (0.80, 0.95) * 
Range Elbow Angle in Stance (º) 24.27 (3.81) 24.92 (4.38) 25.31 (4.49) 24.83 (0.43) 0.694 0.70 (0.52, 0.84) * 0.82 (0.69, 0.91) * 
Minimum Elbow Angle in Swing (º) 52.92 (5.47) 53.22 (4.70) 53.23 (6.07) 53.12 (0.14) 0.976 0.81 (0.67, 0.90) * 0.85 (0.74, 0.92) * 
Maximum Elbow Angle in Swing (º) 95.89 (6.37) 94.50 (6.28) 95.41 (6.75) 95.27 (0.58) 0.757 0.80 (0.65, 0.89) * 0.82 (0.68, 0.91) * 
Range Elbow Angle in Swing (º) 42.97 (4.60) 41.28 (5.31) 42.18 (5.07) 42.16 (0.69) 0.515 0.74 (0.56, 0.86) * 0.73 (0.56, 0.86) * 
*  = ICC >0.50 
       













and 95% CI 
Adjusted ICC and 
95% CI 
Stance Duration (s) 0.40 (0.07) 0.42 (0.10) 0.42 (0.09) 0.41 (0.01) 0.569 0.47 (0.25, 0.70) 0.48 (0.27, 0.71) 
Swing Duration (s) 0.36 (0.02) 0.36 (0.03) 0.36 (0.02) 0.36 (0.00) 0.431 0.37 (0.17, 0.64) 0.53 (0.31, 0.74) * 
Stride Duration (s) 0.75 (0.08) 0.79 (0.12) 0.78 (0.11) 0.77 (0.01) 0.501 0.46 (0.24, 0.69) 0.59 (0.37, 0.77) * 
Ratio Stance To Stride (%) 0.52 (0.04) 0.53 (0.06) 0.53 (0.05) 0.52 (0.00) 0.823 0.46 (0.24, 0.69) 0.30 (0.10, 0.60) 
Ratio Swing To Stride (%) 0.48 (0.04) 0.47 (0.06) 0.47 (0.05) 0.48 (0.00) 0.823 0.46 (0.24, 0.69) 0.30 (0.10, 0.60) 
Ratio Stance To Swing (%) 1.11 (0.18) 1.15 (0.23) 1.15 (0.21) 1.13 (0.02) 0.736 0.46 (0.24, 0.69) 0.30 (0.11, 0.60) 
Hoof Lateral Deviation (cm) 7.59 (2.54) 7.21 (2.98) 7.07 (2.71) 7.29 (0.22) 0.795 0.49 (0.28, 0.71) 0.51 (0.29, 0.72) * 
Hoof Forward Swing Velocity (m/s) 2.74 (0.19) 2.64 (0.23) 2.71 (0.23) 2.70 (0.04) 0.311 0.28 (0.10, 0.59) 0.45 (0.22, 0.69) 
Hoof Vertical Swing Velocity (m/s) 0.37 (0.07) 0.34 (0.07) 0.36 (0.08) 0.36 (0.01) 0.438 0.49 (0.27, 0.71) 0.60 (0.39, 0.78) * 
Range Hoof Height in Swing (cm) 6.63 (1.35) 6.27 (1.37) 6.54 (1.69) 6.48 (0.16) 0.679 0.65 (0.45, 0.81) * 0.70 (0.51, 0.84) * 
Stride Length (cm) 97.83 (5.45) 96.30 (6.12) 98.14 (6.50) 97.44 (0.81) 0.539 0.69 (0.50, 0.84) * 0.80 (0.66, 0.90) * 
Minimum Forelimb Fetlock Angle Stance (º) 5.59 (8.26) 8.40 (8.30) 5.34 (7.73) 6.42 (1.39) 0.363 0.61 (0.40, 0.79) * 0.62 (0.41, 0.79) * 
Maximum Forelimb Fetlock Angle Stance (º) 21.03 (9.15) 23.03 (9.26) 20.80 (9.11) 21.60 (1.00) 0.662 0.65 (0.45, 0.81) * 0.67 (0.48, 0.82) * 
Range Forelimb Fetlock Angle in Stance (º) 15.43 (3.79) 14.62 (3.35) 15.46 (3.96) 15.18 (0.39) 0.683 0.74 (0.56, 0.86) * 0.75 (0.58, 0.87) * 
Minimum Forelimb Fetlock Angle in Swing (º) -26.96 (9.28) -25.34 (10.05) -25.82 (8.92) -26.05 (0.68) 0.833 0.73 (0.55, 0.86) * 0.73 (0.55, 0.86) * 
Maximum Forelimb Fetlock Angle in Swing (º) 13.96 (7.68) 15.59 (8.15) 13.77 (7.97) 14.43 (0.82) 0.691 0.57 (0.36, 0.76) * 0.61 (0.40, 0.79) * 
Range Forelimb Fetlock Angle in Swing (º) 40.92 (5.80) 40.93 (7.05) 39.59 (7.14) 40.48 (0.64) 0.730 0.70 (0.51, 0.84) * 0.70 (0.51, 0.84) * 
Minimum Carpal Angle in Stance (º) -16.97 (5.58) -18.73 (5.75) -17.46 (5.25) -17.70 (0.75) 0.533 0.82 (0.68, 0.90) * 0.84 (0.71, 0.92) * 
Maximum Carpal Angle in Stance (º) -3.27 (4.25) -4.59 (5.02) -3.87 (4.22) -3.90 (0.54) 0.606 0.85 (0.73, 0.92) * 0.84 (0.72, 0.92) * 
Range Carpal Angle in Stance (º) 13.70 (3.83) 14.14 (4.01) 13.58 (3.61) 13.80 (0.24) 0.869 0.66 (0.47, 0.82) * 0.70 (0.52, 0.84) * 
Minimum Carpal Angle in Swing (º) -79.86 (7.27) -78.27 (7.76) -79.72 (8.40) -79.30 (0.72) 0.745 0.78 (0.63, 0.88) * 0.84 (0.72, 0.92) * 
Maximum Carpal Angle in Swing (º) -5.16 (4.64) -6.38 (4.86) -5.47 (4.73) -5.66 (0.52) 0.660 0.88 (0.78, 0.94) * 0.89 (0.80, 0.94) * 
Range Carpal Angle in Swing (º) 74.70 (7.10) 71.89 (6.78) 74.25 (8.29) 73.64 (1.23) 0.387 0.71 (0.52, 0.84) * 0.79 (0.64, 0.89) * 
Minimum Elbow Angle in Stance (º) 53.51 (6.59) 54.30 (6.46) 53.52 (7.87) 53.77 (0.37) 0.908 0.76 (0.60, 0.87) * 0.77 (0.61, 0.88) * 
Maximum Elbow Angle in Stance (º) 77.33 (8.49) 76.95 (8.07) 77.10 (8.14) 77.13 (0.16) 0.987 0.85 (0.74, 0.92) * 0.86 (0.75, 0.93) * 
Range Elbow Angle in Stance (º) 23.82 (5.88) 22.65 (5.57) 23.58 (4.66) 23.36 (0.50) 0.737 0.58 (0.36, 0.76) * 0.61 (0.41, 0.79) * 
Minimum Elbow Angle in Swing (º) 54.66 (6.60) 55.85 (6.54) 55.14 (7.93) 55.20 (0.49) 0.845 0.78 (0.62, 0.88) * 0.79 (0.63, 0.89) * 
Maximum Elbow Angle in Swing (º) 96.14 (8.20) 96.51 (8.16) 95.47 (8.76) 96.03 (0.43) 0.911 0.85 (0.73, 0.92) * 0.85 (0.74, 0.92) * 
Range Elbow Angle in Swing (º) 41.48 (5.58) 40.67 (6.52) 40.33 (5.20) 40.83 (0.49) 0.779 0.69 (0.50, 0.83) * 0.69 (0.50, 0.83) * 
Distance Matching Limb during stance (cm) 51.12 (2.71) 50.98 (3.12) 51.73 (2.59) 51.28 (0.33) 0.623 0.56 (0.34, 0.76) * 0.52 (0.29, 0.74) * 




Table 9.7 Baseline hindlimb parameters (mean +/- SD) 
Left Hindlimb        




and 95% CI 
Adjusted ICC and 
95% CI 
Stance Duration (s) 0.42 (0.07) 0.44 (0.10) 0.43 (0.09) 0.43 (0.01) 0.678 0.43 (0.22, 0.68) 0.47 (0.24, 0.70) 
Swing Duration (s) 0.34 (0.03) 0.34 (0.03) 0.34 (0.03) 0.34 (0.00) 0.883 0.54 (0.33, 0.74) * 0.66 (0.47, 0.82) * 
Stride Duration (s) 0.76 (0.09) 0.78 (0.12) 0.77 (0.11) 0.77 (0.01) 0.737 0.46 (0.24, 0.69) 0.62 (0.41, 0.79) * 
Ratio Stance To Stride (%) 0.55 (0.04) 0.56 (0.04) 0.55 (0.05) 0.55 (0.00) 0.735 0.42 (0.20, 0.67) 0.35 (0.14, 0.64) 
Ratio Swing To Stride (%) 0.45 (0.04) 0.44 (0.04) 0.45 (0.05) 0.45 (0.00) 0.735 0.42 (0.20, 0.67) 0.35 (0.14, 0.64) 
Ratio Stance To Swing (%) 1.24 (0.19) 1.29 (0.20) 1.25 (0.22) 1.26 (0.02) 0.667 0.40 (0.19, 0.65) 0.32 (0.12, 0.62) 
Hoof Lateral Deviation (cm) 7.66 (2.86) 6.86 (2.12) 6.68 (2.04) 7.07 (0.43) 0.324 0.12 (0.01, 0.61) 0.11 (0.01, 0.63) 
Hoof Forward Swing Velocity (m/s) 2.89 (0.21) 2.83 (0.31) 2.88 (0.27) 2.87 (0.03) 0.722 0.39 (0.18, 0.65) 0.66 (0.46, 0.82) * 
Hoof Vertical Swing Velocity (m/s) 0.25 (0.06) 0.24 (0.06) 0.24 (0.07) 0.24 (0.01) 0.718 0.50 (0.28, 0.72) * 0.67 (0.48, 0.83) * 
Range Hoof Height in Swing (cm) 4.35 (0.97) 4.10 (0.94) 4.10 (1.09) 4.18 (0.12) 0.615 0.61 (0.40, 0.79) * 0.72 (0.54, 0.85) * 
Stride Length (cm) 97.90 (5.99) 96.33 (5.93) 98.72 (5.77) 97.67 (0.99) 0.378 0.62 (0.41, 0.79) * 0.73 (0.54, 0.85) * 
Minimum Hindlimb Fetlock Angle Stance (º) 3.68 (8.29) 0.67 (6.97) 1.96 (7.31) 2.12 (1.24) 0.395 0.53 (0.31, 0.73) * 0.52 (0.31, 0.73) * 
Maximum Hindlimb Fetlock Angle Stance (º) 20.41 (9.09) 17.60 (8.82) 18.98 (8.00) 19.02 (1.15) 0.541 0.56 (0.34, 0.75) * 0.56 (0.35, 0.76) * 
Range Hindlimb Fetlock Angle in Stance (º) 16.73 (5.44) 16.93 (4.79) 17.02 (4.99) 16.90 (0.12) 0.980 0.69 (0.50, 0.83) * 0.69 (0.50, 0.83) * 
Minimum Hindlimb Fetlock Angle in Swing (º) -31.51 (8.65) -33.72 (6.22) -30.96 (7.49) -32.04 (1.19) 0.420 0.53 (0.31, 0.73) * 0.55 (0.33, 0.75) * 
Maximum Hindlimb Fetlock Angle in Swing (º) 10.58 (7.78) 7.33 (9.01) 9.35 (7.13) 9.11 (1.34) 0.377 0.52 (0.31, 0.73) * 0.56 (0.34, 0.75) * 
Range Hindlimb Fetlock Angle in Swing (º) 42.09 (6.22) 41.05 (8.01) 40.31 (6.26) 41.15 (0.74) 0.668 0.50 (0.28, 0.72) * 0.67 (0.47, 0.82) * 
Minimum Tarsal Angle in Stance (º) 28.01 (7.37) 27.95 (6.83) 27.14 (8.61) 27.70 (0.40) 0.909 0.84 (0.71, 0.91) * 0.83 (0.70, 0.91) * 
Maximum Tarsal Angle in Stance (º) 63.41 (6.57) 62.82 (7.05) 63.08 (9.01) 63.10 (0.24) 0.965 0.73 (0.56, 0.86) * 0.75 (0.58, 0.87) * 
Range Tarsal Angle in Stance (º) 35.40 (5.51) 34.86 (5.33) 35.94 (5.51) 35.41 (0.44) 0.796 0.72 (0.54, 0.85) * 0.75 (0.58, 0.87) * 
Minimum Tarsal Angle in Swing (º) 28.01 (7.37) 27.98 (6.82) 27.20 (8.59) 27.73 (0.38) 0.916 0.84 (0.71, 0.92) * 0.84 (0.71, 0.92) * 
Maximum Tarsal Angle in Swing (º) 77.93 (6.84) 77.24 (7.98) 76.59 (9.09) 77.25 (0.56) 0.845 0.61 (0.40, 0.78) * 0.73 (0.54, 0.85) * 
Range Tarsal Angle in Swing (º) 49.92 (5.15) 49.25 (7.25) 49.39 (6.95) 49.53 (0.29) 0.933 0.51 (0.29, 0.72) * 0.64 (0.43, 0.80) * 
Minimum Stifle Angle in Stance (º) -69.42 (14.76) -68.28 (14.05) -67.92 (14.30) -68.54 (0.65) 0.931 0.85 (0.73, 0.92) * 0.85 (0.74, 0.92) * 
Maximum Stifle Angle in Stance (º) -46.58 (13.23) -44.31 (14.18) -44.44 (14.87) -45.12 (1.05) 0.825 0.81 (0.66, 0.90) * 0.84 (0.71, 0.92) * 
Range Stifle Angle in Stance (º) 22.85 (4.81) 23.96 (4.58) 23.48 (5.27) 23.42 (0.46) 0.736 0.61 (0.40, 0.78) * 0.60 (0.39, 0.78) * 
Minimum Stifle Angle in Swing (º) -81.80 (13.70) -80.80 (13.65) -79.57 (15.07) -80.72 (0.93) 0.862 0.79 (0.64, 0.89) * 0.85 (0.73, 0.92) * 
Maximum Stifle Angle in Swing (º) -37.38 (14.23) -34.78 (13.99) -34.18 (14.51) -35.46 (1.41) 0.712 0.84 (0.72, 0.92) * 0.85 (0.73, 0.92) * 
Range Stifle Angle in Swing (º) 44.42 (5.04) 46.02 (6.55) 45.39 (4.84) 45.26 (0.66) 0.605 0.52 (0.30, 0.73) * 0.71 (0.51, 0.85) * 
*  = ICC >0.50 
       






Right Hindlimb        




and 95% CI 
Adjusted ICC and 
95% CI 
       
Stance Duration (s) 0.42 (0.07) 0.44 (0.09) 0.44 (0.10) 0.43 (0.01) 0.729 0.46 (0.24, 0.69) 0.49 (0.27, 0.71)  
Swing Duration (s) 0.34 (0.03) 0.34 (0.03) 0.34 (0.03) 0.34 (0.00) 0.785 0.58 (0.37, 0.77) * 0.69 (0.50, 0.83) * 
Stride Duration (s) 0.76 (0.09) 0.78 (0.11) 0.78 (0.11) 0.77 (0.01) 0.692 0.47 (0.25, 0.70) 0.62 (0.41, 0.79) * 
Ratio Stance To Stride (%) 0.55 (0.04) 0.55 (0.05) 0.55 (0.06) 0.55 (0.00) 0.909 0.49 (0.27, 0.71) 0.48 (0.26, 0.71) 
Ratio Swing To Stride (%) 0.45 (0.04) 0.45 (0.05) 0.45 (0.06) 0.45 (0.00) 0.909 0.49 (0.27, 0.71) 0.48 (0.26, 0.71) 
Ratio Stance To Swing (%) 1.24 (0.19) 1.28 (0.22) 1.28 (0.28) 1.27 (0.02) 0.820 0.44 (0.22, 0.68) 0.41 (0.19, 0.66) 
Hoof Lateral Deviation (cm) 7.74 (1.59) 7.71 (2.06) 7.25 (2.13) 7.56 (0.23) 0.620 0.33 (0.13, 0.63) 0.30 (0.10, 0.62) 
Hoof Forward Swing Velocity (m/s) 2.90 (0.22) 2.83 (0.29) 2.86 (0.23) 2.86 (0.03) 0.569 0.40 (0.19, 0.66) 0.68 (0.48, 0.83) * 
Hoof Vertical Swing Velocity (m/s) 0.23 (0.06) 0.22 (0.06) 0.22 (0.06) 0.22 (0.00) 0.786 0.59 (0.37, 0.78) * 0.80 (0.65, 0.90) * 
Range Hoof Height in Swing (cm) 3.96 (0.83) 3.71 (0.78) 3.87 (0.98) 3.85 (0.10) 0.615 0.61 (0.40, 0.79) * 0.76 (0.59, 0.88) * 
Stride Length (cm) 98.04 (5.69) 96.88 (6.02) 97.94 (6.27) 97.63 (0.52) 0.767 0.66 (0.47, 0.82) * 0.74 (0.56, 0.86) * 
Minimum Hindlimb Fetlock Angle Stance (º) 3.50 (8.58) 0.50 (6.64) 2.66 (7.61) 2.25 (1.26) 0.391 0.60 (0.39, 0.78) * 0.60 (0.39, 0.78) * 
Maximum Hindlimb Fetlock Angle Stance (º) 20.68 (9.73) 18.10 (7.16) 20.44 (9.23) 19.77 (1.16) 0.545 0.67 (0.47, 0.82) * 0.67 (0.47, 0.82) * 
Range Hindlimb Fetlock Angle in Stance (º) 17.19 (4.96) 17.60 (3.84) 17.78 (4.56) 17.52 (0.25) 0.896 0.75 (0.58, 0.87) * 0.75 (0.58, 0.87) * 
Minimum Hindlimb Fetlock Angle in Swing (º) -31.36 (7.82) -31.77 (6.67) -29.69 (7.32) -30.93 (0.91) 0.585 0.39 (0.18, 0.65) 0.48 (0.25, 0.71) 
Maximum Hindlimb Fetlock Angle in Swing (º) 10.82 (9.34) 8.19 (6.77) 11.28 (8.74) 10.12 (1.36) 0.401 0.66 (0.46, 0.81) * 0.66 (0.46, 0.82) * 
Range Hindlimb Fetlock Angle in Swing (º) 42.18 (6.70) 39.96 (7.76) 40.98 (7.26) 41.05 (0.91) 0.578 0.63 (0.43, 0.80) * 0.79 (0.64, 0.89) * 
Minimum Tarsal Angle in Stance (º) 24.61 (6.60) 24.46 (7.20) 24.23 (7.05) 24.43 (0.16) 0.982 0.77 (0.60, 0.88) * 0.77 (0.60, 0.88) * 
Maximum Tarsal Angle in Stance (º) 59.87 (7.37) 61.04 (8.54) 60.60 (7.43) 60.50 (0.48) 0.874 0.65 (0.44, 0.81) * 0.67 (0.47, 0.82) * 
Range Tarsal Angle in Stance (º) 35.26 (5.16) 36.58 (5.63) 36.37 (5.36) 36.06 (0.58) 0.664 0.76 (0.60, 0.87) * 0.75 (0.58, 0.87) * 
Minimum Tarsal Angle in Swing (º) 24.63 (6.41) 24.68 (7.12) 24.38 (7.11) 24.56 (0.13) 0.987 0.76 (0.59, 0.87) * 0.76 (0.58, 0.87) * 
Maximum Tarsal Angle in Swing (º) 73.76 (6.84) 74.52 (8.96) 74.23 (8.00) 74.17 (0.32) 0.946 0.62 (0.41, 0.79) * 0.69 (0.50, 0.84) * 
Range Tarsal Angle in Swing (º) 49.13 (4.90) 49.85 (6.63) 49.85 (5.74) 49.61 (0.34) 0.884 0.68 (0.49, 0.83) * 0.72 (0.53, 0.85) * 
Minimum Stifle Angle in Stance (º) -71.48 (13.23) -71.00 (14.49) -70.55 (13.52) -71.01 (0.39) 0.972 0.91 (0.84, 0.96) * 0.91 (0.84, 0.96) * 
Maximum Stifle Angle in Stance (º) -48.67 (11.71) -47.69 (12.99) -47.31 (13.78) -47.89 (0.58) 0.931 0.84 (0.71, 0.92) * 0.88 (0.77, 0.94) * 
Range Stifle Angle in Stance (º) 22.81 (4.62) 23.31 (5.23) 23.24 (5.03) 23.12 (0.22) 0.932 0.62 (0.41, 0.79) * 0.67 (0.47, 0.82) * 
Minimum Stifle Angle in Swing (º) -84.25 (11.65) -83.32 (14.27) -82.52 (14.29) -83.36 (0.72) 0.905 0.87 (0.76, 0.93) * 0.91 (0.83, 0.95) * 
Maximum Stifle Angle in Swing (º) -39.31 (11.24) -38.23 (12.90) -37.47 (12.59) -38.34 (0.77) 0.872 0.87 (0.76, 0.93) * 0.87 (0.76, 0.93) * 
Range Stifle Angle in Swing (º) 44.94 (5.18) 45.09 (6.13) 45.05 (6.71) 45.03 (0.06) 0.996 0.64 (0.44, 0.80) * 0.73 (0.55, 0.85) * 
Distance Matching Limb during stance (cm) 89.01 (6.85) 88.73 (8.15) 89.58 (9.63) 89.11 (0.36) 0.937 0.59 (0.38, 0.77) * 0.70 (0.51, 0.84) * 





9.3.1.2 Baseline Versus Post-stroke Analysis of Global Parameters 
Following stroke, all global parameters were significantly reduced compared to pre-stroke 
(Table 9.8). Animals walked more slowly, on average reducing the mean forward velocity 
of T1 by 0.28 m/s following stroke onset (p<0.001). Animals also held their head more to 
the centre of the run throughout the gait cycle, with the position of the head to T1 in the 
left/right plane closer to 0 (centre of the run) compared with pre-stroke. The vertical position 
of the head, in relation to T1, was on average 8.21 cm lower 3 days following stroke. T1 in 
relation to T13 was also 1.88 cm lower, and T1 to L7 2.27 cm lower, indicating lowering of 
the thorax following stroke onset. 
 
Table 9.8 Baseline compared to post-stroke global parameters (mean +/- SD) 
Variable Direction 
Mean (SD) of 
three 
baselines 
Post-stroke Mean difference (95% CI) P-value 
Mean Absolute Velocity 
T1 (m/s) 
Forward 1.28 (0.20) 1.00 (0.18) -0.28 (-0.35, -0.22) <0.001 * 
Mean Head to T1 (cm) Left/right 3.39 (6.04) 0.61 (4.79) -2.72 (-5.42, -0.02) 0.049 * 
Mean Head to T1 (cm) Vertical 9.89 (4.10) 1.69 (7.29) -8.21 (-10.73, -5.68) <0.001 * 
Mean T1 to T13 (cm) Vertical -0.51 (1.09) -2.40 (1.56) -1.88 (-2.47, -1.30) <0.001 * 
Mean T1 to L7 (cm) Vertical -3.13 (1.46) -5.40 (1.82) -2.27 (-2.88, -1.67) <0.001 * 




9.3.1.2 Baseline Versus Post-stroke Analysis of Limb Parameters 
Following stroke, deficit of the left forelimb (contralateral to the lesion) was the most 
frequently observed limb-specific change although was not observed in all animals (Figure 
9.4). Although analyses were performed on both hind- and fore-limbs, to focus on deficits 
observed qualitatively, only forelimbs results are reported herein. Hindlimb parameters can 
be found in Appendix 9.2. Furthermore, time-by-limb interactions to determine the effect of 
time (pre- versus post- stroke) on sided limb deficit are reported in Appendix 9.3. Parameters 




were statistically significant are considered statistically reliable and reported as such. 
Parameters for which the interaction term (time*side) (Appendix 9.2) was not statistically 



























Figure 9.5. Joint exemplar data over 0-100 % of the gait cycle for 2 different animals.  Shaded grey 
indicates the stance phase. A, B) joint angles pre stroke and C, D) joint angles 3 days following stroke. A, C) 
This animal did not display significant change of the fetlock joint angle pattern following stroke, as identified 
by the blue line in the left forefoot. B, D) In comparison, this animal displayed significant fetlock dysfunction, 
with a decreased left fetlock angle throughout the cycle and a reduction of left stance duration.  
 
For the left forelimb, following stroke, on average the stance (13 s), swing (0.2 s) and stride 
(15 s) duration were longer than pre-stroke. An increase in the ratio of stance to stride (0.6%) 
and stance to swing (32%) and decrease in swing to stride (-0.6%) was also observed. Lateral 
deviation of the hoof was also less (-1 cm), as was forward (-31 m/s) and vertical (-0.04 m/s) 




was considerably reduced following stroke compared with pre-stroke (97 cm). Joint angles 
were also influenced, including a reduction in the range of the fetlock (-3.9 º) and carpus (-
2.8 º) during swing, an increase in the minimum (6 º) and maximum (5 º) angle of the elbow 
during stance, and increase in the maximum angle of the elbow during swing (5 º). When 
adjusted for velocity, the duration in stance and stride remained longer than pre-stroke, as 
did the increased ratio of stance to stride, and decreased ratio of swing to stride. Lateral 
deviation of the hoof remained reduced following adjustment, as did decreased range of 
flexion-extension of the elbow during stance. When both un-adjusted and adjusted for 
velocity, no differences were observed for minimum, maximum or range of the fetlock or 
stifle joint angles.  
 
For the right limb, stroke resulted in an increase in stance (14 s), swing (2 s), and stride (15 
s) duration, and decrease in stride length (-7 cm). This resulted in an increased ratio of stance 
to stride (0.6) and stance to swing (0.33), and decrease in swing to stride (-0.6). A reduction 
in hoof lateral deviation (-1.4 cm), hoof forward swing velocity (-0.3 m/s), range in the hoof 
height during swing (-0.7 cm) and increase in hoof vertical swing velocity (0.05 m/s) were 
also observed. Regarding joint angles, the minimum angle of the fetlock was increased 
during swing (2 º), although the range was reduced (- 3 º). The minimum angle of the carpus 
was increased during swing (3 º) and range decreased (-3 º). Following adjustment for 
velocity, differences in stance, stride, ratio of stance to stride, swing to stride and stance to 
swing remained, as did hoof lateral deviation, vertical swing velocity, and hoof height range. 
No differences were observed for joint angles when adjusted for velocity. The distance 





Parameters observed to have a significant interaction between time and limb side (Appendix 
9.3) included hoof forward swing velocity, range of the fetlock angle during swing, and 
maximum carpal angle during swing. The interaction remained significant for these variables 
following adjustment for velocity. Further, the interaction term for the range of the elbow 
during stance was significant following velocity adjustment. It was, however, not significant 









Table 9.9 Baseline compared to post-stroke fore-limb parameters (mean +/- SD) 
Left Forelimb 
     
Variable Mean Baselines Post-stroke 
Mean difference un-




adjusted (95% CI) 
P-value 
adjusted 
Stance Duration (s) 0.41 (0.01) 0.54 (0.11) 0.13 (0.11, 0.16) <0.001 * 0.02 (0.00, 0.05) 0.037 * 
Swing Duration (s) 0.36 (0.00) 0.38 (0.04) 0.02 (0.01, 0.03) <0.001 * 0.00 (-0.01, 0.01) 0.851 
Stride Duration (s) 0.77 (0.01) 0.92 (0.13) 0.15 (0.12, 0.18) <0.001 * 0.03 (0.00, 0.05) 0.028 * 
Ratio Stance To Stride (%) 0.52 (0.01) 0.58 (0.04) 0.06 (0.05, 0.07) <0.001 * 0.02 (0.00, 0.03) 0.018 * 
Ratio Swing To Stride (%) 0.48 (0.01) 0.42 (0.04) -0.06 (-0.07, -0.05) <0.001 * -0.02 (-0.03, -0.00) 0.018 * 
Ratio Stance To Swing (%) 1.13 (0.02) 1.44 (0.23) 0.31 (0.24, 0.39) <0.001 * 0.06 (-0.01, 0.14) 0.096 
Hoof Lateral Deviation (cm) 7.40 (0.08) 6.39 (2.04) -1.02 (-1.88, -0.16) 0.020 * -1.10 (-2.13, -0.07) 0.036 * 
Hoof Forward Swing Velocity (m/s) 2.72 (0.03) 2.42 (0.25) -0.31 (-0.38, -0.23) <0.001 * -0.05 (-0.12, 0.03) 0.240 
Hoof Vertical Swing Velocity (m/s) 0.37 (0.02) 0.32 (0.09) -0.04 (-0.07, -0.02) 0.003 * -0.03 (-0.07, 0.00) 0.061 
Range Hoof Height in Swing (cm) 6.73 (0.33) 6.10 (1.89) -0.62 (-1.20, -0.03) 0.038 * -0.56 (-1.27, 0.15) 0.124 
Stride Length (cm) 97.88 (0.96) 90.60 (5.41) -7.41 (-9.25, -5.58) <0.001 * -1.50 (-3.34, 0.33) 0.109 
Minimum Forelimb Fetlock Angle Stance (º) 5.12 (0.75) 4.16 (9.73) -1.01 (-5.06, 3.03) 0.624 0.57 (-4.09, 5.24) 0.810 
Maximum Forelimb Fetlock Angle Stance (º) 20.47 (0.70) 19.73 (9.89) -0.83 (-4.90, 3.24) 0.689 -0.38 (-5.21, 4.46) 0.879 
Range Forelimb Fetlock Angle in Stance (º) 15.35 (0.12) 15.57 (4.10) 0.18 (-1.60, 1.96) 0.841 -0.77 (-2.94, 1.39) 0.485 
Minimum Forelimb Fetlock Angle in Swing (º) -28.04 (1.22) -24.69 (11.23) 3.17 (-0.96, 7.30) 0.132 3.26 (-1.54, 8.05) 0.183 
Maximum Forelimb Fetlock Angle in Swing (º) 12.84 (0.63) 12.21 (9.22) -0.73 (-4.74, 3.28) 0.721 0.94 (-3.76, 5.63) 0.696 
Range Forelimb Fetlock Angle in Swing (º) 40.88 (0.59) 36.90 (7.81) -3.90 (-6.62, -1.18) 0.005 * -2.17 (-5.45, 1.11) 0.195 
Minimum Carpal Angle in Stance (º) -14.47 (0.41) -15.47 (4.77) -1.01 (-3.98, 1.96) 0.506 -0.98 (-4.49, 2.53) 0.584 
Maximum Carpal Angle in Stance (º) -2.15 (0.30) -4.31 (4.91) -2.15 (-4.85, 0.54) 0.118 -0.49 (-3.77, 2.79) 0.769 
Range Carpal Angle in Stance (º) 12.32 (0.12) 11.16 (2.99) -1.15 (-3.24, 0.95) 0.283 0.55 (-1.91, 3.01) 0.663 
Minimum Carpal Angle in Swing (º) -76.72 (1.32) -75.37 (6.58) 1.42 (-1.71, 4.54) 0.374 0.70 (-3.10, 4.51) 0.717 
Maximum Carpal Angle in Swing (º) -3.77 (0.43) -5.18 (5.30) -1.40 (-4.54, 1.74) 0.383 -0.00 (-3.79, 3.78) 0.999 
Range Carpal Angle in Swing (º) 72.95 (1.44) 70.19 (6.41) -2.81 (-5.58, -0.05) 0.046 * -0.61 (-3.93, 2.71) 0.719 
Minimum Elbow Angle in Stance (º) 51.94 (0.02) 57.92 (6.73) 6.00 (0.55, 11.45) 0.031 * 4.84 (-1.64, 11.33) 0.143 
Maximum Elbow Angle in Stance (º) 76.78 (0.43) 81.98 (6.87) 5.18 (-0.07, 10.43) 0.053 * 2.08 (-4.06, 8.22) 0.507 
Range Elbow Angle in Stance (º) 24.83 (0.43) 24.05 (3.86) -0.82 (-3.21, 1.57) 0.503 -3.03 (-5.81, -0.25) 0.033 * 
Minimum Elbow Angle in Swing (º) 53.12 (0.14) 58.82 (6.46) 5.71 (0.54, 10.87) 0.030 * 3.50 (-2.66, 9.66) 0.265 
Maximum Elbow Angle in Swing (º) 95.27 (0.58) 100.21 (7.49) 4.88 (-0.49, 10.25) 0.075 2.92 (-3.40, 9.23) 0.365 
Range Elbow Angle in Swing (º) 42.16 (0.69) 41.40 (4.61) -0.83 (-3.12, 1.46) 0.479 -0.91 (-3.67, 1.85) 0.518 









Right forelimb       
Variable Mean Baselines Post-stroke 
Mean difference un-




adjusted (95% CI) 
P-value 
adjusted 
Stance Duration (s) 0.41 (0.01) 0.55 (0.11) 0.14 (0.11, 0.16) <0.001 * 0.03 (0.00, 0.05) 0.020 * 
Swing Duration (s) 0.36 (0.00) 0.38 (0.02) 0.02 (0.01, 0.02) 0.002 * -0.00 (-0.01, 0.01) 0.567 
Stride Duration (s) 0.77 (0.01) 0.92 (0.13) 0.15 (0.12, 0.18) <0.001 * 0.03 (0.00, 0.05) 0.039 * 
Ratio Stance To Stride (%) 0.52 (0.00) 0.59 (0.04) 0.06 (0.05, 0.08) <0.001 * 0.02 (0.01, 0.04) 0.004 * 
Ratio Swing To Stride (%) 0.48 (0.00) 0.41 (0.04) -0.06 (-0.08, -0.05) <0.001 * -0.02 (-0.04, -0.01) 0.004 * 
Ratio Stance To Swing (%) 1.13 (0.02) 1.47 (0.28) 0.33 (0.25, 0.41) <0.001 * 0.08 (0.01, 0.16) 0.033 * 
Hoof Lateral Deviation (cm) 7.29 (0.22) 5.88 (1.57) -1.43 (-2.29, -0.57) 0.001 * -1.51 (-2.54, -0.48) 0.004 * 
Hoof Forward Swing Velocity (m/s) 2.70 (0.04) 2.41 (0.18) -0.30 (-0.37, -0.22) <0.001 * -0.03 (-0.11, 0.04) 0.363 
Hoof Vertical Swing Velocity (m/s) 0.36 (0.01) 0.30 (0.06) -0.05 (-0.08, -0.02) <0.001 * -0.04 (-0.08, -0.01) 0.023 * 
Range Hoof Height in Swing (cm) 6.48 (0.16) 5.71 (1.20) -0.78 (-1.36, -0.19) 0.009 * -0.72 (-1.43, -0.01) 0.048 * 
Stride Length (cm) 97.44 (0.81) 90.52 (5.57) -7.05 (-8.88, -5.22) <0.001 * -1.14 (-2.98, 0.70) 0.224 
Minimum Forelimb Fetlock Angle Stance (º) 6.42 (1.39) 5.87 (8.97) -0.37 (-4.42, 3.67) 0.856 1.21 (-3.46, 5.88) 0.611 
Maximum Forelimb Fetlock Angle Stance (º) 21.60 (1.00) 21.57 (9.46) 0.11 (-3.96, 4.17) 0.959 0.56 (-4.27, 5.40) 0.820 
Range Forelimb Fetlock Angle in Stance (º) 15.18 (0.39) 15.71 (4.29) 0.48 (-1.30, 2.26) 0.596 -0.47 (-2.64, 1.69) 0.669 
Minimum Forelimb Fetlock Angle in Swing (º) -26.05 (0.68) -23.78 (8.87) 2.32 (-1.80, 6.45) 0.270 * 2.41 (-2.39, 7.20) 0.325 
Maximum Forelimb Fetlock Angle in Swing (º) 14.43 (0.82) 13.32 (9.07) -0.99 (-5.00, 3.02) 0.629 0.68 (-4.02, 5.38) 0.777 
Range Forelimb Fetlock Angle in Swing (º) 40.48 (0.64) 37.10 (6.51) -3.31 (-6.03, -0.60) 0.017 * -1.58 (-4.86, 1.70) 0.345 
Minimum Carpal Angle in Stance (º) -17.70 (0.75) -17.55 (4.79) 0.13 (-2.84, 3.10) 0.933 0.15 (-3.36, 3.67) 0.931 
Maximum Carpal Angle in Stance (º) -3.90 (0.54) -5.18 (3.49) -1.28 (-3.98, 1.41) 0.351 0.38 (-2.90, 3.66) 0.821 
Range Carpal Angle in Stance (º) 13.80 (0.24) 12.37 (3.32) -1.41 (-3.50, 0.68) 0.186 0.28 (-2.18, 2.74) 0.822 
Minimum Carpal Angle in Swing (º) -79.30 (0.72) -76.25 (6.76) 3.08 (-0.05, 6.20) 0.054 * 2.36 (-1.44, 6.17) 0.224 
Maximum Carpal Angle in Swing (º) -5.66 (0.52) -6.14 (3.72) -0.47 (-3.61, 2.66) 0.767 0.92 (-2.87, 4.71) 0.634 
Range Carpal Angle in Swing (º) 73.64 (1.23) 70.12 (5.74) -3.55 (-6.31, -0.79) 0.012 * -1.35 (-4.67, 1.97) 0.427 
Minimum Elbow Angle in Stance (º) 53.77 (0.37) 56.38 (9.20) 2.52 (-2.93, 7.97) 0.366 1.36 (-5.12, 7.85) 0.681 
Maximum Elbow Angle in Stance (º) 77.13 (0.16) 81.20 (8.27) 3.98 (-1.27, 9.23) 0.137 0.88 (-5.26, 7.02) 0.778 
Range Elbow Angle in Stance (º) 23.36 (0.50) 24.82 (7.63) 1.46 (-0.93, 3.86) 0.230 -0.75 (-3.53, 2.03) 0.598 
Minimum Elbow Angle in Swing (º) 55.20 (0.49) 57.95 (8.95) 2.65 (-2.51, 7.82) 0.314 0.45 (-5.71, 6.60) 0.887 
Maximum Elbow Angle in Swing (º) 96.03 (0.43) 99.29 (8.73) 3.14 (-2.23, 8.51) 0.252 1.17 (-5.14, 7.49) 0.716 
Range Elbow Angle in Swing (º) 40.83 (0.49) 41.34 (7.18) 0.49 (-1.80, 2.78) 0.677 0.40 (-2.36, 3.16) 0.775 
Distance Matching Limb during stance (cm) 51.28 (0.33) 47.51 (2.87) -3.84 (-5.92, -1.77) <0.001 * -0.62 (-2.92, 1.67) 0.595 





9.3.2 Neuroscore Assessment 
Total neurological scores of 0 were typically seen in all animals across the three baseline 
sessions, with the exception of minor abnormalities in postural reactions (p>0.05, Figure 9.5, 
A). Following stroke, scores at 3 days were significantly higher when compared to pre-injury 
assessment, indicating considerable deficit (p<0.0001).  
 
Assessment of demeanour incorporated both head posture and overall state of consciousness, 
with 21 of the 24 animals displaying evidence of apathy 3 days following stroke. This was 
significantly different to pre-stroke assessment, where demeanour appeared normal in all 
animals across baseline sessions (p<0.0001, Figure 9.5, B). Circling behaviour was observed 
in 6 animals’ post-stroke, with consistent movement in a clockwise direction documented 
(towards side of lesion). Quantitative behavioural changes incorporating circling, torticollis, 
flexion of the fetlock, and dysmetria, however, were not significantly different between pre- 
and post-stroke assessments (p>0.05, Figure 9.5, C). 
 
Regarding postural reactions, following stroke lateral drifting of was observed in 14/24 
animals assessed via “wheelbarrowing” (p<0.05, Figure 9.5, C).  Considering left and right 
sided reactions, there was a significant difference seen in the ipsilateral limbs following 
stroke when compared to baseline (p<0.05, Figure 9.5, E). This was significantly more 












































Figure 9.6. Neurological scores across baseline and post-stroke testing sessions. (A) total neuroscore, and 
scores for (B) demeanour, (C) behaviour, (D) “wheelbarrowing”, (E) ipsilateral postural reactions and (F) 







In this study we present a comprehensive approach to assessing functional outcome in an 
ovine model of stroke. First, using motion capture, we developed a method to assess gait 
kinematics. We have shown this approach to be repeatable in healthy animals through 
comparison of baseline pre-stroke trials and subsequently used these findings to assess 
changes in gait 3 days following stroke. Second, through adaptation of a neurological 
assessment score, we characterised the pre- and post-stroke response of animals, beyond the 
scope of kinematic assessment, including animal circling, behaviour, demeanour and 
postural reactions. Taken together, this approach to functional assessment provides an 
opportunity for the evaluation of medical and surgical interventions following stroke, and 
their contribution to function in a large animal model. 
 
9.10.1 Repeatability of Motion Capture 
In this study we showed that the position of the head in relation to T1, T13 and L7 across 
baseline trials had good repeatability, with animals consistently walking with their head 
upright, and slightly towards the right. Although the average speed of walking was 
comparable across animals with a low reported standard deviation, velocity had poor 
repeatability. This may have subsequently influenced limb specific parameters of interest. 
Indeed, it is well established that gait patterns change as a function of velocity (Fukuchi et 
al., 2019, Broom et al., 2017). This is true under physiological conditions and factoring in 
all velocity-related changes when assessing gait in disease is especially challenging. 
Previous studies suggest observation of gait characteristics when speed is not controlled 
leads to variable speeds from trial to trial, which is often significantly impacted following 
experimental intervention. This is true for both experimental animals (Herbin et al., 2007, 




Iersel et al., 2007, Keene et al., 2016, Astephen Wilson, 2012). Neglect of velocity has also 
been proposed to lead to oversimplification of analysis and loss of potentially valuable data 
(Broom et al., 2017). The repeatability of limb-specific measures of interest reported herein 
improved when adjusted for walking speed via regression analysis. Such use of regression-
based analysis has been suggested as a robust approach to translational gait analysis (Batka 
et al., 2014, Broom et al., 2017). This suggests our method is reproducible and enables 
application in various experimental conditions and environments, especially those where 
velocity is not a controlled measure.  
 
Previous studies have used treadmills for functional assessment in sheep (Safayi et al., 2015, 
Safayi et al., 2016, Wilson et al., 2017). Although this offers the advantage of controlling 
walking speed, the selected speed of the treadmill has been shown to directly influence 
walking patterns (Parvataneni et al., 2009, Chen et al., 2005, Riley et al., 2007). Importantly, 
faster speed has been shown to facilitate a more normal walking pattern following stroke in 
humans (Brouwer et al., 2009). Given the unilateral effects of MCAo, the ability to 
accurately assess deficits of symmetry is imperative. Although we did not detect differences 
in symmetry in the aggregate data presented herein, allowing animals to walk at their own 
pace may enable more accurate assessment of asymmetric gait following stroke, which can 
retrospectively be adjusted for velocity. Further, for humans, treadmill tasks are also often 
used as a means of post-stroke rehabilitation (Tyrell et al., 2011). Ergo, speed-controlled 
treadmill tasks could improve functional outcome via incidental rehabilitation, obscuring 
accurate assessment of intervention. Enabling animals to walk at their own pace also allowed 
us to determine the ‘comfortable’ walking speed pre and post injury: an important 




processing is of benefit from both ethical and experimental perspectives and favours the 
generation of more reliable data.  
 
In addition to accounting for velocity, assessing the variation across baseline trials allowed 
us to determine the reliability of findings following onset of injury. This provided important 
information regarding the utility of motion capture for functional assessment in large animal 
species. Across the three baseline sessions, we observed good repeatability of most, but not 
all, limb-specific outcome measures. Repeatability of human gait kinematics using motion 
capture in multiple laboratories is high (ICC >0.80), suggesting motion capture is a valuable 
tool across a range of environments and in different species (Charlton et al., 2020). Although 
most measures reported were repeatable, the few that were not varied between limb and side 
of the body. Specifically, all joint angles were repeatable with the exception of the left fore 
and right hindlimb minimum fetlock angle during swing, which was observed when both 
adjusted and unadjusted for velocity. The retro-reflective markers on the distal limbs were 
smaller (9 mm) than the other markers (15 mm) due to the close proximity placement on the 
hooves. Due to reduced spatial resolution, these markers frequently required more extensive 
gap filling during post-processing. This may have introduced more error, potentially 
confounding experimental results. Other fetlock angle parameters, however, were repeatable 
throughout baseline testing, including the minimum fetlock angle during swing for both the 
right fore and left hindlimb. Discrepancy may thus also represent variation of animal 
behaviour during overland walking. Future analyses should aim to improve data capture for 
the distal forelimbs and focus on assessing repeatable measures reported herein to accurately 





The baseline gait outcomes reported in this study were generally consistent with other gait 
assessments performed in healthy sheep. Shelton and colleagues reported a stride length of 
approximately 1 m in mature female sheep, comparable to the present study (~98 cm for all 
limbs) (Shelton et al., 2011). The duration of the gait cycle phases was also consistent with 
previous studies as summarised in Table 9.10 (Agostinho et al., 2012, Safayi et al., 2015, 
Tapper et al., 2004, Tapper et al., 2006, Wilson et al., 2017, Kim and Breur, 2008)   
 
Table 9.10 Stride, swing and stance duration in clinically healthy sheep  
  
Forelimb (L/R where applicable)  
























0.41 0.36 0.77   0.43 0.34 0.77  
Tapper 
2004 
- - -   - - - / 0.98  
Tapper 
2006 
- - -   - - - / 0.94  
Agostinho 
2012 
0.41 0.28 0.70   0.43 0.27 0.69  
Safayi 
2015 
0.46 0.37 0.84   0.47 0.37 0.84  
Wilson 
2017 0.51/0.49 0.33/0.34 0.84 
  0.49 0.35 0.84  
Kim 2008 0.55 0.27 0.82   0.57 0.25 0.82  
 
Limb joint flexion and extension throughout walking gait has also been reported in the ovine 
gait literature. Previous studies have primarily focused on the upper hind limb (stifle and 
hock joints). Tapper et al (2004) observed a minimum stifle flexion of -77 and maximum of 
-43 degrees, with a range of 34 degrees in healthy female Suffolk sheep. These values were 
reported over the entire gait cycle. Conversely, we observed a minimum stifle angle of -68 




swing for the right hindlimb. We also observed a maximum stifle angle of -45 in stance and 
-35 in swing for the left hindlimb, and maximum of -47 and -38 for stance and swing 
respectively for the right hindlimb. Ergo, the range of motion of both the left and right stifle 
during stance was 23, however, during swing was 45.  
 
There is limited published data regarding the fetlock angle of ruminants. The fetlock angle 
of horses has, however, been extensively researched (Peham et al., 2006, Crevier-Denoix et 
al., 2013). During cantering (+/- 8.3 m/s) on a synthetic surface, Crevier-Denoix and 
colleagues reported a minimum angle of the equine fetlock of 97 degrees in the leading limb 
and 95 for the trailing limb during stance. The maximal fetlock angle was 166 for the leading 
at 165 degrees for the trailing limb. This equates to a range of motion of 69 degrees for the 
leading and 70 for the trailing limb (Crevier-Denoix et al., 2013). During walking (+/- 2.2 
m/s), Peham et al., reported an approximate minimum joint angle of 140 and maximum of 
220 degrees, equating to a range of 80 degrees (Peham et al., 2006). At an average velocity 
of 1.2 m/s, our study observed a minimum fetlock angle of 5 degrees and maximum of 20 
during stance in the left forelimb, and minimum of 6 degrees and maximum of 21 for the 
right forelimb. This equates to a range of motion of 15 degrees for both limbs. Although 
these values differ from those reported in the equine literature, differences may reflect 
allocation of flexion direction. Indeed, when observing the overall pattern of the gait cycle 
of the equine fetlock, the gait signature was qualitatively comparable to the sheep (Peham et 








We observed a significant reduction in forward velocity following stroke. A reduction of the 
head position in relation to T1, T1 to T13, and T1 to L7, was also observed, indicating 
significant lowering of the head and thorax post-ictus. These findings are potentially 
indicative of motor deficit and/or of animal apathy. Indeed, post-stroke apathy, mood and 
emotional disturbances are common clinically, where patients often present with a loss of 
motivation and initiative (Van Dalen et al., 2013). Conducting cognitive tasks may provide 
a more accurate measure of motivation, with systems developed for use in sheep (Sorby-
Adams et al., 2021, McBride et al., 2016, Morton and Avanzo, 2011, Knolle et al, 2019). 
Although not reported herein, cognitive assessment represents an avenue for future 
assessment. 
 
With regard to limb specific parameters, swing, stance and stride durations were 
substantially longer post-stroke than any reported values in clinically healthy animals, both 
in this study (statistically significant) and others (Agostinho et al., 2012, Safayi et al., 2015, 
Tapper et al., 2004, Tapper et al., 2006, Wilson et al., 2017, Kim and Breur, 2008). The 
increases observed effected both forelimbs irrespective of whether ipsi- or conta- lateral to 
the lesion. Animals also spent a significantly longer duration in stance compared with both 
swing and stride. This, in conjunction with decreased velocity, indicates that animals were 
less willing/able to execute forward movement. Furthermore, lateral deviation of the hoof in 
both left and right limbs was less than pre-stroke, as were forward and lateral swing velocity; 
indicating a slower pace and more ‘drag’ of the limb 
 
Dysfunction of the left forelimb, contralateral to the lesion, was qualitatively observed 
following stroke herein and in previous studies (Sorby-Adams et al., 2019a, Boltze et al., 




two different animals in Figure 9.5. This study observed no statistically significant 
differences in joint angle minimum, maximum and range for this limb, with the exception 
of the range of the elbow joint. It is important to note that the minimum angle of the elbow 
had low repeatability across baseline sessions, so the significance of this finding is 
questionable. Further, although gait durations were reduced, comparable findings of joint 
angle minimum, maximum and range for were observed in the right forelimb. Indeed, when 
comparing the left and right forelimbs, aggregate deficits are almost identical to the right. 
This suggests an overall reduction in animal well-being, rather than the unilateral, stroke 
specific deficit that was anticipated.  
 
Adjusting for velocity reduced the mean difference between pre- and post-stroke for most 
outcomes, although significant differences remained. These findings were true of stance, 
stride and hoof lateral deviation irrespective of limb. This suggests that the change in gait 
parameters seen following stroke may reflect a change in gait signature due to the underlying 
pathology, not just a change in velocity. However, although these changes remained, they 
were not as anticipated. As per the exemplar data, if significant sided deficit was present, a 
reduction in stance of the effected limb due to hemiparesis and inability to execute motor 
control, and subsequent compensatory increase in stride of the unaffected limb would be 
expected. Indeed, the lack of significant differences between pre and post stroke joint angles 
was unexpected, particularly of the fetlock. Although fetlock paresis was observed during 
testing, deficit was not pronounced for every animal. Furthermore, if deficit was present, it 
was not consistent for every step of the gait cycle. Consequently, although we observed a 
qualitative loss of motor control of the left fetlock, it appears we have not accurately captured 
this deficit in this model, or so few animals displayed deficit such that findings were not 




processed due to the significant time commitment. This suggests further trials may be 
necessary to increase the likelihood of accurately detecting sided deficit.   
 
9.10.3 Neuroscore 
Using the modified neuroscore, this study observed significant dysfunction following stroke 
onset, in keeping with previous studies (Boltze et al., 2008). Animals displayed evidence of 
abnormal movement of the thoracic limbs, and both ipsi- and contra- lateral postural 
reactions. Alterations in demeanour, including lowering of the head, were observed 
following stroke onset, in keeping with kinematic findings. Animals were also regarded as 
being apathetic, however, no sheep were reported as being in a state of stupor or comatose. 
Despite promising findings, the post-operative course may be a potential confounder of 
animal demeanour, and this finding may not be a reliable measure of cerebral ischaemia 
(Freret et al., 2011). In comparison, postural disturbances are a reliable indicator of 
veterinary neurological dysfunction, including stroke (Thomsen et al., 2016). Postural 
reactions in large animal species, however, are difficult to obtain because of their large size, 
requiring significant manual handling. Slight variability was consequently observed in 
baseline postural reaction tests. This likely reflects the fact that on occasion, animals were 
unwilling to perform the task, lying down or showing no desire to respond to the 
perturbation.  
 
When assessing the thoracic limbs, we observed a significant deficit during wheelbarrowing. 
Fourteen animals displayed evidence of deficit, stumbling or knuckling during forward 
movement, with an additional 2 animals unable to coordinate movement of the limbs at all, 
and subsequently falling over. In evaluating ipsi- versus contra-lateral deficit, postural 




hopping and lateral drag. Although deficits were comparably more significant in the left 
forelimb, statistically significant differences were also observed in the right following stroke 
onset when compared to baseline. These findings support the motion capture findings, 
suggesting global deficit, rather than limb specific changes. 
 
9.10.4 Limitations of This Method 
There were several limitations in this study. Firstly, markers attached to areas with more 
overlying tissue were prone to skin motion artefact. Marker pins inserted directly into the 
bone eliminate skin motion artefact, although this was not possible in this study due to the 
number of markers and duration of post-stroke assessment, as pins can be painful and 
increase likelihood of infection. Skin motion artefact was minimised by selecting marker 
positions with minimal overlying soft tissue, not performing analysis of joints/bones with 
substantial overlying muscle mass, and tattooing the skin to make marker placement 
repeatable. Tattooing was, however, less distinguishable over the superficial bones of the 
distal limb, so reattachment of markers at these sites may have been more variable. Secondly, 
we only performed 2D analysis predominantly in the sagittal plane. Three-dimensional joint 
angle analysis provides more comprehensive (i.e. rotations about three axes) and accurate 
(i.e. relative to anatomical coordinate systems rather than a global coordinate system) joint 
angle assessment. We were limited in our approach due to the relative size of the animal, 
where given the number of joints assessed, there was insufficient space on rigid bodies to 
place additional markers.  Future analyses should focus on only assessing outcomes of 
relevance and where possible, ensuring markers are placed on rigid bodies. Thirdly, due to 
2D analysis, any deviation from straight line walking in the forward direction (y axis in the 
global coordinate system) could lead to errors in sagittal plane measures. This was 




which the animal was walking over the centre of the motion capture field, and discarding 
trials where animals deviated from straight line walking. Finally, for both motion capture 
and neuroscore, we only reported one occasion post-stroke. To accurately capture the 
temporal profile of post-stroke gait changes, functional studies should, ideally, mimic the 




Functional outcome a major endpoint in stroke clinical trials, and an essential consideration 
in pre-clinical stoke models. In this study we developed a comprehensive method to assess 
function following stroke in a clinically-relevant ovine model. Following stroke, animals 
exhibited deficit, observed both kinematically via motion capture and via composite scoring. 
This method enables the assessment of novel therapeutics on stroke outcome and has the 
potential to be applied to other large animal models of central nervous system injury 
including traumatic brain injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s 
disease.    
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This thesis characterised a clinically relevant model of ovine stroke in which the efficacy of 
an NK1-R antagonist (EU-C-001) was investigated. In Chapter 6, we successfully 
demonstrated that 2 doses of the NK1-R significantly reduced ICP post-stroke, comparable 
to decompressive craniectomy. In Chapter 7, we demonstrated that cerebral oedema and ICP 
rose in a delayed fashion following ovine stroke with reperfusion, peaking at 5-6 days, 
comparable to the clinical scenario. In Chapter 8, we determined that the NK1-R antagonist 
was able to successfully sustain a reduction in ICP compared with vehicle when given both 
acutely (1-3 days) and in a delayed fashion (5 days) post transient stroke. Finally, in Chapter 
9, we developed a novel method of ovine functional assessment, assessing gait kinematics 
using motion capture, in addition to development of a neuroscore to assess deficits beyond 
the scope of biomechanical assessment. Using these methods, we were able to successfully 
detect behavioural changes following stroke onset. Taken together, these findings highlight 
the relevance of NK1-R antagonism as a viable treatment for cerebral oedema and 
concomitant rise in ICP post-stroke. This general discussion will summarise and integrate 
the main findings across doctoral chapters, highlighting the contribution of research to the 
field, and suggest avenues for future analyses.  
 
10.1 NK1-R ANTAGONIST TREATMENT REDUCES ICP - IRRESPECTIVE OF 
REPERFUSION STATUS OR TREATMENT WINDOW 
 
This thesis observed marked increases in ICP following ischaemic stroke under both 
permanent and transient stroke conditions. Following permanent MCAo (Chapter 6), ICP 




mmHg at 19 hours, and 39 mmHg by the terminal 24-hour endpoint. These findings 
corroborate previous studies in our ovine model, where ICP was significantly elevated 
following permanent, but not transient MCAo at 24 hours post-stroke (Wells et al., 2015) . 
To examine more sub-acute time-points after stroke with reperfusion (Chapter 7), this thesis 
observed a significant increase in ICP at 5 (28 mmHg) and 6 days (25 mmHg) post-ictus, 
which began to resolve at 7 days. Across the studies reported herein, both permanent and 
transient stroke animals reported ICP values significantly higher than sham operated animals 
(10 mmHg).  
 
The finding of aggravated ICP following complete MCA occlusion, and delayed increases 
following temporary/partial arterial obstruction, support the human literature where raised 
ICP characteristically presents within 2-5 days of stroke onset following failure of cerebral 
autoregulation (Hacke et al., 1996). In the neurointensive care unit, ICP in excess of 20 
mmHg is associated with an increased risk of herniation, death and disability, necessitating 
appropriate intervention (Jeon et al., 2014, Pinto et al., 2020). Clinical management of 
intracranial hypertension is typically approached in a step wise manner (Chapter 1) seeking  
first to consider general management approaches to reduce ICP (hypertension) and avoid 
factors that aggravate or precipitate elevation of ICP (inadequate venous drainage) (Jeon et 
al., 2014).  Osmotherapeutic agents are typically administered in an attempt to reverse 
osmotic drive, albeit associated with transient effects and increased likelihood of rebound 
oedema (Brogan and Manno, 2015, Cho, 2007, Maioriello et al., 2002, Burgess et al., 2016). 
In patients with MMCAI, elevated ICP is resistant to conservative management, with 
mortality ranging up to 70%-80% with medical treatment alone (Hacke et al., 1996, Qureshi 





When intracranial hypertension is refractory to medical management (remaining between 
20-25 mmHg), surgical intervention with DC is warranted. DC reduces ICP, relieves tissue 
shifts, and improves mortality when performed within 48 hours of stroke (Vahedi et al., 
2007a, Vahedi et al., 2007b, Geurts et al., 2013, Jüttler et al., 2007, Hofmeijer et al., 2009). 
Indeed, DC is superior to other treatment modalities used to manage elevated ICP, bringing 
about at 19 mmHg reduction in pressure when compared with hyperventilation (6 mmHg), 
mannitol (8 mmHg), barbiturates (8 mmHg), hypothermia (10 mmHg), hypertonic saline (15 
mmHg), or CSF drainage (15 mmHg) (Schreckinger and Marion, 2009). Despite 
unequivocal effects on survival, DC is associated with an increased risk of perioperative 
injury and morbidity in the elderly. With a lack of efficacious pharmacological interventions, 
however, it remains the current best-approach to clinical management. Replicating the 
clinical scenario in this thesis, ICP was shown to be attenuated following pterional DC 
performed 2 hours after stroke onset (Chapter 6). Following DC, pressure rose slightly, yet 
was maintained below 19 mmHg (-10 mmHg compared with vehicle) for the duration of the 
24-hour monitoring period.  
 
Attenuated ICP following DC in this model subsequently provided a clinically relevant 
measure in which we were able to compare outcomes following NK1-R administration. 
When treatment was administered following permanent stroke, we observed a significant 
reduction in ICP following 2 (18 mmHg) and 3 (17 mmHg) doses of the NK1-R antagonist 
at 19 hours post-ictus. This reduction was sustained for both regimens (2 doses 20 mmHg: 
3 doses 19 mmHg), with ICP comparable to DC and with no rebound cerebral oedema or 
elevated ICP observed. Indeed, the most remarkable finding of this study was the fact that 
NK1-R antagonist treatment was able to reduce ICP to the same extent as DC surgery. 




effect on ICP. The lack of treatment effect seen in the single bolus NK1-R group may be due 
to the need for the drug to sufficiently saturate binding sites in different body compartments. 
Given that NK1-R are ubiquitously expressed throughout the body, initial dosing may cause 
preferential distribution and saturation of compartments such as the gastrointestinal tract. 
The first dose may thus be required for initial loading to saturate non-brain compartments, 
with the second dose able to bring about a treatment effect in the target organ, which in this 
study is the brain. However, the significant reduction in ICP following 2 × and 3 × doses of 
the NK1-R antagonist administered intravenously suggest it is a promising therapeutic 
strategy to reduce elevated ICP following stroke, due to its ability to produce a clinically-
meaningful and sustained reduction in pressure, whilst at the same time circumventing the 
need for invasive surgery with inherent post-operative risks (Hacke et al., 1996). 
 
Given the increased rate of vascular recanalisation following stroke due to the increased 
uptake of endovascular clot retrieval and extended window for thrombolysis in select 
patients, there is a need for reperfusion-centric pre-clinical research. Accordingly, we also 
investigated the efficacy of NK1-R administration following transient stroke (Chapter 8). 
The clinical course of elevated ICP was determined in Chapter 7, where increased ICP was 
observed at 5-6 days post stroke. This time-course was subsequently used to guide 
administration of the NK1-R antagonist following stroke with reperfusion (Chapter 8). A 
significant reduction in ICP was observed when treatment was administered prior to onset 
of elevated ICP (administration on days 1-3) and following delayed onset when elevated ICP 
was already established at 5 days post-stroke. When ICP was measured at 6 days, early NK1-
R treatment maintained ICP at 13 mmHg, and late treatment at 11 mmHg, compared with 
vehicle animals who reported ICP as high as 24 mmHg during the same period. The ability 




fashion was a particularly promising finding of this study. Indeed, the most significant 
limitation to current stroke intervention is time, hence the stroke mantra ‘time is brain’ 
(Saver, 2006). Prompt diagnosis of stroke subtype is key to expedite treatment and improve 
outcomes for those affected (Marchese et al., 2016, Yew and Cheng, 2015). Time to 
treatment onset can be significantly extended for those living in rural communities, which is 
costly in terms of outcome (Ader et al., 2019). The importance of treatment timing is also 
relevant for the management of post-stroke cerebral oedema. DC performed too soon after 
ictus may cause unnecessary surgical iatrogenic injury, whereas surgery performed after 
signs of herniation have developed may be of little value with an increased risk of 
complications (Jeon et al., 2014). The significant reduction in ICP observed following late 
NK1-R antagonist administration suggests that treatment is directly targeting the 
mechanisms underlying increased barrier permeability and consequent development of 
space-occupying cerebral oedema. Therefore, the ability to produce a significant and 
sustained reduction in ICP following intravenous administration of a novel 
pharmacotherapy, such as the NK1-R antagonist, is potentially of great clinical significance. 
 
10.2 NK1-R ANTAGONIST TREATMENT REDUCES CEREBRAL OEDEMA 
AND MIDLINE SHIFT 
 
Across the studies reported in this thesis, considerable cerebral oedema was observed within 
the infarcted MCA territory on FLAIR MRI following onset of ischaemia, consistent with 
elevated ICP. It is largely accepted clinically that elevations in ICP following stroke onset 
arise as a consequence of malignant fluid accumulation within the non-expansile cranial 
cavity (Ropper and Shafran, 1984, Simard et al., 2007). Following permanent MCA 




and associated midline shift at 24 hours post-stroke. Furthermore, animals who underwent 
DC displayed evidence of significant transcalvarial herniation on MRI. This is comparable 
with clinical stroke, where the brain is shown to expand out of the skull defect created by 
the craniectomy (Liao et al., 2015). Ergo, despite a significant reduction in ICP following 
DC, pressure relief is achieved solely via mechanical means and, as anticipated, DC 
treatment does not significantly reduce the underlying pathology driving the development of 
cerebral oedema and elevated ICP. In comparison, 2 × or 3 × doses of the NK1-R antagonist 
brought about a significant and sustained reduction in cerebral oedema and a reduction in 
midline shift when compared with vehicles.  
 
Congruent with elevated ICP shown in Chapter 7, an evolution of cerebral oedema was also 
observed following transient stroke, which was maximal at 5-6 days. This was accompanied 
by a significant increase in midline shift at 5 days (when compared with 1 day post stroke), 
and an increase in extravasation of gadolinium across the BBB. The finding of enhanced 
gadolinium is of particular importance given its clinical use as a marker of BBB permeability 
in stroke (Kassner et al., 2009, Kassner et al., 2011, Merali et al., 2015, Wardlaw et al., 2008, 
Wardlaw et al., 2009, Vidarsson et al., 2009). Contrast-based MRI accurately enables in vivo 
mapping of gadolinium, which given its large molecular weight (550 Da) can be used as a 
marker of BBB permeability in real time (Montagne et al., 2016). Following NK1-R 
administration, a decrease in gadolinium extravasation within the infarcted hemisphere was 
observed, which was a consistent feature following both the early and late treatment 
regimens. Furthermore, NK1-R antagonist administration was associated with a significant 
reduction in cerebral oedema and midline shift following both early (1-3 days) and delayed 
(5 days) treatment. This was accompanied by a decrease in hemispheric water content which, 




significant in the late NK1-R antagonist treatment group. Taken together, the findings of 
reduced oedema volume following treatment administration in both permanent and transient 
stroke models suggest the reduction in cerebral oedema observed is occurring as a result of 
decreased fluid accumulation in the cerebral hemispheres.  
 
In keeping with significant cerebral oedema, all stroke animals also exhibited significant 
infarction of the MCA territory on DWI MRI (Chapters 6, 7 and 8). Lesion volume was 
greatest following permanent MCAo (Chapter 6), accompanied by tonsillar herniation in 
several animals, whereas lesion volume following transient stroke was comparably less 
(Chapters 7 and 8). However, in all animals the infarct typically involved the temporal lobe 
and insula, and subcortical structures such as the hippocampus, thalamus, putamen and 
caudate nucleus. This is comparable to areas typically involved in MMCAI clinically (Heiss, 
2016, Thomalla et al., 2003, Walcott et al., 2014, Nogles and Galuska, 2020). Taken 
together, these findings highlight the value of the ovine model, and its ability to replicate 
key aspects of clinical stroke. It is important to note that although cerebral oedema was 
reduced following NK1-R antagonist treatment in our models (Chapters 6 and 8), no 
treatment effect on infarct volume was observed following either permanent or transient 
stroke. Nevertheless, these findings are consistent with previous rodent studies where no 
effect on infarct volume was observed following NK1-R antagonist treatment, as measured 
at 24 hours following transient MCAo (Turner et al., 2011a). Such findings are not surprising 
considering the NK1-R antagonist is targeting mechanisms underlying barrier disruption and 
downstream cerebral oedema, rather than other pathways in the ischaemic injury cascade. 
 
Furthermore, across the studies reported in this thesis (Chapters 7 and 8), we did not observe 




and female animals. Although the female oestrous cycle was not monitored in these studies, 
this provides compelling evidence regarding the clinical potential for this therapy for both 
male and female stroke patients. 
 
10.3 MECHANISMS UNDERLYING NK1-R ANTAGONIST TREATMENT 
EFFICACY POST-ISCHAEMIC STROKE 
 
To probe the mechanisms underlying the reductions in ICP and cerebral oedema observed, 
immunohistochemical analyses were also performed to elucidate changes in neurogenic 
inflammation (SP, NK1-R) and BBB (caveolin-1, albumin and claudin-5) markers (Chapters 
6-8). Following stroke, increased SP immunoreactivity in vehicle animals was observed 
following transient MCAo at 5 and 6 days (Chapter 7) post-stroke. However, no SP reactivity 
was observed following permanent occlusion at 24 hours (Chapter 6) post-ictus. 
Consequently, no changes in SP expression between vehicle and NK1-R treatment were 
observed, as all animals had undergone permanent infarction (Chapter 6). These findings are 
consistent with previous IHC studies in rodents, where SP was only observed following 
stroke with reperfusion, but not where there was persistent arterial occlusion (Turner et al., 
2011b, Turner et al., 2006, Turner and Vink, 2012, Turner and Vink, 2014). It is postulated 
that in stroke with a reperfusion component, compromised penumbral cells in ischaemic 
tissue experience long durations of electrical silence and alterations in neuronal function, 
leading to sustained activation of c-fibres and persistent SP release (Astrup et al., 1981, 
Hofmeijer and Van Putten, 2012, Turner, 2007). The physical exertion of pressure on c-
fibres as a consequence of accumulating vasogenic oedema may also lead to their 
mechanical stimulation, whereby release of SP occurs in a vicious cycle. Indeed, prior 




hours following transient stroke, yet was most pronounced at 24 hours (Turner, 2007). 
Conversely, cells exposed to permanent ischaemia undergo rapid necrosis where, after 24 
hours, all compromised cells have succumbed to the persistent cerebral ischaemia. In the 
early stages of ischaemia and cytotoxic oedema, acidosis likely promotes c-fibre stimulation 
and SP release. However, as cytotoxic oedema plateaus, a prompt return of receptor channel 
potential occurs leading to decreased SP release. Ergo, SP release likely occurs early 
following permanent stroke, compared with the sustained release observed following 
transient occlusion. This may explain the absence of SP observed following permanent 
stroke (Chapter 6), as by the time tissue was harvested at 24 hours, SP was no longer 
detectable. 
 
Following transient ovine stroke (Chapter 7), peak SP immunoreactivity was observed 5-6 
days post-ictus, with SP localised to the perivascular tissue, suggesting the source was c-
fibres ensheathing the vasculature (Edvinsson et al., 1983). This corroborates previous IHC 
findings in rodent models of both stroke and TBI (Turner et al., 2011b, Turner et al., 2006, 
Turner and Vink, 2012, Turner and Vink, 2014). SP has also been reported in serum collected 
from both ischaemic and haemorrhagic stroke patients (Lorente et al., 2016, Lorente et al., 
2020). In non-surviving patients following ICH, SP was significantly elevated at 4-, 6- and 
8-days following haemorrhage onset (Lorente et al., 2020). Similarly, elevated serum SP 
levels were observed as early as 12 hours following ischaemic stroke, with significantly 
elevated levels observed in patients who died, as compared with those who survived. A trend 
towards elevated serum SP at 3-7 days following transient stroke was observed in this thesis. 
However, no significant differences were seen within the CSF at 1-, 3- and 6-days following 
onset (Chapter 7), when compared with pre-stroke baseline samples. This highlights the 




timing of sample collection is crucial to detecting any changes. One potential explanation 
for this is that the peak of SP release may not be accurately captured in our studies due to 
timing of sample collection post-stroke, whereby SP release may have occurred at time-
points which weren’t captured in our sampling timeline. In addition, given that SP is a small 
peptide, it is susceptible to rapid degradation. Indeed, unbound SP becomes rapidly 
hydrolysed by peptidases, specifically p-endopeptidase in the extracellular fluid and 
angiotensin-converting hormone in the blood plasma (Kream et al., 1985). Consequently, 
the half-life of SP ranges from seconds to minutes in extracellular fluid, while in extracted 
plasma SP remains stable for hours (Suvas, 2017, Skidgel et al., 1984, Skidgel and Erdos, 
1987). 
 
Although a marked SP response was not seen following permanent stroke, significant NK1-
R immunoreactivity was observed at 24 hours following permanent MCAo (Chapter 6). A 
subsequent decrease in NK1-R immunoreactivity was also observed following 2 × and 3 × 
boluses of the NK1-R antagonist (Chapter 6). This suggests competitive binding of the 
antagonist to the receptor, thereby preventing SP docking. Characteristically, SP binds the 
NK1-R, initiating G-protein subunit disassociation and activation of secondary messenger 
pathways depending on cell type, including phospholipase C, adenyl cyclase and 
phospholipase A2 (Steinhoff et al., 2014, Monastyrskaya et al., 2005). Upon binding, the 
receptor ligand complex is rapidly internalised and undergoes disassociation (Martinez and 
Philipp, 2016). The ultimate fate of the endocytosed complex thereafter depends on the 
stimulation conditions of the surrounding environment (Martinez and Philipp, 2016). Low 
concentrations of SP lead to receptor degradation and recycling to the cell surface, facilitated 
by the β-arrestin pathway (Mcconalogue et al., 1999). The cellular response to SP is then 




membrane bound receptors (Steinhoff et al., 2014, Mcconalogue et al., 1999). Conversely, 
high concentrations of SP and sustained incubation initiates NK1-R ubiquitination and 
degradation (Steinhoff et al., 2014).  
 
Following stroke, aberrant SP release leads to NK1-R upregulation (Turner, 2007, 
Nishimura et al., 1994). In endothelial cells such as those lining the BBB, SP has been shown 
to activate transcription factors such as nuclear-factor (NF)-AT and NF-κB (Quinlan et al., 
1999), with NF-κB being a major regulator of NK1-R expression during neurogenic 
inflammation. Indeed, a putative NF-κB binding site has been identified in the promoter of 
the human NK1-R gene, which has been confirmed experimentally (Takahashi et al., 1992, 
Simeonidis et al., 2003). The magnitude of SP release thus likely determines the extent of 
NK1-R upregulation in endothelial cells of the BBB. This is supported by the findings 
reported in this thesis, where the significant increase in NK1-R reactivity was primarily 
observed in the perivascular tissue following permanent stroke (Chapter 6). Furthermore, 
NK1-R upregulation has also been reported in other models of acute CNS injury, where 
following TBI, increased NK1-R expression has been observed in vehicle animals (Li et al., 
2019). During inflammation, increased release of SP from afferent c-fibres has also been 
shown to cause NK1-R upregulation in the dorsal horn (Zieglgänsberger, 2019). Given the 
rapid degradation of unbound SP, the findings of this thesis suggest that identification of the 
NK1-R may be a more robust measure of neurogenic inflammation. Indeed a decrease in SP, 
in conjunction with a significant increase in NK1-R internalisation, has previously been 
observed (Cipriani et al., 2011). Nevertheless, further investigation into the relative 
concentrations of both SP and NK1-R is warranted to further elucidate the timing of the 





The mechanisms of SP/NK1-R receptor internalisation is an important feature or neurogenic 
inflammation and increased barrier permeability. SP-induced stimulation of the NK1-R has 
been shown to cause relocation of protein kinase C-α to caveolae and subsequent caveolar 
internalisation (Mineo et al., 1998). Endocytosis of the NK1-R/SP complex thus likely 
occurs via caveolae, facilitated by the principal structural protein caveolin-1 (Williams and 
Lisanti, 2004). Indeed, a marked increase in perivascular caveolin-1 expression was 
observed in the thesis studies (Chapters 6 and 7), which was consistent in both permanent 
and transient models. The greatest reactivity was seen in permanent vehicle animals at 24 
hours, and in transient vehicle animals at 5-6 days following stroke onset. Following 
administration of the NK1-R antagonist in permanent stroke, a reduction in caveolin-1 
reactivity was observed, which was most pronounced in the 2 × and 3 × dose treatment 
groups (Chapter 6). Following transient stroke, we also noted a marked reduction in 
perivascular caveolin-1 in both early and late treatment regimens (Chapter 8). In the brain, 
caveolin-1 is generally expressed at a low level. However, upon SP binding, the NK1-R 
localises to caveolae via lipid rafts in the plasma membrane, following which the receptor 
ligand complex is internalised. Ergo, upregulation of NK1-R following stroke may cause an 
aberrant increase in caveolae-formation. Indeed, studies have shown that the NK1-R is co-
expressed within endothelial caveolae, further supporting a dynamic relationship (Kubale et 
al., 2007, Vink et al., 2017, Cipriani et al., 2011, Monastyrskaya et al., 2005). Caveolin-1 is 
also suggested to be involved in signalling activities of long-duration, suggesting a sustained 
upregulation of caveolae following NK1-R activation (Monastyrskaya et al., 2005). 
 
This thesis also observed increased caveolin-1 reactivity in conjunction with marked 
albumin extravasation, which was a consistent feature of both permanent and transient stroke 




keeping with our MRI finings of increase gadolinium extravasation post-ictus. Following 
administration of the NK1-R antagonist in permanent stroke animals, a marked reduction in 
parenchymal albumin was observed. As with caveolin-1, the most pronounced reduction in 
albumin was seen in animals who received 2 × and 3 × treatment doses (Chapter 6). In 
transient stroke, albumin extravasation was greatest at 4-6 days post-stroke, and was 
observed to localise both within the brain parenchyma (Chapter 7) and the perivascular space 
(Chapter 8). NK1-R antagonist administration significantly reduced albumin within the 
infarcted hemisphere, with comparable findings observed for both the early and late NK1-R 
antagonist treatment regimens (Chapter 8). Functionally, albumin maintains colloid osmotic 
pressure across the endothelial barrier, and its concentration gradient is critical in the 
regulation of fluid balance (Minshall et al., 2000). Given the findings of this thesis, it is 
proposed that increased albumin in the parenchyma following stroke is facilitated by 
caveolin mediated transcytosis. Indeed, the albumin docking protein 60-kD glycoprotein 
(gp60) is localised to endothelial caveolae. Upon albumin binding gp60, the gp60/albumin 
domain interacts with caveolin-1 via the heterotrimeric GTP binding protein Gi (Minshall et 
al., 2000). The activation of albumin and its receptor subsequently facilitates migration of 
vesicles from the apical to the basolateral endothelial cell surface, and consequent 
accumulation of albumin in interstitial fluid. Ergo, our finding of enhanced caveolin-1 and 
albumin reactivity post-stroke, which is subsequently attenuated following NK1-R 
antagonist administration, suggest that caveolin-1/NK1-R interactions are a key contributor 
to the increased BBB permeability seen following cerebral ischaemia (Figure 10.1). 
Although loss of TJ integrity is also hypothesised to precipitate oedema formation, we did 
not observe any changes in claudin-5 expression following NK1-R antagonist administration 
in transient MCAo animals (Chapter 8), further supporting a leading role of caveolae in 




In the setting of post-stroke oedema, it is largely accepted that the albumin that accumulates 
within the brain parenchyma is derived from the vasculature due its high plasma 
concentration (Gounden et al., 2021, Weaving et al., 2016). However, in the permanent 
stroke model reported herein, the marked parenchymal albumin observed is contentious 
given that there is no active blood flow to the ischaemic region. This suggests that the 
albumin is derived from a compartment other than the vasculature. Indeed, increasing 
evidence suggests that the fluid in vasogenic oedema may be partially derived from the CSF 
rather than the vasculature alone (Mestre et al., 2020). Our finding of increased albumin 
reactivity following permanent MCAo suggests neurogenic inflammation may cause an 
upregulation of caveolin-1 mediated albumin transcytosis in endothelial cells comprising 
both the blood-brain and blood-CSF (BCSF) barriers. Indeed, the choroid plexus displays a 
high rate of vesicular transport activity, suggesting movement across the barrier is primary 
mediated by transcytosis, facilitated in part by caveolae (Praetorius and Damkier, 2017). If 
the BBB/BCSF barrier integrity is compromised, albumin may consequently be upregulated 
in the circulating CSF. Indeed, the albumin CSF quotient is often used as a marker of BBB 
integrity clinically (Musaeus et al., 2020, Akaishi et al., 2015), with elevated levels in the 
CSF indicative of barrier breakdown and subsequent extravasation from the blood to the 
CSF (Gounden et al., 2021, Akaishi et al., 2015). Previous studies have also documented 
caveolin-1 and NK1-R immunoreactivity in the choroid plexus (Maeno et al., 1993, Mantyh 
et al., 1988, Mantyh et al., 1989, Nag et al., 2007). Although not investigated in this thesis, 
examining the relationship between NK1/SP, BCSF barrier permeability and albumin 
transcytosis may provide further insight into the genesis of vasogenic oedema following 





Figure 10.1. Proposed mechanism of NK1-R facilitated caveolin-mediated albumin transcytosis 
facilitating vasogenic oedema formation. 1) SP released from perivascular c-fibres binds NK1-R embedded 
in the endothelial plasma membrane. 2) The receptor ligand complex is co-localised to lipid-raft caveolae. 3) 
Albumin is bound 60-kD glycoprotein (gp60) colocalised with caveolin-1 to endothelial cell apical plasma 
membrane caveolae. 4) the NK1-R/SP and albumin/gp60 complexes are rapidly endocytosed with dynamin 
facilitating caveolar budding. 5) The caveolae containing albumin migrates to the basolateral surface, where 
albumin is exocytosed into the extracellular parenchymal space. 6) The NK1-R/SP complex is disassociated 
and either degraded or recycled, depending on SP concentration.  
 
10.4 NK1-R ANTAGONIST PHARMACOKINETICS 
 
To establish the molecular pharmacokinetics of the NK1-R antagonist following 
administration of 2 × doses at 5 days following stroke onset (late NK1-R antagonist 
treatment regimen), multiple whole blood samples were drawn at 4 hourly intervals. Peak 
NK1-R concentration was observed in the blood at 8 hours following administration 
(Chapter 8), which began to decline thereafter, with levels returning to baseline within 24 
hours of first dosage. Administration of the NK1-R antagonist intravenously was elected to 




Previous studies have extensively shown that NK1-R antagonists are able to cross the BBB, 
depending on their inherent structure (Garcia-Recio and Gascón, 2015, Muñoz and Coveñas, 
2020) Peptide based NK1-R antagonists are unable to cross the BBB and show poor potency, 
whereas non-peptide molecules show a high affinity for the NK1-R and an ability to cross 
the BBB (Muñoz and Coveñas, 2020). Previous studies have evaluated the barrier 
permeability of EU-C-001 compared with other NK1-R antagonists, with EU-C-001 shown 
to cross the barrier and thus elicit an effect on cerebrovascular endothelial cells (Donkin et 
al., 2011). Taken together, this further highlights the validity of NK1-R treatment for post-
stroke oedema, with the timing of dosing and rate of clearance reported herein potentially 
able to inform clinical application. 
 
10.5 DEVELOPMENT OF A NOVEL APPROACH TO MEASURING FUNCTION 
FOLLOWING OVINE STROKE  
 
Given the promising findings of Chapters 6-8 in which the NK1-R was shown to bring about 
a significant and sustained reduction in ICP in both permanent and transient stroke animals, 
we sought to assess the effect of treatment on functional outcome. Given the lack of 
established methods to evaluate motor function in sheep, a comprehensive approach to 
assessment was subsequently developed in Chapter 9. This study used motion capture to 
assess gait kinematics, in conjunction with a modified neuroscore to assess variables beyond 
the scope of biomechanical assessment.  
 
Assessment of kinematics across baseline trials was shown to be a reliable method to assess 
gait signatures for the majority of outcome measures of interest. Following stroke, a 




decreased walking speed, lowering of the head and first thoracic vertebra, and a significant 
increase in stance, swing and stride duration of the forelimbs. Despite these findings, we did 
not detect a significant change in joint angle variables across all animals, despite qualitative 
identification of deficit of the left forelimb both in Chapter 9 and in previous studies (Sorby-
Adams et al., 2019a). It is important to note that some animals were qualitatively more 
substantially affected than others; some exhibited persistent flexion of the fetlock joint; some 
occasionally ‘knuckled’ on the joint during forward motion; and others appeared completely 
unaffected. Subgroup analysis targeting animals which were substantially, partially or 
seemingly unaffected by transient MCAo may provide more insight into the variability of 
injury response and the gait parameters which most effectively distinguish severity and 
quality of motor deficit. 
 
Correlation of kinematic findings with neuroscore may also enhance the stratification of 
response to injury. Indeed, significant post-stroke deficits were detected via composite 
scoring (Chapter 9). Specifically, after stroke onset animals displayed significant impairment 
in demeanor, willingness and ability to initiate forward movement, and ability to correct and 
detect conscious proprioceptive positioning during postural reaction tests. Following stroke 
onset, patients often present with unilateral deficits including hemiplegia and hemiparesis. 
Via neuroscore, a marked left sided deficit was observed on postural reaction tests. However, 
we also observed deficit of the right forelimb when compared with baseline. This suggests 
an overall impaired demeanour with animals less willing to adjust limbs during forced 
movement rather than an indication of asymmetric neuromotor function. 
 
Animals also show evidence of spontaneous functional recovery following stroke, similar to 




important given there are critical periods for detecting even mild impairment. For both 
kinematic and neuroscore assessment, we chose to assess animals 3 days following stroke to 
reduce the influence of post-operative analgesia and recovery on function, although we may 
not be capturing maximal deficit at 3 days post injury. Ergo, determining changes in gait 
kinematics at other post-stroke time-points suggests an avenue for future assessment. 
 
10.6 LIMITATIONS AND FUTURE DIRECTIONS 
 
Large animal models of stroke represent a promising avenue for improving the clinical 
translation of novel stroke therapeutics (Chapter 3). Nevertheless, as identified in each 
individual chapter, the thesis studies and indeed ovine stroke models are not without their 
own limitations. Notable is the significant time and resources expended generating 
experimental animals and performing analyses, inherent in large animal studies. This was 
especially evident in Chapter 9 given significant training durations required to habituate 
animals, which was a limitation both financially and in terms of physical demand. 
Furthermore, despite promising treatment effects, the small sample size within groups across 
all studies reported herein must be acknowledged as a potential limitation, although deemed 
necessary to reduce extensive experimental costs, and reduce animal numbers in accordance 
with the ARRIVE guidelines (Percie Du Sert et al., 2020).  
 
The promising findings of this thesis, however, provide an exciting opportunity for future 
analyses. Indeed, some studies are underway using tissue collected throughout this PhD, and 
other possible avenues remain as yet unexplored. Projects underway using data collected 
throughout this thesis include those focusing on molecular mechanisms, functional 




extensive biological fluid and tissue collection. The ability to yield significant volumes of 
both blood and CSF is a significant advantage of the ovine model, allowing for 
comprehensive assessment across time points in the same experimental animals. Indeed, for 
animals in Chapter 9, extensive serum, plasma and CSF samples were collected prior to 
stroke and at multiple time-points thereafter. Although initial SP ELISA analysis has been 
carried out on serum and CSF (Chapter 7), samples are currently undergoing metabolomic 
assessment via mass spectroscopy to evaluate key molecules involved in the ischaemic 
cascade following ovine stroke. Fresh brain samples, serum and CSF for each of these 
animals are also in the process of undergoing thorough molecular analysis to investigate key 
molecules involved in regulating BBB integrity, including caveolins, claudins, 
neuroinflammatory cells (microglia, monocytes), MMP’s (MMP2, MMP9) and both pro- 
(IL-6, IL-17, IL-1b, TNF-a, IFN-γ) and anti-inflammatory (IL-10, IL-4) cytokines. 
 
For functional analyses, Chapter 9 presents four time points in which function was assessed: 
8-, 5- and 1- day pre-stroke, and 3 days post-stroke. These sessions were chosen to assess 
repeatability across baseline sessions and subsequently determine if the method developed 
was able to detect changes in behaviour and kinematics 3-days following stroke (with 3 days 
post stroke chosen to reduce the impact of post-surgical course on outcome). In addition to 
these reported time points, however, all animals also underwent testing at 1-, 5-, 7-, 14-, 21- 
and 28-days post-ictus. In this cohort, 12 of the animals also received the late NK1-R 
antagonist treatment regimen at 5 days. Unfortunately, due to the significant time spent post-
processing and optimising coding procedures, I was unable to include this data in the final 
thesis due to time restraints. Future analysis should focus on assessing the effect of treatment 
on outcomes using the method described herein. Animals on whom biomechanics 




at days 1-, 6- and 28-days post stroke. These studies occurred following an upgrade to a 3T 
MRI machine at the SAHMRI PIRL facility. In addition to sequences obtained in previous 
studies (T1, T2, FLAIR, DWI, MRA) animals underwent diffusion susceptibility contrast 
(DSC) and dynamic contrast enhancement (DCE) imaging to comprehensively assess 
dynamics of the barrier and how it is influenced, both with and without treatment. We also 
undertook resting functional MRI (fMRI) and diffusion tractography imaging (DTI). These 
sequences are currently being processed, with the goal to characterise functional brain 
regions affected by stroke and correlate regions of interest with behavioral outcomes.  
 
In addition to assessments already underway, the sheep model of stroke provides a platform 
in which other novel therapeutics can be assessed. Evaluating the response to stroke in aged 
and co-morbid animals could provide an opportunity for future studies, especially given the 
correlation between stroke and increasing age. Furthermore, although we performed 
functional assessment of motor recovery, we did not assess cognition. Cognitive models of 
executive function have been developed in sheep (Sorby-Adams et al., 2021, McBride et al., 
2016, Morton and Avanzo, 2011, Knolle et al, 2019), which may be able to be applied to 
stroke models to determine the effect of infarction and cerebral oedema on cognitive 
outcome. The assessment of later time points following onset of injury may also provide 
insight into the mechanisms underlying secondary neurodegeneration to subsequently 
determine if a positive effect of treatment can be seen on both long term cognitive and motor 








10.7 SUMMARY OF KEY CONTRIBUTIONS  
 
The collective findings of this thesis provide compelling evidence regarding the utility of 
NK1-R antagonist treatment in the management of cerebral oedema and elevated ICP 
following ischaemic stroke, as follows:  
1) Characterised clinically relevant neuroimaging (MRI) and neurophysiological (ICP) 
outcomes following stroke in a large animal model. This has enabled the accurate 
characterisation of the ovine response to both complete and partial MCA occlusion. 
2) Intravenous administration with an NK1-R antagonist produced a clinically meaningful 
reduction in ICP following complete MCA occlusion, bringing about a reduction in 
pressure comparable to DC, all whilst circumventing the need for invasive surgery. 
3) Developed an ovine model of transient stroke, compatible with survival, in which 
marked cerebral oedema and elevated ICP were observed 5-6 days following stroke. This 
provides a model in which putative therapeutics targeting oedema can be assessed in line 
with current stroke research guidelines.  
4) Demonstrated NK1-R administration abates a rise in ICP following stroke with 
reperfusion when administered both early, and in a delayed fashion. Given the 
heterogenous nature of stroke, this provides compelling evidence that treatment will be 
effective across a broad range of stroke patients.  
5) Developed an innovative method to assess functional and kinematic outcomes following 
ovine stroke, enabling the future assessment of interventions on long term recovery. 
6) Demonstrated that the post-stroke elevation in ICP and oedema is associated with an 
increase in BBB permeability, which is likely facilitated by caveolae-mediated albumin 







This thesis has established that NK1-R antagonist treatment is effective in reducing cerebral 
oedema and ICP following stroke in a clinically relevant ovine model. Here, we have shown 
that following permanent stroke, NK1-R antagonist treatment significantly reduces ICP, 
comparable with DC surgery. A significant reduction in both cerebral oedema and ICP was 
also observed with NK1-R antagonist administration following transient stroke, when given 
either before (1-3d) or after (5d) the development of space-occupying oedema and elevated 
ICP. Taken together, these studies support the role of SP and neurogenic inflammation in 
the development of cerebral oedema following stroke. This dataset supports advancement of 
NK1-R antagonist treatment for cerebral oedema and elevated ICP to evaluation in clinical 
stroke. Indeed, the experimental work in this thesis has formed a strong pre-clinical basis for 
the assessment of the NK1-R antagonist in clinical trials, with Phase II trials currently 
underway in Australia (Melbourne), the United Kingdom (Cambridge) and the United States 
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Appendix 3.1 Recommended pre-anaesthetic treatment regimens for feline, canine, 
porcine, ovine and non-human primate species. 
 
 









i.m. Light to 
moderate 
sedation 






















0.07 mg/kg i.m. 





– – – 
Acepromazine 
+ morphine  
0.05 mg/kg 






– – – – 
Alphaxalone/ 
alphadolone  





















mg/kg sc or i.m. 
Anticholinergic 














Azaperone – – 















i.m., sc or i.v. 





12.5 μg/kg i.m. 




Diazepam – – 




1–2 mg/kg i.m., 























0.01 mg/kg i.v. 
Anticholinergic 



































22 mg/kg i.m. + 













i.m., sc + 0.1–
0.5 mg/kg i.m. 
Light to heavy 
sedation, 
– – – 
Medetomidine  
10–150 
μg/kg i.m. or 







i.m., sc or i.v. 







25 μg/kg i.m. 












    
20 μg/kg + 0.5 








Metomidate – – 




Midazolam – – – 
























i.m., or sc 
Light to 
moderate 







0.1 mg/kg i.m. 
















Scheme: Dose rate, route of administration (per os-orally, i.v-intravenous, sc-subcutaneous, i.m-

























Appendix 3.2 Summary of physiological variables of feline, canine, porcine, ovine and 
non-human primate species. 
 
 Cat Dog Pig Sheep NHP (Large) 
Adult body 
weight (kg) 




38.6 38.3 39 39.1 39 
Respiration 
rate (/min) 
26 25 12-18 20 35 
Recommended 







10-15 20-30 (>5kg) 
Resting Heart 
rate (/min) 





















Appendix 3.3 Recommended anaesthetic dose regimens for feline, canine, porcine, 
ovine and non-human primate species. 
 









6 mg/kg i.m. 


























1–2 mg/kg i/v 
(after 
azaperone 1–2 




2–3 mg/kg i.v. 








– – – 
0.5 ml per 50 














20 mg/kg i.m. 





















10–15 mg/kg + 
1–2 mg/kg i.m.  
or 4 mg/kg i.v. 
+ 0.5–1 mg/kg 






15 mg/kg i.m. 










7 mg/kg i.m. + 












1 mg/kg i.v. + 




5 mg/kg i.m. + 






7 mg/kg i.m. + 





i.m. + 40 μg/kg 




10 mg/kg i.m. 






1 mg/kg i.v. + 




5 mg/kg i.m. + 






10 mg/kg i.m. 















22 mg/kg i.m. 




5 mg/kg i.v. + 
1–2 mg/kg i.v. 





1 mg/kg i.v. + 




10 mg/kg i.m. 







































30 mg/kg i.v. 
Immobilization











– – – – 
Propofol 









i.v. (6–8 mg/kg 























































2–4 mg/kg i.m. 
Immobilization
,  






Scheme: Dose rate, route of administration (per os-orally, i.v-intravenous, sc-subcutaneous, i.m-


























Appendix 3.4 Recommended minimal alveolar concentration (MAC%) of commonly 
used inhalational anaesthetic agents for use in feline, canine, porcine, ovine and non-
human primate species 
 
Drug Cat Dog Pig Sheep NHP 
Isoflurane 1.6 2.3 1.45-2.04 1.19-1.53 1.28 
Halothane 1.0 0.9 - 0.69 
0.89–1.15 
(depending on 
size of NHP 
species) 
Desflurane 9.8 7.2 8.28-10.0 - - 
Sevoflurane 2.6 2.3 1-1.5 3.3% 2.0 
 




















Appendix 3.5 Recommended antibiotic and antibacterial treatment regimens in feline, 
canine, porcine, ovine and non-human primate species 
 
Drug Cat Dog Pig Sheep NHP 
Amoxcillin 
7 mg/kg sc 
u.i.d 
7 mg/kg sc 
u.i.d 
7 mg/kg sc 
u.i.d 
7 mg/kg sc 
u.i.d 
7 mg/kg sc 
u.i.d 
Cephalexin 
10 mg/kg sc 
u.i.d 
10 mg/kg sc 
u.i.d 
10 mg/kg sc 
u.i.d 
10 mg/kg sc 
u.i.d 
10 mg/kg sc 
u.i.d 
Chloramphenicol 
25 mg/kg sc 
u.i.d 
50 mg/kg sc 
u.i.d 
11 mg/kg sc 
u.i.d 
- 20 mg/kg sc 
u.i.d 
Enrofloxacin 
5 mg/kg sc 
u.i.d. 
5 mg/kg sc 
u.i.d. 
2.5 mg/kg sc 
u.i.d. 
- 5 mg/kg sc 
b.i.d. 
Neomycin 
10 mg/ml per 
os u.i.d. in 
divided doses 
10 mg/ml per 
os u.i.d. in 
divided doses 
11 mg/ml per 
os u.i.d. in 
divided doses 
11 mg/ml per 
os u.i.d. in 
divided doses 
10 mg/ml per 




30 mg/kg sc 
u.i.d. 






30 mg/kg sc 
u.i.d. 
 
Scheme: dose range (u.i.d-once daily, b.i.d –twice a day, t.i.d-three times a day) application routes (p.o./per 
os=orally; sc= subcutaneous; i.v.=intravenous; i.m.=intramuscular). Table adapted from Flecknell, 2016 
Laboratory Animal Anaesthesia (Fourth Edition). 
 
Note that considerable individual and strain variation in response may be encountered, and that it is therefore 











Appendix 3.6 Recommended Analgesic treatment regimes in feline, canine, porcine, 






























Drug Cat Dog Pig Sheep NHP 
Aspirin 
10–25 mg/kg 




os, every 8 
hourly 
10–20 mg/kg 
per os, 4–6  
hourly 
50–100 
mg/kg per os, 
6–12 hourly 




4 mg/kg sc or 
iv 
4 mg/kg iv 
or sc, once 
daily 1–2 
mg/kg b.i.d. 
per os, for 7 
days 
2–4 mg/kg iv 
or sc, once 
daily 
2–4 mg/kg sc 
or iv, once 
daily (2–3 
days) 
3–4 mg/kg sc 
u.i.d. 
Flunixin 
1 mg/kg sc, 
daily for up to 
5 days 
1 mg/kg iv 
or im, 12 
hourly 1 
mg/kg per 
os, daily for 
up to 3 days 
1–2 mg/kg iv 
or sc, once 
daily 
2 mg/kg iv or 
sc, once daily 
0.5–2 mg/kg 
sc or iv daily 
Ibuprofen – 
10 mg/kg 
per os, 24 
hourly 
– – 7 mg/kg per 
os 
Ketoprofen 
1 mg/kg sc, 
once daily for 
up to 3 days 1 
mg/ kg per os, 
once daily for 
up to 5 days 
2 mg/kg sc, 
im or iv, 
once daily 
for up to 3 
days 1 
mg/kg per 
os, daily for 
5 days 
1–3 mg/kg iv, 
im, sc, per os, 
12 hourly 
– 




u.i.d. sc or 0.3 
mg/kg per os, 
then 0.1 
mg/kg sc or 
per os 
0.2 mg/kg 
u.i.d. sc or 
per os, then 
0.1 mg/kg 
sc or per os 
0.4 mg/kg sc, 
once daily 
0.5 mg/kg iv, 
sc up to b.i.d. 
for 1 day, 
then 0.5 
mg/kg per os 




sc or per os 
Tolfenamic acid 
4 mg/kg sc 
daily for 2 
days 
4 mg/kg sc 
daily for 2 
days 









per os, 6–8 
hourly 


















sc or iv, 6–
12 hourly 
0.01–0.05 




mg/kg im or 
iv, 4 hourly 
0.005–0.01 




0.4 mg/kg sc, 
3–4 hourly 
0.2–0.4 




mg/kg im or 
iv, 4 hourly 
0.5 mg/kg im 






0.1 mg/kg im, 






– – – 
Morphine 0.3 mg/kg sc, 
4 hourly 
0.5–5 mg/kg 
sc or im, 4 
hourly 
0.2–1 mg/kg 
im , ?4 hourly 
0.2–0.5 
mg/kg im, ?4 
hourly 
1–2 mg/kg sc 




mg/kg iv, 3 
hourly 
0.5–2.0 
mg/kg sc or 
im, 3–4 
hourly 
– – – 
Oxymorphone 




sc or iv, 2–4 
hourly 
0.15 mg/kg 





2 mg/kg im 
or iv, 4 
hourly 
2 mg/kg im 
or iv, 4 
hourly 
– 
2–5 mg/kg im 










2 mg/kg im 
or iv, 2–4 
hourly 
2 mg/kg im 
or iv, 2–4 
hourly 
2–4 mg/kg im 
or iv, 2–4 
hourly 
Tramadol 2–4 mg/kg sc 
2–5 mg/kg 




? 1–2 mg/kg 




Scheme: dose range (u.i.d-once daily, b.i.d –twice a day, t.i.d-three times a day) application routes (po/per 
os=orally; sc= subcutaneous; iv=intravenous; im=intramuscular); time intervals in which the medication 
should be repeated to ensure sufficient analgesia. ?-duration of action uncertain. Table adapted from Flecknell, 




Appendix 5.1 Clinical record sheet 
 
 
Project:             AEC# Expiration:   
Primary Researcher:  Annabel Sorby-Adams        Animal ID:   Surgery Date: 
Additional Contact:            Pre-op Weight: 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
17 
18 19 
20 21 22 






































































































































































































































































                           
                    
    
  
 
                           
                           
                           
                           
                           
                           
                           
                           
                           
                           
                           
                           
 
Column 3-6 = Noted Changes Column 7-11 = 0–Normal, 1–Slight Change, 2-Markedly Changed Column 12-16 = 0-No, 1-Yes 
NOTE: Animals to be checked EVERY 15 MINUTES FOR FIRST 4 HOURS and must be free standing prior to leaving facility  
Scores of 3: Require the animal to be checked 3 times per day. 4 or 5 Veterinary Advice Required and Review Treatment  




Appendix 9.1 MATLAB code for functional analysis 
 
init(); def=defaults; 
%Code for Stroke Sheep Gait Analysis 
  
%% SCRIPT DESCRIPTION 
% This script produces figures and data from Ovine MoCap Trials. The 
script calls markers by name directly allowing for ease of comparison 
between limb segments and individual markers 
  
%% TOOLBOXES REQUIRED 
% The following Toolboxes must be installed to run this code: MoCap Tools 
- Labelling, and EpicToolbox. Scripts are available from JCL via 
https://github.com/JonathanCamargo?tab=repositories 
  
%% Stop underscores in titles being subscripted 
set(0, 'DefaulttextInterpreter', 'none') 
  
% Use the init.m script to change scope of analysis and file pathway 
(containing files to be analysed and folder where results and figures 
will be output). init.m allows for modificetion of batch processing via 
the batchrun.m script or individal 








%% SCRIPT OUTPUTS 
% - figures:  Marker positions and gait cycle (0-100%) 
% - .mat file with results 
  
%% LOAD MARKERS 
% Ensure the appropriate marker order is listed so that the marker 
numbers used throughout processing correspond correctly 
orderedMarkerNames={'HEAD','T1','T13','L7','L_GTUB','L_LEPIRAD','L_ULNA',
'L_METAR', 'LF_PPHAL', 'LF_PHAL', 'LF_DPHAL', 'R_GTUB', 'R_LEPIRAD', 
'R_ULNA', 'R_METAR', 'RF_PPHAL', 'RF_PHAL', 'RF_DPHAL', 'L_ILIUM', 
'L_GTROC', 'L_ISCTUB', 'L_LEPI', 'L_LTIB', 'L_TIB', 'L_CALC', 'L_LMAL', 
'L_FTAR','LH_PPHAL', 'LH_PHAL', 'LH_DPHAL', 'R_ILIUM', 'R_GTROC', 
'R_ISCTUB', 'R_LEPI', 'R_LTIB', 'R_TIB', 'R_CALC', 'R_LMAL', 
'R_FTAR','RH_PPHAL', 'RH_PHAL', 'RH_DPHAL'}; 
c3dstruct=Vicon.ExtractMarkers(c3dfile); % Import the marker data from 
the C3D file, according to their abbreviated names, and reorder as above 
c3dstruct=Topics.select(c3dstruct,orderedMarkerNames); % Use the 
prescribed ordered names to make sure order is as expected for the rest 
of the code 
trc=Osim.interpret(c3dstruct,'TRC','table'); % Get the markers ('TRC from 
Vicon') 
trc{:,2:end}=Vicon.transform(trc{:,2:end},'ViconXYZ'); % Flip y and z 
data as Extract markers outputs in Osim Coordinate System  
  
%% Center the Global Coordinate System (GCS) to the middle of the Force 
Plate.  
% Collection GCS is located at the front right Force Plate. Need to shift 




coords by 877/2 = 438.5mm in the negative direction. z-coords remain the 
same. 
  
trc{:,2:3:end}= trc{:,2:3:end}- 438.5;% Shift the x axis 438.5mm 
trc{:,3:3:end}= trc{:,3:3:end}- 337.0;% Shift the y axis 337.0 mm 
Nmarkers = size(trc,2); % From now on the marker data is in the TRC table 
FS=1/mean(diff(trc.Header)); % Determine sampling frequency (from Vicon, 
200Hz), neccesary for determining velocity 
trc{:,2:end}=Vicon.Filter(trc{:,2:end},10/(FS/2)); % Apply 4th order, 
zero lag, butterworth filter, cut off frequency 10Hz 
  




















%% Load model %% JCL added functionality to programatically read the VSK 




%% Plot the model at a given position 
% Plot the first frame for visualising appropriate body segments 




view(-450,4)  %adjust this to rotate view 
%save figure as .png 
info=f.getFields(c3dfile); 






%% Figure: Animation in Real Time View using the VSK 
  
segments=Vicon.model.getSegmentMarkers(vskfile); 
sticks=Vicon.model.getSticks(vskfile); % Compute sticks to save time 
%Comment out when not in use 
%figure(1); clf; 
%for i=1:10:size(trc,1) 
    %clf; 
    %view(-90,1)  %adjust this to rotate view 




    %axis equal 
   % Vicon.model.plot(vskfile,trc(i,:),sticks)  





%% Plot the vertical displacement of distal markers on the fore and hind 
limbs 
h2= figure(2); clf;  
subplot(4,1,1); hold on; 
plot(trc.RF_DPHAL_z,'r'); title('R Fore (RF_DPHAL)'); 
subplot(4,1,2); hold on; 
plot(trc.LF_DPHAL_z,'r'); title('L Fore (LF_DPHAL)'); 
subplot(4,1,3); hold on; 
plot(trc.RH_DPHAL_z,'r'); title('R Hind (RH_DPHAL)'); 
subplot(4,1,4); hold on; 
plot(trc.LH_DPHAL_z,'r'); title('L Hind (LH_DPHAL)'); 
ylabel ('Vertical displacement (mm)') 
xlabel ('data point') 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='figures'; info.Folder='Results'; 




%output seems to make sense, R fore and L hind in contact together, then 
R 
%hind and L fore in contact together. 
  
%%  Plot the displacement of distal markers on the fore and hind (Nicer 
version with for loop) 
legs={'R_forefoot','L_forefoot','R_hindfoot','L_hindfoot'}; 
distalmarkers={'RF_DPHAL','LF_DPHAL','RH_DPHAL','LH_DPHAL'}; 
h3=figure(3); clf  
gc=trc(:,1); %Copy header 
for i=1:numel(distalmarkers) 
    x1=GaitCycleFromTRC(trc,'Markers',distalmarkers{i}); 
    x2=GaitCycleFromTRC(trc,'Markers',distalmarkers{i},'Toeoff',true); 
    subplot(4,1,i); hold on; 
    plot(trc.Header*200,trc.([distalmarkers{i} '_z']),'r'); 
title(distalmarkers{i}); 
    plot(trc.Header*200,x1{:,2},'--'); % Plot the gait cycle from 0 to 
100% 
    plot(trc.Header*200,x2{:,2},'--'); 
    gc=[gc x1(:,2) x2(:,2)];     
end 
ylabel ('Vertical displacement (mm)') 
legend('Vertical position','StanceStarts','SwingStarts'); 
  
% save figures as png 






%% Figure: Plot Vertical Hoof Displacement in Z axis (ASA) 
h4= figure(4); clf; 




plot(trc.RF_DPHAL_z,'r'); plot(trc.LF_DPHAL_z,'b'); title('Forelimb 
Vertical (z) Hoof Displacement'); 
legend('R Fore','L Fore'); 
ylabel ('Displacement (mm)') 
subplot(2,1,2); hold on; 
plot(trc.RH_DPHAL_z,'r'); plot(trc.LH_DPHAL_z,'b'); title('Hindlimb (z) 
Hoof Displacement Hindlimbs'); 
legend('R Hind','L Hind'); 
ylabel ('Displacement (mm)') 
xlabel ('Data Point') 
  
% save figures as png 






%% Figure: Plot Distal Hoof Forward Velocity in Y axis (ASA) 
markers=Osim.interpret(trc,'TRC','struct'); 
RF_DPHAL=markers.RF_DPHAL{:,2:end}; 
velocity_RF_DPHAL_y = smooth(gradient(RF_DPHAL(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 





velocity_LF_DPHAL_y = smooth(gradient(LF_DPHAL(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 




velocity_RH_DPHAL_y = smooth(gradient(RH_DPHAL(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 




velocity_LH_DPHAL_y = smooth(gradient(LH_DPHAL(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 
accel_LH_DPHAL_y = smooth(gradient(velocity_LH_DPHAL_y(:,1),1/FS)); % 
  
h5 = figure (5); clf; hold on 
subplot(2,1,1); hold on 
plot(velocity_RF_DPHAL_y(:,1), 'r'); title("Forelimb Foward (y) Hoof 
Velocity"); ylabel ('Velocity (m/s)'); hold on 
plot(velocity_LF_DPHAL_y(:,1), 'b'); 
legend('R Fore','L Fore'); 
subplot(2,1,2); hold on 
plot(velocity_RH_DPHAL_y(:,1), 'r'); title("Hindlimb Foward (y) Hoof 
Velocity"); ylabel ('Velocity (m/s)'); hold on 
plot(velocity_LH_DPHAL_y(:,1), 'b'); 
legend('R Hind','L Hind'); 
xlabel ('time (s)'); 
  
% save figures as png 









%% Figure: Plot Distal Hoof Vertical Velocity in Z axis (ASA) 
markers=Osim.interpret(trc,'TRC','struct'); 
RF_DPHAL=markers.RF_DPHAL{:,2:end}; 
velocity_RF_DPHAL_z = smooth(gradient(RF_DPHAL(:,3),1/FS)/1000); %incl. 
conversion mm/s to m/s 





velocity_LF_DPHAL_z = smooth(gradient(LF_DPHAL(:,3),1/FS)/1000); %incl. 
conversion mm/s to m/s 




velocity_RH_DPHAL_z = smooth(gradient(RH_DPHAL(:,3),1/FS)/1000); %incl. 
conversion mm/s to m/s 




velocity_LH_DPHAL_z = smooth(gradient(LH_DPHAL(:,3),1/FS)/1000); %incl. 
conversion mm/s to m/s 
%accel_LH_DPHAL_z = smooth(gradient(velocity_LH_DPHAL_z(:,1),1/FS)); % 
  
h6 = figure (6); clf; hold on 
subplot(2,1,1); hold on 
plot(velocity_RF_DPHAL_z(:,1), 'r'); title("Forelimb Vertical (z) Hoof 
Velocity"); ylabel ('Velocity (m/s)'); hold on 
plot(velocity_LF_DPHAL_z(:,1), 'b'); 
legend('R Fore','L Fore'); 
subplot(2,1,2); hold on 
plot(velocity_RH_DPHAL_z(:,1), 'r'); title("Hindlimb Vertical (z) Hoof 
Velocity"); ylabel ('Velocity (m/s)'); hold on 
plot(velocity_LH_DPHAL_z(:,1), 'b'); 
legend('R Hind','L Hind'); 
xlabel ('time (s)'); 
  
% save figures as png 





















subplot(2,1,1); hold on 
plot(LF_fetlockangle, 'b'); title("Forelimb Fetlock Angle"); ylabel 
('Angle (deg)'); hold on 
plot(RF_fetlockangle, 'r'); 
legend('L Fore','R Fore'); 
subplot(2,1,2); hold on 
plot(LH_fetlockangle, 'b'); title("Hindlimb Fetlock Angle"); ylabel 
('Angle (deg)'); hold on 
plot(RH_fetlockangle, 'r'); 
legend('L Hind','R Hind'); 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='figures'; info.Folder='Results'; 




%% Figure: Plot Stifle Angle (ASA) 
markers=Osim.interpret(trc,'TRC','struct'); 
LF_stifleangle=jointangle_2D(markers,'R_LEPIRAD','R_ULNA','R_GTUB','R_LEP








h8 = figure (8); clf; hold on 
subplot(2,1,1); hold on 
plot(LF_stifleangle, 'b'); title("Forelimb Stifle Angle"); ylabel ('Angle 
(deg)'); hold on 
plot(RF_stifleangle, 'r'); 
legend('L Fore', 'R Fore'); 
subplot(2,1,2); hold on 
plot(LH_stifleangle, 'b'); title("Hindlimb Stifle Angle"); ylabel ('Angle 
(deg)'); hold on 
plot(RH_stifleangle, 'r'); 
legend('L Hind','R Hind'); 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='figures'; info.Folder='Results'; 















h9 = figure (9); clf; hold on 




plot(LF_hockangle, 'b'); title("Forelimb Hock Angle"); ylabel ('Angle 
(deg)'); hold on 
plot(RF_hockangle, 'r'); 
legend('L Fore','R Fore'); 
subplot(2,1,2); hold on 
plot(LH_hockangle, 'b'); title("Hindlimb Hock Angle"); ylabel ('Angle 
(deg)'); hold on 
plot(RH_hockangle, 'r'); 
legend('L Hind','R Hind'); 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='figures'; info.Folder='Results'; 




%% Analysis table now contains gait cycle from 0-100% to use for 








    s=segment_gc(trial,'GCtopic','gc','GCChannel',[distalmarkers{i} 
'_Strike']); %Split gait cycle         
    % Here you can discard the segments that are not good before copying 
to     
    goodStrides=[]; 
    for j=1:numel(s)                 
        % Some if statements to discard each segment? 
        % for now lets say that if segment starts or ends with the trial 
it 
        % is probably bad. % Manually? yes or no? 
        if (s{j}.trc.Header(1)==trial.trc.Header(1)) || 
(s{j}.trc.Header(end)==trial.trc.Header(end)) 
            continue; 
        end    
         
        % For convenience on each stride determine the indices of stance 
phase and 
        % swing phase.         
        strikeIdx=find(s{j}.gc.([distalmarkers{i} '_Strike'])==0); 
        offIdx=find(s{j}.gc.([distalmarkers{i} '_Off'])==0);         
        s{j}.stanceIdx=[strikeIdx(1) offIdx(1)]; 
        s{j}.swingIdx=[offIdx(1) strikeIdx(2)];         
        s{j}.leg=legs{i}; 
        if numel(goodStrides)>0 
            break; 
        end 
        goodStrides=[goodStrides;s(j)]; 
    end 
    strides=[strides;goodStrides];    
end 
% strides contains strides based on each individual leg 
%% %%%%%%%%%%%%%%%%%%%%%% ANALYSIS CODE 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%% A. Analyses / plots that are global in the trial and not stride by 




% Forward trajectory velocity, based on pelvis motion (centre point of 
ilium) (m/s) 
% derive some new points from markers on rigid bodies % 


















globalresults.Properties.VariableUnits={'m/s', 'm/s', 'm/s', 'm/s', 
'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 'm/s', 
'm/s', 'm/s'}; 
  
























































velocity_midilium_y = smooth(gradient(mid_ilium(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 
accel_midilium_y = smooth(gradient(velocity_midilium_y(:,1),1/FS)); % 
velocity_midilium_x = smooth(gradient(mid_ilium(:,1),1/FS)/1000); %incl. 
conversion mm/s to m/s 
accel_midilium_x = smooth(gradient(velocity_midilium_x(:,1),1/FS)); % 
velocity_midilium_z = smooth(gradient(mid_ilium(:,3),1/FS)/1000); %incl. 
conversion mm/s to m/s 
accel_midilium_z = smooth(gradient(velocity_midilium_z(:,1),1/FS)); % 
t=virtualmarkers.mid_ilium.Header; 
  
%% Figure: Ilium displacement (ASA) 
  
h10 = figure (10); clf; hold on 
subplot(3,1,1); hold on 
plot(mid_ilium(:,1), 'b'); title("Mid Ilium, x (+ve right)"); ylabel ('x 
displacement (mm)') 
subplot(3,1,2); hold on 
plot(mid_ilium(:,2), 'b'); title("Mid Ilium, y (+ve forward)"); ylabel 
('y displacement (mm)') 
subplot(3,1,3); hold on 
plot(mid_ilium(:,3), 'b'); title("Mid Ilium, z (+ve up)"); ylabel ('z 
displacement (mm)') 
xlabel ('time (s)'); 
  
h11 = figure(11); clf; hold on 
subplot(3,1,1); hold on 
plot(t,mid_ilium(:,2), 'b'); ylabel ('displ, m/s') 
title('Mid-Ilium Displacement') 
subplot(3,1,2); hold on 
plot(t,velocity_midilium_y, 'b'); ylabel ('velocity, m/s') 
title('Mid-Ilium Velocity') 
subplot(3,1,3); hold on 
plot(t,accel_midilium_y, 'b'); ylabel ('accel, m/s^2') 
title('Mid-Ilium Acceleration') 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='figures'; info.Folder='Results'; 













%% Figure: T1 displacement (ASA) 
  
% Forward trajectory velocity, based on T1 motion 
markers=Osim.interpret(trc,'TRC','struct'); 
T1=markers.T1{:,2:end}; 
velocity_T1_y = smooth(gradient(T1(:,2),1/FS)/1000); %incl. conversion 
mm/s to m/s 
accel_T1_y = smooth(gradient(velocity_T1_y(:,1),1/FS)); % 
t=markers.T1.Header; 
  
h12 = figure (12); clf; hold on 
subplot(3,1,1); hold on 
plot(T1(:,1), 'b'); title("T1, x (+ve right)"); ylabel ('x displacement 
(mm)') 
subplot(3,1,2); hold on 
plot(T1(:,2), 'b'); title("T1, y (+ve forward)"); ylabel ('y displacement 
(mm)') 
subplot(3,1,3); hold on 
plot(T1(:,3), 'b'); title("T1, z (+ve up)"); ylabel ('z displacement 
(mm)') 
xlabel ('time (s)'); 
  
h13 = figure(13); clf; hold on 
subplot(3,1,1); hold on 
plot(t,T1(:,2), 'b'); ylabel ('displ, m/s') 
title('T1 Displacement') 
subplot(3,1,2); hold on 
plot(t,velocity_T1_y, 'b'); ylabel ('velocity, m/s') 
title('T1 Velocity') 
subplot(3,1,3); hold on 
plot(t,accel_T1_y, 'b'); ylabel ('accel, m/s^2') 
title('T1 Acceleration') 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='Results'; 

































% Head Range w.r.t T1 analysis [Annabel's request]  (cm) 
head_T1=markers.HEAD{:,2:end}-markers.T1{:,2:end};  
% T1 Range to T13 analysis [Annabel's request]  (cm) %%%%%%% 
T1_T13=markers.T1{:,2:end}-markers.T13{:,2:end};  
% T1 Range to L7 analysis [Annabel's request]  (cm) %%%%%%% 
T1_L7=markers.T1{:,2:end}-markers.L7{:,2:end};  
% T1 analysis. Distance of T1 to floor, deviation left-right 
T1=markers.T1{:,2:end};  
  
%Distance between markers 









% T1 analysis. Distance of T1 relative to floor, deviation left-right 
(cm) 
globalresults.MinAbsStrideT1_x=min(abs(T1(:,1))/10); %(cm) 




































% Forward trajectory velocity, based on Head motion 
markers=Osim.interpret(trc,'TRC','struct'); 
HEAD=markers.HEAD{:,2:end}; 
velocity_HEAD_y = smooth(gradient(HEAD(:,2),1/FS)/1000); %incl. 
conversion mm/s to m/s 
accel_HEAD_y = smooth(gradient(velocity_HEAD_y(:,1),1/FS)); % 
t=markers.HEAD.Header; 
  
h14 = figure (14); clf; hold on 
subplot(3,1,1); hold on 
plot(HEAD(:,1), 'b'); title("Head, x (+ve right)"); ylabel ('x 
displacement (mm)') 
subplot(3,1,2); hold on 
plot(HEAD(:,2), 'b'); title("Head, y (+ve forward)"); ylabel ('y 
displacement (mm)') 
subplot(3,1,3); hold on 
plot(HEAD(:,3), 'b'); title("Head, z (+ve up)"); ylabel ('z displacement 
(mm)') 
xlabel ('time (s)'); 
  
h15 = figure(15); clf; hold on 
subplot(3,1,1); hold on 
plot(t,HEAD(:,2), 'b'); ylabel ('displ, m/s') 
title('Head Displacement') 
subplot(3,1,2); hold on 
plot(t,velocity_HEAD_y, 'b'); ylabel ('velocity, m/s') 
title('Head Velocity') 
subplot(3,1,3); hold on 
plot(t,accel_HEAD_y, 'b'); ylabel ('accel, m/s^2') 
title('Head Acceleration') 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='Results'; 













h16 = figure (16); clf; hold on 
subplot(3,1,1); hold on 
plot(HEAD_T1(:,1), 'b'); title("Head-T1 Distance, x (+ve right)"); ylabel 
('x displacement (mm)') 
subplot(3,1,2); hold on 
plot(HEAD_T1(:,2), 'b'); title("Head-T1 Distance, y (+ve forward)"); 
ylabel ('y displacement (mm)') 
subplot(3,1,3); hold on 
plot(HEAD_T1(:,3), 'b'); title("Head-T1 Distance, z (+ve up)"); ylabel 
('z displacement (mm)') 
xlabel ('time (s)'); 
  













h17 = figure (17); clf; hold on 
subplot(3,1,1); hold on 
plot(T1_T13(:,1), 'b'); title("T1-T13 Distance, x (+ve right)"); ylabel 
('x displacement (mm)') 
subplot(3,1,2); hold on 
plot(T1_T13(:,2), 'b'); title("T1-T13 Distance, y (+ve forward)"); ylabel 
('y displacement (mm)') 
subplot(3,1,3); hold on 
plot(T1_T13(:,3), 'b'); title("T1-T13 Distance, z (+ve up)"); ylabel ('z 
displacement (mm)') 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='Results'; 








h18 = figure (18); clf; hold on 
subplot(3,1,1); hold on 
plot(T1_L7(:,1), 'b'); title("T1-L7 Distance, x (+ve right)"); ylabel ('x 
displacement (mm)') 
subplot(3,1,2); hold on 
plot(T1_L7(:,2), 'b'); title("T1-L7 Distance, y (+ve forward)"); ylabel 
('y displacement (mm)') 
subplot(3,1,3); hold on 
plot(T1_L7(:,3), 'b'); title("T1-L7 Distance, z (+ve up)"); ylabel ('z 
displacement (mm)') 
xlabel ('time (s)'); 
  
% save figures as png 
info=f.getFields(c3dfile); info.Folder='Results'; 











h19 = figure(19); clf; hold on 
subplot(2,1,1); hold on 
plot(R_forefoot1(:,1),R_forefoot1(:,2),'r'); title("Fore foot") 
plot(L_forefoot1(:,1),L_forefoot1(:,2),'b'); 




subplot(2,1,2); hold on 
plot(R_hindfoot1(:,1),R_hindfoot1(:,2),'r'); title("Hind foot") 
plot(L_hindfoot1(:,1),L_hindfoot1(:,2),'b'); 
legend("Right foot", "Left foot") 
  
%% Figure: Trajectory of lowest foot marker for each limb, in global te 
%system, x-axis (sideways motion, +ve x to right) 
h20 = figure(20); clf; hold on 
subplot(6,1,1); hold on 
plot(t,R_forefoot1(:,1),'r'); title("Fore: R lateral trajectory, +ve 
right") 
ylabel ('lateral displ (mm)'); 
subplot(6,1,2); hold on 
plot(t,L_forefoot1(:,1),'b'); title("Fore: L lateral trajectory, +ve 
right") 
ylabel ('lateral displ (mm)'); 
subplot(6,1,3); hold on 
plot(t,(R_forefoot1(:,1) - L_forefoot1(:,1)), 'k'); title("Fore: R-L, 
lateral") 
ylabel ('lateral R-L difference (mm)'); 
subplot(6,1,4); hold on 
plot(t,R_hindfoot1(:,1), 'r' ); title("Hind: R lateral trajectory, +ve 
right") 
ylabel ('vert displ (mm)'); 
subplot(6,1,5); hold on 
plot(t,L_hindfoot1(:,1), 'b' ); title("Hind: L lateral trajectory, +ve 
right") 
ylabel ('vert displ (mm)'); 
subplot(6,1,6); hold on 
plot(t,(R_hindfoot1(:,1) - L_hindfoot1(:,1)), 'k'); title("Hind: R-L, 
lateral") 
ylabel ('lateral R-L difference (mm)'); 
ylabel ('lateral displ (mm)'); 
xlabel ('time (s)'); 
  
%conclusion: x displacement are not cyclic in relation to swing and 
stance phase 
  













%% B. Leg-Independent analyses  




% Calculate durations (s) (Wilson et al., 2019)  
results.StanceDuration=nan(n,1);  
results.SwingDuration=nan(n,1);   
results.StrideDuration=nan(n,1);  
results.Properties.VariableUnits(2:4)={'s'}; 










% Range of hoof height during swing (cm) [Wilson et al., 2019] 
results.HoofHeightRange=nan(n,1); 
results.Properties.VariableUnits{8}='cm'; 
% Stride length (cm) 
results.StrideLength=nan(n,1); results.Properties.VariableUnits{9}='cm'; 
% Stance base [requested by Annabel) (cm) 
results.DistanceMatchingLimbStance=nan(n,1); 
results.Properties.VariableUnits{10}='cm'; 




















% Here for loop the strides and compute every analysis code 
for i=1:numel(strides) 
   s=strides{i};    
   distalmarker=distalmarkers{strcmp(legs,s.leg)}; 
   markers=Osim.interpret(s.trc,'TRC','struct'); 
   results.LegName{i}=s.leg; 
   %{ 
   figure(1); % Look at the gait cycle   
   thisLegStrike=s.gc.([distalmarkers{i},'_Strike']);    
   thisLegOff=s.gc.([distalmarkers{i},'_Off']);    
   plot(thisLegStrike); hold on; 
   plot(thisLegOff); hold off; 
   figure(2); % Look at the animation 
   plotAnimation(vskfile,s.trc);    
   %}      
   %% Calculate durations (s) (Wilson et al., 2019) 
   % stance: off-start   % swing: end-off    % duration: end-start 
   results.StanceDuration(i)=diff(s.stanceIdx)/FS; 
   results.SwingDuration(i)=diff(s.swingIdx)/FS; 
   results.StrideDuration(i)=(s.swingIdx(2)-s.stanceIdx(1))/FS; 
   %% Lateral deviation of hoof during swing (cm) [Wilson et al., 2019] 
   thismarker=markers.(distalmarker){:,2:end}; 
   
results.HoofLateralDeviation(i)=range(thismarker(s.swingIdx(1):s.swingIdx
(2),1))/10; %(cm) 
   %% (Forward and Vertical) Velocity of hoof during swing (m/s) [Wilson 
et al., 2019] 




   results.ForwardSwingVelocity(i)= 
mean(abs(velocity_y(s.swingIdx(1):s.swingIdx(2))))/1000; %(m/s) 
   velocity_z= gradient(thismarker(:,3),1/FS); %(mm/s) 
   results.VerticalSwingVelocity(i)= 
mean(abs(velocity_z(s.swingIdx(1):s.swingIdx(2))))/1000; %(m/s) 
   %% Range of hoof height during swing (cm) [Wilson et al., 2019] 
   
results.HoofHeightRange(i)=range(thismarker(s.swingIdx(1):s.swingIdx(2),3
))/10; %(cm) 
   %% Stride length (cm) 
   
results.StrideLength(i)=range(thismarker(s.stanceIdx(2):s.swingIdx(2),2))
/10; %(cm) 
   %% Stance base [requested by Annabel) (cm) 
   % (Lateral) Distance between matching limbs (cm) during stance (mean 
   % value throughout entire stance phase) 
   % forelimbs 
   switch s.leg 
        case 'L_forefoot' 
            matchingLeg='R_forefoot'; 
        case 'R_forefoot' 
           matchingLeg='L_forefoot'; 
        case 'L_hindfoot' 
           matchingLeg='R_hindfoot'; 
        case 'R_hindfoot' 
           matchignLeg='L_hindfoot'; 
   end 
       
   % Get the distance during stance phase 
   matchingMarkerName=distalmarkers{strcmp(legs,matchingLeg)}; 
   matchingMarkerTbl=markers.(matchingMarkerName); 
matchingMarker=matchingMarkerTbl{:,2:end}; 
   matchingLeg_strikeIdx=find(s.gc.([matchingMarkerName,'_Strike'])==0); 
   matchingLeg_offIdx=find(s.gc.([matchingMarkerName,'_Off'])==0); 
      
   % Get indices of stance for the matching leg 
   stanceIdx=[matchingLeg_strikeIdx(1) 
min([matchingLeg_offIdx(matchingLeg_offIdx>matchingLeg_strikeIdx) 
size(s.gc,1)])]; 
    
   %% Figure: Limb Distance Distal Markers 
    
   h21 = figure(21); 
   if i==1 
       clf; 
   end 
   
   switch s.leg 
        case 'L_forefoot' 
           subplot(2,1,1); hold on; 
           % s.leg most distal marker 
           plot(s.trc{s.stanceIdx(1):s.stanceIdx(2),([distalmarker 
'_x'])},s.trc{s.stanceIdx(1):s.stanceIdx(2),([distalmarker '_y'])},'x'); 
           title("Forelimb Stance")   
      
           % corresponding marker on the contralateral side 
           plot(s.trc{stanceIdx(1):stanceIdx(2),([matchingMarkerName 
'_x'])},s.trc{stanceIdx(1):stanceIdx(2),([matchingMarkerName 
'_y'])},'x'); 
        case 'R_forefoot'  




        case 'L_hindfoot' 
           subplot(2,1,2); hold on; 
           % s.leg most distal marker 
           plot(s.trc{s.stanceIdx(1):s.stanceIdx(2),([distalmarker 
'_x'])},s.trc{s.stanceIdx(1):s.stanceIdx(2),([distalmarker '_y'])},'x'); 
           title("Hindlimb Stance")   
           
           % corresponding marker on the contralateral side 
           plot(s.trc{stanceIdx(1):stanceIdx(2),([matchingMarkerName 
'_x'])},s.trc{stanceIdx(1):stanceIdx(2),([matchingMarkerName 
'_y'])},'x'); 
            
        case 'R_hindfoot'            
   end 
  
info=f.getFields(c3dfile); info.Folder='Results'; 




       
   %% Check the animation of strides 
   %figure(); 
   %plotAnimation(vskfile,s.trc(stanceIdx(1):stanceIdx(2),:)) 
   %plotAnimation(vskfile,s.trc(s.stanceIdx(1):s.stanceIdx(2),:)) 
         
   markers=Osim.interpret(s.trc,'TRC','struct');    
   x1=mean(thismarker(s.stanceIdx(1):s.stanceIdx(2),:)); 
   x2=mean(matchingMarker(stanceIdx(1):stanceIdx(2),:)); 
   results.DistanceMatchingLimbStance(i)=norm(x1-x2)/10; %(cm) 
    
   %% Preliminary 2D joint angle analysis (deg) 
   % Fetlock joint (equivalent to ankle or wrist) 
   switch s.leg 
       % Left Forelimb  
       % Phalanx Group = LF_PHAL and LF_DPHAL; Metatarsal Group = L_METAR 
and LF_PPHAL 
        case 'L_forefoot' 
            
jointangle=jointangle_2D(markers,'LF_PHAL','LF_DPHAL','L_METAR','LF_PPHAL
'); 
       % Right Forelimb  
       % Phalanx Group = RF_PHAL and RF_DPAHL; Metatarsal Group = R_METAR 
and RF_PPHAL 
        case 'R_forefoot' 
           
jointangle=jointangle_2D(markers,'RF_PHAL','RF_DPHAL','R_METAR','RF_PPHAL
'); 
       % Left Hindlimb  
       % Phalanx Group = LH_PHAL and LH_DPHAL; Tarsal Group = L_FTAR and 
LH_PPHAL 
        case 'L_hindfoot' 
           
jointangle=jointangle_2D(markers,'LH_PHAL','LH_DPHAL','L_FTAR','LH_PPHAL'
); 
       % Right Hindlimb  
       % Phalanx Group = RH_PHAL and RH_DPHAL; Tarsal Group = R_FTAR and 
RH_PPHAL 




           
jointangle=jointangle_2D(markers,'RH_PHAL','RH_DPHAL','R_FTAR','RH_PPHAL'
); 
   end 
   % During Stance (∞) 
   
results.MinFetlockStance(i)=min(jointangle(s.stanceIdx(1):s.stanceIdx(2))
); 
   
results.MaxFetlockStance(i)=max(jointangle(s.stanceIdx(1):s.stanceIdx(2))
); 
   
results.RangeFetlockStance(i)=range(jointangle(s.stanceIdx(1):s.stanceIdx
(2))); 
   % During Swing (∞) 
   
results.MinFetlockSwing(i)=min(jointangle(s.swingIdx(1):s.swingIdx(2))); 
   
results.MaxFetlockSwing(i)=max(jointangle(s.swingIdx(1):s.swingIdx(2))); 
   
results.RangeFetlockSwing(i)=range(jointangle(s.swingIdx(1):s.swingIdx(2)
)); 
    
   % Knee/Hock joint (equivalent to knee or elbow) 
   switch s.leg 
       % Left Forelimb  
       % Metatarsal Group = L_METAR and LF_PPHAL; Radius/Ulna group = 
L_LEPIRAD and L_ULNA 
        case 'L_forefoot' 
            
jointangle=jointangle_2D(markers,'L_METAR','LF_PPHAL','L_LEPIRAD','L_ULNA
'); 
       % Right Forelimb 
       % Metatarsal Group = R_METAR and RF_PPHAL; Radius/Ulna group = 
R_LEPIRAD and R_ULNA 
        case 'R_forefoot' 
           
jointangle=jointangle_2D(markers,'R_METAR','RF_PPHAL','R_LEPIRAD','R_ULNA
'); 
        % Left Hindlimb  
        % Tarsal Group = L_FTAR and LH_PPHAL; Tibia group = L_LTIB and 
L_LMAL 
        case 'L_hindfoot' 
           
jointangle=jointangle_2D(markers,'L_FTAR','LH_PPHAL','L_LTIB','L_LMAL'); 
        % Right Hindlimb  
        % Tarsal Group = R_FTAR and RH_PPHAL; Tibia group = R_LTIB and 
R_LMAL 
        case 'R_hindfoot' 
           
jointangle=jointangle_2D(markers,'R_FTAR','RH_PPHAL','R_LTIB','R_LMAL'); 
   end 
   % During Stance (∞) 
   
results.MinHockStance(i)=min(jointangle(s.stanceIdx(1):s.stanceIdx(2))); 
   
results.MaxHockStance(i)=max(jointangle(s.stanceIdx(1):s.stanceIdx(2))); 
   
results.RangeHockStance(i)=range(jointangle(s.stanceIdx(1):s.stanceIdx(2)
)); 
   % During Swing (∞) 
   results.MinHockSwing(i)=min(jointangle(s.swingIdx(1):s.swingIdx(2))); 




   
results.RangeHockSwing(i)=range(jointangle(s.swingIdx(1):s.swingIdx(2))); 
    
   % Stifle/Shoulder joint (equivalent to hip or shoulder) 
   switch s.leg 
       % Left Forelimb  
       % Radius/Ulna group = L_LEPIRAD and L_ULNA; Humerus group = L_GTUB 
and L_LEPIRAD 
        case 'L_forefoot' 
            
jointangle=jointangle_2D(markers,'L_LEPIRAD','L_ULNA','L_GTUB','L_LEPIRAD
'); 
       % Right Forelimb  
       % Radius/Ulna group = R_LEPIRAD and R_ULNA; Humerus group = R_GTUB 
and R_LEPIRAD 
        case 'R_forefoot' 
           
jointangle=jointangle_2D(markers,'R_LEPIRAD','R_ULNA','R_GTUB','R_LEPIRAD
'); 
       % Left Hindlimb  
       % Tibia group = L_LTIB and L_LMAL; Femur group = L_GTROC and 
L_LEPI 
        case 'L_hindfoot' 
           
jointangle=jointangle_2D(markers,'L_LTIB','L_LMAL','L_GTROC','L_LEPI'); 
       % Right Hindlimb  
       % Tibia group = R_LTIB and R_LMAL; Femur group = R_GTROC and 
R_LEPI 
        case 'R_hindfoot' 
           
jointangle=jointangle_2D(markers,'R_LTIB','R_LMAL','R_GTROC','R_LEPI'); 
   end 
   % During Stance (∞) 
   
results.MinStifleStance(i)=min(jointangle(s.stanceIdx(1):s.stanceIdx(2)))
; 
   
results.MaxStifleStance(i)=max(jointangle(s.stanceIdx(1):s.stanceIdx(2)))
; 
   
results.RangeStifleStance(i)=range(jointangle(s.stanceIdx(1):s.stanceIdx(
2))); 
   % During Swing (∞) 
   
results.MinStifleSwing(i)=min(jointangle(s.swingIdx(1):s.swingIdx(2))); 
   
results.MaxStifleSwing(i)=max(jointangle(s.swingIdx(1):s.swingIdx(2))); 
   
results.RangeStifleSwing(i)=range(jointangle(s.swingIdx(1):s.swingIdx(2))
);      
          
end 




















adjusted (95% CI) 
P-value 
adjusted 
Stance Duration (s) 0.43 (0.01) 0.56 (0.11) 0.13 (0.10, 0.15) <0.001 * 0.02 (-0.01, 0.04) 0.132 
Swing Duration (s) 0.34 (0.00) 0.37 (0.04) 0.03 (0.02, 0.04) <0.001 * 0.01 (-0.00, 0.02) 0.061 
Stride Duration (s) 0.77 (0.01) 0.93 (0.13) 0.16 (0.13, 0.19) <0.001 * 0.03 (0.01, 0.05) 0.015 * 
Ratio Stance To Stride (%) 0.55 (0.00) 0.60 (0.03) 0.05 (0.03, 0.06) <0.001 * 0.00 (-0.01, 0.02) 0.599 
Ratio Swing To Stride (%) 0.45 (0.00) 0.40 (0.03) -0.05 (-0.06, -0.03) <0.001 * -0.00 (-0.02, 0.01) 0.599 
Ratio Stance To Swing (%) 1.26 (0.02) 1.51 (0.22) 0.25 (0.17, 0.32) <0.001 * -0.00 (-0.08, 0.07) 0.962 
Hoof Lateral Deviation (cm) 7.07 (0.43) 6.55 (1.97) -0.55 (-1.41, 0.31) 0.208 -0.63 (-1.66, 0.40) 0.231 
Hoof Forward Swing Velocity (m/s) 2.87 (0.03) 2.45 (0.27) -0.43 (-0.50, -0.35) <0.001 * -0.17 (-0.24, -0.09) <0.001 * 
Hoof Vertical Swing Velocity (m/s) 0.24 (0.01) 0.21 (0.08) -0.03 (-0.06, 0.00) 0.056 -0.02 (-0.05, 0.02) 0.319 
Range Hoof Height in Swing (cm) 4.18 (0.12) 3.97 (1.35) -0.22 (-0.80, 0.37) 0.469 -0.16 (-0.87, 0.55) 0.666 
Stride Length (cm) 97.67 (0.99) 90.13 (6.06) -7.70 (-9.53, -5.87) <0.001 * -1.79 (-3.63, 0.05) 0.056 
Minimum Hindlimb Fetlock Angle Stance (º) 2.12 (1.24) 1.81 (7.61) -0.35 (-4.39, 3.70) 0.867 1.24 (-3.43, 5.91) 0.603 
Maximum Hindlimb Fetlock Angle Stance (º) 19.02 (1.15) 17.28 (7.29) -1.79 (-5.85, 2.28) 0.389 -1.33 (-6.17, 3.50) 0.589 
Range Hindlimb Fetlock Angle in Stance (º) 16.90 (0.12) 15.47 (4.24) -1.44 (-3.22, 0.34) 0.112 -2.39 (-4.56, -0.23) 0.03 * 
Minimum Hindlimb Fetlock Angle in Swing (º) -32.04 (1.19) -25.68 (8.63) 6.35 (2.22, 10.47) 0.003 * 6.43 (1.64, 11.23) 0.009 * 
Maximum Hindlimb Fetlock Angle in Swing (º) 9.11 (1.34) 7.16 (7.82) -2.00 (-6.01, 2.02) 0.329 -0.33 (-5.03, 4.37) 0.891 
Range Hindlimb Fetlock Angle in Swing (º) 41.15 (0.74) 32.84 (6.18) -8.34 (-11.06, -5.63) <0.001 * -6.61 (-9.89, -3.33) <0.001 * 
Minimum Tarsal Angle in Stance (º) 27.70 (0.40) 27.15 (7.76) -0.35 (-3.32, 2.62) 0.818 -0.32 (-3.84, 3.19) 0.857 
Maximum Tarsal Angle in Stance (º) 63.10 (0.24) 58.01 (9.57) -5.07 (-7.77, -2.37) <0.001 * -3.41 (-6.69, -0.12) 0.042 * 
Range Tarsal Angle in Stance (º) 35.41 (0.44) 30.86 (6.08) -4.72 (-6.81, -2.63) <0.001 * -3.03 (-5.49, -0.56) 0.016 * 
Minimum Tarsal Angle in Swing (º) 27.73 (0.38) 27.14 (7.59) -0.38 (-3.51, 2.75) 0.812 -1.09 (-4.90, 2.71) 0.573 
Maximum Tarsal Angle in Swing (º) 77.25 (0.56) 70.65 (11.40) -6.53 (-9.67, -3.39) <0.001 * -5.14 (-8.92, -1.35) 0.008 * 
Range Tarsal Angle in Swing (º) 49.53 (0.29) 43.51 (7.20) -6.15 (-8.91, -3.39) <0.001 * -3.95 (-7.26, -0.63) 0.02 * 
Minimum Stifle Angle in Stance (º) -68.54 (0.65) -65.60 (15.97) 3.01 (-2.44, 8.46) 0.279 1.86 (-4.63, 8.34) 0.575 
Maximum Stifle Angle in Stance (º) -45.12 (1.05) -39.39 (14.56) 5.81 (0.56, 11.06) 0.03 * 2.71 (-3.43, 8.85) 0.387 
Range Stifle Angle in Stance (º) 23.42 (0.46) 26.22 (4.98) 2.80 (0.41, 5.19) 0.022 * 0.58 (-2.20, 3.36) 0.68 
Minimum Stifle Angle in Swing (º) -80.72 (0.93) -74.06 (15.27) 6.69 (1.52, 11.86) 0.011 * 4.48 (-1.68, 10.64) 0.154 
Maximum Stifle Angle in Swing (º) -35.46 (1.41) -32.70 (14.73) 2.84 (-2.53, 8.21) 0.3 0.87 (-5.44, 7.19) 0.786 
Range Stifle Angle in Swing (º) 45.26 (0.66) 41.36 (3.87) -3.85 (-6.14, -1.56) 0.001 * -3.94 (-6.70, -1.18) 0.005 * 
* = p<0.05 
      




       
       
Right hindlimb 
 




adjusted (95% CI) 
P-value 
adjusted 
Stance Duration (s) 0.43 (0.01) 0.56 (0.11) 0.12 (0.10, 0.15) <0.001 * 0.02 (-0.01, 0.04) 0.184 
Swing Duration (s) 0.34 (0.00) 0.37 (0.03) 0.03 (0.02, 0.04) <0.001 * 0.01 (-0.00, 0.02) 0.148 
Stride Duration (s) 0.77 (0.01) 0.92 (0.12) 0.15 (0.12, 0.18) <0.001 * 0.03 (0.00, 0.05) 0.038 * 
Ratio Stance To Stride (%) 0.55 (0.00) 0.60 (0.04) 0.05 (0.03, 0.06) <0.001 * 0.00 (-0.01, 0.02) 0.57 
Ratio Swing To Stride (%) 0.45 (0.00) 0.40 (0.04) -0.05 (-0.06, -0.03) <0.001 * -0.00 (-0.02, 0.01) 0.57 
Ratio Stance To Swing (%) 1.27 (0.02) 1.52 (0.26) 0.25 (0.17, 0.32) <0.001 * 0.00 (-0.07, 0.08) 0.972 
Hoof Lateral Deviation (cm) 7.56 (0.23) 5.80 (1.81) -1.81 (-2.67, -0.95) <0.001 * -1.89 (-2.92, -0.86) <0.001 * 
Hoof Forward Swing Velocity (m/s) 2.86 (0.03) 2.46 (0.26) -0.41 (-0.48, -0.33) <0.001 * -0.15 (-0.22, -0.07) <0.001 * 
Hoof Vertical Swing Velocity (m/s) 0.22 (0.00) 0.18 (0.08) -0.05 (-0.08, -0.02) 0.001 * -0.04 (-0.08, -0.00) 0.03 * 
Range Hoof Height in Swing (cm) 3.85 (0.10) 3.24 (1.22) -0.64 (-1.23, -0.06) 0.032 * -0.58 (-1.29, 0.13) 0.109 
Stride Length (cm) 97.63 (0.52) 90.33 (6.45) -7.44 (-9.28, -5.61) <0.001 * -1.53 (-3.37, 0.30) 0.102 
Minimum Hindlimb Fetlock Angle Stance (º) 2.25 (1.26) 1.38 (8.05) -0.85 (-4.89, 3.20) 0.681 0.73 (-3.93, 5.40) 0.758 
Maximum Hindlimb Fetlock Angle Stance (º) 19.77 (1.16) 19.52 (9.10) -0.18 (-4.25, 3.88) 0.93 0.27 (-4.56, 5.11) 0.912 
Range Hindlimb Fetlock Angle in Stance (º) 17.52 (0.25) 18.15 (4.99) 0.67 (-1.11, 2.45) 0.462 -0.29 (-2.45, 1.88) 0.796 
Minimum Hindlimb Fetlock Angle in Swing (º) -30.93 (0.91) -24.00 (6.68) 6.95 (2.82, 11.07) 0.001 * 7.03 (2.24, 11.83) 0.004 * 
Maximum Hindlimb Fetlock Angle in Swing (º) 10.12 (1.36) 8.84 (8.72) -1.24 (-5.26, 2.77) 0.544 0.43 (-4.27, 5.12) 0.859 
Range Hindlimb Fetlock Angle in Swing (º) 41.05 (0.91) 32.84 (5.43) -8.19 (-10.90, -5.47) <0.001 * -6.46 (-9.74, -3.18) <0.001 * 
Minimum Tarsal Angle in Stance (º) 24.43 (0.16) 23.85 (6.69) -0.42 (-3.39, 2.55) 0.781 -0.39 (-3.91, 3.12) 0.826 
Maximum Tarsal Angle in Stance (º) 60.50 (0.48) 55.07 (7.94) -5.33 (-8.02, -2.63) <0.001 * -3.66 (-6.95, -0.38) 0.029 * 
Range Tarsal Angle in Stance (º) 36.06 (0.58) 31.22 (4.90) -4.91 (-7.00, -2.81) <0.001 * -3.21 (-5.67, -0.75) 0.011 * 
Minimum Tarsal Angle in Swing (º) 24.56 (0.13) 23.56 (6.64) -0.83 (-3.96, 2.29) 0.602 -1.55 (-5.36, 2.26) 0.426 
Maximum Tarsal Angle in Swing (º) 74.17 (0.32) 66.53 (8.89) -7.51 (-10.65, -4.37) <0.001 * -6.12 (-9.90, -2.33) 0.002 * 
Range Tarsal Angle in Swing (º) 49.61 (0.34) 42.97 (5.81) -6.68 (-9.44, -3.91) <0.001 * -4.47 (-7.79, -1.15) 0.008 * 
Minimum Stifle Angle in Stance (º) -71.01 (0.39) -66.98 (14.54) 4.09 (-1.37, 9.54) 0.142 2.93 (-3.55, 9.41) 0.376 
Maximum Stifle Angle in Stance (º) -47.89 (0.58) -40.12 (12.71) 7.77 (2.52, 13.02) 0.004 * 4.67 (-1.47, 10.82) 0.136 
Range Stifle Angle in Stance (º) 23.12 (0.22) 26.86 (4.81) 3.69 (1.30, 6.08) 0.002 * 1.48 (-1.30, 4.26) 0.298 
Minimum Stifle Angle in Swing (º) -83.36 (0.72) -75.97 (14.00) 7.41 (2.24, 12.58) 0.005 * 5.20 (-0.96, 11.36) 0.098 
Maximum Stifle Angle in Swing (º) -38.34 (0.77) -33.28 (13.34) 5.06 (-0.31, 10.43) 0.065 3.10 (-3.22, 9.41) 0.336 
Range Stifle Angle in Swing (º) 45.03 (0.06) 42.69 (3.77) -2.35 (-4.64, -0.06) 0.044 * -2.43 (-5.19, 0.33) 0.084 
Distance Matching Limb during stance (cm) 89.11 (0.36) 79.66 (5.02) -9.38 (-11.46, -7.31) <0.001 * -6.16 (-8.46, -3.87) <0.001 * 









Overall Unadjusted Overall Adjusted 
Outcome  P-value interaction P-value interaction*   
Stance Duration (s) 0.923 0.789 
Swing Duration (s) 0.151 0.114 
Stride Duration (s) 0.996 0.986 
Ratio Stance To Stride (%) 0.181 0.084 
Ratio Swing To Stride (%) 0.181 0.084 
Ratio Stance To Swing (%) 0.287 0.13 
Hoof Lateral Deviation (cm) 0.207 0.208 
Hoof Forward Swing Velocity (m/s) 0.027 * 0.002 * 
Hoof Vertical Swing Velocity (m/s) 0.677 0.678 
Range Hoof Height in Swing (cm) 0.577 0.578 
Stride Length (cm) 0.97 0.943 
Minimum Fetlock Angle Stance (º) 0.994 0.994 
Maximum Fetlock Angle Stance (º) 0.921 0.921 
Range Fetlock Angle in Stance (º) 0.337 0.336 
Minimum Fetlock Angle in Swing (º) 0.314 0.314 
Maximum Fetlock Fetlock Angle in Swing (º) 0.975 0.975 
Range Fetlock Angle in Swing (º) 0.01 * 0.009 * 
Minimum Carpal/Tarsal Angle in Stance (º) 0.963 0.963 
Maximum Carpal/Tarsal Angle in Stance (º) 0.085 0.082 
Range Carpal/Tarsal Angle in Stance (º) 0.012 * 0.011 * 
Minimum Carpal/Tarsal Angle in Swing (º) 0.286 0.287 
Maximum Carpal/Tarsal Angle in Swing (º) 0.002 * 0.002 * 
Range Carpal/Tarsal Angle in Swing (º) 0.141 0.139 
Minimum Elbow/Stifle Angle in Stance (º) 0.82 0.818 
Maximum Elbow/Stifle Angle in Stance (º) 0.789 0.782 
Range Elbow/Stifle Angle in Stance (º) 0.052 0.049 * 
Minimum Elbow/Stifle Angle in Swing (º) 0.595 0.588 
Maximum Elbow/Stifle Angle in Swing (º) 0.912 0.91 
Range Elbow/Stifle Angle in Swing (º) 0.051 0.051 
  
